{"title": "PDF", "author": "PDF", "url": "https://minerva.usc.es/xmlui/bitstream/10347/9787/1/rep_575.pdf", "hostname": "PDF", "description": "PDF", "sitename": "PDF", "date": "PDF", "cleaned_text": "y aplicaciones en Qu\u00edmica Farmac\u00e9utica 2013 1 UNIVERSIDAD DE SANTIAGO DE COMPOSTELA Facultad de Farmacia Departamento de Qu\u00edmica Org\u00e1nica Cumarinas: Versatilidad estructural y aplicaciones en Qu\u00edmica Farmac\u00e9utica Colaboraci\u00f3n con el Departamento de Qu\u00edmica y Bioqu\u00edmica de la Facultad de Ciencias de la Universidad de Porto - Portugal Memoria para optar al t\u00edtulo de Doctora en Farmacia presenta Maria Jo\u00e3o Correia Pinto Carvalho de Matos Cumarinas: Versatilidad estructural y aplicaciones en Qu\u00edmica Farmac\u00e9utica 2013 3 D. Maria Fernanda Martins Borges, Profesora Asociada de Qu\u00edmica Org\u00e1nica de la Universidad de Porto y D. Eugenio Uriarte Villares, Catedr\u00e1tico de Qu\u00edmica Org\u00e1nica de la Universidad de Santiago de Compostela CERTIFICAN Que la Memoria titulada \"Cumarinas: Versatilidad estructural y aplicaciones en Qu\u00edmica Farmac\u00e9utica\", que para optar al grado de Doctora en Farmacia presenta MARIA JO\u00c3O CORREIA PINTO CARVALHO DE MATOS, ha sido realizada bajo nuestra direcci\u00f3n, en el Departamento de Qu\u00edmica y Bioqu\u00edmica de la Facultad de Ciencias de la Universidad de Porto y en el Departamento de Qu\u00edmica Org\u00e1nica de la Facultad de Farmacia de la Universidad de Santiago de Compostela. Y considerando que el trabajo constituye tema y labor de Tesis Doctoral, autorizamos su presentaci\u00f3n en la Universidad de Santiago de Compostela. Y para que conste, expedimos el presente certificado en Santiago de Compostela a 27 de mayo de dos mil trece. Fdo. Maria Fernanda Martins Borges Fdo. Eugenio Uriarte Villares Cumarinas: Versatilidad estructural y aplicaciones en Qu\u00edmica Farmac\u00e9utica 2013 5 A mis queridos padres y a mi querido Jose Cumarinas: Versatilidad estructural y aplicaciones en Qu\u00edmica Farmac\u00e9utica 2013 7 \"A ci\u00eancia desenha a onda; Pascoaes (1877 -1952) Cumarinas: Versatilidad estructural y aplicaciones en Qu\u00edmica Farmac\u00e9utica 2013 9 Agradecimientos \"I'm a great believer in luck, and I find the harder I work the more I have of it.\" Thomas Jefferson Cuando he empezado esta aventura, no ten\u00eda ni idea de lo bonito que iba a ser recorrer este camino... ni tampoco de todo aquello que iba a significar para m\u00ed a nivel profesional y personal. A Lourdes y Eugenio, que han dado todo el apoyo a mi proyecto, tengo que darles las gracias por estar ah\u00ed en todo el momento... pero sobre todo por el cari\u00f1o y amistad con que me han acogido desde el primer d\u00eda. A Profesora Fer nanda por apoyar este proyecto y por su dinamismo y sus consejos. Por todas las agradables reuniones gastron\u00f3micas en la frontera, tambi\u00e9n compartidas con Alexandra. Al Profesor Gianni Podda por la oportunidad de realizar una parte de este trabajo en su gr upo y por su disponibilidad en el tiempo que he pasado en Italia. A mis compa\u00f1eros de laboratorio, en particular a Andr\u00e9, Carmen Picciau (por todos los buenos momentos que pasamos juntas en Cagliari) , Chachy, Eduardo, El\u00edas, Fran, Humber, Gabriele, Giovanna (por todos los buenos momentos que pasamos juntas en Cagliari) , Giovanni, Giulio, Javi, Jose, Ricci, Santi, Silvia, Silvana ..., que han estado ah\u00ed todos los d\u00edas. Una palabra especial para Saleta, amiga y compa\u00f1era de viajes, de charlas en el caf\u00e9, de debates cient\u00edficos y de todos los d\u00edas. Recuerdo tambi\u00e9n con mucho cari\u00f1o todos los j\u00f3venes investigadores que han trabajado conmigo en sus proyectos de tesina, de master y doctorado: Veronika, Carla, Carmen, Jo\u00e3o, Juliana, Eleonora, Alessandra, Mar\u00eda, R ita, Niccol\u00f2, Andrea ... por todo el esfuerzo y dedicaci\u00f3n. Todo este proyecto no podr\u00eda existir sin los compa\u00f1eros de Farmacolog\u00eda, y de una forma muy especial Dolo (adem\u00e1s de por su amistad, por los ensayos biol\u00f3gicos y por la valiosa ayuda en la parte farmacol\u00f3gica) y Paco Orallo ( en memoria), por tanto \u00e1nimo que ha dado a este proyecto. Tambi\u00e9n merecen especial referencia todos los profesores que proporcionaron sus medios para colaborar con nosotros en los ensayos biol\u00f3gicos: Prof. Ysa Santos y Prof. Angeles Mu\u00f1oz, Prof. Marcella Corda y Prof. Antonella Fais, Prof. Ana Maria Brett, Prof. Claudio Olea y Prof. Karl-Norbert Klotz. Un agradecimiento especial a los amigos de Cuba, Kike y Estela, por todo el cari\u00f1o y amistad y por el trabajo compartido. 9Cumarinas: Versatilidad estructural y aplicaciones en Qu\u00edmica Farmac\u00e9utica 2013 10 Merece tambi\u00e9n un agradecimiento especial Xos\u00e9, nuestro t\u00e9cnico, que siempre ha tenido disponibilidad para todo el apoyo t\u00e9cnico que hemos necesitado al largo de este proyecto. Por todo el apoyo, cari\u00f1o, \u00e1nimo y amor, un agradecimiento muy especial a Jose, por estar ah\u00ed siempre... Nada hubiese sido igual sin los amigos. Los que han estado m\u00e1s cerca, y aquellos que de lejos han dado todo su \u00e1nimo a este proyecto. Por Santiago han estado Tati, mi compa\u00f1era de piso, de fiestas, de trabajo, de todos los momentos y mi AMI GA. Sin ella nada hubiese sido lo mismo. Tambi\u00e9n Rosa, mi dulce amiga de siempre, de todos los momentos . Y Ana Carro, con su sonrisa dulce y sus palabras amigas. Tambi\u00e9n son parte fundamental de este proyecto muchos otros amigos especiales que descubr\u00ed en Santiago... mi Ana Mag\u00e1n y mi Calili, por todos los buenos momentos juntos... Tambi\u00e9n Pili y su peque\u00f1o Noel, Marga, Esteban, Graciela, Valentina, Cris, Joana, Carmen y Santi, Sofia y Bruno, Pedro, Luchi y Bego (...) y tantos, tantos otros que han hecho parte de mi camino todos estos a\u00f1os... Y con especial cari\u00f1o a mis compa\u00f1eras de danza y claqu\u00e9, Salom\u00e9 (adem\u00e1s de tantas otras cosas, compartimos tambi\u00e9n esta pasi\u00f3n), Pilar, Natalia, Yana, Leo, Archana, Marta, y mi querida Gail. A todos los compa\u00f1eros de las clases de fotograf\u00eda y del fotoforum, por lo bien que lo pasamos. En especial Paola, Mino, Marcos y Manuel, los MMMM&P. Y del curso de innovaci\u00f3n, por los proyectos y aventuras en que no metimos. Un poco m\u00e1s lejos, pero siempre cerca, mis ni\u00f1as: Rita, Raquel y su peque\u00f1a Pipa, Isa, Vanessa, Daniela, Cristina, Carolina, Diana, Mariana, Aninhas, Eva y Catarina. Las amigas para quien no hay distancia ni ausencia... Y los ni\u00f1os: Miguel, Helder, J o\u00e3o, Tiago, Pedro, Z\u00e9... Uno de los principales apoyos todos estos a\u00f1os han sido mi madre Maria Cristina y mi padre Manuel Jo\u00e3o, que son quienes m\u00e1s sienten y valoran todas mis peque\u00f1as victorias. Es por ellos todo el esfuerzo y toda la dedicaci\u00f3n. Tambi\u00e9n merecen todo mi agradecimiento mi hermana Ana (ahora doblemente por nuestro peque\u00f1o Bernardo , mi ahijado m\u00e1s lindo! ), que siempre ha sido mi ejemplo, mi hermano peque\u00f1o Henrique, que es la luz de mis ojos y el abrazo m\u00e1s dulce, y mi cu\u00f1ado Z\u00e9. Por tanto amor... Y mis queridos abuelos y padrinos Mil\u00fa y Edgardo ( en memoria), por el amor que me han dado toda mi vida... y por los buenos momentos que pasamos juntos cuando compartimos 10Cumarinas: Versatilidad estructural y aplicaciones en Qu\u00edmica Farmac\u00e9utica 2013 11 piso en algunos de mis a\u00f1os de facultad... Tambi\u00e9n mi abuelo Jorge ( en memoria), un ejemplo de fuerza y alegr\u00eda de vivir. A mis primas Mafalda y Raquel, y mis t\u00edos, Luisa y Pedro, por tanto cari\u00f1o y amistad. Y Margarida y Ang\u00e9lica, porque tambi\u00e9n son mi familia. Tambi\u00e9n formaron parte de este proyecto mi nueva familia de Santiago: Carmen y Ram\u00f3n, mi s cu\u00f1adas Marta, Eva y Silvia y mis cu\u00f1ados Alberto, Carlos y Tito, y mis dos sobris m\u00e1s lindos Ahinara y Hugo. Una referencia especial a mis primeros amigos espa\u00f1oles Golla, Nano, Gloria y Fernando, porque tambi\u00e9n ellos son mi familia. No puedo olvidar mis compa\u00f1eros de carrera de Coimbra y de Porto... por todos los buenos momentos que pasamos juntos. Y todos mis viejos y nuevos amigos, que han estado siempre presentes y me han apoya do en todas mis aventuras!... Esta tesis tiene un poco de todos aquellos que l lenaron mi vida y han dado sentido a todo este proyecto... en Santiago, en Cagliari, en Esposende, en Coimbra, en Porto y por todos los sitios donde deje un poco de aquello que hoy soy. Por ultimo, un agradecimiento muy especia l a la Funda\u00e7\u00e3o para a Ci\u00eancia e Tecnologia por haber financiado este proyecto (SFRH/BD/61262/2009). 11Cumarinas: Versatilidad estructural y aplicaciones en Qu\u00edmica Farmac\u00e9utica 2013 13 Resumen En esta Memoria se describe un trabajo de dise\u00f1o, s\u00edntesis y evaluaci\u00f3n farmacol\u00f3gica de derivados cumarin\u00edcos de diferente complejidad, mostrando la versatilidad qu\u00edmica de este esqueleto y algunas de sus aplicaciones en la Qu\u00edmica Farmac\u00e9utica. En esta Memoria se hace una selecci\u00f3n del trabajo global realizado, mostrando un conjunto de 134 compuestos que han sido los publicados hasta este momento de un total de m\u00e1s de 500. Todos ellos incorporan en una sola estructura el n\u00facleo de la cumarina y del estilbeno, o bien de la cumarina y funciones de tipo \u00e9ster, amida o carbamato. Modificaciones sencillas de estos esqueletos han permitido adem\u00e1s la obtenci\u00f3n de compuestos con diferentes sustituyentes (\u00e1tomos de bromo o cloro, y/o grupos metilo, metoxilo, etoxilo, hidroxilo, nitro, amino, etc) en diversas posiciones de las mol\u00e9culas. La s\u00edntesis de estos compuestos, con pureza y en cantidad suficiente par a sus ensayos farmacol\u00f3gicos, se ha realizado utilizando metodolog\u00edas directas, eficientes y generalizables. Se presentan los resultados obtenidos en la posterior evaluaci\u00f3n farmacol\u00f3gica de estos derivados como inhibidores enzim\u00e1 ticos (MAO-A, MAO-B, AChE y tirosinasa), ligandos de adenosina, antioxidantes y antimicrobianos. La selecci\u00f3n de los mismos se hizo teniendo en cuenta el conocimiento previo ayudado por herramientas de dise\u00f1o racional (QSAR y docking) y se obtuvieron muy buenos resultados en todos los campos estudiados. 13Cumarinas: Versatilidad estructural y aplicaciones en Qu\u00edmica Farmac\u00e9utica 2013 15 Summary This Report describes a work of versatility of this skeleton and some of its applications i n Pharmaceutical Chemistry. In this Report it was made a selection of the overall work done, showing a set of 134 compounds that have been published so far, of a total of more than 500 compounds. All incorporated in a single structure the core of the coumarin and the stilbene, or the core of the coumarin and ester, amide or carbamate functions. Simple positions of the molecules. The synthesis of these compounds, in and into prior docking) and there were obtained very good results in all the studied areas. 15Cumarinas: Versatilidad estructural y aplicaciones en Qu\u00edmica Farmac\u00e9utica 2013 17 I. \u00cdndice Cumarinas: Versatilidad estructural y aplicaciones en Qu\u00edmica Farmac\u00e9utica 2013 19 1. Introducci\u00f3n 21 1.1. Estructuras qu\u00edmicas 26 1.1.1. Las cumarinas 26 1.1.1.1. Actividad biol\u00f3gica de las cumarinas 29 1.1.1.2. S\u00edntesis de cumarina 34 1.1.2. Los estilbenos (resveratrol) 37 1.2. Enfermedades neurodegenerativas 41 1.2.1. Enfermedad de Parkinson (EP) 42 1.2.2. Enfermedad de Alzheimer (EA) 46 1.3. Principal diana farmacol\u00f3gica en la Memoria - MAOs 47 1.3.1. Cumarinas y las MAOs 52 2. Antecedentes y objetivos 57 2.1. Antecedentes 59 2.2. Objetivos 61 3. Discusi\u00f3n de resultados 65 3.1. S\u00edntesis 68 3.1.1. Preparaci\u00f3n de los esqueletos cumar\u00ednicos 68 3.1.1.1. Reacci\u00f3n de Perkin y Perkin-Oglialoro 68 3.1.1.2. Reacci\u00f3n de acoplamiento con paladio 69 3.1.2. Transformaciones funcionales 69 3.1.2 .1. Reacci\u00f3n de hidr\u00f3lisis de grupos \u00e9ter o \u00e9ster 69 3.1.2.2. Reacci\u00f3n de halogenaci\u00f3n 70 3.1.2.3. Reacci\u00f3n de formaci\u00f3n de arilaminas 71 3.1.2.4. Reacci\u00f3n de alquilaci\u00f3n - reacci\u00f3n de Williamson 72 3.1.2.5. Preparaci\u00f3n de amidas, \u00e9steres y carbamatos 73 3.1.3. Series de compuestos sintetizados 73 3.2. Estudio biol\u00f3gico y relaci\u00f3n estructura-actividad (REA) 79 3.3. Aportaciones estructurales y te\u00f3ricas 81 4. Parte experimental 83 4.1. Art\u00edculos publicados 85 4.2. Art\u00edculos en fase de publicaci\u00f3n 87 6. Concl usiones \u0016\u0015\u0018 7. Bibliograf\u00eda \u0016\u0015 19Cumarinas: Versatilidad estructural y aplicaciones en Qu\u00edmica Farmac\u00e9utica 2013 21 1. Introducci\u00f3n Cumarinas: Versatilidad estructural y aplicaciones en Qu\u00edmica Farmac\u00e9utica 2013 23 Desde siempre el Hombre ha intentado solucionar los problemas que iban surgiendo en su vida cotidiana. Con la necesidad de curar las enfermedades que le han afectado, el Hombre ha desarrollado preparaciones medicamentosas utilizando a lo largo de los tiempos aquellas estrategias que mejor serv\u00edan este objetivo. Hasta el siglo XVIII, la conocida como \"era de los bot\u00e1nicos\",1 las preparaciones de uso farmac\u00e9utico eran, en la gran mayor\u00eda de los casos, obtenidas de plantas, en forma de pociones. El descubrimiento de nuevas drogas y tratamientos estaba basado en la utilizaci\u00f3n de esas mismas plantas y otros productos naturales seg\u00fan la intuici\u00f3n y la observaci\u00f3n emp\u00edrica, siendo el \"azar\" el principal factor de \u00e9xito. M\u00e1s tarde, siglo XIX, puede entenderse como el comienzo de la era de los medicamentos, se empezaron a aislar, purificar e identificar las sustancias activas como las entidades responsables de la acci\u00f3n de los extractos naturales y posteriormente la \"era industrial\" ha transformado la producci\u00f3n de nuevos f\u00e1rmacos. El siglo XX, se inicia con la intro ducci\u00f3n del salvars\u00e1n o \"bala m\u00e1gica\" de Paul Ehrlich en el tratamiento de la s\u00edfilis, y con la utilizaci\u00f3n de la aspirina en terap\u00e9utica. La introducci\u00f3n de nuevas t\u00e9cnicas de elucidaci\u00f3n estructural ha permitido el desarrollo de nuevas metodolog\u00edas de s\u00ed ntesis como estrategia para el descubrimiento de nuevos f\u00e1rmacos y da paso a la denominada \"edad de oro\" de los medicamentos durante el per\u00edodo 1940 -1960 gracias a la introducci\u00f3n de una gran mayor\u00eda de clases f\u00e1rmaco -terap\u00e9uticas que hoy d\u00eda constituyen f \u00e1rmacos de gran inter\u00e9s tales como los antibi\u00f3ticos y junto con ellos el concepto de medicina preventiva y la vacunaci\u00f3n. Las Ciencias Farmac\u00e9uticas se separaron de las Ciencias M\u00e9dicas y surgieron nuevas \u00e1reas de conocimiento que transformaron la Farmacia en un conjunto multidisciplinar de saberes. El crecimiento ha sido exponencial y \u00e1reas como la Farmacolog\u00eda, la Biolog\u00eda, la Fisiolog\u00eda, la Biolog\u00eda Molecular, la Gen\u00e9tica y la Qu\u00edmica pasaron a coordinarse en un intento de dilucidar los mecanismos de acci\u00f3n de los f\u00e1rmacos y establecer las relaciones la estructura y la actividad farmacol\u00f3gica de los mismos. La modificaci\u00f3n estructural sobre un compuesto cabeza de serie y/o la b\u00fasqueda de nuevos prototipos pas\u00f3 a ser uno de los aspectos m\u00e1s estudiados 2 con un objetivo claro: mejorar el \u00edndice terap\u00e9utico de los f\u00e1rmacos, es decir aumentar la actividad y/o disminuir su toxicidad y efectos adversos. 23Cumarinas: Versatilidad estructural y aplicaciones en Qu\u00edmica Farmac\u00e9utica 2013 24 El desarrollo de metodolog\u00edas sint\u00e9ticas, de an\u00e1lisis estructural o te\u00f3ricas como el QSAR y el docking, entre otras, han a\u00f1adido un valor adicional a las Ciencias Farmac\u00e9uticas permitiendo un dise\u00f1o m\u00e1s racional de f\u00e1rmacos y la producci\u00f3n a gran escala.3 La expansi\u00f3n tecnol\u00f3gica y el recurso a medios de informaci\u00f3n r\u00e1pidos y asequibles, han tra\u00eddo progresos incre \u00edbles a un \u00e1rea conocida por su dinamismo. R\u00e1pidamente se ha percibido un cambio radical en la industria farmac\u00e9utica, que es hoy en d\u00eda una de las que m\u00e1s presupuesto invierte a nivel mundial. La innovaci\u00f3n se ha transformado en el objetivo n\u00famero uno de las empresas: ideas que sean rentables y sostenibles. Todo esto conlleva sin duda ventajas y desventajas. Existen muchos casos de las conocidas como enfermedades olvidadas que afectan a millones de personas y que, por su bajo aporte econ\u00f3mico versus elevado gasto en investigaci\u00f3n y desarrollo, son tambi\u00e9n olvidadas por la industria farmac\u00e9utica. En su mayor\u00eda se trata de enfermedades tropicales infecciosas que afectan fundament almente a la poblaci\u00f3n m\u00e1s empobrecida , como por ejemplo la leishmaniosis, la tuberculosis, la enfermedad del sue\u00f1o, la malaria o la enfermedad de Chagas, que generan un impacto devastador en la humanidad. El descubrimiento de f\u00e1rmacos se considera una actividad compleja y lenta. Sin embargo, en las \u00faltimas d\u00e9cadas, se est\u00e1n desarrolla ndo nuevos enfoques y m\u00e9todos con la intenci\u00f3n de descubrir nuevas entidades qu\u00edmicas de un modo nuevo y m\u00e1s eficiente nuevos paradigmas han tomado fuerza, como el conocimiento claro de la relaci\u00f3n mol\u00e9cula -receptor, de mecanismos moleculares/celulares implicados en las enfermedades o de modelos precl\u00ednicos que mimetizan de forma m\u00e1s real los procesos bioqu\u00edmicos y patol\u00f3gicos o de marcadores que monitorizan los efectos terap\u00e9uticos . Todas estas herramientas constituyen un buen soporte para la obtenci\u00f3n m\u00e1s eficaz de nuevos f\u00e1rmacos m\u00e1s eficaces y seguros. 4 Los qu\u00edmicos farmac\u00e9uticos, o qu\u00edmicos medicinales, presentan un papel importante en todo este proceso de cambio. Est\u00e1 en sus manos el conocimiento general de diferentes \u00e1reas que permiten el desarrollo de nuevos f\u00e1rmacos. Y su principal ventaja viene de la capacidad de adaptaci\u00f3n que los caracteriza.5 Por otro lado, tambi\u00e9n la organizaci\u00f3n de la forma de trabajo de los investigadores viene cambiando en los \u00faltimos a\u00f1os. Muchos cient\u00edficos est\u00e1n trabajando en fundaciones para la 24Cumarinas: Versatilidad estructural y aplicaciones en Qu\u00edmica Farmac\u00e9utica 2013 25 investigaci\u00f3n, centros paralelos a la universidad y compa\u00f1\u00edas virtuales, y han surgido nuevas colaboraciones entre grupos de trabajo de universidades e industria. Este aumento de la \"libertad de trabajo\" y de movilidad hace emerger importantes expectativas para el desarrollo de f\u00e1rmacos. Por otra parte, se est\u00e1n llevando a cabo inversiones significativas en cuanto a espacios modernos, nuevos equipamientos, y personal, en el sentido de aprovechar todo su potencial.4 Sin embargo, esta tendencia positiva de cambios en investigaci\u00f3n y desarrollo de f\u00e1rmacos no se extiende de forma global a la industria farmac\u00e9utica, y la cada vez m\u00e1s baja productividad medida en funci\u00f3n del n\u00famero de nuevos f\u00e1rmacos aprobados por la FDA, limitan de manera muy notable la contrataci\u00f3n de nuevos investigadores. 6 25Cumarinas: Versatilidad estructural y aplicaciones en Qu\u00edmica Farmac\u00e9utica 2013 26 1.1. Estruc turas qu\u00edmicas 1.1.1. Las cumarinas Las cumarinas son una gran clase de lactonas, de origen natural o s int\u00e9tico, constituidas por un anillo de benceno condensado a una anillo -pirona (Figura 1), y esencialmente poseen un sistema - conjugado rico en electrones, que posee buenas propiedades de transporte de carga.7,8 El primer representante de esta familia ha sido aislado por Vogel en el a\u00f1o de 1820, del haba de la tonka, cuyo nombre com\u00fan en Caribe es cumaru, que ha dado nombre a esta familia de compu estos. Esta especie de haba es designada en el sistema binominal por Coumarona odorata Aube (tambi\u00e9n conocida por Dipteryx odorata Willd) .8 Dicha estructura qu\u00edmica es denominada seg\u00fan la IUPAC como 2H-cromen-2-ona. O O234 5 6 7 8 Figura 1. 2H-1-benzopiran- 2-ona o 2H -cromen -2-ona (cumarina). Las cumarinas se producen de forma natural en plantas y microorganismos, y se han aislado aproximadamente 1000 derivados de m\u00e1s de 800 especies (ejemplos en la Figura 2). Figura 2. Angelica archangelica L. y Psoralea corylifolia. 26Cumarinas: Versatilidad estructural y aplicaciones en Qu\u00edmica Farmac\u00e9utica 2013 27 En la naturaleza las cumarinas pueden encontrar se en ra\u00edces, hojas, flores o frutos de diferentes familias de las Angiospermas, tales como Apiaceae, Rutaceae, Asteraceae, Umbelliferae, entre otras (Figura 3).7 Figura 3. Cumarinas existentes en las principales familias de Angiospermas. El esqueleto cumar\u00ednico se originan biosint\u00e9ticamente por lactonizaci\u00f3n del \u00e1cido cumar\u00ednico (2-hidroxi-Z-cin\u00e1mico), seg\u00fan la v\u00eda s int\u00e9tica descrita en la Figura 4.8 La bios\u00edntesis de cumarinas en las plantas superiores empieza con una reacci\u00f3n de 2- o bien 2,4-hidroxilaci\u00f3n del \u00e1cido cin\u00e1mico. Los hidroxicin\u00e1micos formados son posteriormente glucosilados y como tal se isomerizan posteriormente a los is\u00f3meros E. La ciclaci\u00f3n posterior de los mismos origina finalmente la cumarina o su 7-hidroxi derivado, la umbeliferona. Otros derivados de la cumarina, tales como esculetina (6,7 -dihidroxicumarina) o escopoletina (7-hidroxi-6-metoxicumarina) parecen derivar de la o xidaci\u00f3n de la umbeliferona y no a partir del correspond iente derivado \u00e1 cido o-cumaricoCOOH O O Cumarina Figura 4. Esquema general de la bios\u00edntesis de la cumarina. 27Cumarinas: Versatilidad estructural y aplicaciones en Qu\u00edmica Farmac\u00e9utica 2013 28 Las cumarinas son, en general, solubles en alcoholes y disolventes org\u00e1nicos. Son lactonas y como tales en un medio alcalino sufren hidr\u00f3lisis con formaci\u00f3n de sales y solubilizaci\u00f3n de la misma. Pueden someterse de nuevo al cierre del anillo de pirona en condiciones \u00e1cidas. Presentan un espectro ultravioleta (UV) caracter\u00edstico, que es fuertemente influenciado por sus sustituyentes. Presentan fluorescencia a la luz UV de coloraciones entre azul, amarillo o morado y que se intensifican en presencia de vapor es de amon\u00edaco.10 La diversidad estructural de los compuestos derivados de las cumarinas permite su clasificaci\u00f3n en cumarinas simples, o bien en cumarinas m\u00e1s complejas en general condensadas con otros heterociclos: furocumarinas, piranocumarinas, biscumarinas, cumarinolignanos y triscumarinas. 11 En cualquier caso, sobre la estructura base de la cumarina se pueden introducir sustituyentes de distinta naturaleza, lo que lleva a que existan cumarinas12 que pueden ser utilizadas, seg\u00fan el tipo de sustituyentes que poseen, con diversas finalidades: aditivos alimentarios, perfumes, cosm\u00e9ticos, productos agroqu\u00edmicos o bien como f\u00e1rmacos con la finalidad de estudiar, mejorar y ampliar el espectro de su actividad terap\u00e9utica. 13,14,15,16 El anillo cumar\u00ednico tiene la capacidad de establecer diverso tipo de interacciones no covalentes que incluyen interacciones hidr\u00f3fobas, - y electrost\u00e1ticas, as\u00ed como enlaces de hidr\u00f3geno, fuerzas de van der Waals, entre otras, con otras mol\u00e9culas activas y el sitio de activo en diferentes dianas de organismos vivos. As\u00ed, estas mol\u00e9culas presentan eficacia en una amplia gama de actividades biol\u00f3gicas. Las cumarinas presentan inter\u00e9s farmacol\u00f3gico como anticoagulantes, antioxidant es, antivirales, inhibidores enzim\u00e1ticos y antibacterianos. Adem\u00e1s, la caracter\u00edstica \u00fanica de contener ox\u00edgeno en el anillo de lactona tambi\u00e9n puede hacer de estas mol\u00e9culas un tipo de ligandos ideales para producir ensamblaje supramolecular y, por lo tan to, naturalmente, ser empleado en el dise\u00f1o racional y la s\u00edntesis de supramol\u00e9culas como agentes medicinales, en particular en los campos antibacteriano y antif\u00fangico, en que han demostrado ya un papel importante al que se ha prestado mucha atenci\u00f3n en lo s \u00faltimos a\u00f1os. Adem\u00e1s, las excelentes capacidades fluorescentes de los compuestos derivados de la cumarina basadas en las propiedades de riqueza en electrones y las 28Cumarinas: Versatilidad estructural y aplicaciones en Qu\u00edmica Farmac\u00e9utica 2013 29 propiedades de un buen transporte de carga favorecidas por un sistema conjugado -, las hace interesantes como receptores artificiales de iones, sondas fluorescentes para especies biol\u00f3gicamente importantes y marcadores biol\u00f3gicos para supervisar la actividad de enzimas, complejos eventos biol\u00f3gicos, as\u00ed como detectores de propiedades farmacol \u00f3gicas y farmacocin\u00e9ticas precisas. 17 1.1.1 .1. Actividad biol\u00f3gica de las cumarinas Como ya ha sido referido, desde hace mucho tiempo el estudio de diferentes grupos de trabajo se ha dirigido a la separaci\u00f3n y purificaci\u00f3n de cumarinas de origen natural, a partir de una gran variedad de plantas, animales y microorganismos, as\u00ed como hacia la s\u00edntesis de nuevos derivados de las cumarinas con el objetivo de explorar un amplio espectro de actividades farmacol\u00f3gicas. 18 Derivados de las cumarinas se encuentran en casi todas las categor\u00edas f\u00e1rmaco-terap\u00e9uticas. Algunas cumarinas han sido estudiada s por sus propiedades como cardioprotectores (anticoagulantes y/o vasodilatadores).19,20 Uno de los casos m\u00e1s conocidos son la warfarina y el a cenocumarol, ampliamente utilizados en cl\u00ednica como anticoagulante s. El carbocromeno, tambi\u00e9n disponible en la terap\u00e9utica actual, es otro ejemplo de una conocida cumarina con actividad cardioprotectora , debido a su acci\u00f3n vasodilatadora e inhibidora de la agregaci\u00f3n plaquetaria (Figura 5 ).18 Por otra parte, la modulaci\u00f3n del anillo cumar\u00ednico, permite obtener interesantes f\u00e1rmacos antiinflamatorios21,22 y/o antioxidantes23, sobre todo cuando sobre dicho anillo se introduce un anillo heteroarom\u00e1tico tipo pirazol (Figura 5).24,25,26 29Cumarinas: Versatilidad estructural y aplicaciones en Qu\u00edmica Farmac\u00e9utica 2013 30 O ONH3C CH3 Anti-inflamatorios y/o antioxidantesR = H Warfarina R = NO 2 AcenocumarolR Figura 5. Ejemplos de cumarinas con importancia terap\u00e9utica como cardioprotectores, antiinflamatorios y antioxidantes . Los derivados hidroxilados de cumarinas y flavonoides, tales como la umbeliferona y la esculetina (Figura 6 ), han sido descritos como inhibidores de la 5 -reductasa y de la tirosinasa.27,28 O O HOR R = H Umbeliferona R = OH Esculetina Figura 6. Estructuras de la umbeliferona y de la esculetina . En otros casos, las cumarinas se han revelado como agentes antivirales. As\u00ed, ha sido descrita una interesante actividad antivi ral HVC en cumarinas 3- y/o 4 -substituidas29,30,31,32,33,34 y m\u00e1s recientemente en sus ribonucle\u00f3sidos conjugados.35 Por su parte, la condensaci\u00f3n de un anillo pir\u00e1nico en el enlace h ha permitido el dise\u00f1o de cumarinas an\u00e1logas de la suksdorfina, compuesto natural con actividad anti-HIV (Figura 7).36 30Cumarinas: Versatilidad estructural y aplicaciones en Qu\u00edmica Farmac\u00e9utica 2013 31 OOO O ON NNN O HOOHS HOO O OO SuksdorfinaAntivirales anti-HIVO OOH Figura 7. Cumarinas 3/4-sustituidas y an\u00e1logos tric\u00edclicos , compuestos con actividad antiviral. Otro campo farmacol\u00f3gico en el que destaca cada vez m\u00e1s el n\u00facleo cumar\u00ednico es en el de la terapia anti-c\u00e1ncer. La geiparvarina (Figura 8) es uno de los ejemplos de compuestos cumar\u00ednicos con inter\u00e9s en dicha \u00e1rea. Es un derivado natural aislado de la Geijera parvioflora Lindl, conocido por su actividad citost\u00e1tica en ensayos in vitro. El n\u00facleo furano de esta mol\u00e9cula ha probado ser esencial para su actividad. Por su parte, cumarinas tambi\u00e9n en este caso 3 y/o 4-aril/heteroaril substituidas se han descrito como buenos inhibidores de la tubulina. 37,38 M\u00e1s recientemente, a partir de la importancia del antimicrobiano novobiocina, se han desarrollado los primeros an\u00e1log os con actividad anti- c\u00e1ncer (Figura 8).39,40 OO OS O O OH N OAntineopl\u00e1 sicos O O OOO GeiparvarinaOCH 3 OCH 3 H3CNH3CO O AntimicrobianoHN OOH O OOHO OONH2 NovobiocinaO OOH Geiparvarina y otros compuestos a nti-c\u00e1ncer . 31Cumarinas: Versatilidad estructural y aplicaciones en Qu\u00edmica Farmac\u00e9utica 2013 32 Las propiedades antibacterianas de las cumarinas han sido descritas por primera vez en 1945 por Goth y col. cuando se estudi\u00f3 el dicumarol.41 Es de destacar la actividad antimicrobiana encontrada para diversas cumarinas tales como la ya mencionada novobiocina (Figura 8) y sus an\u00e1logos, la clorobiocina y la cumermicina A 1. La novobiocina, aislada de Streptomyces niveus, es principalmente activa frente a bacterias Gram -positivas, si bien no se utiliza en la cl\u00ednica debido sobre todo a sus efectos secundarios y la dif\u00edcil solubilidad en agua.42 Por otro lado, estos tres ejemplos son antibi\u00f3ticos que presentan actividad contra Staphylococcus aureus (S. aureus) resistente a meticilina (MRSA).43 El n\u00famero de bacterias resistentes a m\u00faltiples f\u00e1rmacos es cada vez mayor y de especial importancia es el caso de las bacterias Gram -positivas MRSA. La capacidad de muchas especies tales como el de S. aureus para desarrollar resistencia a pr\u00e1cticamente todos los antibi\u00f3ticos es una preocupaci\u00f3n importante.44 Ello ha provocado el estudio de nuevos antimicrobianos sobre nuevas dianas terap\u00e9uticas y en este campo han emergido estructuras cumar\u00ednicas que interaccionan con la DNA helicasa,45,46 y que son activas frente a cepas resistentes a la ciprofloxacina.47 Algunos derivados de la cumarina han demostrado adem\u00e1s de las actividades antibacterianas, actividades antif\u00fangicas .48 Un estudio de los derivados cumar\u00ednicos sustituidos en el anillo pirona (derivados 3 -carboxilados) muestran tambi\u00e9n importantes actividades.49 Diferentes cumarinas 4- sustituidas, tal como las 4-clorocumarinas, mostraron tambi\u00e9n un interesante perfil antimicrobiano.50 Por otra parte, es tambi\u00e9n conocida la actividad antiparasitaria de estructuras derivadas de este anillo, y la creciente demanda de nuevos antiprotozoarios ha provocado la s\u00ed ntesis de nuevos f\u00e1rmacos de estructura flavonoide de lo s que destacamos la 8-(3-furil)cumarina, compuesto natural con actividad antileishmania, 51 o las 3-cinamoilcumarinas con actividad antimalaria.52 En otros casos, aunque menos frecuentes, se han desarrollado 4 - arilsulfonilmetilcumarinas con mar cada actividad tuberculost\u00e1tica (Figura 9).53,54 32Cumarinas: Versatilidad estructural y aplicaciones en Qu\u00edmica Farmac\u00e9utica 2013 33 O OO O OO OH R Antimal\u00e1 ricos Antileismania Tuberculost\u00e1 ticosO OSO2 Ar R Figura 9. Mol\u00e9culas con actividad antimicrobiana. Adem\u00e1s de las actividades farmacol\u00f3gicas mencionadas, merece una especial consideraci\u00f3n la importancia del anillo cumar\u00ednico como prototipo estructural en el dise\u00f1o de nuevos inhibidores de sistemas enzim\u00e1ticos muy directamente implicados en el desarrollo las enfermedades neurodegenerativas. 55,56 En 2006, se describi\u00f3 la actividad inhibidora de diversas 6-amidocumarinas (Figura 10 ) sobre la -secretasa (generalmente referenciada como BACE 1) y su potencial uso en la terapia de la enfermedad de Alzheimer (EA). 57 En el mismo a\u00f1o, se sintetizaron diver sas 8- sulfooxicumarinas (Figura 10) que parecen ser \u00fatiles en el tratamiento del estr\u00e9s oxidativo.58 Los inhibidores de la acetilcolinesterasa (AChE) han sido tambi\u00e9n ampliamente estudiados por el elevado inter\u00e9s de las cumarinas en enfermedades neurodegenerativas, en especial la EA. 59 O OX NO N O O OSO 3HHOHO Figura 10. 6-Amidocumarinas y 8-sulfooxicumarinas, compuestos con actividad como inhibidores enzim\u00e1tico s. En otros casos se han descr ito derivados cumar\u00ednicos multidiana con actividad inhibidora de la BACE 1 y de la AChE, ambas dianas de inter\u00e9s en la terapia de la EA (Figura 11).60 33Cumarinas: Versatilidad estructural y aplicaciones en Qu\u00edmica Farmac\u00e9utica 2013 34 O OO O O H3COH3CON CH2CH3 N HO F F N CH2CH3 Figura 11. Compuestos multidiana (BACE 1 y AChE). Como ya ha sido descrito, son muchas m\u00e1s las aplicaciones relacionadas con esta familia de mol\u00e9culas, sin embargo, la actividad farmacol\u00f3gica de las cumarinas m\u00e1s directamente relacionada con el presente trabajo es su acci\u00f3n inhibidora selectiva de la monoamino oxidasa B (MAO -B)59,60 y sus posibles aplicaciones terap\u00e9uticas,61,62 encontr\u00e1ndose en los \u00faltimos a\u00f1os una interesante actividad inhibidora de la MAO (IMAO) en algunos an\u00e1logos cumar\u00ednicos, 63 an\u00e1logos a los que nos referiremos m\u00e1s adelante. Teniendo en mente la etiolog\u00eda compleja de las enfermedades neurodegenerativas, y las diferentes dianas implicadas en ellas, tambi\u00e9n dedicaremos especial atenci\u00f3n en esta Memoria a la actividad inhibitoria dual MAO/AChE y a las propiedades antioxidantes de las cumarinas. Tambi\u00e9n se har\u00e1 una breve referencia a las cumarinas como ligandos de adenosina. 1.1.1 .2. S\u00edntesis de cumarina La s\u00edntesis de cumarinas y de sus derivados es un \u00e1rea de gran y permanente inter\u00e9s por el gran n\u00famero de compuestos de esta familia y el amplio espectro de actividades biol\u00f3gicas que presentan, tal y como se ha descrito anteriormente. En otros casos son muchas veces utilizadas como productos intermediarios en la s\u00edntesis de compuestos con po tencial inter\u00e9s farmacol\u00f3gico 64 tales como piranocumarinas,65 furocumarinas o 2-acil- resorcinoles.66,67 Cl\u00e1sicamente han sido estudiados varios procesos de s\u00edntesis para la obtenci\u00f3n de estos derivados,68,69 y si bien los primeros m\u00e9todos presentaban demasiados pasos y en general bajos rendimientos,70 hoy en d\u00eda las rutas 34Cumarinas: Versatilidad estructural y aplicaciones en Qu\u00edmica Farmac\u00e9utica 2013 35 sint\u00e9ticas m\u00e1s utilizadas recurren a reacciones de condensaci\u00f3n de Pechmann, Perkin, Knoevenagel , Reformatsky o Wittig (Figura 12).71,72,73,74 La primera es, sin duda, la m\u00e1s usada por la simplicida d de los materiales de partida y por los moderados rendimientos obtenidos en la utilizaci\u00f3n de determinados substratos.75,76 O O O O O OPechmann Knoevenagel 2EtBrR1 Figura 12. M\u00e9todos m\u00e1s com\u00fanmente empleados en la s\u00edntesis de las cumarinas. Hoy en d\u00eda, sin embargo, es cada vez mayor la utilizaci\u00f3n de la \" Green Chemistry\" que tiende a disminuir el uso de solventes potencialmente t\u00f3xicos y/o caros, recurriendo a la utilizaci\u00f3n de zeolitas, resinas etc. en las reacciones de Knoevenagel y Wittig,77 as\u00ed como a t\u00e9cnicas de irradiaci\u00f3n con microondas o la utilizaci\u00f3n de l\u00edquidos i\u00f3nicos, no detalladas en esta Memoria.78,79,80 En general, las cumarinas son obtenidas por condensaci\u00f3n de fenoles con - cetoesteres, en presencia de un catalizador \u00e1cido. Esta reacci\u00f3n, conocida como reacci\u00f3n de Pechmann, cursa con la formaci\u00f3n intermedia del \u00e9ster fen\u00f3lico y su posterior ciclaci\u00f3n en medio \u00e1cido. Esta v\u00eda sint\u00e9tica es muy utilizada para la obtenci\u00f3n de cumarinas naturales y otras benzopironas de inter\u00e9s biol\u00f3gico o industrial. 81 La reacci\u00f3n de Perkin consiste en la formaci\u00f3n de una cumarina mediante condensaci\u00f3n ald\u00f3lica entre un orto-hidroxibenzaldeh\u00eddo y el anh\u00eddrido de un \u00e1cido o el \u00e1cido, en presencia de la sal alcalina del mismo \u00e1cido.82 En un primer 35Cumarinas: Versatilidad estructural y aplicaciones en Qu\u00edmica Farmac\u00e9utica 2013 36 paso, el m\u00e1s r\u00e1pido de la reacci\u00f3n, la base genera el ani\u00f3n enolato del anh\u00eddrido que reac ciona con el aldeh\u00eddo (Figura 13 ).83 O H OHO OHO OO O OO OO O OHO OO H2O OHOH O O O Figura 13. Mecanismo general de la reacci\u00f3n de Perkin. En estos casos, el objetivo es mejorar las condiciones de reacci\u00f3n, disminuyendo el uso de reactivos, el tiempo de reacci\u00f3n, aumentando a la vez el rendimiento de la misma. Cambios de temperatura han sido muy favorables a esta reacci\u00f3n. Temperaturas muy ba jas llevaban a reacciones incompletas, y temperaturas muy altas a mezclas de reacci\u00f3n muy complejas y de dif\u00edcil purificaci\u00f3n. La utilizaci\u00f3n de la N,N'-diciclohexilcarbodiimida (DCC), en dimetilsulf\u00f3xido (DMSO), favorece la ciclaci\u00f3n posterior para formar el anillo cumar\u00ednico. Esta v\u00eda permite la reacci\u00f3n one-pot de una serie de cumarinas susceptibles de una s\u00edntesis en paralelo. En el caso particular del trabajo realizado en esta Memoria, las reacciones se llevaron a cabo por condensaci\u00f3n de salicilaldeh\u00ed dos sustituidos con los \u00e1cidos ac\u00e9ticos apropiados, usando DCC como agente deshidratante. Esta es una reacci\u00f3n muy vers\u00e1til proporcionando diferentes fam ilias de cumarinas sustituidas. En particular, los derivados acetoxilados de la cumarina se han sintetizado mediante la reacci\u00f3n de Perkin -Oglialoro de los derivados del \u00e1cido ac\u00e9tico con los respectivos salicilaldeh\u00eddos, en anh\u00eddrido ac\u00e9tico (Ac acetato pot\u00e1sico (CH 3COOK). La reacci\u00f3n de Perkin-Oglialoro es de hecho la modificaci\u00f3n m\u00e1s importante de la reacci\u00f3n tradicional de Perkin, donde se desarrolla la condensaci\u00f3n de aldeh\u00eddos arom\u00e1ticos con \u00e1cidos -arilac\u00e9ticos en anh\u00eddrido ac\u00e9tico y en presencia de una base d\u00e9bil (a trav\u00e9s de anh\u00eddridos mixtos generados in situ) para obtener \u00e1cidos -arilcin\u00e1micos. 84 36Cumarinas: Versatilidad estructural y aplicaciones en Qu\u00edmica Farmac\u00e9utica 2013 37 1.1.2. Los estilbenos (resveratrol ) El resveratrol85 es un compuesto de origen natural presente en especies de espermatofitas, como las vides, en respuesta a un da\u00f1o externo o interno, por ejemplo una infecci\u00f3n por hongos o exposici\u00f3n a la radiaci\u00f3n UV.86 Su presencia depende mucho del origen geogr\u00e1fico, de la especie o de la forma de cultivo de las vides, entre otros factores.87 Dado que se encuentra en la piel de la uva y no en la pulpa, existe en mayor concentraci\u00f3n en el vino tinto que en el vino blanco (donde el tiempo de contacto con la piel de la uva en la fermentaci\u00f3n es mucho m\u00e1s grande - mayor tiempo de maceraci\u00f3n). 88 Fue por primera vez detectado en la especie Vitis vin\u00edfera (Figura 14), en 1976, por Langcake y Pryce89 y en el vino tinto, en 1992, por Siemann y Creasy.90 Figura 14. Vitis vin\u00edfera. El inter\u00e9s por este compuesto y sus derivados se increment\u00f3 cuando los estudios epidemiol\u00f3gicos establecieron una relaci\u00f3n inversa entre el consumo de vino tinto y la incidencia de enfermedades cardiovasculares (paradoja francesa),91 adem\u00e1s de las propiedades hemost\u00e1ticas y del aumento del HDL circulante descrita para el etanol.92 Estructuralmente el resveratrol es el 3,4',5-trihidroxiestilbeno que, debido a la presencia del doble enlace, puede asumir las dos formas isom\u00e9ricas trans y cis (Figura 15). 37Cumarinas: Versatilidad estructural y aplicaciones en Qu\u00edmica Farmac\u00e9utica 2013 38 HOOH OH OHHO OH Figura 15. Formas isom\u00e9ricas del resveratrol (trans - y cis-resveratrol). La forma trans del resveratrol, parece ser la responsable de las principales propiedades farmacol\u00f3gicas de esta mol\u00e9cula. Es, hoy en d\u00eda, un producto comercial com\u00fan, a partir del que se puede obtener por irradiaci\u00f3n UV la forma cis. El distinto comportamiento de estos dos is\u00f3meros depende de su estructura tridimensional. La extracci\u00f3n del resveratrol y productos similares de las fuentes naturales es costosa en t\u00e9rminos de tiempo, dinero y bajos rendimientos, por lo que su extenso estudio y proyecci\u00f3n solo han sido posib les despu\u00e9s de su s\u00edntesis en laboratorio. Hoy en d\u00eda est\u00e1 bastante bien caracterizado, siendo sus bandas de UV (m\u00e1xima absorbancia a 307 nm para la forma trans y 280 nm para la forma cis) y absorci\u00f3n IR (banda de 2800 a 3500 cm -1 para el grupo hidroxilo y 965 cm-1 para el doble enlace en su forma trans) bien definidas.93 Por su gran inter\u00e9s farmacol\u00f3gico, el re sveratrol ha sido muy ampliamente estudiado en los \u00faltimos a\u00f1os.94,95 Presenta un gran n\u00famero de actividades destacando sobre todo sus propiedades antineopl\u00e1sicas,96 antiinflamatorias,97 cardioprotectoras (vasodilatador e inhibidor de la agregaci\u00f3n antioxidantes,99 mostrando ser muy eficiente convenientemente funcionalizado, como captador de radicales libres.96,100 Por otra parte, se ha comprobado la actividad inhibidora de la MAO en los is\u00f3meros cis y trans del resveratrol, siendo el cis-resveratrol menos efectivo que el trans-resveratrol, sobre dicha enzima.101 Este interesante perfil farmacol\u00f3gico hace del resveratrol un importante prototipo a partir del cual se ha iniciado la b\u00fasqueda de an\u00e1logos capaces de mejorar y/o incrementar su perfil farmacol\u00f3gico sobre todo en lo que respecta a su potencial aplicaci\u00f3n en enfermedades relacionadas con la edad , sobre todo las neurodegenerativas .102 Por este motivo, en la presente Memoria hemos incorporado dicha estructura a las ya mencionadas cumarinas con las que comparte en gran medida el mismo espectro ter ap\u00e9utico. 38Cumarinas: Versatilidad estructural y aplicaciones en Qu\u00edmica Farmac\u00e9utica 2013 39 A partir de este cabeza de serie, se han desarrollado nuevos polifenoles casi siempre mediante modificaciones muy sencillas del prototipo pero para los que se han encontrado una interesante actividad biol\u00f3gica (Figura 16). De ellas, seguramente la mas estudiada es la actividad antioxidante.103,104 Recientemente se ha llevado a cabo un estudio que establece la relaci\u00f3n entre dicha actividad antioxidante y su relaci\u00f3n con la quimioprevenci\u00f3n del c\u00e1ncer,100,105 mediante variaci\u00f3n del n\u00famero y/o posici\u00f3n de los grupos hidroxilo sobre el esqueleto estilbenico .106 Un estudio QSAR sobre dicho compuesto corrobora a su vez la influencia de fac tores est\u00e9ricos, de tama\u00f1o y forma, de los sustituyentes sobre el esqueleto estilb\u00e9nico.107 Por su parte, la introducci\u00f3n de sustituyentes sencillos tales como grupos metoxilo, amino, sulfato o \u00e1tomos de hal\u00f3genos, confiere al estilbeno diversas actividades tales como la antioxidante y neuroprotectora (debido a su actividad inhibidora de la agregaci\u00f3n amiloide) , encontrada tambi\u00e9n para los metabolitos sulfato conjugados a los que hemos aludido.104,108 Recientemente, se ha encontrado una interesante actividad antineopl\u00e1sica de an\u00e1logos polimetoxilados, actividad que sin embargo desaparece en los an\u00e1logos hidroxilados.109 Por su parte, la introducci\u00f3n de \u00e1tomos de fl\u00faor, as\u00ed como los grupos amino parecen sicosN(CH 3)2F de la mol\u00e9cula del resveratrol ( variaci\u00f3n de sustituyentes sobre la estructura trans -estilb\u00e9nica). 39Cumarinas: Versatilidad estructural y aplicaciones en Qu\u00edmica Farmac\u00e9utica 2013 40 Modificaciones m\u00e1s dr\u00e1sticas sobre el resveratrol implican la obtenci\u00f3n de imino an\u00e1logos mediante la substituci\u00f3n isost\u00e9rica del doble enlace etil\u00e9nico, que conservan la actividad anti oxidante,111 y para los que se encontr\u00f3 una interesante actividad inhibidora de la agregaci\u00f3n -amiloide (A) (Figura 17).112 N Atrapamiento radicales la SO2 CH3Cl Cl Figura 17. Substituci\u00f3n isost\u00e9rica del doble enlace etil\u00e9nico. Otra interesante modificaci\u00f3n sobre el estilbeno, supone la sustituci\u00f3n de uno de los dos anillos benc\u00e9nicos por un anillo het eroc\u00edclico m\u00e1s o menos complejo o la condensaci\u00f3n de este con otros ciclos, modificaciones que han permitido la preparac i\u00f3n de inhibidores enzim\u00e1ticos MAO -B como en el caso de los derivados de la estiril-cafe\u00edna113 o de la estiril-isatina (Figura 18).114 N NNNO ON HO O Estiril-isatina Inhibidores MAOCloro-estiril-cafeinaCl Figura 18. Substituci\u00f3n de uno de los dos anillos benc\u00e9n icos por biciclos . A su vez, la introducci\u00f3n de anillos heteroarom\u00e1ticos del tipo tiofeno o benzotiazol (Figura 19), permite la s\u00edntesis de estilbenoides capaces de actuar, por sus propiedades fluorescentes, como pru ebas de detecci\u00f3n de las placas A en la diagnosis de la EA.115 El an\u00e1logo pirid\u00ednico Amyvid (Figura 19) es uno de los cuatro agentes utilizados en el diagn\u00f3stico de la EA en humanos.116 40Cumarinas: Versatilidad estructural y aplicaciones en Qu\u00edmica Farmac\u00e9utica 2013 41 ArAr S RN SNMe 2S NH3CHN OF 3 Amyvid Figura 19. Introducci\u00f3n heteroarom\u00e1ticos de tipo tiofeno, benzotiazol o piridina . 1.2. Enfermedades neurodegenerativas Las enfermedades neurodegenerativas son cada vez m\u00e1s frecuentes con el envejecimiento general de la poblaci\u00f3n mundial. El siglo XX fue testigo de un importante cambio demogr\u00e1fico en la poblaci\u00f3n humana del mundo industrializado que se ha seguido de un cambio similar de la esperanza de vida a edades superiores en Asia, \u00c1frica y Am\u00e9rica Central y del Sur. La calidad de vida de la poblaci\u00f3n de edad avanzada en la sociedad de hoy es, en gran medida, determinada por el proceso normal de envejecimiento de las neuronas en el sistema nervioso central (SNC) y especialmente por la aparici\u00f3n de enfermedades caracterizadas por la p\u00e9rdida neuronal acelerada, que tradicionalmente son designadas como enfermedades neurodegenerativas. Estas enfermedades son las principales causas de morbilid ad y discapacidad en todo el mundo. La EA es la m\u00e1s prevalente enfermedad neurodegenerativa seguida de la enfermedad de Parkinson (EP). La EA es la causa m\u00e1s com\u00fan de demencia senil, que afecta a aproximadamente el 3% de la poblaci\u00f3n entre las edades de 65-74 a\u00f1os y casi el 50% de las personas de 85 a\u00f1os o m\u00e1s. 117,118 La esclerosis lateral amiotr\u00f3fica (ELA) y la enfermedad de Huntington afectan a un n\u00famero menor de pacientes, pero tienen consecuencias devastadoras. Un gran n\u00famero de enfermedades neurodegenerativas raras tienen similares efectos en los pacientes y sus familias que est\u00e1n tambi\u00e9n afecta das por estas enfermedades. La investigaci\u00f3n sobre la patog\u00e9nesis y el tratamiento de estos trastornos est\u00e1 creciendo de manera exponencial. En gran medida esto ha sido 41Cumarinas: Versatilidad estructural y aplicaciones en Qu\u00edmica Farmac\u00e9utica 2013 42 fomentado por importantes avances en la gen\u00e9tica, ya que ahora sabemos que las mutaciones se asocian con un gran n\u00famero de estas enfermedades . Esto incluye formas familiares de la EA, EP, la demencia fronto -temporal, ELA, enfermedad de Huntington y una variedad de ataxias. La mayor parte de los casos espor\u00e1dicos de las neurodegeneraciones co munes, tales como EA, EP y ELA parecen ser de origen polig\u00e9nica y son influenciados por factores ambientales todav\u00eda mal caracterizados. El objetivo final del diagnostico y terap\u00e9utica es prevenir estas enfermedades , ya sea en individuos en riesgo , antes de la aparici\u00f3n de manifestaciones cl\u00ednicas o para desarrollar eficaces terapias neuroprotectoras que retardan o detienen la progresi\u00f3n de la enfermedad en las primeras etapas. Las enfermedades neurodegenerativas son consideradas como uno de los retos m\u00e1s importantes de la medicina de hoy en d\u00eda debido a su complejidad, la frecuencia de aparici\u00f3n y el desarrollo progresivo. Las enfermedades neurodegenerativas son procesos patol\u00f3gicos que se caracterizan por degeneraci\u00f3n y muerte de las neuronas como consecu encia de la acumulaci\u00f3n de prote\u00ednas anormales en su interior, resultado de la desregulaci\u00f3n de diferentes neurotransmisores. Los procesos que generan este ac\u00famulo de prote\u00ednas son sumamente complejos y en la actualidad a\u00fan no son totalmente conocidos. En funci\u00f3n del estado de evoluci\u00f3n del paciente este va a presentar s\u00edntomas concretos que con el paso del tiempo se van acentuando. Por lo tanto, si las neuronas afectadas pertenecen al hipocampo, zona relacionada con la memoria, el paciente perder\u00e1 memoria y si el cuadro progresa desarrollar\u00e1 EA. Si la p\u00e9rdida neuronal se localiza en la sustancia negra, el paciente desarrollar\u00e1 EP por tratarse de un \u00e1rea relacionada con el movimiento; y si lo que se afectan son las neuronas motrices el paciente desarrollar\u00e1 ELA, que se caracteriza por causar una debilidad progresiva. Diferentes caracter\u00edsticas y procesos bioqu\u00edmicos tienen en com\u00fan generar procesos patol\u00f3gicos tr\u00e1gicos y devastadores, siendo necesaria una gran inversi\u00f3n en la investigaci\u00f3n para aliviar el sufrimiento humano causado por estas enfermedades. 117,118,119 1.2.1 . Enfermedad de Parkinson (EP) 42Cumarinas: Versatilidad estructural y aplicaciones en Qu\u00edmica Farmac\u00e9utica 2013 43 La principal aplicaci\u00f3n terap\u00e9utica de los inhibidores de la MAO -B es el tratamiento de la EP, un trastorno neurodegenerativo cr\u00f3nico y progresivo, caracterizado por una sintomatolo g\u00eda predominantemente motora acompa\u00f1ada casi siempre de s\u00edntomas no motores como depresi\u00f3n y ansiedad, y que es debido a una disminuci\u00f3n de los niveles de dopamina (DOPA) en el estriado por disfunci\u00f3n progresiva de neuronas nigroestriadas. 120 Esta enfermedad ha sido descrita por primera vez en 1817, por James Parkinson, en el \"An Essay on the Shaking Pulse\", como un desorden neurol\u00f3gico severo. Es una de las enfermedades de mayor incidencia en ancianos (prevalencia estimada en 1% de la poblaci\u00f3n por encima d e los 60 a\u00f1os de edad) y es caracterizada por cuatro se\u00f1ales esenciales: rigidez, temblor, bradicinesia e inestabilidad postural.121 Desde un punto de vista patol\u00f3gico, la EP se caracteriza por la p\u00e9rdida de las neuronas dopamin\u00e9rgicas de la v\u00eda nigroestriada, que se proyectan desde la zona compacta de la sustancia negra (SNC) hasta el estriado. Los s\u00edntomas de la EP aparecen cuando se ha destruido en torno al 80% de las neuronas dopamin\u00e9rgicas de esta v\u00eda. Adem\u00e1s de esta p\u00e9rdida neuronal, en la neurofisiopatolog\u00eda de la EP tambi\u00e9n aparecen cuerpos de Lewy, inclusiones de prote\u00ednas citoplasm\u00e1ticas, que no s\u00f3lo est\u00e1n presentes en neurona s dopamin\u00e9rgicas, sino tambi\u00e9n en sistemas noradren\u00e9rgicos ( Los cuerpos de Lewy est\u00e1n compuestos por distintas prote\u00ednas como la -sinucle\u00edna, la parkina, y la ubiquitina. N o son exclusivos de la EP, pudiendo encontrarse tambi\u00e9n, por ejemplo en la EA, o en la demencia de cuerpos de Lewy. El papel que desempa\u00f1an los cuerpos de Lewy en la EP no est\u00e1 todav\u00eda esclarecido. La etiolog\u00eda de esta enfermedad est\u00e1 todav\u00eda por esclarece r completamente debido a la complejidad y variedad de los factores implicados en su desarrollo. Son posibles causas de la EP la acci\u00f3n de neurotoxinas ambientales, producci\u00f3n de radicales libres, anomal\u00edas mitocondriales, predisposici\u00f3n gen\u00e9tica, envejecimiento cerebral, o incluso una asociaci\u00f3n de m\u00e1s de uno de estos factores. En lo que se refiere a la patog\u00e9nesis hay abiertas varias hip\u00f3tesis de investigaci\u00f3n, que incluyen distintos mecanismos que parecen estar implicados en el desarrollo de la enfermedad tales como el estr\u00e9s 43Cumarinas: Versatilidad estructural y aplicaciones en Qu\u00edmica Farmac\u00e9utica 2013 44 oxidativo, uno de los primeros factores de los que se pens\u00f3 que pod\u00eda contribuir al desarrollo de esta enfermedad. Basado fundamentalmente en la formaci\u00f3n de especies reactivas de oxigeno (ROS) a partir del metabolismo oxidativo de la DOPA, provocando un aumento de los niveles de hierro y una disminuci\u00f3n de los niveles del glutati\u00f3n reducido. Hay evidencias de que la inflamaci\u00f3n es otro proceso que podr\u00eda estar implicado en la patog\u00e9nesis de la EP. Tambi\u00e9n la excitotoxicidad, un proceso patol\u00f3gico que es capaz de da\u00f1ar a las neuronas y en el que aumenta la concentraci\u00f3n de glutamato, que a trav\u00e9s de radicales libres acaba provocando la muerte de las c\u00e9lulas por distintos mecanismos: apoptosis y autofagia. Por estos motivos, es necesario un gran esfuerzo en el estudio y nuevas alternativas terap\u00e9uticas de dicha enfermedad, alternativas que hoy en d\u00eda, tratan de paliar los s\u00edntomas de la EP, a la vez de otras que inhiben la evoluci\u00f3n del proceso neurodegenerativo. En otros casos, se recurre a terapias que act\u00faan en m\u00e1s de una diana, produciendo beneficios sintom\u00e1ticos y neuroprotectores, terapias que suelen ser m\u00e1s efectivas en el tratamiento de esta compleja enfermedad. 122 En los a\u00f1os 50, Arvid Carlsson demostr\u00f3 que la DOPA era un neurotransmisor y sus niveles en los ganglios basales eran bajos en modelos animales de parkinsonismo. Sus trabajos fueron la base para el desarrollo de distintos ensayos con levodopa (L -DOPA). Gracias a los buenos resultados del primer ensayo controlado de L -DOPA frente a placebo, publicados por Yahr y col. en 1969, este f\u00e1rmaco se convirti\u00f3 en fundamental para el tratamiento de la EP. La principal estrategia actual para el tratamiento de la EP est \u00e1 enfocada a la restauraci\u00f3n de la funci\u00f3n dopamin\u00e9rgica en el tejido estriado del cerebro. 123 El principal objetivo de esta terapia es aumentar/mantener los niveles normales de DOPA a nivel del SNC, donde existe un d\u00e9ficit de la inervaci\u00f3n dopamin\u00e9rgica, como consecuencia de le degeneraci\u00f3n de las neuronas dopamin\u00e9rgicas nigroestriales y consiguiente bajada de las reservas de DOPA. 124 Desde hace muchos a\u00f1os el aumento de los niveles de DOPA se consigue mediante administraci\u00f3n de L -DOPA,125 el intermediario metab\u00f3lico precursor de la DOPA, en combinaci\u00f3n con inhibidores de la dopa descarboxilasa perif\u00e9rica (DDC). Al mismo tiempo son administrados f\u00e1rmacos agonistas dopamin\u00e9rgicos que mimetizan los neurotransmisores mediadores de la 44Cumarinas: Versatilidad estructural y aplicaciones en Qu\u00edmica Farmac\u00e9utica 2013 45 DOPA.91 Esta estrategia es la metodolog\u00eda com\u00fan para el tratamiento de la enfermedad. As\u00ed, el aumento de los niveles de DOPA se puede conseguir con diversas estrategias: Facilitando la s\u00edntesis de la DOPA; Favoreciendo la liberaci\u00f3n de la DOPA de los dep\u00f3sitos presin\u00e1pticos; Disminuyendo la recaptaci\u00f3n de la DOPA ; Inhibiendo el catabolismo de la DOPA; Estimulando los receptores dopamin\u00e9rgicos. Estas terapias dopamin\u00e9rgicas ofrecen un ef ectivo alivio de los efectos motores asociados con la enfermedad, especialmente en estados poco avanzados de la misma. Sin embargo, la restituci\u00f3n de los niveles de la DOPA no evita la progresi\u00f3n neurodegenerativa de la EP y con el tiempo progresa la p\u00e9rdida neuronal y la eficacia de los f\u00e1rmacos si va disminuyendo. 92 Por este motivo, en los \u00faltimos a\u00f1os han surgido nuevas alternativas terap\u00e9uticas como la utilizaci\u00f3n de inhibidores de la catecol -o-metiltransferasa (COMT), como el caso de la entacapona, y de inhibidores selectivos de la MAO-B,126,127 de los cuales est\u00e1n comercializados en Espa\u00f1a la selegilina128 y la rasagilina (adem\u00e1s de su efecto inhibidor de la MAO -B, es tambi\u00e9n un importante neuroprotector)129 y a las que haremos alusi\u00f3n mas adelante. La selegilina ha sido el primer IMAO -B que se utiliz\u00f3 en cl\u00ednica. Administrada conjuntamente con L-DOPA permit\u00eda reducir la dosis a administrar de \u00e9sta. En monoterapia en pacientes con EP en estadios tempranos pod\u00eda retasar el comienzo del tratamiento con L -DOPA. La selegilina se metaboliza a derivados anfetam\u00ednicos, responsables de sus efectos secundarios y de la reducci\u00f3n del efecto neuroprotector. Uno de ellos, la metanfetamina es neurot\u00f3xica e interfiere con la acci\u00f3n neuroprotectora de la misma. La rasagilina es otro IMAO -B, m\u00e1s potente y selectivo, su principal diferencia respecto a la selegilina es que no se metaboliza en anfetamina o metanfetamina. Se metaboliza dando un \u00fanico compuesto que, a diferencia de lo que ocurre con los metabolitos de la selegi lina, el 1 -aminoindano ha mostrado actividad neuroprotectora. 45Cumarinas: Versatilidad estructural y aplicaciones en Qu\u00edmica Farmac\u00e9utica 2013 46 1.2.2 . Enfermedad de Alzheimer (EA) La EA, como dicho anteriormente, es una enfermedad neurodegenerativa y progresiva, que supone la causa m\u00e1s com\u00fan de demencia senil.130 La demencia es un trastorno cerebral que afecta gravemente la capacidad de una persona de llevar a cabo sus actividades cotidianas. La enfermedad debe su nombre al Dr. Alois Alzheimer que la ha descrito por primera vez en 1906. Sus s\u00edntomas incluyen p\u00e9rdida de la memoria, problemas de lenguaje y comportamiento impredecible. La EA comienza lentamente y progresa al largo del tiempo, primero afectando las partes del cerebro que controlan el pensamiento, la memoria y el lenguaje. La repercusi\u00f3n de esta enfermedad es tal, que se calcula entre 18 y 22 000 000 de personas afectadas a nivel mundial, con una prevalencia media entre el 3 y el 15% y una incidencia anual entre 0,3 y 0,7%. El desarrollo de la EA, est\u00e1 muy relacionado con los cambios histopatol\u00f3gicos que ocurren en el cerebro de estos pacientes. Estos cambios neuropatol\u00f3gicos, entre los que se citan: la p\u00e9rdida de neuronas y sinapsis, la angiopat\u00eda amiloidea, la placa senil, el cambio neurofibrilar de Alzheimer y el descubrimiento m\u00e1s reciente de las placas no amiliodes \"AMY plaque\", ocurren o se inician antes del comienzo de la declinaci\u00f3n cognitiva propia de la enfermedad (Figura 20). Existen evidencias, en pacientes con EA, de atrofia del hipocampo, liberaci\u00f3n de la prote\u00edna Tau por las neuronas lesionadas, uso de sustratos como energ\u00eda alternativa, dep\u00f3sito excesivo de la prote\u00edna A, presencia del alelo de la apolipoprote\u00edna E4 y mutaciones en los genes del precursor de la prote\u00edna amiloide (PPA) (cromosoma 21) y la presenilina 1 y 2 (cromosomas 14 y 1 respectivamente). 131 Aunque esta patolog\u00eda tiene como hemos indicado una etiolog\u00eda m\u00faltiple, parece ser fundamentalmente debida a la acumulaci\u00f3n de placas A en el cerebro, lo cual puede promover la degeneraci\u00f3n o atrofia de las neuronas colin\u00e9rgicas, fundamentalmente en la corteza cerebral y en el hipocampo. En consecuencia, cl\u00e1sicamente se ha recurrido al uso de los inhibidores de la AChE para su tratamiento farmacol\u00f3gico. 132,133 46Cumarinas: Versatilidad estructural y aplicaciones en Qu\u00edmica Farmac\u00e9utica 2013 47 Figura 20. Algunas de las caracter\u00edsticas m\u00e1s comunes de la EA. En la actualidad, sin embargo, se est\u00e1n generando nuevas expectativas al tener en cuenta otros aspectos relacionados con la etiolog\u00eda de la enfermedad tales como la disminuci\u00f3n en los niveles de DOPA, noradrenalina (NA) y serotonina o 5-hidroxitriptamina (5-HT), o bien el aumento de la actividad MAO - B cerebral, lo que origina un incremento de radicales libres, responsables del estr\u00e9s oxidativo y muerte celular, as\u00ed como del desarrollo de las placas A en los enfermos que padecen de EA. 134 Aunque se requieren m\u00e1s estudios para su clarificaci\u00f3n, se cree que el efecto beneficioso de los inhibidores selectivos de la MAO-B como la selegilina es debido a un doble efecto: reduc ci\u00f3n en la formaci\u00f3n de radicales libres y de incremento en los niveles de monoaminas en el cerebro de dichos enfermos.135 Por la complejidad de la etiolog\u00eda de esta enfermedad, la terap\u00e9utica actual se encamina al desarrollo de f\u00e1rmacos mutidiana en concreto a la obtenci\u00f3n de mol\u00e9culas que incorporan fragmentos estructurales responsables de una inhibici\u00f3n de las diferentes enzimas implicadas BACE, MAO -B, y/o de AChE136,137 y que adicionalmente confieran a las mol\u00e9culas caracter\u00edsticas antioxidantes .138,139,140,141 Esta es como indicamos una de las metodolog\u00edas m\u00e1s prometedoras y en la que nuestro grupo de investigaci\u00f3n est\u00e1 trabajando. 1.3. Principal d iana farmacol\u00f3gica en la Memoria - MAO s 47Cumarinas: Versatilidad estructural y aplicaciones en Qu\u00edmica Farmac\u00e9utica 2013 48 La MAO (E.C 1.4.3.4) fue descubierta por Mary Hare en 1928 y la denomin\u00f3 tiramina oxidasa. Posteriormente se vio que la oxidaci\u00f3n tambi\u00e9n afectaba a varias etilaminas como la DOPA, NA, adrenalina (A), 5 -HT y entonces se reconoci\u00f3 como MAO. Al tener como sustratos a ne urotransmisores tan importantes como estos, parece clara la influencia que tendr\u00e1 esta enzima en distintas funciones y patolog\u00edas cerebrales.142 Las MAO son una familia heterog\u00e9nea de flavoenzimas que catalizan la desaminaci\u00f3n de neurotransmisores y aminas ex\u00f3genas.143,144,145 Las MAO tienen unido de forma covalente el cofactor FAD.146 Las MAO est\u00e1n presentes en las membranas externas de las mitocondrias de c\u00e9lulas neuronales de la gl\u00eda, entre otras.147 La distribuci\u00f3n de las MAO no se restringe al SNC sino que tambi\u00e9n est\u00e1n presentes en la periferia. La MAO -A predomina en h\u00edgado y tracto gastrointestinal y la MAO -B en las plaquetas, en el cerebro y en menor cantidad en el h\u00edgado. Ambas isoformas est\u00e1n p resentes en el cerebro, aunqu e en distinta proporci\u00f3n (75 -80% de MAO-B) y con diferente distribuci\u00f3n, la MAO - B es la forma mayoritaria en los ganglios basales y predomina en neuronas seroton\u00e9rgicas y c\u00e9lulas de la gl\u00eda, a diferencia de la MAO -A que abunda en neuronas adren\u00e9rgicas, dopamin\u00e9rgicas y catecolamin\u00e9rgicas. 148,149 Como catalizadores de la desaminaci\u00f3n oxidativa de las monoaminas, las MAO utilizan el ox\u00edgeno para eliminar un grupo amino de una mol\u00e9cula, resultando el correspondiente aldeh\u00eddo y amoniaco, con la generaci\u00f3n de per\u00f3xido de hidr\u00f3geno (Figura 21). Los aldeh\u00eddos se metabolizan r\u00e1pidamente a los correspondientes \u00e1cidos. Las MAO catalizan la desaminaci\u00f3n oxidativa de neurotransmisores y aminas bi\u00f3genas, actuando sobre aminas primarias, y tambi\u00e9n en algunas secundarias y terciarias. En esta reacci\u00f3n son formadas especies reactivas de oxigeno (ROS), siendo que compuestos capaces de desarrollar mecanismos antioxidantes de destoxificaci\u00f3n pueden ser interesantes adyuvantes en la t erap\u00e9utica. !CH HR NH2+O2+H2O CH R O+NH3+H2O2 Figura 21. Reacci\u00f3n de desaminaci\u00f3n de neurotransmisores por las MAO. 48Cumarinas: Versatilidad estructural y aplicaciones en Qu\u00edmica Farmac\u00e9utica 2013 49 Las dos isoformas denominadas MAO -A y MAO-B (Figura 22)150,151 han sido identificadas en base a su secuencia de amino\u00e1cidos, su estructura tridimensional y la preferencia por determinados sustratos e inhibidores espec\u00edficos. 152 Aunque compartan 70% de la identidad de sus secuencias de amino\u00e1cidos,153 la MAO-A tiene mayor afinidad por 5-HT, A y NA154,155 mientras que la MAO-B desamina preferentemente la -feniletilamina y la bencilamina.156,157 Estas propiedades determinan la importancia cl\u00ednica de los inhibidores de la MAO158 como promisores f\u00e1rmacos para el tratamiento de enfermedades neurodegenerativas, depresi\u00f3n y/o obesidad.159 Existen evidencias de que con el paso de los a\u00f1os, a medida que progresa el envejecimiento aumenta la actividad cerebral de la MAO -B pero no la de la MAO-A. Los mayores aumentos aparecen en los ganglios bas ales y en el t\u00e1lamo, seguidos de la corteza frontal y en menor medida, cerebelo y cortezas parietal y temporal. 160 ! ! Figura 22. Diagrama virtual de los sitios activos de las isoformas MAO -A y MAO -B con un ligando 3 -arilcumar\u00ednico (im\u00e1genes del trabajo descrito en esta Maemoria) . El centro activo de las MAOs, donde se unir\u00e1 el sustrato, es una gran cavidad que se extiende desde el sitio de uni\u00f3n del FAD en el centro de la enzima a la superficie de la prote\u00edna en el lado opuesto del anillo de adenosina. Esta cavidad es de mayor tama\u00f1o en la isoforma MAO -B que en la MAO-A y en realidad, se compone de dos espacios separados: la cavidad del sustrato y la cavidad de entrada, la segunda frente al bucle 99 -112. El centro activo de la MAO-B es un ejemplo de flexibilidad ya que puede ser una gran cavidad \u00fanica o una cavidad dividida en dos seg\u00fan la conformaci\u00f3n del amino\u00e1cido Ile 199. 49Cumarinas: Versatilidad estructural y aplicaciones en Qu\u00edmica Farmac\u00e9utica 2013 50 Otro amino\u00e1cido que tambi\u00e9n est\u00e1 implicado, aunque no directamente, en la divisi\u00f3n en dos cavidades es el Tyr 326. De hecho, este par de residuos de amino\u00e1cidos junto con los Phe 208 -Ile 335 en el caso de la MAO -A determinan diferencias espec\u00edficas entre sustratos e inhibidores de ambas enzimas.161 Los primeros inhibidores de la MAO tales como la isoniazida y iproniazida eran no selectivos pero tras el descubrimiento de las distintas isoformas de la MAO comenzaron a desarrollarse inhibidores relativamente espec\u00edficos. Los inhibidores MAO -A selectivos (IMAO-A) como la clorgilina o la moclobemida son utilizados en el tratamiento del des\u00f3rdenes neurol\u00f3gicos tales como la depresi\u00f3n, mientras que los IMAO -B selectivos, tales como la selegilina y la rasagilina, son de utilidad y est\u00e1n autorizados en Espa\u00f1a para el tratamiento de la EP.162,163 Estos dos f\u00e1rmacos inhiben de forma selectiva e irreversible a la MAO-B, as\u00ed que no presentan los efectos no deseados de los inhibidores no selectivos. Al inhibir a la MAO -B, incrementan el tiempo de DOPA en el espacio sin\u00e1ptico, ya que entorno al 80% de la DOPA es metabolizada por esta enzima. Pierden la selectividad por la MAO -B a dosis altas, aumentando las reacciones adversas. Si se administran conjuntamente con L -DOPA pueden aparecer s\u00edntomas de hiperactividad dopamin\u00e9rgica que se solucionan disminuye ndo la dosis de L-DOPA administrada. Estos f\u00e1rmacos se pueden utilizar en estadios tempranos de la enfermedad por su posible efecto neuroprotector, ya que durante el metabolismo normal de la DOPA por la MAO -B se pueden generan radicales libres y tambi\u00e9n pa ra tratar los fen\u00f3menos de p\u00e9rdida de respuesta a L-DOPA. La selegilina fue el primer IMAO -B que se utiliz\u00f3 en el tratamiento de la EP. Es un derivado de propargilamina que inhibe de forma irreversible a la enzima. La absorci\u00f3n a trav\u00e9s del tracto gastroin testinal y la distribuci\u00f3n son r\u00e1pidas. Cruza la barrera hematoencef\u00e1lica y se acumula en regiones cerebrales ricas en MAO-B. Se metaboliza a N-desmetilselegilina, L-metanfetamina y L - anfetamina. La rasagilina tiene eficacia mejorada ya que presenta propiedades neuroprotectoras y tiene la ventaja de que se metabo liza en metabolitos no t\u00f3xicos. Al igual que la selegilina, es un derivado de propargilamina que inhibe a la enzima de forma irreversible. Se comporta como un inhibidor suicida y la interacci\u00f3n tiene lugar entre el N del grupo propargil y el N -5 del anillo de 50Cumarinas: Versatilidad estructural y aplicaciones en Qu\u00edmica Farmac\u00e9utica 2013 51 isoaloxazina del FAD. Se metaboliza por N -desalquilaci\u00f3n a nivel hep\u00e1tico, dando un \u00fanico compuesto no t\u00f3xico el 1 -(R)-aminoindano. A diferencia de lo que ocurre con los metabolitos de la selegilina, el 1-aminoindano ha mostrado actividad neuroprotectora.164 El perfil farmacol\u00f3gico de los IMAO -B no se limita a la inhibici\u00f3n de esta enzima sino que pueden tener un efecto neuroprotector, efecto antioxidante, protecci\u00f3n frente a neurotoxinas, aumento de la liberaci\u00f3n de DOPA, etc. Algunos de los inhibidores (MAO -A y MAO-B) de referencia est\u00e1n recopilados en la Figura 23. N O N HHNCH3 CH3 Iproniazida ClO N CH3 Clorgilina (I) (A) H N N HO N O (I) (I) (B)N ClO NHNH2 Lazabemida (R) (B) Figura 23. Inhibidores MAO -A y MAO -B reversibles (R) e irreversible (I). La reacci\u00f3n de desanimaci\u00f3n oxidativa catalizada por las MAO -A y MAO-B parece ser el mecanismo mayoritario sufrido por la DOPA a nivel del estriado (Figura 24). Inhibiendo estas enzimas a nivel central, se consigue inhibir la depleci\u00f3n de los niveles de la DOPA y elevar los niveles de DOPA end\u00f3gena y de DOPA producida por administraci\u00f3n de L -DOPA ex\u00f3gena.165 51Cumarinas: Versatilidad estructural y aplicaciones en Qu\u00edmica Farmac\u00e9utica 2013 52 NH2 HO HO Dopamina HO HO 3,4-dihidroxifenil- DOPA. 1.3.1 . Cumarinas y las MAOs En 1981 se encontr\u00f3 por primera vez una interesante actividad IMAO del n\u00facleo de las cumarinas, cuando un grupo organofosforado fue unido al anillo de la umbeliferona.166 Pero no fue hasta el 1990 cuando el n\u00facleo de las cumarinas ha sido convertido en un prometedor esqueleto con propiedades inhibidoras de las MAOs. 167,168 En particular, algunas cumarinas Psoralea corylifolia L., Peucedanum japonicum L. y Monascus anka K. han sido descritas como IMAOs.169 Aunque las cumarinas naturales, en general, muestran baja potencia inhibidora de las MA Os, modificaciones sobre estas cumarinas naturales han llevado a la obtenci\u00f3n de productos que han sido caracterizados como potentes y selectivos IMAOs. Por ejemplo, el an\u00e1logo desmetilado de la ya mencionada geiparvarina , una cumarina natural 7- substituida, extra\u00edda de las hojas de Geijera parviflora L., exhibe una potente y selectiva inhibici\u00f3n de la MAO -B (Figura 25).170 O O O O OO O OP ROROA A = S o O Figura 25. Derivados de la umbeliferona y de la geiparvarina. 52Cumarinas: Versatilidad estructural y aplicaciones en Qu\u00edmica Farmac\u00e9utica 2013 53 Varios grupos de investigaci\u00f3n han explorado la importancia del n\u00famero y posici\u00f3n de los diferentes sustituyentes en el n\u00facleo de cumarina , teniendo en cuenta el volumen est\u00e9rico, lipofilia y/o propiedades electr\u00f3nicas, con el fin de mejorar la actividad y la selectividad (Figura 26). O OR'O R O OO ONO O N O OHeterociclo OO de cumarinas estudiadas como IMAOs (parte de las estructuras pertenecen al trabajo descrito en esta Maemoria) . Aunque las posiciones 3 y 7 del anillo de cumarina han sido las m\u00e1s estudiadas, todas las posibilidades de sustituci\u00f3n se han tenido en cuenta y han sido sintetizados y evaluados un gran n\u00famero de derivados de la cumarina como IMAOs, siendo la mayor\u00eda de ellos activos y selectivos frente a la isoenzima MAO-B. 171 Los primeros estudios de relaci\u00f3n estructura -actividad (REA) sobre derivados de las cumarinas han sugerido que la selectividad viene determinada principalmente por la naturaleza de la uni\u00f3n entre la c umarina y el grupo 53Cumarinas: Versatilidad estructural y aplicaciones en Qu\u00edmica Farmac\u00e9utica 2013 54 sustituyente en la posici\u00f3n 7. Una serie de 7 -hidroxicumarinas con sustituyentes de tipo \u00e9ter, \u00e9ster o carbamato en la posici\u00f3n 7, con tama\u00f1o variable y diferente lipofilia, han sido investigados por su actividad inhibidora de las MAO-A y MAO-B. La mayor\u00eda de estos compuestos result\u00f3 ser preferentemente IMAO -B. Estudios de REA tambi\u00e9n han demostrado que la lipofilia es una propiedad importante para modular la potencia de inhibici\u00f3n de la MAO-B de las cumarinas anteriormente mencionadas. L a presencia de un grupo benciloxi en posici\u00f3n 7 result\u00f3 favorecer la uni\u00f3n de las cumarinas a la MAO-B, mientras que un anillo de fenilo -pobre en electrones en esa misma posici\u00f3n si bien parece mejorar tanto la actividad inhibitoria MAO -A como MAO- B, dando lugar a inhibidores menos selectivos. Por otra parte, se ha demostrado que un grupo alquilsulfoniloxi en la posici\u00f3n 7 proporciona actividad IMAO-A, como es el caso de la esuprona. Este efecto es a\u00fan m\u00e1s pronunciado en los grupos fenilsulfonatos, en que la sustituci\u00f3n con grupos aceptores de electrones conduce a m\u00e1s potentes y altamente selectivos IMAO - A. Tambi\u00e9n, B. Rendenbach-Mueller y col. han sintetizado y estudiado el potencial de derivados de \u00e9teres y \u00e9ster es de \u00e1cido sulf\u00f3nico (Figura 27 ), comprobando que la introducci\u00f3n de un enlace \u00e9ster sulf\u00f3nico, en lugar del puente \u00e9ter, cambia dr\u00e1sticamente el perfil de actividad de los nuevos compuestos. 51 O O O O O O O O OR3R4 R6R4 R3 R6 O2 S ZH3CH2CO2SR Esuprona Z (Substituido o no) Derivados cumar\u00ednicos 7- alkiloxi y sulfoniloxi substituidos. Sustituciones en las posiciones 3 y/o 4 del n\u00facleo de cumarina tambi\u00e9n contribuyen a modular la actividad inhibidora y la selectividad MAO -B de los derivados anteriormente descritos. Se puede inferir que el sitio de uni\u00f3n de la MAO-B debe aceptar sustituyentes lipof\u00edlicos de tama\u00f1o limitado en las posiciones 3 y/o 4 del n\u00facleo de cumarina, mientras que los grupos hidr\u00f3fobos, hidr\u00f3filos y/o m\u00e1s grandes, no son bien tolerados. Sin embargo, los derivados de 7-benziloxicumarinas, teniendo sustituyentes polares debidamente 54Cumarinas: Versatilidad estructural y aplicaciones en Qu\u00edmica Farmac\u00e9utica 2013 55 seleccionados en la posici\u00f3n 4, condujeron a nuevos IMAO -B con un mejor perfil farmacocin\u00e9tico.172 B. Rendenbach-M\u00fcller y col. tambi\u00e9n han explorado la importancia de la presencia de un grupo heteroarilalcoxi en la posici\u00f3n 7 del esqueleto de cumarina para modular la actividad contra las isoformas de la MAO. En este estudio, los peque\u00f1os grupos tipo alquilo, fenilo o hal\u00f3geno se introdujeron en las posiciones 3 y 4 del esqueleto. Los mismos autores han evaluado y descrito heteroarilalcoxicumarinas como p otentes y selectivos IMAO -B123,173 en los que se introdujeron peque\u00f1os sustituyentes , como grupos metilo, en las posiciones 3 y 4 de este n\u00facleo de cumarina. Desde el trabajo pionero de H. A. Kadir y col., y el descubrimient o del potencial del esqueleto de la cumarina frente a ambas isoformas de la MAO, han sido sintetizadas nuevas generaciones de mol\u00e9culas diferentemente sustituidos y evaluadas in vitro en ensayos farmacol\u00f3gicos. Algunos de los derivados descritos son compuestos muy activos y selectivos, con CI50 en el rango nanoMolar. Sobre la base de estos importantes estudios, hay varios proyectos en curso para el dise\u00f1o racional de f\u00e1rmacos basado en la estructura de las nuevas mol\u00e9culas.174 Estos descubrimientos sin duda facilitar\u00e1n la obtenci\u00f3n de nuevas terap\u00e9uticas eficaces y seguras de un problema creciente e importante de los pa\u00edses desarrollados: las e nfermedades neurodegenerativas. 55Cumarinas: Versatilidad estructural y aplicaciones en Qu\u00edmica Farmac\u00e9utica 2013 57 2. Antecedentes y objetivos Cumarinas: Versatilidad estructural y aplicaciones en Qu\u00edmica Farmac\u00e9utica 2013 59 2.1. Antecedentes En los \u00faltimos a\u00f1os se ha hecho un gran esfuerzo por conocer el mecanismo molecular de la interacci\u00f3n de los IMAO con los receptores de las MAO y ello ha originado un elevado n\u00famero de compuestos con esta actividad. Nuestro grupo ha elaborado una base de datos con la actividad I MAO experimental de m\u00e1s de 1000 compuestos entre los que hab\u00eda algunas estructuras cumar\u00ednicas preparadas en nuestro laboratorio ( Figura 28). No solo se encontraron algunos compuestos de inter\u00e9s y con cierta selectividad MAO - A, sino que adem\u00e1s se ha podido establecer un modelo QSAR capaz de predecir la actividad de actividad IMAO nuevas mol\u00e9culas.178,179 O O OO O O OO Cn IMAO -A IMAO -B Figura 28. Algunos derivados preparados previamente en el laboratorio. Desde su origen nuestro grupo de investigaci\u00f3n viene estudiando el esqueleto cumar\u00ednico y su modificaci\u00f3n estructural dirigida a diferentes intereses farmacol\u00f3gicos,18,56,175,176,177,178,179 habiendo realizados varias revisiones recientes sobre este tema.11,15 Adem\u00e1s de los referidos estudios de actividad IMAO, realizados en colaboraci\u00f3n con el Laboratorio de Farmacolog\u00eda de nuestra Facultad, est\u00e1bamos tambi\u00e9n colaborando en el estudio de otros prototipos cumar\u00ednicos , como potenciales cardioprotectoresy/o vasodilatadores .15 El destacado investigador de este grupo, Francisco Orallo, trabajaba desde hace tiempo en este campo obteniendo excelentes resultados y de manera muy destacada con el resveratrol, demostrando que posee una interesante actividad vasodilatadora e inhibidora de la agregaci\u00f3n plaquetaria, propiedades que permiten considerar al mismo como un interesante cardioprotector.55,87 A lo largo del trabajo presentado en esta Memoria hemos tambi\u00e9n tenido en cuenta como referencia para el dise\u00f1o de algunos de los compuestos estudiados como neuroprotectores, las estructuras de la sele gilina o la 59Cumarinas: Versatilidad estructural y aplicaciones en Qu\u00edmica Farmac\u00e9utica 2013 60 rasagilina como IMAO -B, o de la AP2238 o la fenserina como inhibidores de AChE (Figura 29), incorporando sobre el esqueleto cumar\u00ednico o 3 - arilcumar\u00ednico partes estructurales de estos compuestos buscando, en alg\u00fan caso, f\u00e1rmacos multidiana. NCH3 Selegilina MAOI-B/neuroprotectorCH3H Figura 29. Algunos de los compuestos de referencia usados en el dise\u00f1o de los nuevo s compuestos descritos en esta M emoria. Utilizamos tambi\u00e9n como estructuras de referencia la umbeliferona, conocida como inhibidor de la tirosinasa o la novobiocina, conocida como antibacteriano. Tambi\u00e9n las estructuras de la quercetina y de la catequina, importantes antioxidantes cumar\u00ednicos, han sido fuente de inspiraci\u00f3n para los estudios electroqu\u00edmicos y de capacidad antioxidante de nuestras mol \u00e9culas. 60Cumarinas: Versatilidad estructural y aplicaciones en Qu\u00edmica Farmac\u00e9utica 2013 61 2.2. Objetivos Debido a las propiedades encontradas en el resveratrol y algunas cumarinas,178 nos ha parecido muy interesante dise\u00f1ar y sintetizar compuestos que incorporasen en su esqueleto estas dos estructuras y que a su vez pueden considerarse an\u00e1logos estructurales de las citadas 3,4-benzocumarinas en las que el anillo benc\u00e9nico es introducido en la p osici\u00f3n 3 de la misma (Figura 30). O O O O Figura 30. Derivados h\u00edbridos cumarina- resveratrol. As\u00ed pues hemos planteado el estudio exhaustivo de estas nuevas estructuras h\u00edbridas, 3-arilcumarinas, en las cuales el anillo cumar\u00ednico comparte el anillo benc\u00e9nico y el doble enlace con el resveratrol de forma que este queda bloqueado como is\u00f3mero trans.179 Adem\u00e1s se pens\u00f3 en ampliar el estudio a h\u00edbridos donde la posici\u00f3n 3 estuviese sustituida por diferentes heterociclos (Figura 31). O ORR' O ORR'S O ON RR' Figura 31. Prototipo estructural del esqueleto de la s 3-aril y 3-heteroaril cumarina s (R y R' pueden ser \u00e1tomos de bromo o cloro, o bien grupos alquilo, alcoxi, hidroxilo, nitro, amino, etc). Se intentar\u00eda la s\u00edntesis de estas seri es utilizando metodolog\u00edas lo m\u00e1 s directas y vers\u00e1tiles posible intentado estrategias de alta eficacia, que nos permitiesen obtener los diferentes compuestos con alta pureza y en cantidad suficiente para los ensayos farmacol\u00f3gicos previstos. El estudio farmacol\u00f3gico inicial supon\u00eda observar la eficacia de serie s seleccionadas de estos compuestos sobre determinadas dianas con inter\u00e9s en 61Cumarinas: Versatilidad estructural y aplicaciones en Qu\u00edmica Farmac\u00e9utica 2013 62 problemas relacionados con la edad y en particular con trastornos neurodegenerativos. Especialmente MAO y AChE , implicadas de manera muy fundamental en enfermedades tales como la EP o la EA respectivamente. Adem\u00e1s, se pretend\u00eda asociar a estas propiedades mas espec\u00edficas, otras que pudiesen coadyuvar como son las propiedades antioxidantes. La selecci\u00f3n de estas series se realizar\u00eda con dos visiones complementarias: a) introducir sustituyentes de diferente naturaleza en distinto n\u00famero y posici\u00f3n, atendiendo fundamentalmente a variabilidad est\u00e9rica, electr\u00f3nica y/o de lipofilia (\u00e1tomos de cloro o bromo, grupos arilo, alquilo, alcoxilo, hidroxilo, nitro, amino y/o combinaciones de varios de estos \u00e1tomos y/o grupos , utilizado el diagrama de Craig) y b) utilizando datos precedentes y la l\u00f3gica bioqu\u00edmica, adem\u00e1s de la ayuda que pudi\u00e9semos obtener por el uso de metodolog\u00edas computacionales tanto de QSAR como de modelado molecular . En otras series, la posici\u00f3n 3 de la cumarina se substituy\u00f3 por puentes de tipo \u00e9ster, amida y carbamato, incorporando rasgos estructurales espec\u00edficos presentes en mol\u00e9culas de utilidad cl\u00ednica. En el sentido de explotar diferencias de reactividad y de actividad, los mismos sustituyentes han sido introducidos en diferentes posiciones del n\u00facleo cumar\u00ednico (Figura 32). O O O ORH N O R' OHN OR' R O OO ORR Figura 32. Prototipo estructural de diferentes derivados sintetizados y estu diados (R y R' pueden ser diferentes grupos ). Fue tambi\u00e9n un marcado objetivo intentar explorar con estas series o con modificaciones espec\u00edficas de las mismas en algunos casos, otras dianas farmacol\u00f3gicas o intereses terap\u00e9uticos. As\u00ed, se pens\u00f3 en explorar actividades quimioter\u00e1picas de diferente tipo, otras inhibiciones enzim\u00e1ticas como la tirosinasa, o interacci\u00f3n con otros receptores como los de adenosina... y esta es todav\u00eda una tarea inacabada. El objetivo global de la Tesis fue realizar un exhaustivo estudio de REA en este grupo de cumarinas y su inter\u00e9s en trastornos neurodegenerativos, siguiendo una metodolog\u00eda c\u00edclica de s\u00edntesis, evaluaci\u00f3n farmacol\u00f3gica, dise\u00f1o y de nuevo s\u00edntesis, intentando conocer mejor los procesos involucrados 62Cumarinas: Versatilidad estructural y aplicaciones en Qu\u00edmica Farmac\u00e9utica 2013 63 y obtener mol\u00e9culas de alto inter\u00e9s como nuevos f \u00e1rmacos. Un objetivo colateral pero no olvidado fue tambi\u00e9n explorar el valor de estas estructuras o an\u00e1logos muy pr\u00f3ximos , con intereses farmacol\u00f3gicos diferentes. 63Cumarinas: Versatilidad estructural y aplicaciones en Qu\u00edmica Farmac\u00e9utica 2013 65 3. Discusi\u00f3n de resultados Cumarinas: Versatilidad estructural y aplicaciones en Qu\u00edmica Farmac\u00e9utica 2013 67 El trabajo descrito en esta Memoria incluye la s\u00edntesis de series seleccionadas de compuestos y su caracterizaci\u00f3n estructural con la pureza y la calidad necesarias para su estudio farmacol\u00f3gico. Adem\u00e1s, incluye estudios te\u00f3ricos de las mismas. Parte de estos estudios son fruto de interesantes colaboraciones con grupos de la Universidad de Santiago de Compostela (en colaboraci\u00f3n con el Prof. Francisco Orallo y la Prof. Dolores Vi\u00f1a han sido realizados estudios de inhibici\u00f3n de la MAO -A, MAO-B, AChE y estudios de neuroprotecci\u00f3n, y en colaboraci\u00f3n con la Prof. Ysabel Santos y la Prof. Angeles Mu\u00f1oz han sido realizados estudios antibacterianos), de la Universidad de Cagliari (en colaboraci\u00f3n con la Prof. Marcella Corda han sido realizados estudios de inhibici\u00f3n de la tirosinasa), de la Universidad de Coimbra (en colaboraci\u00f3n con la Prof. Ana Maria Brett han sido realizados estudios electroqu\u00edmicos), de la Universidad de Santiago de Chile (en colaboraci\u00f3n con el Prof. Claudio Olea han sido realizados estudios de evaluaci\u00f3n de la capacidad antioxidante) y de la Universidad de W\u00fcrzburg (en colaboraci\u00f3n con el Prof. Karl-Norbert Klotz han sido realizados estudios en receptores de adenosina). Para tratar d e explicar los datos experimentales obtenidos, y extraer informaci\u00f3n de los ensayos in vitro y in vivo, han sido realizados estudios de docking y estudios te\u00f3ricos de capacidad de paso de membranas y otros par\u00e1metros de ADME (en colaboraci\u00f3n con Santiago V ilar y Giulio Ferino). Sin el esfuerzo conjunto no habr\u00edamos llevado a cabo todos estos proyectos ni hab\u00edamos obtenido los resultados presentes en esta Memoria. Estos estudios interdisciplinares demue stran que algunos de los compuestos evaluados son m\u00e1s activos y m\u00e1s selectivos que los compuestos de referencia frente a diferentes dianas farmacol\u00f3gicas. Adem\u00e1s, nos han permitido establecer interesantes REAs que nos permiten un dise\u00f1o racional de nuevos f\u00e1rmacos basados en las estructuras de los receptores y en las estructuras de los ligandos de los mismos. Como ha sido descrito en la I ntroducci\u00f3n, a lo largo del trabajo experimental presentado en esta Memoria, hemos utilizado la versatilidad de diferentes v\u00edas sint\u00e9ticas para obtener las amplias familias de derivados que han sido posteriormente caracterizados y estudiados. Hemos buscado las rutas sint\u00e9ticas m\u00e1s r\u00e1pidas y cuyos reactivos, preferencialment e de bajo coste, se 67Cumarinas: Versatilidad estructural y aplicaciones en Qu\u00edmica Farmac\u00e9utica 2013 68 adaptaban mejor a nuestras necesidades. A continuaci\u00f3n son brevemente descritas las reacciones m\u00e1s utilizadas en el trabajo experimental de esta Memoria. 3.1. S\u00edntesis 3.1.1. Preparaci\u00f3n de los esqueletos cumar\u00ednicos 3.1.1.1 . Reacci\u00f3n de Perkin y Perkin -Oglialoro La etapa clave del planteamiento sint\u00e9tico para la obtenci\u00f3n de las 3-aril y 3- heteroarilcumarinas ha sido una reacci\u00f3n de tipo Perkin180 entre un aldeh\u00eddo salic\u00edlico (orto-hydroxybenzaldeh\u00eddo) y un \u00e1cido aril /heteroarilac\u00e9tico, ambos convenientemente substituidos, en presencia de la sal s\u00f3dica del \u00e1cido.181 Las condiciones de esta reacci\u00f3n son sencillas, y el rendimiento muy satisfactorio.182 La versatilidad de esta reacci\u00f3n permiti\u00f3 obtener varias familia s de compuestos cuyos rendimientos var\u00edan entre 45 y 80%, dependiendo de los sustituyentes de los reactivos de partida. Los productos de reacci\u00f3n obtenidos se purificaron f\u00e1cilmente por cromatograf\u00eda de columna. En el caso de la preparaci\u00f3n de la s cumarinas planteadas para este trabajo, la s\u00edntesis v\u00eda Perkin ha sido llevada a cabo en presencia de DCC, usada como agente des hidratante, en DMSO a 110 \u00baC. Estas condiciones han sido la mejor soluci\u00f3n para la preparaci\u00f3n de todos los derivados, con excepci\u00f3n a los derivados con sustituyentes hidroxilo y los nitro derivados. Los derivados hidroxilados han sido prepa rados v\u00eda hidr\u00f3lisis de los respectivos derivados metoxilados, etoxilados o acetoxilados. Los derivados de tipo \"acetoxilo\" han sido preparados usando una reacci\u00f3n de Perkin modificada, tipo Perkin -Oglialoro, entre los salicilaldeh\u00eddos y los \u00e1cidos arilac\u00e9ticos, (Ac 2O) acetato pot\u00e1sico (CH 3COOK). Los derivados de tipo \"nitro\" se obtuvieron a trav\u00e9s de una reacci\u00f3n de Perkin modificada con nuevas condiciones, utilizando un salicilaldeh\u00eddo y un \u00e1cido arilac\u00e9tico, en presencia de hidru ro s\u00f3dico (NaH) en anh\u00eddrido ac\u00e9tico, por 20 horas.183 68Cumarinas: Versatilidad estructural y aplicaciones en Qu\u00edmica Farmac\u00e9utica 2013 69 La presencia de los anillos arom\u00e1ticos de las cumarinas preparadas es muy clara en los espectros de 1H RMN. Los protones arom\u00e1ticos aparecen en el espectro alrededor de 6.5-8 ppm, siendo H-4 el prot\u00f3n m\u00e1s desapantallado y el m\u00e1s f\u00e1cilmente identificable ya que es un singlete debido a la presencia de un grupo arilo en posici\u00f3n 3 de la cumarina. 3.1.1.2 . Reacci\u00f3n de acoplamiento con paladio Al largo del trabajo experimental hemos desarrollado alternativas a las v\u00edas sint\u00e9ticas tradicionales para la obtenci\u00f3n de nuestros compuestos. Un protocolo novedoso para la r\u00e1pida y eficiente s\u00edntesis de las 3 -arilcumarinas ha sido llevado a cabo, utilizando una reacci\u00f3n de cross-coupling catalizada por paladio en la forma de un complejo de paladio. Con esta metodolog\u00eda hemos preparado diferentes derivados a partir de \u00e1cidos bor\u00f3 nicos y 3-halogenocumarinas. La reacci\u00f3n se ha realizado en presencia de carbonato s\u00f3di co y una mezcla de DMF/H 2O (1:1), a 110 oC, por 120-180 minutos. Los rendimientos de reacci\u00f3n son del orden del 60%. Este m\u00e9todo directo tiene la desventaja de la limitaci\u00f3n de los reactivos de partida. Por esta raz\u00f3n lo hemos utilizado simplemente como v\u00eda alternativa a las reacciones que tradicional ven\u00edamos utilizando.184 3.1.2. Transformaciones funcionales 3.1.2.1 . Reacci \u00f3n de \u00e9ter los derivados mono- o poli-metoxilados y/o etoxilados y/o acetoxilados han sido hidrolizados para la obtenci\u00f3n de los correspon dientes derivados hidroxilados. Los m\u00e9todos m\u00e1s comunes para esta transformaci\u00f3n recurren a reacciones en la presencia de un \u00e1cido de Lewis como el MgI 2,185 el AlCl 3,186 el BBr 3187 o el AlBr 3. Como fuentes de protones son utilizados \u00e1cidos o alcoholes, siendo de uso com\u00fan el HCl, el MeOH o el EtOH. Estas reacciones se llevan a cabo, en su gran mayor\u00eda, utilizando como disolventes diclorometano, acetonitrilo, acetona, tetrahidrofurano o piridin a. 69Cumarinas: Versatilidad estructural y aplicaciones en Qu\u00edmica Farmac\u00e9utica 2013 70 Otra forma de hidrolizar los derivados preparad os, utilizada por nuestro grupo, es la reacci\u00f3n con el \u00e1cido yodh\u00eddrico, en presencia de \u00e1cido ac\u00e9tico y anh\u00eddrido ac\u00e9tico. Esta reacci\u00f3n se llev\u00f3 a cabo a reflujo, durante 4 -5 horas. Los productos de reacci\u00f3n han sido de dif\u00edcil purificaci\u00f3n, pero con rendimientos muy satisfactorios. La caracterizaci\u00f3n de los compuestos obtenidos es muy clara por 1H RMN, ya que el/los picos de los grupos -OCH 3 desaparecen claramente de la zona entre 3-4 ppm, apareciendo uno o m\u00e1s picos/bandas muy caracter\u00edsticos en la regi\u00f3n de los 10 ppm. Los compuestos acetoxilados originaron los correspondientes derivados hidroxilados mediante la desacetilaci\u00f3n en presencia de una soluci\u00f3n acuosa de HCl 2N y metanol, en reflujo, por 4 horas. As\u00ed, cuando el objetivo del trabajo se centraba en los derivados hidroxilados y no en los metoxilados precursores, seguimos fundamentalmente esta v\u00eda porque te trata de una reacci\u00f3n m\u00e1s limpia y m\u00e1s f\u00e1cil de procesar. 3.1.2.2 . Reacci\u00f3n de halogenaci\u00f3n La halogenaci\u00f3n de compuestos arom\u00e1ticos y heteroarom\u00e1ticos es una importante reacci\u00f3n en s\u00edntesis org\u00e1nica. 188 Derivados de bromuros de arilo y heteroarilo pueden ser potenciales antioxidantes, antibacterianos o agentes antitumorales.189,190 Adem\u00e1s, la introducci\u00f3n de hal\u00f3genos en las 3 - arilcumarinas hace de estas mol\u00e9culas precursores interesantes para muchos otros derivados sustituidos. Esto hace de la bromaci\u00f3n una reacci\u00f3n muy vers\u00e1til y, por lo tanto, ampliamente estudiada. Habitualmente son utilizados como agentes de bromaci\u00f3n el tribromuro del tetraalquilamonio,191 el tribromuro de hexametilenotetramina192 y la N-bromosuccinimida (NBS).193,194 Sin embargo, debido a su disponibilidad y el f\u00e1cil manejo, este \u00faltimo es el principal agente de bromaci\u00f3n. En fase s\u00f3lida195 o en reacciones tradicionales, el uso de NBS es un m\u00e9todo de monobromaci\u00f3n eficaz y vers\u00e1til de arom\u00e1ticos y sus derivados, como son las cumarinas. 196,197 Las condiciones de reacci\u00f3n, la simplicidad y la velocidad del proceso son las vent ajas de este m\u00e9todo, llevado a cabo con rendimientos muy buenos. La bromaci\u00f3n sobre el n\u00facleo de la cumarina no substituida ocurre preferentemente en el C-3. Como en las 3- 70Cumarinas: Versatilidad estructural y aplicaciones en Qu\u00edmica Farmac\u00e9utica 2013 71 arilcumarinas esta posici\u00f3n se encuentra bloqueada por un arilo, la posici\u00f3n de bromaci\u00f3n sobre estas mol\u00e9c ulas depender\u00e1 de la naturaleza de los sustituyentes presentes en los anillos arom\u00e1ticos.198 En nuestro caso todos los derivados han sido preparados mediante una reacci\u00f3n de bromaci\u00f3n cl\u00e1sica, con NBS y una cantidad catal\u00edtica de azobisisobutironitrilo (AIBN), en tetracloruro de carbono (CCl 4). Las reacci\u00f3n se mantuvo a reflujo 24 horas, y los productos obtenidos han sido separados por cromatograf\u00eda en columna. Los rendimientos de reacci\u00f3n var\u00edan entre 40 y el 60%. Siempre que la 3-arilcumarina no presentaba sustituyentes en el grupo 3- arilo, y ten\u00eda un metilo en cualquiera de los otros dos anillos, la bromaci\u00f3n ocurri\u00f3 en este grupo metilo, permitiendo la obtenci\u00f3n de un derivado bromometilado. As\u00ed, en el caso de la 6-metil -3-fenilcumarina, tuvo lugar la bromaci\u00f3n benc\u00edlica, lo que ha permitido la obtenci\u00f3n de la 6-bromometil-3- fenilcumarina.199 En el caso de los derivados con sustituyentes activantes (por ejemplo grupos metoxilo) en el 3-arilo la bromaci\u00f3n tuvo lugar en una posici\u00f3n orto respecto a los mismos. La reacci\u00f3n descrita ha permitido la obtenci\u00f3n de un gran n\u00famero de derivados halogenados en diferentes posiciones del n\u00fac leo de la cumarina. Estos pudieron ser, adem\u00e1s de nuevos productos, importantes precursor es para otros derivados, ya que es posible su substituici\u00f3n. 3.1.2 .3. Reacci\u00f3n de formaci\u00f3n de arilaminas Por aminaci\u00f3n de derivados halogenados Las arilaminas primarias pueden tener inter\u00e9s biol\u00f3gico por si mismas y son adem\u00e1s importantes intermediarios de reacci\u00f3n en la s\u00edntesis de nuevos f\u00e1rmacos. Cuando se obtienen a partir de los correspondientes haluros de arilo se realiza utilizando amoniaco como nucle\u00f3filo.200 Los principales problemas de esta reacci\u00f3n son la necesidad de presi\u00f3n y temperatura elevadas, y que l os arinos intermediarios son muy inestables, haciendo esta reacci\u00f3n muy complicada. Por este motivo, la utilizaci\u00f3n de catalizadores de cobre y otros metales de transici\u00f3n ha sido ampliamente estudiada , pero a\u00fan asi sus 71Cumarinas: Versatilidad estructural y aplicaciones en Qu\u00edmica Farmac\u00e9utica 2013 72 condiciones de presi\u00f3n y temperatura son bastante elevadas y la reacci\u00f3n es compatible con muy pocos grupos funcionales.201 Para evitar estos inconvenientes ha sido desarrollado un m\u00e9todo sus tituyendo el amoniaco por trifluoracetamida. En est e caso el grupo trifluoracetilo se puede eliminar f\u00e1cilmente en condiciones suaves. El punto clave de esta reacci\u00f3n es el acoplamiento cruzado entre la amida y los haluros de arilo. Distintos ligandos han sido probados para promover el acoplamien to cruzado catalizado por cobre, siendo la N,N'-dimetiletilenodiamina (DMEMA) la que mejores rendimientos presenta. 202 En presencia de un yoduro de arilo necesita apenas de 45 \u00baC para que la reacci\u00f3n ocurra , si bien, en nuestro caso, los bromuros de arilo necesitaron de una temperatura de 75 \u00baC para optimizar la reacci\u00f3n. El mejor sistema catal\u00edtico ha mostrado ser el CuI/DMEDA y la reacci\u00f3n ha sido optimizada mediante tubo sellado a presi\u00f3n. Los bromuros de arilo han pudido ser convertidos en los productos deseados co n rendimientos aceptables entre 60-80 %) . El grupo trifluoracetilo formado e n la reacci\u00f3n pudo ser eliminado de forma sencilla a\u00f1adiendo una mezcla de metanol/agua en el tubo de reacci\u00f3n. El \u00e9xito de la reacci\u00f3n tambi\u00e9n fue debido a la presencia de carbona to de potasio (K2CO 3) en el paso de amidaci\u00f3n, que promovi\u00f3 la hidr\u00f3lisis del grupo trifluoracetilo cuando el agua fue a\u00f1adida. Teniendo en cuenta todos estos factores, la reacci\u00f3n ha sido llevada a cabo seg\u00fan este nuevo m\u00e9todo one-pot de s\u00edntesis de arilaminas primarias partiendo de haluros de arilo, sin necesidad de aislar intermediarios de reacci\u00f3n. 203 Por reducci\u00f3n de grupo s nitro Las 3-aminocumarinas se prepararon a partir de las 3 -nitrocumarinas previamente sintetizadas o comerciales, en etanol, con Pd/C como catalizador en atm\u00f3sfera de hidrogeno (H 2). La reacci\u00f3n se ha llevado a cabo a temperatura ambiente por 5 horas. El rendimiento es del orden del 92-98%. 3.1.2.4 . Reacci\u00f3n de alquilaci\u00f3n - reacci\u00f3n de Williamson 72Cumarinas: Versatilidad estructural y aplicaciones en Qu\u00edmica Farmac\u00e9utica 2013 73 Uno de los objetivos de este trabajo ha sido estudiar la presencia de distintos grupos sustituyentes para estudios de REA para lo que interes\u00f3 introducir en los compuestos diferentes cadenas alqu\u00edlicas. Algunos de los derivados hidroxilados han sido transformados en \u00e9teres de forma sencilla y eficaz utilizando la reacci\u00f3n de Williamson.204 La utilizaci\u00f3n de una clorocetona como halogenuro de partida ha permitido la preparaci\u00f3n numerosos derivados con sustituyentes en las posiciones deseadas. Los datos de 1H RMN permitieron claramente observar la formaci\u00f3n de los -ceto\u00e9teres deseados. En todos los casos se ha visto claramente la desaparici\u00f3n del prot\u00f3n hidrox\u00edlico. Y la aparici\u00f3n de nuestros grupos a diferentes ppm. La versatilidad de esta reacci\u00f3n ha permitido introducir en la mol\u00e9cula alcanos, cicloalcanos (en nuestro caso particular de cinco o seis \u00e1tomos) o bien haloalcanos m\u00e1s o menos grandes. 3.1.2.5 . Preparaci\u00f3n de amidas , \u00e9steres y carbamatos La segunda parte de los objetivo s del trabajo descrito en esta Memoria ha sido la s\u00edntesis de cumarinas con funciones amida , \u00e9ster o carbamato partiendo de las correspondientes aminocumarinas o hidroxicumarinas precursoras. Hemos recurrido a aminocumarinas comerciales sencillas o nitrocumarinas que han sido previamente reducidas. Una reacci\u00f3n de acilac i\u00f3n de las amino/hidroxicumarinas con un cloruro de \u00e1cido convenientemente sustituido, utilizando piridina y diclorometano, a la temperatura ambiente, durante tres horas, nos permiti\u00f3 obtener las diferentes cumarinas substituidas, con muy buenos rendimientos (80-95%). 3.1.3. Series de compuestos sintetizados En las siguientes tablas est\u00e1n reunidas todas las estructuras qu\u00edmicas de las mol\u00e9culas descritas en la publicaciones presentadas en esta Memoria. Tabla 1. Cumarinas sencillas. 73Cumarinas: Versatilidad estructural y aplicaciones en Qu\u00edmica Farmac\u00e9utica 2013 74 OR3 R8R7R4 R6 Compuesto R3 R4 R6 R7 R8 1 NO 2 H H H H 2 NO 2 H H OCH 3 H 3 NO 2 H H H OCH 3 4 NO 2 H CH 3 H H 5 NO 2 H H H CH 3 6 NO 2 H OCH 3 H H 7 NO 2 H H OCH 3 H 8 NH 2 H H H H 9 NH 2 H OCH 3 H H 10 NH 2 H H OCH 3 H 11 NH 2 H H H OCH 3 12 NH 2 H H OH H 13 NH 2 H H H OH 14 NH 2 OH H H H Tabla 2. H H H H H H 16 H H H OCH 3 H H 17 H H H H OCH 3 H 18 H H H OH H H 19 H H H NO 2 H H 20 H H H H NO 2 H 21 H H H NH 2 H H 22 H H H H CH 3 H 74Cumarinas: Versatilidad estructural y aplicaciones en Qu\u00edmica Farmac\u00e9utica 2013 75 23 H H H H Cl H 24 CH 3 H H H H H 25 CH 3 H H CH 3 H H 26 CH 3 H H H CH 3 H 27 CH 3 H OCH 3 H H H 28 CH 3 H H OCH 3 H H 29 CH 3 H H H OCH 3 H 30 CH 3 H H OCH 3 H OCH 3 31 CH 3 H H OCH 3 OCH 3 H 32 CH 3 H H OCH 3 OCH 3 OCH 3 33 CH 3 H H Br OCH 3 H 34 CH 3 H H OCH 3 Br H 35 CH 3 H Br OCH 3 H OCH 3 36 CH 3 H Br OCH 3 OCH 3 OCH 3 37 CH 3 H OH H H H 38 CH 3 H H OH H H 39 CH 3 H H H OH H 40 CH 3 H H OH OH H 41 CH 3 H Br H H H 42 CH 3 H H Br H H 43 CH 3 H H H Br H 44 CH 3 H H C2H5O2 H H 45 CH 3 H H H NO 2 H 46 CH 3 H H NH 2 H H 47 CH 3 H H H NH 2 H 48 OCH 3 H H H H H 49 OCH 3 H H CH 3 H H 50 OCH 3 H H H CH 3 H 51 OCH 3 H H H OCH 3 H 52 OCH 3 H H NO 2 H H 53 OCH 3 H H H NO 2 H 54 OCH 3 H H Br H H 55 OCH 3 H H H Br H 75Cumarinas: Versatilidad estructural y aplicaciones en Qu\u00edmica Farmac\u00e9utica 2013 76 56 OH H H H H H 57 OH H H H CH 3 H 58 OH H H Br H H 59 OH H H H Br H 60 C2H5O2 H H H CH 3 H 61 C2H5O2 H H Br H H 62 C2H5O2 H H H Br H 63 C5H9O H H H CH 3 H 64 C5H9O H H Br H H 65 C5H9O H H H Br H 66 C2H2O2Cl H H Br H H 67 C2H2O2Cl H H H Br H 68 NO 2 H H NO 2 H H 69 NO 2 H H H NO 2 H 70 NO 2 H H OCH 3 H H 71 NO 2 H H H OCH 3 H 72 NO 2 H H CH 3 H H 73 NO 2 H H H CH 3 H 74 NO 2 H H Br H H 75 NH 2 H H H H H 76 NH 2 H H NH 2 H H 77 Br H H H OCH 3 H 78 BrCH 3 H H H H H 79 CH 3 Br H H H H 80 CH 3 Br H H OCH 3 H 81 CH 3 Br H OCH 3 H OCH 3 82 CH 3 Br H OCH 3 OCH 3 OCH 3 83 Br OCH 3 H H H H 84 Br OCH 3 H H OCH 3 H 85 Br OCH 3 H H CH 3 H 86 Br OH H H H H 87 Br OH H H OH H 88 Br OH H H CH 3 H 76Cumarinas: Versatilidad estructural y aplicaciones en Qu\u00edmica Farmac\u00e9utica 2013 77 89 NH 2 OCH 3 H H H H 90 H OCH 3 H H H H 91 H OCH 3 H H Br H 92 H OCH 3 H H OCH 3 H 93 H CH 3 H H H H 94 H CH 3 H H OCH 3 H 95 H CH 3 H H CH 3 H 96 H CH 3 H H Br H 97 H CH 3 H OH OH H 98 H CH 3 H OH OH OH 99 H CH 3 H OH H OH 100 H OCH 2CH 3 H H H H 101 H OCH 2CH 3 H H OCH 3 H 102 H OCH 2CH 3 H H CH 3 H 103 H OH H H H H 104 H OH H H OH H 105 H OH H H CH 3 H Tabla 3. 3-Heteroarilcumarinas. O OH3C R3 Compuesto R3 106 N Cl 107 S 108 S Br 109 S NH2 Tabla 4. (Cumarin-3-il)-4-metilbenzoato. 110 O OO OCH3 77Cumarinas: Versatilidad estructural y aplicaciones en Qu\u00edmica Farmac\u00e9utica 2013 78 Tabla 5. 3-Amidocumarinas. O OH N OR1' R6R4 Compuesto R4 R6 R1' 111 H H CH 3 112 OH H CH 3 113 H H CH 2Br 114 H H CH 2Cl 115 H CH 3 CH3 116 H H 117 H H CH3 118 H H OCH3 119 H H Cl 120 H H NO2 121 H H OCH3 OCH3 122 H H OCH3 OCH3OCH3 123 H H Cl Cl 124 H H Tabla 6. 3-Carbamatocumarinas. O OH N O R1' OR4 Compuesto R4 R1' 78Cumarinas: Versatilidad estructural y aplicaciones en Qu\u00edmica Farmac\u00e9utica 2013 79 125 H CH 3 126 H CH 2CH 3 127 H CH(CH 3)2 128 H CH 2CH(CH 3)2 129 H CH 2Cl 130 H CH 2CH 2Br 131 H 132 H 133 OH CH 2CH 3 134 OH CH 2CH(CH 3)2 3.2. Estudio biol\u00f3gico y relaci\u00f3n estructura -actividad (REA) Despu\u00e9s de realizados diferentes ensayos biol\u00f3gicos in vitro y en algunos casos in vivo, y de un estudio REA m\u00e1s detallado, ha sido posible establecer importantes conclusiones de la relaci\u00f3n estructura/actividad de los compuestos preparados. En general los compuestos descritos son potentes inhibidores selectivos de la MAO -B,205 la diana m\u00e1s estudiada en este trabajo , siendo los que presentan el esqueleto 3 -arilcumarina los que demostraron ser los m\u00e1s interesantes.206,207 De todas las posiciones estudiadas, es muy favorable la introducci\u00f3n de grupos poco voluminosos (por ejemplo metilo, bromo o metoxilo) tanto en posici\u00f3n 6 y/o 8 como en las posiciones 3' y/o 4' del n\u00facleo de la 3 -arilcumarina.208 Grupos de diferente tama\u00f1o, como otros anillos o diferentes \u00e9teres, han demostrado bajar en gran escala la actividad de dichas mol\u00e9culas. La 3-arilcumarina por si sola tampoco presenta una actividad notable. Los estudios de docking han corroborado la informaci\u00f3n obtenida experimentalmente. La cavidad de la enzima tiene las dimensiones ideales para nuestras 3-arilcumarinas cuando presentan peque\u00f1os sustituyentes en su esqueleto base. A mayores, experimentalmente y a trav\u00e9s de dichos estudios te\u00f3ricos, tambi\u00e9n hemos sido capaces de con cretar las posiciones del anillo en 3 que mejor favorecen la interacci\u00f3n con el receptor. Las posiciones meta y para, como dicho anteriormente, han demostrado ser las ideales. Los valores 79Cumarinas: Versatilidad estructural y aplicaciones en Qu\u00edmica Farmac\u00e9utica 2013 80 de CI50 de estos compuestos son, en muchos casos, del rango de bajo nano y picoMolar. Hemos encontrado que la 3-(3'-bromofenil)-6-metilcumarina (compuesto 42) es m\u00e1s de 6000 veces m\u00e1s activo ( CI50 = 134.04 pM) y m\u00e1s de 200 veces m\u00e1s selectivo que la selegilina, usada como compuesto de referencia. Estos datos nos han incent ivado a seguir estudiando este tipo de derivados frente a esta diana. Hemos realizado diferentes estudios electroqu\u00edmicos209 y de capacidad antioxidante de algunas de las 3 -arilcumarinas hidroxiladas.210 Los resultados han sido estimulantes , ya que los potenciales de oxidaci\u00f3n de estos compuestos son bajos y los ORAC-FL bastante elevados con respecto al trolox, el compuesto de referencia. El compuesto m\u00e1s interes ante de la serie estudiada, la 3-(4'-hidroxifenil)-8-hidroxicumarina (compuesto 104), ha presentado un valor de ORAC-FL de 13,5, conjuntamente al m\u00e1s bajo potencial de oxidaci\u00f3n y el 100% de atrapamiento de radicales hidroxilo. La asociaci\u00f3n de este tipo de actividad con la ya mencionada actividad IMAO es una importante estrategia en la obtenci\u00f3n de f\u00e1rmacos con actividades m\u00faltiples. Avanzando un poco m\u00e1s en el estudio, hemos encontrado algunas 3 - amidocumarinas con actividad inhibitoria dual de MAO -B y AChE. 211 El perfil de estos derivados nos ha abierto un camino en el estudio de inhibidores duales y multi-diana. Los derivados con grupos metilo y clorofenil adjuntos al enlace am\u00eddico han sido los m\u00e1s interesantes frente a las dos enzimas. En un estudio posterior algunos de los derivados tipo carbamato han mejorado las actividades IMAO -B obtenidas para las amidas correspondientes, perdiendo algunos de ellos la actividad inhibidora de la AChE. As\u00ed que el mejor compuesto de esta serie (bencil(cumarin-3-il)carbamato (compuesto 132), CI 50 MAO-B = 45 nM) fue estudiado in vivo y los resultados han sido muy esperanzadores.212 De estas dos series, y buscando ligandos de receptores de adenosina implicados en enfermedades neurodegenerativas, hemos encontrado compuestos con actividades moderadas que nos han incentivado a un estudio m\u00e1s profundo en esta \u00e1rea. 213 Estudios antibacterianos han sido realizados en diferentes familias de las cumarinas sintetizadas.214,215 Los resultados frente a bacterias humanas m\u00e1s interesantes han sido obtenidos con cumarinas sencillas y algunas 3 - arilcumarinas nitro-sustituidas. De todas las l\u00edneas bacterianas estudiadas los 80Cumarinas: Versatilidad estructural y aplicaciones en Qu\u00edmica Farmac\u00e9utica 2013 81 resultados m\u00e1s relevantes han sido encontrados frente a S. aureus y E. coli, dos de las bacterias m\u00e1s comunes en patolog\u00edas. Alguna de las mol\u00e9culas estudiadas ha pr esentado resultados comparables a los compuestos de referencia, y nos han permitido establecer importantes REAs. En particular, la 3-(3'-metilfenil) -6-nitrocumarina (compuesto 72) ha presentado un halo de inhibici\u00f3n frente a S. aureus de 32 mm y un MIC de 8 \u00b5g/mL, valores comparables con la ampicilina (hal o = 32 mm y MIC = 2 \u00b5g/mL), usada como compuesto de referencia.215 Algunas cumarinas sencillas estructuralmente parecidas a la tirosina y algunas 3-arilcumarinas con \u00e1tomos de bromo en diferentes posiciones han probado tener inter\u00e9s en estudios de inhibici\u00f3n de tirosinasa. Estos compuestos han presentado interesantes perfiles cuando comparados con la umbeliferona, el compuesto de referencia. El compuesto 6 -bromo-3-(4\u00b4-hidroxifenil)-8- hidroxicumarina (compuesto 87) ha presentado un valor de inhibici\u00f3n de la tirosinasa inferior a la umbeliferona, pero fue la 3 -amino-7-hidroxicumarina (compuesto 12) el compuesto m\u00e1s activo de todos los estudiados ( CI 50 = 0.05 mM). Este compuesto es 8 veces m\u00e1s activo que el compuesto de referencia.216,217 Las rutas sint\u00e9ticas utilizadas, la caracterizaci\u00f3n de los compuestos, los ensayos farmacol\u00f3gicos y electroqu\u00edmicos, y los estudios te\u00f3ricos y de REA est\u00e1n presentados y discutidos en los respectivos manuscritos, incluidos en el apartado experimental de esta Memoria. 3.3. Aportaciones estructurales y te\u00f3ricas A lo largo del trabajo descrito, diferentes estudios te\u00f3ricos (modelizaci\u00f3n y semi-emp\u00edricos) han aportado informaci\u00f3n clave de apoyo a los estudios de REA de los compuestos evaluados . Han sido realizados estudios de docking recurriendo al uso de los programas MAESTRO y MOE, usando como referencia para la validaci\u00f3n de los estudios las estructuras cristalinas de las prote\u00ednas encontradas en el PDB. Simulaciones de docking se han realizado utilizando el protocolo Quantum Mechanical Polarized Ligand Docking (QPLD), implementado en 81Cumarinas: Versatilidad estructural y aplicaciones en Qu\u00edmica Farmac\u00e9utica 2013 82 Schrodinger.218 El algoritmo ha utilizado la metodolog\u00eda ab initio para calcular las cargas del ligando dentro del entorno de prote\u00edna. En nuestro protocolo QPLD, despu\u00e9s de la preparaci\u00f3n del ligando y de la prote\u00edna, el Glide realiz\u00f3 el primer c\u00e1lculo de docking, con la generaci\u00f3n de las carga s iniciales con m\u00e9todos semiemp\u00edricos. En el segundo paso, la teor\u00eda funcional de densidad (DFT), con Jaguar, fue aplicado para el tratamiento completo de la mec\u00e1nica cu\u00e1ntica del ligando (QM). Un re-docking de los ligandos mediante el uso de las cargas calculadas por Jaguar y, por \u00faltimo, el algoritmo de QPLD llevaron a la obtenci\u00f3n de las poses energ\u00e9ticamente m\u00e1s favorables para cada ligando. Una minimizaci\u00f3n utilizando el P rimer MM-GBSA se llev\u00f3 a cabo con el \u00fanico objetivo de minimizar las poses derivadas del QPLD, teniendo en cuenta la flexibilidad de los residuos del bolsillo de uni\u00f3n dentro de una distancia de 5 \u00c5 a los ligando. La metodolog\u00eda de docking mencionada ha demostrado ser muy \u00fatil para proponer poses de uni\u00f3n de los derivados estudiados , destacando la importancia de las sustituciones en las posiciones 3, 6 y 8 de la cumarina, bien como de las posiciones meta y para del anillo arom\u00e1tico en posici\u00f3n 3 de la 3 - arilcumarina.205,208 Estudios semi-emp\u00edricos como el AM1 y el PM3 han sido llevados a cabo para comparar los resultados de los rayos X con los obtenidos por el an\u00e1lisis conformacional seguido por estas metodo log\u00edas. Los c\u00e1lculos te\u00f3ricos dieron resultados que reprodujeron eficazmente la estructura tridimensional (3D) de las mol\u00e9culas estudiadas por rayos X, lo cual significa que la determinaci\u00f3n estructural te\u00f3rica en la fa se gaseosa puede ser extrapolada .219 82Cumarinas: Versatilidad estructural y aplicaciones en Qu\u00edmica Farmac\u00e9utica 2013 83 4. Parte experimental Cumarinas: Versatilidad estructural y aplicaciones en Qu\u00edmica Farmac\u00e9utica 2013 85 4.1. Art\u00edculos publicados 1. \"Regioselective synthesis of different 2011, 52, 1225 -1227. 3. \"Improved synthesis (Matos, M.J.*; Gaspar, Santana, L.) - Organic Preparations and Procedures International 2012, 44, 522 -526. 4. \"3-Phenylcoumarin\" (Matos, M.J.*; Santana, L.; Uriarte, E.) - Crystallographica E68, o2645. 5. \"N-(2-Oxo-2H-chromen-3-yl)cyclohexanecarboxamide \" (Matos, M.J.*; Matos, M.J.*; Uriarte, E.; Santana, L.; Vilar, - Journal of Molecular Structure 2013, 1041, 144 -150. 7. \"A new tters 2009, 19, Uriarte, Chemistry Letters 2010, 20, 5157 -5160. 85Cumarinas: Versatilidad estructural y aplicaciones en Qu\u00edmica Farmac\u00e9utica 2013 86 10. \"MAO inhibitory activity 2011, 21, 4224 -4227. 11. \"Synthesis and study of a series of 3 -arylcoumarins as potent an Medicinal Chemistry 2011, 54, - ChemMedChem 2012, Rodriguez, S.; E.; Santana, L.*) - Current Topics -161. 15. \"3-Substituted coumarins as dual inhibitors of AChE and MAO for of (Vi\u00f1a, D.; Matos, M.J.*; Y\u00e1\u00f1ez, M.; Gaspar, A.; 86Cumarinas: Versatilidad estructural y en Qu\u00edmica Farmac\u00e9utica 2013 87 Kachler, S.; Klotz, K.-N.; Borges, F.; Santana, L.; Uriarte, E.) - Journal of Pharmacy & Pharmacology 2013, 65, 30 -34. 19. \"Looking for & Medicinal Chemistry 2013, 21, 3900 - 3906. 4.2. Art\u00edculos en fase de publicaci\u00f3n 22. New Insights into Functional and Structural Properties of Synthesis and adenosine receptors binding affinities of aDepartamento de Qu\u00edmica Org\u00e1nica, Facultad de Farmacia, Universidad de Santiago de Compostela, 15782 Santiago de Compostela, Spain Fax 4 March 2010; revised 6 May 2010 SYNTHESIS 2010, No. 16, pp 2763-2766 xx .x x.2 01 ring, the coumarin moiety or on a lateral chain of a coumarin is reported. The regioselectivity is influenced by phenyl ring is present as a substituent at anyposition on the coumarin nucleus. via construction of the coumarin nucleus with the aryl ring already place, Mukaiyama,5 Knoevenagel6 or Perkin- Oglialoro7 we utilize the second method, and specifically the classical Perkin con-densation. 8 This represents a direct and general method for analogues featuring the coumarin struct ural of biological The the the and commonly used brominating agent.The use of N-bromosuccinimide in the traditional of that bromination mainly at C-3, leading to the corresponding monobromoderivatives. 17 In the present compounds this position is blocked by a phenyl ring leading to a change in the reac- tivity of the coumarin. Side-chain bromination in of synthesizing bioactive natural prod-ucts. 29,30 As part of our 3-arylcoumarins, we previouslyreported the synthesis of 6-met hyl-3-arylcoumarins with (MAO) enzymatic inhibition.10 We found that the presence of a methoxy group on the 3-phenyl ring was important, especially inhibitor (MAOI) activity. In this selective synthesis of various bromo-substituted 6-alkyl-3-arylcoumarins. O O UNIVERSIDAD DE SANTIAGO DE COMPOSTELA. Copyrighted material. 892764 M. J. Matos et al. PAPER Synthesis 2010, No. 16, 2763-2766 \u00a9 Thieme Stuttgart \u00b7 New YorkThe bromine atom can be installed on the 3-phenyl ring (compound 3) or on the aromatic ring of the coumarin (compound 5). In addition, conditions which allow the bromine atom to be substituted on a lateral chain (com-pound 7) are described. 3-Arylcoumarins \u00baC for 24 hours (Scheme 1).8,31,32 Coumarins 210 and 5 were obtained in yields of 61% and 50%, respectively, by salicylaldehydes 1 and 8,31,32 with ylacetic Treatment of 6-methyl-3-(4 of 3 occurred as result of activation of the ortho position in substrate 2 by the electron-donating methoxy group. Under these conditions, the 6-methyl group was prepared from yield, using same asdescribed hydroxy substituent, and meta to the aldehyde, was the most active, and as such was the position at which bro- precursor 1 and bro- mine in carbon tetrachloride using a tungsten light regioselective- 3-arylcoumarins 5 (from 4 ) and 7 (from 6), via the classical Perkin condensation, in 50% and 60% yields, ofthe bromine atom in the final coumarin product to be var-ied. It is interesting to note that with compounds 1 and 2 , 34 8 h. CHOOHO 161%41%50% 68%34%44% ( substituent on the 3-phenyl ring, under the same brominat- ing conditions to afford 6-bromomethyl-3-phenylcou-marin (7 ) in a yield of 49% (Scheme 1). In this case, with no sufficiently strong activating group for aromatic bro- mination, the bromine was instead directed to chain. This reaction sequence represents obtain bromoalkylcoumarin 7. of 3 and 7 from 6-methyl-3-arylcoumarins 2 and 8, respectively, the pres- ence of a methoxy group results on 3- substitution on the lateral chain. Introduction ofa bromine on the coumarin ring is aro-matic conclusion, convenient been are uncorrect- 13C (75 MHz) and 1H (300 MHz) were MHz shifts d, Hz) are reported in ppm relative to TMS as the plates 4 (5.0 mL) was stirred under reflux for 18 h. The resulting (18), 346 (98), 345 (19), 344 (100) [M +], 303 (45), 301 (45), 275 (11), 250 (17), 222 (13), 194 (11), 178 (13), 165 (58), 163 (11), 139 (15), 132 (42), 82 (18), 76 (14), 63 (19), 50 (14). Anal. Calcd for C17H13BrO3: C, (2.0 mL), was heated at 100- 110 \u00b0C in an oil bath for 24 h. Ice (20 g) and AcOH (3.0 mL) wereadded and the mixture was stirred at r.t. for 2 h, and then extracted with Et 2O (3 \u00d7 25 mL). The layer was with 5% aq NaHCO3 and The solvent was evaporated under vacuum due was purified by flash chromatography 9:1) 346 (99), 345 (15), 344 (100) [M+], 303 (53), 301 (54), 275 (15), 207 (15), 166 (17), 165 (72), 138 (17), 89 (13), 76 (14), 58 (41). Anal. Calcd for C17H13BrO3: C, 59.15; H, 3.80. 14.69 mmol) in (23.0 mL), under reflux and with tungsten light irradiation (300 W, Philips Reflector R125 35\u00b0), was added Br2 (3.29 g, 20.57 mmol) over a period of 3 h. The soln was stirred at r.t. for a further 15 h the resulting precipitate was filtered and H, = 8.4 Hz, 1 H, H-3), 7.49-7.53 (m, 2 H, H-4, H-6), 9.88 (s, 1 216 (14), 215 (61), 214 (100) [M+], 184 (17), 168 (12), 121 (15), 17 (10). Anal. Calcd for C8H7BrO2: C, 44.68; to the procedure described for the synthesis of compound 5. The same product was also obtained in 49% yield starting from coumarin 8 identical method to that described for = 315 (23), 314 (100), 179 (21), 176 (40), 152 (12), 118 (19), 89 (15), 76 (16).Anal. Calcd for C 16H11BrO2: C, 60.98; 60.89; H, 3.47. thank the Spanish Ministry (PI061457 and P509/ 00501) and Xunta da Galicia (PXIB20304PR) support. DE SANTIAGO DE COMPOSTELA. Copyrighted material. 912766 M. J. Matos et al. PAPER Synthesis 2010, No. 16, 2763-2766 \u00a9 Thieme Hayashi, T. Org. Lett. 2005 , 7, 2285. (2) Perkin, W. H. J. Chem. Soc. 1868 , 21, 53. (3) Mukaiyama, T. Angew. Chem., Int. Ed. Engl. 1979, 18, 707. (6) Bogdal, D. J. Chem. 3268. (11) Larock, R. Comprehensive Transformations: A Guide to Functional Group Preparations ; Wiley-VCH: New York, 1997 . (12) Butler, A.; Walker, J. V. Chem. Rev. 60, (14) Muathen, H. J. Chem. 1992 , 2740. Bisarya, S. C.; McGhie, A. J. J. Chem. Perkin 2 , 1119. (19) Yi, 2004 , 47, 756. (21) Organic Solid State Chemistry ; Desiraju, G. R., Ed.; Elsevier: 1987. (22) Seebach, D. Angew. Chem., Int. Engl. 1990, 29, 1320. (23) Goud, B. S.; Desiraju, G. R. J. Chem. (24) Sarma, J. A.; A. J.; Ray, T. Tetrahedron Lett. 1986, 27, 111. (27) Dai, W.; Katzenellenbogen, J. A. J. Org. Chem. 1991, 56, 6893. (28) Schmid, H. Helv. Chim. Org. Incl. D'Souza, M.; S. K.; Beauchamp, P. S. J. Chem. Res., Synop. 2002, 24 2. (33) Adams, R. J. Am. Chem. Soc. 1919 , 41, 247. (34) Wang, L.; Jing, H.; Bu, X.; Chang, T.; Jin, 2007, 8 , 80. Downloaded by: UNIVERSIDAD DE COMPOSTELA. 92Synthesis 3-arylcoumarins via Suzuki-cross-coupling Lourdes Santanaa, Eugenio Uriartea aDepartamento de Qu\u00edmica Org\u00e1nica, Facultad de Farmacia, Universidad de Santiago de Compostela, 15782 Santiago de Compostela, Spain bCIQUP/Departamento de Qu\u00edmica e Bioqu\u00edmica, Faculdade de Ci\u00eancias, Universidade do Porto, Portugal article Coumarins are an important class of benzopyrones that are found in the vegetable kingdom, either in free or combined state.1 They occupy an important enzymatic inhibitors6are well-known.1In the last few years our research group has been engaged in the synthesis of new biologically active coumarins. In particular, the 3-phenylcoumarin's scaffold has been the focal point of our most recent studies. In fact we have demon- strated potential 3-arylcoumarins in Health Sciences as topic rins. classical Perkin condensation is perhaps the most direct and simple method known the preparation of 3-arylcoumarins.16Although used, it drawbacks as application of strong acids and high sometimes the request reactions.An alternative in complexes are in the rst case, some of these ligands are expensive, toxic, and sensitive to air and a ma- jor challenge lies in the separation of product from the expensive catalyst, much green alternative chemistry to the conventional organic methodologies, but they moisture-stable palladium ligands.25However, these ligands ligands have explored for arylation 0040-4039/$ - such triflates or tosylates coupling with aryl- boronic acids (via Suzuki type In other cases, the aryl substituents have been as starting material is till now an uncommon subject.32,33To our knowledge, few papers have been published so far concerning the 3-arylation of coumarin nucleus by direct coupling under Suzuki conditions: in all these cases, the halide was 3-bromocoumarin. And the catalysts were been time.38,39Salen ligand a bright yellow solid, soluble organic solvents, and effective symmetrical palladium(II) complex was a product of the reaction of the Salen li- gand with palladium acetate (for 20 h at room temperature) in a good yield. This complex promotes a catalytic activity in a low con- centration (0.5 mol %). to mention that Na 2CO3in 2O (1:1) was found to be an efcient catalytic system to obtain a variety of may the cleavage was optimization, the influence reaction involving of acids with a variety of works with than the the iodide ones, the use of the 3-chlorocoumarin as starting material in the reaction is related with its commercial availability. The synthesis involves reported by us,7,8one can verify that both are easy and not too expensive methodologies. The main advantage of thisnew synthetic reaction was not clean and product was complex purication pared by the while compounds 1-3,8, and 9 can can be easily and almost totally recuperated at the end of the process. The catalyst is recovered from the reaction mixture when the prod- uct is puried by flash chromatography and it is ready to be reused. This subject has great interest because of the toxicity and the cost of palladium complexes. In conclusion, a and have the Spanish Ministry (PS0900501) and Xunta da Galicia (INCITE09E2R203035ES and PGIDIT09CSA030203PR) for support. M.J.M. 58 % 56 % 64 % 65 % 55 % 59 % 63 % 61 % Scheme 1. Synthesis of 3-arylcoumarin Yield (%) Time (min) Yield (%) 1 1440 60 120 61 2 1440 65 120 58 3 1440 68 120 56 4 180 64 5 160 65 6 160 55 7 160 59 8 1440 70 120 63 9 2160 63 140 61 10 140 60 *Compounds 1225-1227 2009 ,19, 5053-5055. 10. Mali, R. S.; Joshi, P. P. Synth. Commun. 2001 ,31, 2753-2767. 11. Ming, Y.; Boykin, Grover, B 1989 ,28B, 766- 769. 15. Langmuir, M. Yang, J. R.; A. M.; Laura, R.; A.; P.; Silva, H. Bioorg. Med. Chem. 2007 ,15, 1516-1524. 18. Bogdal, D. J. Chem. Res. (S) 1998 , 19. Mali, R. S.; Tilve, S. G. Synth. 1990 ,20, 1781-1791. 20. Suzuki, A. J. 2002 ,653, 83-90. 21. Wang, J.; P.; Mignani, G. Chem. Rev. 2006 2651-2710. 23. Dupont, J.; de Souza, R. F.; Suarez, A. Chem. Rev. 2002 ,102, Mol. Genet, M. J. Organomet. Chem. 1999 ,576, A.; ,346, 28. Farina, V. Adv. Synth. ,346, 1553-1582. Luo, J.; Liao, Y.; Yang, Z. J. Org. Chem. 2001 ,38, 249-250. 33. Martins, S.; Branco, P. S.; de la Torre, M. C.; Sierra, M. A.; Pereira, A. Synlett 35. Chen, L.; Hu, T.-S.; Yao, Z.-J. Org. Chem. 2008 ,36, 6175-6182.36. Guo, H.-M.; Tanaka, F. J. 37. Zhang, L.; Meng, T.; Fan, R.; Wu, J. J. Org. Chem. 7279-7286. 38. Miller, K. J.; Baag, A.; P. C.; da Silva, M. F.; Ferreira, V. F.; de Souza, M. C.; Sa, M. Moraes, V.; C. General method to prepare 3-arylcoumarins : To a 20 mL two neck round- bottomed flask was added DMF/H (1:1). The reaction mixture was heated 120-180 reaction was monitored by chromatography. the 267 (M+, 100), 239 (24), 221 (38), 193 (17) 165 (52), 164 (16), 163 (19), 139 (12), 82 (11). Anal. calcd. for C 15H9NO 4(267.24): (10), 238 (19), 237 (M+, 100), 182 (36), 181 (12), 152 (50), 124 (18), 89 (45), 63 (28), 62 (18). Anal. calcd. for C 15H11NO 2(237.25): C, 259 (32), 258 (15), 257 (M+, 100), 223 (18), 182 (34), 152 (44) 123 (13), 89 (40), 85 (23), 71 (30), 63 (18), 57 (35). Anal. calcd. for C 14H8ClNO 2(257.57): C, 65.26; H, (Italian Edition) 1964 G.; Rao, A. V. Synth. Commun. 1987 ,17, 341-354. Chem. Soc., Sect B: Phys. Org. ,3, 266-270.M. J. Matos et al. / Tetrahedron Letters 52 (2011) 1225-1227 1227 95This , Alexandra Gaspar a , Fernanda Borges a , Eugenio Uriarte b & Lourdes Santana b a CIQUP/Departamento de Qu\u00edmica e Bioqu\u00edmica, Faculdade de Ci\u00eancias, Universidade do Porto, 4169-007, Porto, Portugal b Departamento de Qu\u00edmica Org\u00e1nica, Facultad de Farmacia, Universidad de Santiago de Compostela, Santiago de Compostela,15782, Spain To cite this article: Maria Jo\u00e3o Matos, Alexandra Gaspar, Fernanda Borges, Eugenio Improved Synthesis of 522-526 To link to this article: http://dx.doi.org/10.1080/00304948.2012.730937 PLEASE SCROLL DOWN FOR ARTICLE Full terms and conditions of use: http://www.tandfonline.com/page/terms-and-conditions This article may be used for research, teaching, anyone is expressly forbidden. The publisher does not give any warranty express or implied or make any representation that the contents will be complete or accurate or up to date. The accuracy of anyinstructions, drug orindirectly in connection with or arising out of the use of this material. 97Organic Preparations and Procedures International , 44:522-526, 2012 Copyright \u00a9 Portugal 2Departamento de Qu \u00b4mica Org \u00b4anica, Facultad de Farmacia, Universidad de Santiago de Compostela, Santiago de Compostela, 15782 Spain Coumarins(benzopyrones) are widely distributed in state,1and occupy anti-cancer,4vasorelaxants,5or enzymatic inhibitors.6Over the last few years, our research group has paid special attention to the synthesis of new biologically active coumarins as enzymatic inhibitors;7-12in particular, 3-arylcoumarins have been the focal point of our recent studies13,14as they play an important role or con- densation (4-bromothien-3-yl)acetic acid (DMEDA) using TFA useful for the bromides. Received March 9, 2012. Address correspondence to Maria Jo ao Matos, Departamento de Qu \u00b4mica Org \u00b4anica, Facultad de Farmacia, Universidad de Santiago de Compostela, Santiago de Compostela, 15782 Spain. E-mail: mariacmatos@gmail.comDownloaded by [University 2CO 2H 2i 3a-eR1iii O OAr' R 1 conclusion, novel and versatile route for the synthesis trifluoroacetamide goodammonia substitute and of CuI/DMEDA as reported in as at 07:48 05 et flash Analytical TLC was performed on plates precoated with silica (Merck 60 F254, mm). preparation and characterization of 3c,3d, and 3fhave been described in references 10, 12, and General Preparation of 3-Arylcoumarins 3a, ml), was heated at 110C in an oil bath for 24 h. Ice (20 g) and AcOH (10 ml) were added and the mixture was stirred at r.t. for 2 h, and then extracted with Et 2O( 3\u00d725 ml). The washed aq. NaHCO 3solution (50 ml) and H 2O (20 ml), dried (Na 2SO4). The solvent was evaporated under residue was puried solid, 62% yield, mp. R( C D C l 3):2.44 (s, 3H, CH 3), 7.24 (dd, 316 (99), 315 (19), 314 (100) [M+], 288 (34), 287 (22), 286 (34), 285 (17), 179 (17), 178 (36), 152 (9), 118 (14), 89 (11), 76 (12). Anal. Calcd for C 16H11BrO 2: C, solid, 59% yield, mp. 141C-142C.1HN M R( C D C l 3):2.45 (s, 3H, CH 3), (38), 314 (100) [M+], 236 (32), 235 (80), 178 (22), 117 (7), 89 (7), 76 (9). Anal . Calcd for C 16H11BrO 4(5 ml) reflux give desired bromo derivative 3e(1.0 g, 75%) as a colorless solid, mp. 175C-176C.1HN M R( C D C l 3):2.43 (s, 3H, CH 3), 7.25-7.37 (m, 5/prime), 7.9 242 (18), 241 (10), 184 (18) 152 (8), 138 (11), 115 (10), 92 (12), 63 (11), 58 (14). Anal. Calcd for C 14H9BrO 2S: C, the ml two-neck round-bottom flask, a catalytic amount of CuI (8 mol%), K 2CO 3 (0.276 g, 2.0 mmol), and molecular sieves (4 AMS, 0.500 g) were added. The two-neckround-bottom flask was evacuated and back lled with ml) were added and the mixture was stirred for 24 h, at 75 C. The mixture was then cooled to room temperature and a mixture of methanol/H 2O( 3 : 3m l )w a s added. The suspension was stirred for 5 h and then extracted with EtOAc (3 \u00d720 ml). TheDownloaded was yield D C l 3):2.43 (s, 3H, CH 3), 3.70 (s, (100) [M+], 236 (20), 152 (21), 134 (45), 129 (23), 112 (31). Anal. Calcd for C 16H13NO 2: solid, 90% yield, mp. 139C-140C.1HN M R( C D C l 3):2.43 (s, 3H, CH 3), 3.99 (s, 2H, (89) [M+], 236 (29), 235 (12), 178 (23), 152 (33), 76 (13). Anal . Calcd for C mp. M R( C D C l 3):3.85 (s, 3H, -CH 3), 3.97 (s, 2H, (100) [M+], 248 (9), 182 (13), 167 (16), 139 (17). Ana. Calcd for C 16H13O3: C, D C l (s, 3H, CH 3), 7.27 (s, (18), 152 (10). Anal. Calcd for C 14H11NO The thank Spanish Ministry Galicia(PGIDIT09CSA030203PR INCITE09E2R203035ES) for partial Ci encia e Tecnologia for scholarships. References 1. F. Borges, F. Roleira, N. Milhazes, E. Uriarte and L. Santana, Front. Med. Chem., 4, 23 (2009). 2. C. Kontogiorgis and D. Hadjipavlou-Litina, J. Enzyme Inhib. Med. Chem. ,18, 63 (2003). 3. and S. Sotheeswaran, Bioorg. Med. 3475 4. Papapostolou, N. Thierry, L. Pochet, S. Counerotte, B. Masereel, J. M. Foidart, M. J. Reboud-Ravaux, A. Noel and B. Pirotte, Br. J. Cancer, 88, 1111 (2003).Downloaded at 07:48 05 November 2012 101526 Matos et al. 5. S. Vilar, E. Quezada, L. Santana, E. Uriarte, M. Yanez, N. Fraiz, C. Alcaide, E. Cano and F. Orallo, Bioorg. Med. Chem. Lett. ,16, 257 (2006). 6. E. Quezada, G. Delogu, C. Picciau, L. Santana, G. Podda, F. V . Garcia-Moraes, D. Vina and F. Orallo, Molecules, 15, 270 7. L. Santana, H. Gonz \u00b4alez-D \u00b4az, E. Quezada, E. Uriarte, M. Y \u00b4anez, D. Vi n aa n dF .O r a l l o , J. Med. Chem., 51, 6740 (2008). 8. M. J. Matos, D. Vi na, E. Quezada, C. Picciau, G. Delogu, F. Orallo, L. Santana and E. Uriarte, Bioorg. Med. Chem. Lett. ,19, 3268 (2009). 9. M. J. Matos, D. Vi na, C. Picciau, F. Orallo, L. Santana and E. Uriarte, Bioorg. Med. Chem. Lett. , 19, 5053 (2009). 10. M. J. Matos, D. Vi na, P. Janeiro, F. Borges, L. Santana and E. Uriarte, Bioorg. Med. Chem. Lett. , 20, 5157 (2010). 11. A. Fais, M. Corda, B. Era, M. B. Fadda, M. J. Matos, E. Quezada, L. Santana, C. Picciau, G. Podda and G. Delogu, Molecules, 14, 2514 (2009). 12. M. J. Matos, L. Santana, E. Uriarte, G. Delogu, M. Corda, M. B. Fadda, B. Era and A. Fais, Bioorg. Med. Chem. Lett. ,21, 3342 (2011). 13. M. J. Matos, G. Delogu, G. Podda, L. Santana and E. Uriarte, Synthesis, 2763 (2010). 14. M. J. Matos, S. Vazquez-Rodriguez, F. Borges, L. Santana and E. Uriarte, Tetrahedron Lett., 52, 1225 (2011). 15. R. S. Mali and P. P. Joshi, Synth Commun., 31, 2753 (2001). 16. Y . Ming and D. W. Boykin, Heterocycles, 26, 3229 (1987). 17. C. Khiri, F. Gharbi and Y . Le Bigot, Synth. Commun., 29, 1451 (1999). 18. S. Mohanty, J. K. Makrandi and S. K. Grove, Indian J. Chem., Sect B ,28B, 766 (1989). 19. M. E. Langmuir, J. R. Yang, A. M. Moussa, R. Laura and K. A. Lecompte, Tetrahedroon Lett., 36, 3990 (1995). 20. W. H. Perkin, J. Chem. Soc.,5 3( 1868). 21. L. M. Kabeya, A. A. de Marchi, A. Kanashiro, N. P. Lopes and C. H. da Silva, Bioor g. Med. Chem., 15, 1516 (2007). 22. D. Bogdal, J. Chem. Res., Synop. ,8, 468 (1998). 23. R. S. Mali and S. G. Tilve, Synth. Commun., 20, 1781 (1990). 24. D. V . Rao, A. A. R. Sayigh and H. Ulrich, US 3644413 A 19720222, 1972; Chem. Abst., 77, C.-Z. Tao, J. Li, Y . Fu, L. Liu and Q.-X. Guo, Tetrahedron Lett., 49, 70 (2008). 27. D. Wang, Q. Cai and K. Ding, Adv. Synth. Catal., 351, 1722 (2009). 2 8 . H .Z h a i ,H .L i n ,X .L ua n dX . - H .X i a ,Chem. Lett., 35, 1358 (2006). 29. Z. Wu, Z. Jiang, D. Wu, H. Xiang and X. Zhou, Eur. J. Org. Chem. , 1854 (2010). 30. H. Xu and C. Wolf, Chem. Med. Commun., 3035 (2009). 31. D. Wang, Q. Cai and K. Ding, Adv. Synth. Catal., 351, 1722 (2009).Downloaded R.T. Tiekink and M. Weil 3-Phenylcoumarin Maria J. Matos, Lourdes Santana and Eugenio Uriarte Acta Cryst. (2012). E 68, o2645 This open-access article is distributed under the terms Attribution , medium, provided over 4000 structures per publication time less E 68, o2645 Matos et al. \u00b7C15H10O2 1033-Phenylcoumarin Maria J. Matos,* Lourdes Santana and Eugenio Uriarte Department of Organic Chemistry, University of Santiago de Compostela, Santiago e-mail: mariacmatos@gmail.com Received = 0.104; data-to-parameter ratio = 12.5. In the title compound, C 15H10O2, a 3-phenyl derivative of the coumarin (c) the phenyl (p) ring is /C047.6 (2)/C14. Related literature For the synthesis of the title compound, see: Matos, Santana et al.. et al. (2011); Matos, Tera \u00b4net al.. et al. (2011). For examples of biological activity of coumarin derivatives, see: Borges et al. (2009); Matos et al. (2009, 2010); Matos, Santana et al.. et al. (2011); Matos, Tera \u00b4net al.. et al. (2011); Vin a, Matos, Ferino et al.(2012); Vin a, Matos Ya \u00b4nezet al. 1999). This work was supported by funds from the Xunta da Galicia (09CSA030203PR), the Ministerio de Sanidad y Consumo (PS09/00501) and the Fundac \u00b8ao para a Cie ncia e Tecnologia (SFRH/BD/61262/2009). Supplementary data and gures for IUCr electronic (Reference: G. L., Giacovazzo, C., Guagliardi, A., Moliterni, A. G. G., Polidori, G. & Spagna, R. (1999). J. Appl. Cryst. 32, 115-119. Borges, F., Roleira, F., Milhazes, N., Uriarte, E. & Santana, L. (2009). Front. Med. Chem. 4, 23-85. Bruker (2002). SMART ,SAINT andSADABS . Bruker AXS Inc., Wisconsin, USA. Farrugia, L. J. (1997). J. Appl. Cryst. 30, 565. Farrugia, L. J. (1999). J. Appl. Cryst. 32, 837-838. Matos, M. J., Santana, L., Uriarte, E., Delogu, G., Corda, M., Fadda, M. B., Era, B. & Fais, A. (2011). Bioorg. Med. Chem. Lett. 21, 3342-3345. Matos, M. J., Tera \u00b4n, C., Pe \u00b4rez-Castillo, Y., Uriarte, E., Santana, L. & Vin a, D. (2011). J. Med. Chem. 54, 7127-7137. Matos, M. J., Vin a, D., Janeiro, P ., Borges, F., Santana, L. & Uriarte, E. (2010). Bioorg. Med. Chem. Lett. 20, 5157-5160. Matos, M. J., Vin a, D., Quezada, E., Picciau, C., Delogu, G., Orallo, F., Santana, L. & Uriarte, E. (2009). Bioorg. Med. Chem. Lett. 19, Vina, D., Matos, M. J., Ferino, G., Cadoni, E., Laguna, R., Borges, F., Uriarte, E. & Santana, L. (2012). Chem. Med. Chem. 7, 464-470. Vina, D., Matos, M. J., Ya \u00b4nez, M., Santana, L. & Uriarte, E. (2012). Med. Chem. Commun. 3, 213-218.organic compounds Acta Cryst. Comment 4 Coumarin derivatives are very interesting molecu les due to the biologic al properties that they may display (B orges et al. 5 2009 and Matos et al. 2009, 2010, 2011, 2012 ). The title structure is a 3-p henyl that 6 aromatic ring linked at that position. Therefore, the X- ray analysis of this c ompou nd (figure 1) aims to contribu te to struct ural requirements can conclude that experimental 9 bond lengt hs are within normal values with the average the molecu le bond lengt hs. The planarity of the by the rotation of the henyl ring. ing diagram of the structure allows the 12 interpretation of the spatial orientation of the molecu les (figure 2). 13 Experimental 14 oumarin was prepared according to the protoc ol Matos et gave added, and the mixture was heated at 110 \u00b0C for 24 h. Ic e (100 ml) and acetic acid (10 ml) were added to the reaction 18 mixture. After k eeping it at room temperat ure for 2 h, the mixture was extra cted with ether (3 x 25 ml). The organi c layer 19 was extracted with sodium bicarbonate solution (50 ml, 5%) and then water (20 ml). Th e solvent was evaporated under 20 vacuu m, and the dry resid ue was purified by flash ch romatograp hy (hexane/ethyl acetate 9:1). A white solid was obtained 21 in a yield of 67% (1.1 g). Suitable crystals for 16), 222 ( M+, Anal. F2, conventional 28 R-factors R are based on F, with F set to zero for negative F2. The threshold expression of F2 calculating R- factors(gt) etc. and is t twice as large as those based on F, and R- factors based on ALL data will be even 31 Computing details KER Saint used to 33 solve struct ure: SIR97 (F arrugia, 1997); software u sed to prepare fig1.tif Figure 1 37 The molecular struct ure of the title compou nd with the atom- numbering scheme. 39 fig2.tif Figure 2 40 A packing diagram of the title structure viewed along the b axis. 41 106supplementary materials sup-3 (I) 42 Crystal data 43 C15H10O2 44 Mr = 222. 23 45 Mono clinic, C2/c 46 Hall symbol: - C 2yc 47 a = 18.469 (4 ) \u00c5 48 b = 5.9596 (12 ) \u00c5 49 c = 1 9.274 (4) \u00c5 50 = 99. 079 (3)\u00b0 51 V = 2094.9 (7) \u00c5352 Z = 8 53F(000) = 928 F(000) = 928 Dx = 1.409 Mg m3 Mo K = I > 2(I) Rint = 0.042 max = 25. 4\u00b0, min = 2.1\u00b0 h = 22 21 k = 07 l = 023 Refinement 61 Refinement on F262 Least 2(F2)] = 0.040 64 wR(F2) = 0 .104 65 S = 1.03 66 1924 reflec tions 67 154 parameters 68 0.001 = Special 72 s.u. the dihedral angle between two l.s. planes) are estimated u sing the full covarianc e s.u.'s in cell parameters are only u sed when they are defined by crystal symmetry . An appro ximate F2, conventional R-factors R are based on F, with F set to zero for negative F2. The threshold expression of F2 > 2(F2) is for R-factors(gt) etc. and is as those based on F, and R- factors based on ALL data will be even 105 C1 0 0.0160 (8) (7 0.0025 0.0156 (8) 0.0040 (7) C4 .0215 0.0188 (9) 0.0167 (8) 0.0050 (7) 0.0051 (8) 0.0182 (8) 0.0012 (8) (8) (6) 133 C5\u2014H50 13\u2014H 13 0.95 134 C6\u2014C7 1 .483 (2) C14\u2014O11 .3776 (18) 135 C7\u2014 C8 C 11\u2014C10 \u2014C9 120.29 (15) 144 C 1.9 (2) C10\u2014C11\u2014C12\u2014 C13 0.8 (2) 165 C2\u2014C3\u2014C4\u2014C5 0.2 (2) C11\u2014C12\u2014C13\u2014C14 0 166 C3\u2014C4\u2014C5\u2014C6 and M. Weil N-(2-Oxo-2 H-chromen-3-yl)cyclohexanecarboxamide Maria J. Matos, Lourdes Santana and Eugenio Uriarte Acta Cryst. (2012). E 68, o3447-o3448 This open-access article is distributed under the terms Attribution , medium, provided over 4000 structures per publication time less Cryst. o3447-o3448 Matos al. \u00b7C16H17NO 3 111N-(2-Oxo-2 H-chromen-3-yl)cyclo- hexanecarboxamide Maria J. Matos,* Lourdes Santana and Eugenio Uriarte Department of Organic Chemistry, University of Santiago de Compostela, Santiago de = 0.113; data-to-parameter ratio = 13.4. In the title compound, C 16H17NO 3, the coumarin moiety is essentially planar [maximum deviation from the mean plane formed by the C and O atoms of the coumarin = 0.0183 (12) A ] and that the cyclohexane ring adopts the usual chair conformation. The the mean plane of residue and the plane of the amide residue (dened as the N, C and O atoms) 18.9 (2)/C14. There are two intramolecular hydrogen bonds involving the amide group. In one, the N atom acts as donor to the ketonic O atomand in the other, the amide O atom acts as acceptor of a C\u2014H group of the coumarin. In the crystal, molecules observed. Related literature For the synthesis of the title compound, see: Vin a, Matos, Ferino et al. (2012); Vin a, Matos, Ya \u00b4nezet al. (2012). For the biological activity of coumarin derivatives, see: Borges et al. (2009); Matos et al. (2009, 2010); Matos, Santana et al. (2011); Matos, Tera \u00b4net al. (2011). For graph-set analysis of hydrogen bonds, see: Bernstein et al. 2012). This work was supported by funds of Xunta da Galicia (09CSA030203PR), Ministerio de Sanidad y Consumo (PS09/ 00501) and Fundac \u00b8aop a compounds Acta IUCr electronic (Reference: G. L., Giacovazzo, C., Guagliardi, A., Moliterni, A. G. G., Polidori, G. & Spagna, R. (1999). J. Appl. Cryst. 32, 115-119. Bernstein, J., Davis, R. E., Shimoni, L. & Chang, N.-L. (1995). Angew. Chem. Int. Ed. Engl. 34, 1555-1573. Borges, F., Roleira, F., Milhazes, N., Uriarte, E. & Santana, L. (2009). Front. Med. Chem. 4, 23-85. Bruker (2012). J. (2012). J. Appl. Cryst. 45, 849-854. Matos, M. J., Santana, L., Uriarte, E., Delogu, G., Corda, M., Fadda, M. B., Era, B. & Fais, A. (2011). Bioorg. Med. Chem. Lett. 21, 3342-3345. Matos, M. J., Tera \u00b4n, C., Pe \u00b4rez-Castillo, Y., Uriarte, E., Santana, L. & Vin a, D. (2011). J. Med. Chem. 54, 7127-7137. Matos, M. J., Vin a, D., Janeiro, P ., Borges, F., Santana, L. & Uriarte, E. (2010). Bioorg. Med. Chem. Lett. 20, 5157-5160. Matos, M. J., Vin a, D., Quezada, E., Picciau, C., Delogu, G., Orallo, F., Santana, L. & Uriarte, E. (2009). Bioorg. Med. Chem. Lett. 19, (2009). D., Matos, M. J., Ferino, G., Cadoni, E., Laguna, R., Borges, F., Uriarte, E. & Santana, L. (2012). Chem. Med. Chem. 7, 464-470. Vina, D., Matos, M. J., Ya \u00b4nez, M., Santana, L. & Uriarte, E. (2012). MedChemComm ,3, 213-218.organic compounds o3448 Matos et al./C15C16H17NO 68, o3447-o3448 113supplementary materials sup-1 Acta Cryst. (2012). E 68, 1107/S1600536812047903] N-(2-Oxo-2H -chromen-3-yl)cyclohexanecarboxamide Uriarte Comment Coumarin derivatives are very interesting molecu les due to the biologic al properties that they may display (B orges et al. 2009; Matos et al. 2009 , 2010; Matos, Santana et al. , 2011 ); Matos, T er\u00e1n et al. , 2011 ). The title struct ure is a 3- substitu ted c oumarin derivative that posses one c yclohexane ring linked by an amidic bridge at that position. Therefore, the X-ray analysis of this compou nd (figure 1) aims to te ural be the experimental bond lengths are within normal values with the average the molecu le bond length s. The planarity of the permitted by the rotation of the amidic of a cyclohexane ring. There are intramolecular short contac ts N12-H12\u00b7\u00b7\u00b7011 and C4-H4 \u00b7\u00b7\u00b7O14. x+1,-y, -z) hydrogen R22 pairs, (B these a chain of the c rings c ontaining O 11 and C9 respec tively at (-x, -y,-z). In addition there is - stack ing between the rings c ontaing O 1 at (x,y,z) and (-x ,-y+1,-z) in which the c entroid to centroid distanc e is 3.8 654 (10)\u00c5, the perpendicular distanc e between the rings is by (V i\u00f1a, Matos, Ferino et al. 2012; V i\u00f1a, Matos, Y\u00e1\u00f1e z et al. 2012). T o a solution of 3- amino coumarin was and the reaction was stirred, at room temperatu re, for 3 h. Th e solvent was evaporated under vacuum and the dry residu e was purified by FC (hexane/ethyl acetate 9 :1). A pale yellow solid was obtained in a yield of 72%. Suitable c rystals for X- ray studies were grown from evaporation acetone/ethanol: Mp F2, conventional R-factors R are based on F, with F set to zero for negative F2. The threshold expression of F2 > E o3447-o3448 calculating factors(gt) etc. and is not as those based on F, and R- factors based on ALL data for publication: WinGX (Farru gia, 2012). Figure 1 The molecular struct ure of the title c ompou nd with the atom- numbering level. dashed lines indic ate intramolecu lar close c ontac ts. materials sup-3 Acta Cryst. (2012). E 68, o3447-o3448 Figure 2 Part of the crystal struc ture of (2) showing the chain Atoms labelled with an asterisk (*), hash (#) = symbol: -P 1 a = 6.4486 (6) \u00c5 b = 9.63 24 (11) \u00c5 c = 11 .0837 (11) \u00c5 = F(000) = 288 F(000) = 288 116supplementary materials sup-4 Acta Cryst. (2012). E 68, o3447-o3448 Dx = 1.372 Mg m3 Melting point: 100 K Mo K 2(I) Rint = 0.044 max = 25. 7\u00b0, min = 1.9\u00b0 h = 77 k = 1111 l = 013 Refinement Refinement on F 2 Least-squares matrix : full R[F2 > 2(F2)] = 0.045 wR(F2) = 0 .113 onstrained refinement w = 1/[2(Fo2) + (0.0577 P)2] where P = (F o2 + 2Fc2)/3 (/)max < 0.001 max = 0.20 e \u00c53 min .25 e \u00c53 angle between two l.s. planes) are estimated u sing the full covarianc e matrix. The c ell s.u.'s are taken into account individually in s.u.'s in cell parameters are only u sed when they are defined by crystal symmetry . An approx F2, conventional R-factors R are based on F, with F set to zero for negative F2. The threshold expression of F2 > 2(F2) is for R-factors(gt) etc. and is not relevant as those based on F, and R- factors based on ALL data will be even 1.391 derivatives of the coumarin scaffold Maria J. Matos, Eugenio Uriarte, Lourdes Santana, Santiago Vilar Department of Organic Chemistry, Faculty of Pharmacy, University of Santiago de Compostela, Santiago de Compostela, Spain highlights and PM3 yielded resultsreproducing the whole in 6 March 2013 Accepted 6 March in a good agreement with X-ray structural analysis. The global structures of the two compounds are very similar in the two studied environments, meaning that the structural determination in the can be extrapolated. A comparative study between compounds 1 and 2, the actual prevalence of neurodegen- erative diseases have led to an for compounds that interact with some specic receptors. In particular, in our research group we have paid special attention to compounds that acetylcholinester- last years we are synthesizing and an important family those targets. Coumarin (2H-1-benzopyran-2-one) is a natural compound that can be found in several plants like tonka bean, vanilla grass and sweet woodruff [1-3] . Derivatives of this benzopyrone are of AChE inhibitory activity, have been reported by our research group, and some of them are suggested as (E. Uriarte), cic and between the different compounds involved. An important step in the study of molecular interaction processes is the determi- nation of the structure of the potential drugs. This means carrying out an analysis of the spatial arrangement of the different atomic groups and their chemical properties. In this way, the rst step must be to obtain information about the intramolecular features responsible for the 3D structure of the molecule under study. The X-ray structure is an important tool to better understand the inter- action of the compound with the active site of the enzyme. According to the latest ndings related theoretical approaches. Computational approaches can offer an alternative solution to determine the three-dimensional molecular structure of the compounds under study. Depending on the molecular complexity and the precision required for the study, different types of calculations can be carried out. Molecular mechan- ics methods [21] be appropriate the calculation the the calculations a limitingfactor to be applicable in large systems. An intermediate level of accuracy by the user-friendly AM1 and two of [24,25] The analysis of semiempirical methods results design of active molecules. In the current work described here, experimental and theoreti- structural analysis of two 3-substituted coumarin derivatives, presenting at that position an amide (compound 1) or an ester (compound 2), were undertaken. Their structures were characterized by theoretical and the crystal structure for both compounds showed a level of the capability of the theoretical meth- ods to reproduce the experimental molecular geometry being an alternative methodology to obtain three-dimensional information when the crystal structure is not available. 2. Experimental section 2.1. Material and areScheme 0 /C176C to data and structure renement parameters for compounds 1 and 2. Compound and /C00.259 e 144-150 as Silica 230-00 mesh) was used for flash chromatography (FC). Analytical (TLC) was performed on plates pre- coated with silica gel (Merck 60 F254, 0.25 mm). The purity of compounds was assessed by HPLC and was found to be higher than 95%. Fig. 1. Molecular structures of compounds 1 and 2 with the atom-numbering scheme. ellipsoids are drawn at the 30% probability level.146 M.J. Matos et al. Journal 1041 (2013) 144-150 1232.2. Synthesis of compounds 1 2 ( Scheme 1 ) were prepared according to the protocol by is described 279 (M+, 50), 239 (20), 134 (23), 112 (20), 98 (42) Elem. Anal. Calc. forC17H13NO3: 1H, J = 7.6 Hz, (M+, 8), 119 (100), 91 (29), 77 (8), 65 (12). Elem. Anal. Calc. for C17H12O4: C, Pale prismatic of compounds 1 (C17H13NO3) and 2 (C17H12O4) were a ber for data collec- and structure direct all conformational search was carried with software [32]. Partial charges were calculated using MMFF94 force was 0.005 with an interac- tion limit of 500. The conformations with the lowest energy were representative of the calculation and were optimized with MOPA- Fig. 2. Superposition of the crystal (green a and PM3 (panels b and d) for compounds 1 and 2. (For interpretation of the references to color in this gure legend, the reader is referred to the web version of this article.) Table 4 RMSD between the conformations obtained through theoretical methods and the ray RMSD coordinates (hydrogens were not taken into Structure 1041 (2013) 144-150 147 3. Results and discussion Compound 1 was prepared in 71% yield, of the )[16]. yield, by pounds. Also, the solved by X-ray diffractometry and are shown in Fig. 1 , together with the atomic numbering scheme used. As it can be observed in Fig. 1 , both molecules adopted some similar aspects in the coumarin nucleuses aromatic rings of both structures viewed along the b axis.148 M.J. Matos et al. / Journal of Molecular Structure 1041 (2013) 144-150 125bridges in both molecules are planar, as expected. The main differ- ence between the molecular structures of compounds 1 and 2 is that in the rst case the substitution at position 3 of the coumarin scaffold is almost aligned with the substituent, and in the second case it is almost perpendicular to it. The torsion angles between the the rotation of the amidic group at position 3. The torsion angles between the permit- ted by the rotation of the ester group at position 3. The greatest conformational freedom of the molecules resides, therefore, in the amidic bridge of compound 1 and in the ester bridge of com- pound 2, composed by C3-N12-C13-C15 and contacts are pres- ent in both compounds. In particular, looking to Fig. 1 compound 1 shows interesting C4H /C1/C1/C1O14, C20H C16H /C1/C1/C1O12 contact. Moreover in compound 1 a short contact between two hydrogens (that bonded to C16, [35,36] is structurally to the compound described by Jotani et al. The ring system. In compound 1, as in that molecule, a dihe-dral angel of 5.84/C176 is formed between the phenyl ring and the fused system. The observed conformation is also intramolecular molecules (voluminous substituents - a benzyl group at position 3 and a phenylamine at position 4) changed the related position of the coumarin nucleus and the benzylamide at position 3. Tables 2 and 3 (presented in Supplementary data) list the bond lengths, dihedral The results for the calculations (conformational analysis the AM1 and PM3 for both with the through X-ray. For the compound 1, two possible conformational states are obtained differing in the orientation of the 4-methylphenyl system regard- ing the plane of coumarin value for different conformations was obtained compound 2 through the calculations. Both possible conformational states differ in the orientation of the carbonyl group regarding to the plane of the coumarin ring. The dihedral an- gle value in C(3)-O(12)-C(13)-O(14) \u00c5 for the conformers (AM1 method). Fig. 2 shows the superposition of the structure and the conformations obtained through dihedral and C(3)-O(12)-C(13)-O(14) dihedral value of /C07.7 for the comparison between the theoretical and the a The deviation) 4 ). described in this article do not justify the selection of one of the methods. Similarresults 5 The presence of these hydrogen bonds and the conformation of the substituent at the interpretation spatial orientation of the molecules and are shown in Fig. 3 . 4. Conclusion deriva- tives (with amide or ester functions at position 3), and proved that the results are well Theoretical approaches can be an alternative methodology to determine the 3D conforma- tion for this type of derivatives when the crystal structure is not available. We can also conclude that it is possible to modulate the relative position of the coumarin scaffold and the aromatic ring at position 3 by the chemical substituent between both moieties. Acknowledgements Partial nancial support from Ministerio de Sanidad y Consumo (PS09/00501) and Xunta de Galicia (PGIDIT09CSA030203PR) are thanks the Angeles Alvari\u00f1o program from Xunta de Galicia (Spain). Appendix A. Supplementary material Supplementary data associated with this article can be found, in the online version, at http://dx.doi.org/10.1016/ j.molstruc.2013.03.014 . References [1] F. Borges, F. L. Santana, E. Uriarte, Curr. Med. Chem. 12 (2005) 887. [2] F. Borges, F. Roleira, N. Milhazes, E. Uriarte, L. Santana, Med. Chem. 4 (2009) 23. [3] M.E. Riveiro, N. De Kimpe, C. Shayo, C. Curr. Chem. 54 (2011) 3839. [5] S. Vilar, E. Quezada, L. Santana, E. Uriarte, M. Yanez, N. Fraiz, C. Alcaide, E. Cano, F. Orallo, Bioorg. Med. Chem. Lett. 16 (2006) 54 (2011) 2114. [8] I. Kostova, Curr. HIV Res. (2006) Chilin, Battistutta, A. Bortolato, G. Zagotto, E. Uriarte, A. Guiotto, F. Meggio, S. Moro, J. Chem. 3845. [11] M.J. Matos, S. Vazquez-Rodriguez, L. Santana, E. Uriarte, C. Fuentes-Edfuf, Y. Santos, A. Mu\u00f1oz-Crego, Med. Chem. 8 (2012) 1140. [12] M.J. Matos, L. Santana, E. Uriarte, S. Serra, M. Corda, M.B. Fadda, B. Era, A. Fais, J. Pharm. Pharmacol. 64 (2012) 742. [13] P. Anand, B. Singh, N. Singh, Bioorg. Med. Chem. 20 (2012) 1175.M.J. Matos et al. / Journal of Molecular Structure 1041 (2013) 144-150 149 126[14] M.J. Matos, D. Vi\u00f1a, C. Picciau, F. Orallo, L. Santana, E. Uriarte, Bioorg. Med. Chem. Lett. 19 (2009) 5053. [15] Quezada, C. Picciau, G. Delogu, F. Orallo, L. Santana, Bioorg. Chem. Lett. 19 (2009) 3268. [16] D. Vi\u00f1a, M.J. Matos, M. Y\u00e1\u00f1ez, L. Santana, E. Uriarte, MedChemComm 3 (2012) 213. [17] M.J. Matos, C. Ter\u00e1n, Y. P\u00e9rez-Castillo, E. Uriarte, L. Santana, D. Vi\u00f1a, J. Med. Chem. 54 (2011) 7127. [18] M.J. Matos, S. V\u00e1zquez-Rodriguez, E. Uriarte, L. Santana, Vi\u00f1a, Bioorg. Med. Chem. Lett. 21 (2011) 4224. [19] E. Molina, E. Sobarzo-S\u00e1nchez, A. Speck-Planche, M.J. Matos, E. Uriarte, L. Santana, M. Y\u00e1\u00f1ez, F. Orallo, Med. Chem. 12 (2012) 947. [20] D. Vi\u00f1a, M.J. Matos, G. Ferino, E. Cadoni, R. Laguna, F. Borges, E. Uriarte, L. Santana, Chem. Med. Chem. 7 (2012) 464. [21] J.C.A. Helgaker, S. Coriani, P. Jorgensen, K. Kristensen, J. Olsen, K. Ruud, Chem. Rev. 112 (2012) 543. [23] C.B. Barnett, K.J. Neidoo, J. Phys. Chem. B 114 (2010) 17142. [24] E. Estrada, J. Gonzalez, L. Santana, E. Uriarte, A. Casti\u00f1eiras, Struct. Chem. 11 (2000) 249. [25] E. Quezada, S. Vilar, L. Valencia, L. Santana, R.A. Mosquera, E. Uriarte, Struct. Chem. 17 (2006) 459.[26] Bruker, APEX2, SAINT and [27] SHELXL97. Program for the Renement G\u00f6ttingen, Germany, 1997. Sheldrick, Crystallography, Netherlands, 65 (2009) J. Cryst. 45 (2012) 849. [32] MOE software, version 2011.10; Chemical Computing Group, Inc., 2011. <www.chemcomp.com/ >. [33] MOPAC, James J.P. Stewart, Stewart Computational USA, < http://OpenMOPAC.net > (accessed 10.12). [34] Maestro, version 9.2, Schr\u00f6dinger, LLC, New York, NY, 2011.[35] S. Aime, E. Diana, R. Gobetto, M. Milanesio, E. D. (2010) 778. [38] S. Dong, X. Liu, Y. Zhang, L. Lin, X. Feng, Org. Lett. 13 (2011) 5060.150 M.J. Matos et al. / Journal of Molecular Structure 1041 (2013) 144-150 127A aDepartamento de Qu\u00edmica Org\u00e1nica, Facultad de Farmacia, 15782 Santiago de Compostela, Spain bDipartimento Farmaco Chimico Farmacia, de Farmacolog\u00eda, Facultad de Farmacia, 15782 Santiago de Compostela, Spain article info Article history: Received March 2009Revised these hybrids) carried out with good yield by Perkin reaction, from the 5-methylsalicylaldehyde and the corresponding phenylacetic acid. They show high selectivity to the MAO-B isoenzyme, with IC 50val- ues in the nanomolar range. Compound 5is the most active compound and is several times more and selective than Coumarins (or benzopyrones) are a large family of compounds, of natural and synthetic origin, that show numerous appropriate substitutions in the coumarin ring, in in the 3:4 and 6:7 positions.7-11 The resveratrol (3,40,5-trihydroxystilbene) is a phytoalexin in species such efcient a large group of in vitro, ex vivo and/or in vivo experiments.12-15The resveratrol's cis and iso- can the trans isomeric form. A series of these molecules, with different number and position of methoxy groups in the 3-phenyl two known isoforms (MAO-A present in the mitochondrial outer membrane of glial, neuronal and other cells. inter- vene in possessing receptors mediators.21 The iMAO are a class of compounds that act by blocking the MAO enzymatic action, being used by several years in the treat- ment of sites isoenzymes (MAO-A and MAO-B) are not completely known and for this reason there is a lack ofinformation in respect of how the inhibitors act selectively in one of the two of them. 10Recent X-ray crystal structures of MAO-B24,25and MAO-A,21,26completed with irreversible and reversible inhibitors, can be used in the future as a tool to the structural basis to help understanding the MAO inhibitory activity and selectivity, we decided in this work to ex- plore the importance of the number and position of different meth- oxy groups under the benzenic ring in 3-position (compounds 427,28-6), to establish a relation them the non substituted analogue (compound 327-29). The preparation of these via classical Perkin reaction.29This obtain 3-6 is very clean between and 70%.30-33The obtained ucts of Compound 3, none substituted in the phenyl itself and selective againstMAO-B isoenzyme. Compound 4(with a one. The most potent molecule of this family is compound 5, bearing two methoxy groups in 30- and 50-positions (IC 50= 8.98 \u00b1 1.42 nM). This one is two times more active and several times more iMAO-B selective than the R-(/C0)- deprenyl. Compound more active than 3(none substituted) but it loses activity methoxy in the 3 0- and 50-positions on the phenyl ring, compound Increasing 3-phenyl ring seems to show nanomolar in the can improve the the Parkinson's disease. Acknowledgements Thanks the Spanish Ministerio de Sanidad y Consumo (PI061457 and PI061537) and to Xunta da Galicia (PXIB20304PR, L.; ,12, 887. 2. Hoult, J. R. S.; Pay\u00e1, M. Gen. Pharmacol. 1996 Hadjipavlou-Litina, D. J. 3697. 12. Fr\u00e9mont, L. Life Sci. 2000 ,66, 663. 13. Orallo, F. In Resveratrol in Health and Disease ; Aggarwal, B. B., Shishodia, S., Eds.; CRC ,75, 1156. 15. Orallo, F. Curr. N. R.; Chen, K.; Shih, J. C. J. C. White, H. L. J. Med. Chem. 1996 ,39, 1857. 23. Wouters, J. Curr. Med. Chem. Reagents conditions: (a) DCC, >352b the highest tested 27. Hans, N.; Singhi, M.; Sharma, V.; Grover, S. K. ,35, 1159. 28. Mohanty, S.; K.; Grover, S. K. Indian J. Chem., Sect. B 1989 ,28, 766. 29. Kamat, \u00b4Souza, A. M.; Paknikar, S. P. J. Chem. Res. (S) 2002 , 242. 30. 6-Methyl-3-phenylcumarin (3). It was obtained 208 (50), 178 (8), 165 (8) 76 (6), 51 (69). Anal. Calcd for C 16H12O2: C, 81.34; H, 5.12; O, 13.54. Found: C, 81.44; H, 4.84. 31. 3-(40-Methoxy)phenyl-6-methylcumarin (4). It obtained with 6.96 100), 223 (60), 195 (24), 165 (16), 152 (13), 115 (5), 89 (5), 63 (7), 50 (6). Anal.Calcd for C 17H14O3: C, 76.68; H, 3-(30,50-Dimethoxy)phenyl-6-methylcumarin (5). It 110-111oC.1H 100), 295 (17), 267 (16), 210 (8), 181 (22), 152 (13), 139 (6), 105 (8), 76 (9). Anal. Calcd for C 18H16O4: C, 72.96; H, 6-Methyl-3-(30,40,50-trimethoxy)phenylcumarin (6). It 100), 311 (89), 283 (43), 253 (12), 225 (30), 197 (10), 169 (10), 148 (5), 115 (8). Anal. Calcd for C 19H18O5: C, 69.93; H, 0.1 mL of sodium phosphate buffer (0.05 M, pH the dark fluorimeter chamber and incubated for 15 min at 37 /C176C. The reaction was 2O2and, consequently, of (excitation, 545 nm, emission, 590 nm) over a 15 min period, in which the fluorescence increased linearly.Control experiments were carried adding to solutions the activity, which vials all components were replaced by a sodium phosphate buffer solution. On the other hand, in our experiments and under our experimental conditions, the control activity of hMAO-A and hMAO-B (using p-tyramine as a common substrate for isoforms) oxidized the table are expressed as means \u00b1 SEM from ve experiments.3270 M. J. Matos et al. / Bioorg. Med. Chem. Lett. 19 (2009) Lourdes Santanaa, Eugenio Uriartea aDepartamento de Qu\u00edmica Org\u00e1nica, Facultad de Farmacia, Universidad de Santiago de Compostela, 15782 Santiago de Compostela, Spain bDipartimento Farmaco Chimico Tecnologico, Cagliari, Italy cDepartamento de Farmacolog\u00eda, Facultad de Farmacia, Universidad de Santiago de Compostela, 15782 Santiago de Compostela, Spain article info Article history: Received 12 June 2009 Revised MAO-B) between the these new resveratrol-cou- marin hybrids was carried out by a Perkin compounds show high selectivity to the MAO-Bisoenzyme, some of them with IC 50values in the low nanomolar range. Compound 4, with the methoxy group in meta position, is the most active of this series, with an IC 50against MAO-B of 0.80 nM, and is Coumarins are present in remarkable amounts in the nature. They have attracted considerable interest their been used for several treatment of depression L. and other spermatophytespecies, produced in response to an exterior or interior than the interesting and molecules.19,25In previous work, our re- search group had reported a comparative study of the importanceto the MAOI activity of the different number of methoxy groups on the phenyl ring in the 3 position of coumarin. This study contrib- uted to establish a and with the non- substituted analogue. 8Based on this, and with the aim of helping to better understand a structure/activity relationship for the MAO inhibitory activity and selectivity, in this paper we report the synthesis and evaluation of a new series. Maintaining the 6- structure, the three possible different 3-phenyl ring explored. We also explored the importance of the hydrolysis of methoxy group. The synthesis of the 6-methyl-3-phenylcoumarins was carried out via the classical Perkin reaction.26This reaction 0960-894X/$ - derivative 3was hydrolyzed with hydriodic acetic acid and acetic anhydride, at 110/C176C, for 5 h 1 residue was the nano to picomolar range. Compound 4was the most active compound of this series, making the meta methoxy position the most interesting position MAO-B- inhibiting that the methoxy group in favorable to enzymatic inhi- Changes on ring in coumarin's 3 position can modulate the shown that the hydrolysis of methoxy groups is not, in this case, a strategy to improve the MAOI activity. The IC for of MAO-B activity is approximately 10 times bigger than this value is also in activity introduc-tion of ortho and para positions. Compound 4is about 24 times more active that R-(/C0)-deprenyl, and several times more selective than this drug. The hydrolysis of methoxy groups is strategy of Parkinson's disease. Acknowledgments Thanks to the Spanish Ministerio de Sanidad y Consumo (PI061457 and PI061537) and to Xunta da Galicia (BTF20303PR, L.; ,12, 887. 2. Hoult, J. R. S.; Pay\u00e1, M. Gen. Pharmacol. 1996 Hadjipavlou-Litina, D. J. 9877. 15. Johnston, J. P. Biochem. 1968 ,17, 1285. Lan, N. Neve, R.; Chen, K.; Shih, J. C. White, H. L. J. Med. Chem. 1996 ,39, 1857. 18. Fr\u00e9mont, L. Life Sci. 2000 ,66, 663. 19. Vilar, 2006 ,16, 257. 20. Orallo, F. In Resveratrol in Health and Disease ; Aggarwal, B. B., Shishodia, S., Eds.; CRC ,75, 1156. 22. Orallo, F. Curr. Med. Chem. 2008 ,15, 1887. Paknikar, S. P. Res. 2002 , 242. 27. 3-(30-Methoxy)phenyl-6-methylcumarin (4): It was obtained 266 (M+, 100), 239 (16), 238 (70), 237 (20), 195 (48), 194 (16), 166 (10), 165 (29), 152 (23). Anal. Calcd for C17H14O3: C, 76.68; H, 5.30. Found: 3-(20-Methoxy)phenyl-6-methylcumarin (5): It the highest concentration tested (100 Matos et 266 (M+, 100), 265 (10), 249 (29), 237 (22), 235 (14), 223 (22), 220 (12), 195 (29), 173 (26), 165 (25), 152 (17),145 (19), 118 (19). Anal. Calcd for C 17H14O3: C, 76.68; H, 5.30. Found: H, 252 (M+, 75), 224 (58), 223 (26), 165 (12) 152 (15), 143 (23), 99 (37), 98 (25), 83 (12), 70 (20), 56(100), 55 (27). Anal. Calcd for C 16H12O3: C, 76.18; H, 4.79. in the table are expressed as means \u00b1 SEM from ve experiments.M. J. Matos et al. / Bioorg. Santanaa, Eugenio Uriartea aDepartamento de Qu\u00edmica Org\u00e1nica, Facultad de Farmacia, Universidad de Santiago de Compostela, 15782 Santiago de Compostela, Spain bCIQUP/Departamento de Qu\u00edmica e Bioqu\u00edmica, Faculdade de Ci\u00eancias, Universidade do Porto, 4169-007 Porto, Portugal cDepartamento de Farmacolog\u00eda, Facultad de Farmacia, Universidad de Santiago de Compostela, 15782 Santiago de Compostela, Spain dDepartamento de Qu\u00edmica, Faculdade de Ci\u00eancias e Tecnologia, Universidade 3004-535 Coimbra, article Article Received 24 Revised out structural features for the MAO inhibitory activity and selectivity, in present communication we report the synthesis and pharmacological evaluation of a new series of bromo-6-methyl-3-phenylcoumarin derivatives (with bromo atom in both different benzene rings of the skeleton) with and without different number of methoxy substituent at the 3-phenyl ring. The meth- oxy substituents introduced, in this new scaffold, in the meta para positions of the The Ltd. All rights reserved. Coumarins are large family of compounds, of natural and syn- thetic origin, that presents different pharmacological activities.1 Due to their structural variability, they occupy an products synthetic organic chemistry. Representatives of these groups of are found to occur in the vegetable kingdom, either in the free or in the combined state.2Recent studies is a natural polyphenolic compound present in grapes and red wine.15In in vitro, ex vivo, and in attracting a huge interest since the last decade. Recently, it that res- other cells.23,24These of in recent years. In an attempt plates were pattern the 3-phenyl 0960-894X/$ - see front in Scheme 1 . The experimental details are given in Ref. 35. The treatment of the pre- cursor 1with N-bromosuccinimide (NBS) preparation of the 8-bromo-6-methyl-3-phenylcoumarins (4 -7) performed by with yields between 45% and 50%. Compound 3was pre- pared in the same conditions described for compounds but starting The 3-7 in vitro the of effect the introduction of a halogen substituent was was shown in the Table 1 , compound 3, with the halogen atom in the 3-phenyl ring, has an IC 50in the micromolar range(IC50= activity. The structural change obtained with compound the halogen atom in the coumarin nucleus, leads 50= 11.0 nM). In fact it was greater than the IC 50found for 6-methyl-3-phenylcoumarin and com- pound 3. So, as consequence, MAO-B selectivity had increased too (see Table 1 ). A change of the bromo atom position in the 3- phenylcoumarin nucleus, from 20to 8, to improve activity (compounds with a p-methoxy substituent in the 3-phenyl ring, was the most potent and selective molecule, against MAO-B isoenzyme, of this series, an IC 50in the low nanomolar range (IC 50= 3.2 nM). This compound is six times more active and to a great extent more selective than groups 30and potent nM) is still better than the non-phenylsubstituted com- pound 4. Compound 7, with three methoxyl groups, present a loss of activity (activity in the micromolar range) and selectivity is an important factor to discriminate the potentialtherapeutic application of this kind of molecules. In summary one can say that the presence of a bromo atom in 8-position and a restricted number of methoxyl substituents (one or two) in the ring seems to be important of the 6-methyl-3-phenylcoumarins. In conclusion, in the present study it was shown that the resveratrol-coumarin hybrid Br(b) 1 5:R=4 ' - O M e 6:R=3 ' , 5 ' - O M e 7:R=3 ' , 4 ' , 5 ' - O M e2R (b) Me O O 3Br Scheme 1. Reagents the highest concentration tested (100 Matos et Bioorg. Med. Chem. Lett. 20 (2010) 5157-5160 138selectivity of them inhibitory activity is in the low nanomolar range. The presence of a bromo atom in position 8 of the coumarin improves the activity re- spect to the presence of a bromo atom linked to the 3-phenyl ring. The introduction of one para-methoxy group in the 3-phenyl ring of the 8-bromo-6-methyl-3-phenylcoumarin improve to a great extent MAO-B the other prepared In introduction of a of be effectively a candidate for the treatment of neurodegenerative diseases. These nds have encouraged us to continue the 6-methyl-3-phenylcoumarin. Acknowledgments Thanks to the Spanish Ministry(PS0900501), to Xunta da (PGIDIT09CSA030203PR and INCITE09E2R203035ES) L.; ,12, 887. 2. Hoult, J. R. S.; Pay\u00e1, M. Gen. Pharmacol. 1996 Hadjipavlou-Litina, D. J. 3697. 15. Fr\u00e9mont, L. Life Sci. 2000 ,66, 663. 16. 2006 ,16, 257. 17. Orallo, F. In Resveratrol in Health and Disease ; Aggarwal, B. B., Shishodia, S., Eds.; CRC ,75, 1156. 19. Orallo, F. Curr. Med. Chem. 2008 ,15, 1887. Medica: Amsterdam, 1982; p 197. 26. Singer, T. P., Muller, F., Eds.; CRC Press: London, H. Neurotoxicology 2004 ,25, 11. 29. Rudorfer, M. V.; Potter, V. Z. Drugs 31. Guay, D. R. Am. H.; Fridkin, M.; Zheng, H. J. Neural Transm. 2004 34. Cesura, A. M.; Pletscher, A. Prog. Drug Res. 1992 ,38, (3): A of 2-hydroxy-6- methylbenzaldehyde at 110 /C176C for 24 h. Triturate ice (100 mL) and acetic acid (10.0 mL) were added to the reaction mixture. After keeping it at room temperature for 2 h, the mixture was extracted with ether (3 /C225 mL). The organic layer was extracted with sodium bicarbonate solution (50 mL, 5%) and then water (20 mL). The solvent was evaporated under vacuum and the dry residue waspuried by FC (hexane/ethyl acetate 9:1) to give 3(1.36 g, 59%) as solid. Mp 141-142 /C176C. NMR 315 (38), 314 (M+, 100), 236 (32), 235 (80), 178 (22), 117 (7), 89 (7), 76 (9). Anal. Calcd for C 16H11BrO 2: C, 60.98; H, 3.52. procedure A at 110 /C176C for 24 h. Triturate ice (20 mL) and acetic acid (3.0 mL) were added to the reaction mixture. After keeping it at room temperature for 2 h, the mixture was extracted with ether (3/C225 mL). The organic layer was extracted with sodium bicarbonate solution (50 mL, 5%) and then water (20 mL). The solvent was evaporated under vacuum and the dry residue was puried by (hexane/ethyl acetate 9:1) togive a solid. 8-Bromo-6-methyl-3-phenylcoumarin (4): It 315 (42), 314 (M+, 100), 313 (99), 288 (36), 286 (15), 285 (36), 207 (30), 178 (26), 89 (10), 76 (10). Anal. Calcd for C 16H11BrO 2: C, (5): 345 (15), 344 (M+, 100), 303 (53), 301 (54), 275 (15), 207 (15), 166 (17), 165 (72), 138 (17), 89 (13), 76 (14), 58 (41). Anal. Calcd for C 17H13BrO 3: 375 (26), 374 (M+, 100), 238 (37), 209 (14), 181 (36), 165 (30), 153 (18), 152 (41), 151 (17), 126 (15), 76 (22). Anal. Calcd for C 18H15BrO 4: 406 (99), 405 (21), 404 (M+, 100), 391 (56), 389 (56), 363 (19), 361 (19), 303 (21), 247 (13), 187 (15), 186 (15), 139 (19). Anal. Calcd for C 19H17BrO 5: C, 56.31; V.; 1159. 38. Mohanty, J. Sect B 1989 ,28B, 766. 39. the dark fluorimeter chamber and incubated for 15 min at 37 /C176C. The reaction was 2O2and, consequently, of (excitation, 545 nm, emission, 590 nm) over a 15 min period, in which the fluorescence increased linearly. Control experiments wereM. J. Matos et Chem. (2010) adding to solutions only the Amplex/C210 Red was the activity, which vials all components hMAO isoforms, which were replaced by a sodiumphosphate buffer solution. On the other hand, in our experiments and under our experimental conditions, the control activity of hMAO-A and hMAO-B (using p-tyramine as a common 2 pmol ofp-tyramine in the table are expressed as means 344, J. Matos et al. Santanaa, Dolores Vi\u00f1ab, aDepartamento de Qu\u00edmica Org\u00e1nica, Facultad de Farmacia, Universidad de Santiago de Compostela, 15782 Santiago de Compostela, Spain bDepartamento de Farmacolog\u00eda, Facultad de Farmacia, Universidad de Santiago de Compostela, 15782 Santiago de Compostela, Spain article info Article history: Received 5 April 2011 Revised 18 May 2011Accepted 20 May 2011 Available for the human MAO inhibitory activity and selectivity, the present communication we report the synthesis, pharmacological evaluation and a comparative study of a new series of 3-phenylcoumarins (compounds 1-4) and 3-benzoylcoumarins (compounds 5-8). A bromo atom and a methoxy/hydroxy substituent were introduced in these scaffolds, at six absence of a carbonyl group between the coumarin and the phenyl substituent bound to the outer mitochondrial many other as MAO-A and and anxi- ety. 40,41All these ndings have led us to an intensive search for novel, selective and efcient MAO inhibitors. With the aim of were differ- ently substituted. experimental data previous 3-phenylcoumarins experimental results, in this paper we describe a new project with a comparative study between 3-phenylcoumarins (compounds 1-4) and 3-benzoylcoumarins (compounds 5-8), are of coumarin 0960-894X/$ the synthetic protocol outlined in Scheme 1 boron tribromide give corresponding hydroxy derivatives 7and 8.Starting from the same salicylaldehyde, we afford two series, differing just in the presence (compounds 5-8) or absence (com- pounds 1-4) of a carbonyl group between the phenyl substituent at the 3 position and the coumarin MAO activity calculated the communication, the effect of the presence or the absence of a carbonyl group between the coumarin and the 3-phe- nyl ring deriva- tives. It shown that introduction of both bromo addition, the introduction of a the para position of the 3-phenyl ring might help to improve the activity. Consequently, when this substituent MAO-B replacement of can even decrease selectivity. On the other hand, when we analyze the second series where a 3-benzoyl group has the MAO-B selectivity of the rst series. A small change in the structure causes a big change in the afnity of the molecules for the receptor. These preliminary results allow us to understand slightly better interactions between molecule and receptor and the molecular fragments that are essential to main- tain and improve As However, of the 3-ben- zoyl = OMe, R3 = = R2 = R3 OH 7: Br, = OH, = R1 = Br, R2 = Matos et of the couma- rins' substituent. In the present study it was 2, with a p-methoxy substituent in the 3-phenyl ring was the most selective molecule of the rst seriesagainst the low (IC 50= 1.35 nM). This compound is fteen times more active times the different apeutic the efforts optimization pharma-cological prole Thanks to Spanish Ministry de Galicia (PGIDIT09CSA030203PR and S.V.R. to Ministerio de Educaci\u00f3n y Ciencia for a PhD grant (AP2008- 04263). L.; Uriarte, F.; Roleira, Milhazes, N.; Uriarte, E.; Santana, L. Front 2009 ,4, 23. 3. Hoult, J. R. S.; Pay\u00e1, M. Gen. Pharmacol. 1996 ,27, 713. 4. Murray, R. D. H. Prog. Chem. Org. Nat. Prod. 2002 ,83,1 . 5. Go, M. L.; Wu, X.; Liu, X. L. Curr. Med. Chem. 2005 ,12, 483. 6. Nowakowska, Z. Eur. J. Med. Chem. 2007 ,42, 125. 7. Kontogiorgis, C.; Hadjipavlou-Litina, D. J. 2009 ,52, 1486. 13. Kostova, I. Curr. HIV Res. 2006 ,4, 347. 14. Rao, Y. K.; Fang, S.; Tzeng, Y. Bioorg. Med. J. A. Expert Opin. 5053. Matos, Vi\u00f1a, Janeiro, P.; Santana, 9750. P.; Strolin Medica: Amsterdam, 1982; p 197. 33. Singer, T. P. F. Muller (Ed.) ; CRC Press: London, 1991. p. 437. 34. Hsu, Y. P.; X. O. Pharmacol. Ther. 391. 36. Guay, D. R. Am. J. Geriatr. Pharmacother. 2006 Riederer, P.; H.; Fridkin, M.; Zheng, H. J. Neural Transm. 2004 39. Cesura, A. M.; Pletscher, A. Prog. Drug Res. 1992 ,38, 171. 40. Rudorfer, M. V.; Potter, V. Z. Drugs for the preparation oil-bath at 110 /C176C for 24 h. Triturate ice (20 mL) and acetic acid (3.0 mL) were added to the reaction mixture. After keeping it at room temperature for 2 h, the mixture was extracted with ether (3 x 25 mL). The organic layer was extracted with sodium bicarbonate solution (50 mL, 5%) and then with water (20 mL). The solvent was evaporated under vacuum and the dry residue was puried by FC (hexane/ethyl 9:1) to desired 6-Bromo-8-methoxy-3-phenylcoumarin ( 1): it was 331 (30), 330 (M+, 100), 304 (40), 302 (40), 261 (25), 259 (26), 194 (16), 165 (12), 153 (14), 152 (88), 151 (23), 102 (19), 76(34). Anal. Calcd for C 16H11BrO 3: 362 (M+, 100), 361 (19), 360 (59), 334 (24), 332 (23), 319 (33), 317 (34), 291 (11), 289 (11), 182 (18), 167 (17), 139 (21), 91 (11). Anal. Calcd forC 17H13BrO of hydroxylated 3-phenylcoumarins ( 3 and 4). a solution of the corresponding methoxy-3-phenylcoumarin (0.50 mmol) in acetic acid (5.0 mL) and anhydride (5.0 mL), at 0 /C176C, was prepared. Hydriodic 57% (10.0 Themixture under temperature for 3 wasevaporated vacuum and the dry 318 (99), 317 (17), 316 (M+, 100), 291 (12), 290 (78), 289 (13), 288 (81), 153 (22), 152 (51), 151 (12), 76 (25). Anal. Calcd for C 15H9BrO 3: 334 (99), 333 (45), 332 (M+, 100), 307 (31), 306 (99), 305 (35), 304 (99), 225 (26), 197 (29), 169 (35), 168 (46), 153 (24), 141 (21), 140 (16), 139 (51), 118 (17), 115 (28), 98 (13), 89 (14), 84 (18), 84 (46), 75 (11), 63 (13). Anal. Calcd for C 15H9BrO 4: C, was cooled and the precipitated was ltered and washed with cold ethanol and 359 (M+, 58), 358 (18), 357 (58), 105 (100), 77 (70). Anal. Calcd for C17H11BrO 4: C, 56.85; H, 3.09; Found: C, H, J. Matos et 388 (17), 387 (M+, 90), 135 (100), 77 (56). Anal. Calcd for C 18H13BrO 5: C, the reaction mixture /C176C 48 crude (M+, 45), 105 (100), 77 (58). Anal. Calcd for C 16H9BrO 4: 360 (M+, 30), 121 (100), 93 (16), 65 (15). Anal. Calcd for C 16H9BrO 5: C, 53.21; 1159. 44. Mohanty, J. Sect B 1989 ,28B, 766. 45. O.; Tetrahedron the fluorimeter and incubated for15 min at 37 /C176C. The was 2O2and, consequently, of (excitation, 545 nm, emission, 590 nm) over a 15 min period, in which the fluorescence increased linearly. Control experiments were adding to solutions only the Amplex\u00d2 Red the activity, which vials all components were replaced by a sodium phosphate buffer solution. 52. All IC 50values shown in the table are expressed as means Matos et Chem. (2011) 4224-4227 7127 and Selective Monoamine of Pharmacy, University of Santiago de Compostela, 15782 Santiago de Compostela, Spain Department of Organic Chemistry, Faculty of Chemistry, University of \u00a7Department of Pharmacology, Faculty of Pharmacy, University of Santiago de Compostela, 15782 Santiago de Compostela, Spain 'INTRODUCTION Coumarins are a wide family of compounds present amounts in the common substrates for treatment of neurological disorders Parkinson 's disease.29,30All of these aspects have led to an intensive search for novel MAO inhibitors. Additionally,the description of the crystal structure of the two MAO isoformsby Binda et al. has provided relevant information about the interactions the discovery that expression levels of this isoenzyme in neuronal tissue increase resulting in an increment of as well production of hydrogen peroxide, cause oxidative stress and may as adjuvant for the treatment of Parkinson 's and Alzheimer 's diseases. For instance, it has been reported that selegiline protects neuronal cells from the consequences of the oxidativestress in these patients.36 In the past few years, a broad consensus has been reached concerning the necessity for the new, more less toxic MAO-B selective compounds with and eval-uated inhibitors. studied compounds is the most active compound of this series, being 64 times more active than selegiline and h-MAO-B study provided enzyme interaction and the therapeutic application of sca old. 1457128 dx.doi.org/10.1021/jm200716y | J. Med. Chem. 2011, structural sca olds.37/C042Therefore, the coumarin nucleus has emerged in the 1990s as promising t e r m i n e db yt h en a t u r eo ft h el i n k a g eb e t w e e nt h ec o u m a r i na n dt h e lipophilic aryl groups in and when an addi-tional acetonyloxy group was present in the 7 position, thisresulted in compounds with very high MAO-B selectivity. These results us to analyze the importance of the aryl substituent at and hasmoved at C3, including di on it. 47/C049 The selectivity for this new 3-arylcoumarin scaold encouraged us to synthesize and study the MAO inhibitory activity of new analogues, in which a variety of groups with di erent size, electronic, and lipophilic properties were introduced in rings, in clarify the in fluence substitution pattern protocol in Scheme 1. The chemical structure of the compounds is organized in Table 1. reaction conditions the characterization are described d presence of acetic acetic anhydride.48 Finally, the was investigated by measuring their production of peroxide 2O2) kit Oregon, SA, Alcobendas, Spain) were used as source for the two micro- somal MAO isoforms.53The production of H 2O2catalyzed by isoforms can be detected using (Amplex Red reagent), fluores- highly sensitive probe that reacts with H 2O2in the presence of horseradish peroxidase to produce a fluorescent resoru these drugs do not interfere with the measure-ments. On the other hand, in our experiments and under our experimental conditions, hMAO-A displayed reac- MAOactivity and selectivity of study was performed. The crystallographic of code 2ZX5)51were to the The docking simulations were carried out using the DOCK v. 6.3 docking having bulky substituents at the 3-position the case coumarin studywhether able or mode that the the docking protocol, we also included 3, 5, and 6 structural water molecules in the receptorstructure, yielding similar scoring and orientations for the compounds as in the water depleted receptor structure. This is the main reason we did not use any structural water molecule in the modeling of the compounds included in the paper. Further- more, the use of the water depleted receptor would allow the ligands to explore the lower region of the binding pocket. In this way, the docking algorithm is able explore orientations of the 3-substituent oriented to the upper subpocket and to the FAD cofactor. Despite the fact a continuous solvent model the predicted complexes structures.55,56 These results support the use of our protocol for the predictionand analysis of the binding mode of the coumarin derivativesdescribed in this study. The molecular docking studies were done for di erent com- binding pocket, 32,33,50,52with substituent and Tyr60. The coumarin of substrate cavity, interacting cofactor as well as 54, 7127-7137Journal of Medicinal ChemistryARTICLE with Cys172, favorable the formation hydrogen between the subpocketexisting only in 3 HC H 3 HH b 17.05(0.88 nM >5882e 2 OCH 3 HH C H 3 H b 1.52(0.08 nM >6789e 3 OH H H CH 3 H 24.90(1.33 67.10(2.99 nM 372 4 C3H5O2 HH C H 3 H b 5.52(0.29M >18e 5 C5H9OH H C H 3 H b 14.47(0.78M >6.9e 6 CH 3 HH HH b 283.75(19.90 nM >352e 7 CH 3 HH C H 3 H b 0.31(0.02 nM >333333e 8 CH 3 HC H 3 HH c 15.01(0.83 nM >6667e 9 CH 3 H H OCH 3 H b 13.05(0.90 nM >7663 10 CH 3 H OCH 3 HH b 0.80(0.05 nM >125000 11 CH 3 OCH 3 HH H bb 12 CH 3 H OCH 3 H OCH 3 b 8.98(1.42 nM >11136e 13 CH 3 H OCH 3 OCH 3 H 25.14(1.68 2.73(0.12 nM 9209 14 CH 3 H OCH 3 OCH 3 OCH 3 b 160.64(1.01 nM >623e 15 CH 3 H Br OCH 3 H b 0.74(0.02 nM >135870e 16 CH 3 H OCH 3 Br H b 3.25(0.17 nM >31250e 17 CH 3 Br OCH 3 H OCH 3 b 54.03(3.91M >1.9e 18 CH 3 Br OCH 3 OCH 3 OCH 3 bb 19 CH 3 H H OH H b 155.59(17.09 nM >643e 20 CH 3 H OH H H 35.04(1.88 650.03 (34.82 nM 54 21 CH 3 OH H H H 21.58(1.16 120.02 (6.43 nM 180 22 Chem. 2011, 54, 7127-7137Journal of Medicinal ChemistryARTICLE inhibit the A and B isoforms hMAO. well as the and docking results, can help us with an interesting SAR study. From the experimental results, it can be observed that most of the are selective inhibitors toward MAO-B, with the low micro, nano, and picomolar range. Ten of the 22 tested compounds have similar or better IC 50= 19.60 nM, reference MAO-B a or a methoxy group, respectively. With the of derivatives MAO-B MAO-A colored by are represented as green pseudobonds. Superposition to Phe208 J. Med. Chem. 2011, 54, 7127-7137Journal of Medicinal ChemistryARTICLE of introducing a group with di erent physicochemical properties under the 3-phenyl ring of and a bromo groups, respectively. This com-pound proved to be one of the three most active compounds, with IC 50against hMAO-B of 0.74 nM. This new substitution makes a better MAO-B inhibitor than the corresponding derivative without the bromo atom, compound 9, with an IC 50of 13.05 nM. On the other hand, compound 16, with the para andmeta positions substituted with a bromo lose MAO-B inhibitory activity. that the presence of an electron donor at the para position is an important modi cation to improve the activity. From coumarin 7, with a p-methyl substituent in the 3-phenyl a 6-methyl sub- in the coumarin aromatic ring, potent and selective one against MAO-B isoenzyme. This compound was 63 times more active than resulting reported point out that almost all the substitutions at ortho position of the 3-phenyl seem to unfavorable for the activity. with methoxy or bromo substituent, respectively, at the ortho position inactive at (highest concentration tested). The corresponding compound 14, compared with compound 18 but without the ortho -bromo atom, has an activity in the nanomolar range. Compound 17, also with a bromo atom at ortho position, has an MAO-B inhibitory activity in the high micromolar range, while their correspondent nonbrominated compound 12, with a \"free\"ortho position, has an activity against MAO-B in the low nanomolar range. It seems clear that the presence of is substituted with a hydroxyl group (compound 21). In this case, the methoxy derivative (compound 11) has no activity against MAO-B and the hydroxyl one has an IC 50in the nanomolar range. This is going to be one In addition, a hydroxyl group incorporated in para-o rmeta-positions of the phenyl ring of the moiety the MAO-B inhibition than a methoxy ormethyl group at the same position, as it can be seen by comparing the IC 50values of respectively. Finally, in the 6 moiety 7) provides alkoxy as an cyclopentyloxy group 5), signi reduced the activity, being better tolerated in the 3-phenyl ring, in particular in the meta position (compound 22). Almost all the studied compounds with substituents in the the basis of the docking results, the proposed binding mode for this series of compounds in the pocket of hMAO-B isconsistent with the observation that only small substituents are tolerated at position 6, as can be seen analyzing the results of thecompounds 4and5. The increase in of disruption proposed mode because partof the space used by thisbulky substituent, resulting in the ligand Additionally, the by the docking simulations show a small angle between the planes de ned by the coumarin and the 3-phenyl ring. These conformations, which are stericallyprohibited when a methoxy group is included at 2 0position of the 3-phenyl ring, are however permitted for a hydroxyl group at the same position. These conformational changes can explain why theortho considerably decreased or abolished the activity and why the Phe208 residue instead of the Ile199 present in the same position of MAO-B. On the basis of the docking studies information, the high MAO-B selectivity of these series compounds could beexplained by into account two factors: the recognize exploit entrance more distant position into the binding pocket to t in the cavity and interact with the binding points (ligand in magenta ball and sticks, Figure 4d). This movement to a deeper region in the results in the displacement of some water molecules conserved in the X-ray structures of the necessary for to MAO-B, according to the proposed models. is expensive between the inhibitors and MAO-A. 'CONCLUSION In this paper, we have used the Perkin reaction as a key step of a good methodology for the e cient and general synthesis of a selected series of 3-arylcoumarins. Most of the studied com-pounds show a high and selectivity MAO-B isoenzyme. Several MAO-B binding pocket are more intense than those with the MAO-A one. The docking results are in accord with the biological data and allowed us to support an interesting SAR study. Additionally, all the resultsshow that a small substitution at C6 (methyl or methoxy groups) of the coumarin core seems to be important when a phenyl group is located at C3. A Chem. 2011, 54, 7127-7137Journal of Medicinal ChemistryARTICLE substituent at C6, both kind and position of substituents included in the 3-aryl group play a crucial role in activity and selectivity. Meta andpara activity. Currently, further research is going to be conducted on the 3-arylcoumarin sca old as potential agents for the treatment of Parkinson 's disease. apparatus and calculated values all cases. Silica gel (Merck 60, 230 /C000 mesh) was used for flash chromatography (FC). Analytical chromatography (TLC) was performed on platesprecoated with silica gel (Merck F254, The purity of compounds 1/C022was assessed by HPLC and was found be than 95%. General Procedure for the Preparation of 3-Phenylcou- marins (1, 2, 6 /C014). A and the mixture was heated in an oil bath at 110 /C176C for 24 h. Ice (100 mL) and acetic acid (10 mL) were added to the reaction mixture.After keeping it at room temperature for 2 h, the mixture was extractedwith ether (3 /C225 mL). The organic layer was extracted with sodium bicarbonate solution (50 mL, 5%) and then water (20 mL). The solventwas evaporated under vacuum, and the 266 (M+, 100), 238 (38), 195 (25), 167 (14), 165 (17), 152 (24). Anal. Calcd for C 17H14O3: C, 76.68; H, 266 (M+, 100), 238 (25), 195 (18), 165 (9), 152 (16). Anal. Calcd for C 17H14O3: C, 76.68; 250 (M+, 100), 222 (56), 221 (24), 178 (27), 150 (12), 136 (12), 124 (19). Anal. Calcd for C 17H14O2: C, 250 (M+, 100), 222 (72), 221 (39), 178 (32), 150 (10), 136 (10), 124 (10). Anal. Calcd for C 17H14O2: C, 81.58; H, 5.64. (5 mL) was stirred under reflux for 18 h. The resulting solution was filtered to the succinimide. (98), 345 ([M + 1]+, 19), 344 (M+, 100), 303 (45), 301 (45), 275 (11), 250 (17), 222 (13), 194 (11), 178 (13), 165 (58), 163 (11), 139 (15), 132 (42), 82 (18), 76 (14), 63 (19), 50 (14). Anal. Calcd for C17H13BrO 3: + 1]+, 10), 344 (M+, 100), 266 (49), 265 (45), 238 (24), 237 (67), 194 (42), 165 (29), 133 (28). Anal. Calcd for C 17H14O2:C + 1]+, 18), 375 (M+, 100), 282 (59), 279 (14), 239 (11) 208 (9), 152 (10), 118 (9), 58 (12). Anal. Calcd for C 18H15BrO 4: + 1]+, 12), 406 (M+, 68), 404 (5) 326 (22), 325 (59), 282 (15), 264 (15) 169 (9), 139 (10).Anal. Calcd for C 19H17BrO 6-meth- (0.50 mmol) in acetic acid (5 mL) aceticanhydride (5 mL), at 0 /C176C, was prepared. Hydriodic acid 57% (10 mL) The mixture was stirred, under reflux temperature, for 3 h. The solvent was evaporated under vacuum, and the 1]+, 51), 252 (M+, 100), 225 (35), 224 (96), 223 (62) 195 (13), 181 (17), 165 (19), 152 (31), 139 (10), 125 (15), 115 (15). Anal. Calcd for C 16H12O3: C, 76.18; H, 4.79. Found: H, dx.doi.org/10.1021/jm200716y 63), 252 (M+, 73), 251 (15), 225 (46), 223 (53), 195 (33), 194 (18), 181 (29), 178 (17), 166 (12), 165 (42), 152 (43), 139 (13), 126 (24), 111 (19), 63 (16), 51 (16). Anal. Calcd for C16H12O3: C, 252 (M+, 100), 251 (10), 234 (12), 223 (58), 195 (35), 194 (5), 181 (18), 165 (17), 152 (18), 126 (5), 63 (6), 51 (6). Anal. Calcd for C 16H12O3: C, 76.18; H, 4.79. added. The suspension was stirred, at reflux temperature, for 16 h. The was and was 308 (M+, 100), 266 (12), 265 (50), 236 (15), 235 (26), 207 (31) 195 (12), 179 (16),178 (16), 165 (11), 153 (12), 129 (20). Anal. Calcd for C 19H16O4:C 308 (M+, 70), 266 (55), 265 (50), 237 (29), 236 (21), 235 (20), 178 (24), 165 (10). Anal. Calcd for C 19H16O4: C, 74.01; H, The suspension was stirred, reflux temperature, for 24 h. The was and was under the 320 (M+, 28), 253 (19), 252 (100), 224 (38), 223 (13), 152 (11). Anal. Calcd for C 21H20O3: C, 78.75; 7.4) containing different conditions the same reaction velocity, i.e., to oxidize (in the control group) the same concentration of substrate: 165 pmol of in a flat-black- bottom 96-well microtest plate and placed in the dark fluorimeterchamber. After incubation period, the reaction was started 2O2and, consequently, of resorufin (excitation, 545 nm, emission, 590 nm) over a 15 min period, in which the fluorescence increased linearly. Control experiments were carried out Red determined by adding drugs to solutions containing only the Amplex Red reagent in a sodium phosphate bu er. above) the activity, which vials all components were replaced by a sodium phosphate bu er solution. In our experimental conditions, this was code 2ZX5)51were used to For both isoenzymes, hydrogen atomsand charges to UCSFChimera, 57and the of 50000 conformations per molecule were generated using maximum number saved theMOLCHARGE is part of the docking was carried maximum was saved, maximum of for Afterward, 7127-7137Journal of ChemistryARTICLE into account small structural rearrangements on both ligand and receptor as well as the e ect of the solvent through a GB/SA continuum model for the solvation graphics images produced using the for Biocomputing, Visualization, and Informatics at the the Xunta de Galicia (09CSA030203PR, PGIDIT07PXIB, 10PXIB203303PR) and Ministerio de Sanidad y Consumo (FIS PI09/00501) for nancial support. M. Jo ~ao Matos thanks providing an Academic License for using their software at the Laboratory for Medicinal Chemistry of the Rega Institute for Medical Research at the Katholieke Universiteit Leuven. 'DEDICATION This article is dedicated to the Prof. Francisco Orallo A. The natural coumarins and Biochemistry ; John Wiley and Sons: Chichester, UK, 1982. (2) R. D. Naturally plant coumarins. Prog. Chem. ,4,2 3-85. R. Coumarins. Applications R. D., Ed.; John Wiley and Sons: New A.; Le, N.; Rowe, C. Discovery of novel DNA gyrase inhibitors by high-throughput Coumarins as inhibitors of HIV reverse transcrip- tase. (13) Zhou, X.; Wang, X. B.; L. oxidase Elsevier: 1982; pp 197. Singer, T. P. In Chemistry and Biochemistry of Flavoenzymes ; Muller, F., Ed.; CRC Press: Boca Raton FL, 1991; Vol. 2, pp 437. (21) Bach, A. W. J.; Lan, N. C.; Johnson, D. N. C.; Neve, R.; Chen, Shih, J. C. Tissue distribution of human monoamine oxidase A and B mRNA. J. Neuro- 1169. its catalytic site and mechanism. Med. Res. Rev. 1995 ,15, 325 -388. 1537136 dx.doi.org/10.1021/jm200716y | J. Med. Chem. 2011, for human monoamine oxidase A and B are influenced by a single amino acid. J. Biol. c for inhibitors. J. V.; Potter, V. Z. Antidepressants. A comparative review of the clinical pharmacology and therapeutic of the \"newer \" versus the \"older \"drugs. Drugs 1989 J. J. Monamine oxidase inhibitors: current forthe of neurological disorders. Nature Struct. Mol. Biol. 2002 , 9,2 2 -26. (32) (a) to the of rat MAO-A and human MAO B. Proc. Natl. Acad. Sci. in four inhibitors of the N-propargylaminoindane class. J. Med. Chem. 47, oxidase J. Med. Chem. 2008 ,51,8 0 1 9 -8026. (35) Sayre, L. M.; Perry, G.; (37) Filip, V.; Kolibas, E. Alzheimer 's disease: a long-term randomized placebo-controlled trial. Czech and Slovak senile dementia of Alzheimer type study group. J. Psychiatr. Neurosci. 1999 ,24, 234 -243. (38) (a) Annan, N.; Silverman, R. B. New analogs of N-(2- aminoethyl)-4-chlorobenzamide (Ro /C06491). Some Chem. 2008 inhibitors on the 5H -indeno[1,2- c]pyridazin-5-one core. nervous system agents. (BASF B inhibitors. J. Med. Chem. 2008 the control of opening the entry for substrates/inhibitors.Proc. Natl. Sci. ized Born 2004 ,55, for Predictions and Testing. J. Mol. Biol. 2008 , 377, 914 -934. (57) Pettersen, E. F.; T. Chem. of Medicinal ChemistryARTICLE visualization system for exploratory research and analysis. J. Comput. Chem. 2004 ,25, 1605 -1612. (58) Dupuis, M.; Montgomery, J. A. General atomic and molecular electronic structure system. J. Comput. Chem. version 1.3.1 M. J. Matos,* G. Ferino,* E. Cadoni, R. Laguna, F . Borges, E. Uriarte, L. Santana 464 - B. high affinity and selectivity for pathologies. population is among the most important chal- lenges today. Alzheimer's disease (AD) is prevalent of the NDs, Parkinson's stages, or palli- ate the appearance of symptoms, is one of the main goals for researchers in this area. Increased activity in monoamine oxidase A B quantities of endoge-nous exogenous The such as neuronal, and other mammalian cells.[3]MAO-A and B have been recent years. This is relat-ed the recent discovery that the increase in MAO-B activity is associated with gliosis, of expression levels of this isoform in neuronal tissue in- crease with age. The the role ND. [15,16]Rasagiline is a good MAO-B inhibitor due to its capacity to protect neuronal conse- quences of oxidative stress in patients.[16,17] [a]Dr. CIQUP/Departamento Qu/C237mica e Bioqu/C237micaFaculdade Cagliari (Italy) E-mail: giulioferino@unica.it [c]Dr. M. J. Matos, Prof. E. Uriarte, Prof. L. Santana Departamento de Qu/C237mica Org/C181nica, Facultad de Farmacia Universidad de Santiago de Compostela 15782 Santiago de Compostela (Spain) [d]Dr. D. Vi\u00c7a, Dr. R. LagunaDepartamento de Farmacolog/C237a, Facultad de Farmacia Universidad de Santiago de Compostela 15782 Santiago de Compostela (Spain)Neurodegenerative disorders are aging population. This has inspired active research in the development of new drugs that couldmark an important advance in the treatment of complex dis- eases such as Alzheimer 's and Parkinson 's. With the aim of finding new MAO-B-selective inhibitors, we report the synthe- sis, in vitro evaluation, simulation of series of substituted at the 8-position. Most of the high affinity and selectivity for the IC 50values in the low micro- compound 8being fivefold more information about the enzyme-inhibitor interaction and potential therapeutic application has shown pro- tective effects central nervous owing to is modulated by the nature and position of the linkage between the coumarin moiety and the lipophilic aryl 6 of the coumarin moiety and the introduction of an aryl ring at position 3 of the proved the coumarin inhibitors such as 7 with a benzene ring fused at positions 3 or 4 led tocompounds with very high MAO-B selectivity. [39]Therefore, it the coumarin scaffold, has also been carried out. Those with substituents 3 of theg-pyrone nucleus act preferentially as ring system. We were motivated to syn- thesize and study the MAO inhibitory activity of new ana- logues in which of various size and lipophi- licity were introduced at position 8 of the coumarin aromatic ring and at position 4 of the 3-aryl ring. Both aromatic rings were substituted in order by the 3-arylcoumarins. Given that there are no other published studies regarding coumarins,this is an interesting scaffold to the two helpful for corroborating clarifying the experimental conditions and compound charac- terization data toafford the desired 3-arylcoumarins. This is a very easy that affords different was per- by production of hydro- gen peroxide from para -tyramine (a common substrate Red The of hydrogen peroxide catalyzed by reacts with H2O2in the presence of horseradish peroxidase to produce fluorescent re- do not interfere with the 8C, 24 h. 7, 464 - 470 2012 inhibitors. irreversible in the lack of with 4-carboxaldehyde-7-(3-chlorobenzy- because theyform an extensive hydrogen amongst each other the enzyme; moreover, some of these water molecules proximal to as protocol for this study. Briefly, in the QPLD step, theligand was first enzyme using Glide; [54]quan- tum mechanical calculations were then made to take into ac- count the polarization of the charges in Experimental below for de- tails). The pose of each derived from QPLD was subjected to an energy calculation and minimization with Prime MM-GBSA. Prime was used in this study with the sole aim of minimizing the input poses derived from QPLD, taking into account a flexible enzyme region defined by a distance of 5 /C138 from the ligand. We validated protocol inside binding an RMSD of 0.47 /C138 for heavy atoms. The first simulation was made with the aim of visualizing the binding mode of the most active compounds (Figure 1 a). The best docking poses were retrieved for compounds 7,8, and 9, which manifest the by a hydrogen bond between the carbonyl oxygen atom of the best- pose solutions b). The patterns adopted from compounds 1,2,a n d 3 could be considered generally the same, while small differen- ces can be observed between the most active compounds 2 and 3with respect to compound 1. The hydrogen bond with Cys172 was maintained for all the three coumarins. The me- thoxy oxygen atom of compound 2acts acceptor with a water molecule, forming a hydrogen bond at adistance of Furthermore, the ethoxy groupat position 8 is positioned in manner compound 1than its positioning a bulkier (relative to methoxy or methyl) hydrophobic analyzing the differences between substitutions at positions 8 and 6 p<0.01 KGaA, Weinheim ChemMedChem 2012, 7, 464 - 470MED M. J. Matos, G. Ferino, et al. 161analyzed the most stable pose retrieved for compound 6and compared leave the methyl group oc- cupying the same position in the binding pocket. In both structures the methyl group complex stabili- zation is related molecule group. Indeed, the carbonyl group is placed (Scheme 1). They were also evaluated for their ability to inhibit the A 1. of the 3-arylcoumarin moiety has never been de- MAO-A and MAO-B. Analysis of the experimental data revealed that seven of the nine tested compounds are se- lective inhibitors of MAO-B, the low micro- and nanomolar ranges. Three compounds of this series have similar or better IC50values than (IC50=19.60 coumarin derivatives 7 (IC 50=3.43 nm)a n d 8(IC50=4.51 nm), which are about sixfold more active than the reference compound. Compound 8is Figure 1. a) Comparison of the most stable binding compounds format; carbon atoms are yellow for 7, green for 8, and purple for 9. The FAD cofactor and water molecules are depicted in wire, with carbon atoms in grey. The hydrogen bond is displayed as a yellow dotted line, hydrogen omitted. groups are colored by the same scheme: green for 1, purple for 2, and turquoise for 3. Tyr326 and Cys172 hydrogen (yellow dotted line) and FAD are represented in ball-and-stick format with carbon atoms in grey. c) Best poses compound colored in accordance with the residueswith which they interact (green for 6and purple for 6-methyl-3-phenylcou- marin). Residues colored yellow interact with both ligands (see text fordiscussion). Cys172 (carbon atom in green) and a water molecule (ball andstick) are also shown. The hydrogen bond is as a yellow dottedline. FAD is shown in ball-and-stick format with carbon binding pocket. These results are in accordance with experimental data. In comparing the 8-methyl derivatives 6-9, the introduction of various substituents at the para position of the 3-phenyl ring is a good strategy for that position, are very selective cate that substitution of the 3-phenylcoumarin at position 8 could be a good strategy for out better the results of biological and docking studies, can help with a SAR study. The activity data for these compounds indicate that the varied nature of the substitutions at posi- tion 8 of the aromatic ring of the coumarin are 4 of the 3-phenyl ring. Conclusions We used Perkin reaction as a suitable method for the effi-cient and general synthesis of a of 8-substituted 3-aryl- coumarins. Most of the compounds the nature interactions between the com- pounds and the MAO-B enzyme. Both the type and position of the substituents on the 3-aryl group and at position 8 of the coumarin moiety play a crucial role in both General reagents suppliers and were used without purification (Sigma-Aldrich). Melt- ing points a Reichert Kofler and within all cases. The show all compounds. Flash silica gel (Merck was performed on pre-coated silica plates over mmol) was added, and the mixture was heated in an oil bath at 110 8Cf o r 24 h. Triturate ice (100 mL) and acetic acid (10 mL) were added tothe reaction mixture. After keeping it at room temperature for 2 h, the mixture was extracted with Et 2O (3 /C148 25 mL). The precipitated dicyclohexylurea was filtered off. The organic layer was washed with a solution of sodium bicarbonate (50.0 mL, 5%). The organic phase unreacted (Na2SO4). The solvent was evaporated under vacuum, and residue was purified by FC (hexane/EtOAc 9:1). 8-Ethoxy-3-phenylcoumarin 70 eV): 76.66, H 5.28. 4.20 Weinheim ChemMedChem 2012, 7, 464 - 470MED M. J. G. Ferino, et al. 163160.3 ppm; IR (KBr): 70 eV): 6 '), 7.58 (dd, J= 7.8, 1.5 Hz, 2 H, H-3' ,H - 5 '), 7.80 ppm (s, 1 76.58, H 81.61, m, pH 96-well the dark fluorimeter chamber. After this incubation period, the re- action was started by adding (final concentrations) 200 mmAmplex Red reagent, 1 U mL/C01horseradish peroxidase and 1 m mp-tyra- mine. The production of H2O2and, consequently, of resorufin ( lexcitation : 545 nm, lemission : 590 nm) over a 15 min period, in which the fluorescence increased linearly. Control experiments were carried out Red was determined by adding these drugs to solutions containing only the Amplex Red of background activity, fromvials all components a was employed for all computer cal- culations /C138 from the reorients at /C62.0 and The c17 with alength of 20 /C138 and a receptor van der Waals scaling of 1.0. The ini-tial docking was performed with Standard charges on the ligands semiempiri- density functional theory (DFT) was used for 464 - 2012 for each ligand. Acknowledgements We are grateful to the Xunta de Galicia (09CSA030203PR, PGI- DIT07PXIB, 10PXIB203303PR), the Spanish Ministerio de Sanidad y Consumo (FIS PS09/00501), MIUR, Cagliari University Elsevier, Amsterdam, 1982, pp. 197 - 208. [2] T. P. Singer in Chemistry and Biochemistry of Flavoenzymes, Vol. 2 (Ed.: F. Muller), CRC Press, Boca Raton, 1991 , -470. [3] K. F. Biochem. Funct. 1986 ,4, 79 - 87. [4] A. W. J. Bach, N. C. Lan, D. L. Johnson, C. W. Abell, M. E. Bembenek, S. W. Kwan, P . H. Seeburg, J. C. J. Wouters, Curr. Med. Chem. 1998 ,5, 137 - 162. [6] J. Grimsby, N. C. Lan, R. Neve, K. Chen, J. C. Shih, J. Neurochem. 1990, 55, 1166 - 1169. [7] A. S. Kalgutkar, N. Castagnoli, Jr., B. Testa, Med. Res. Rev. 1995 ,15, 325 - 388. [8] R. M. Geha, I. Rebrin, K. Chen, J. C. J. Biol. Chem. 2001, 276, 9877 - Ma, Yoshimura, E. Yamashita, A. Nakagawa, A. Ito, T. Tsukihara, J. Biol. -115. ,47, 391 - 417. [11] M. V. Rudorfer, V. Z. Potter, Drugs 1989 ,37, 713 - 738. [12] M. Gerlach, K. Double, H. Reichmann, P. Riederer, Transm. Suppl. 2003 , 167 - 193. [13] H. H. Fernandez, J. J. Chen, Clin. Neuropharmacol. 2007 ,30, 150 - 168. [14] P . Riederer, W. Danielczyk, E. Grunblatt, Neurotoxicology 2004, 25, 271 - 277. [15] L. M. Sayre, G. Perry, M. A. Smith, Chem. Res. Toxicol. 2008 ,21, 172 -188. [16] M. Yamada, H. Yasuhara, Neurotoxicology 2004, 25, 11 -20. [17] H. Zheng, M. Fridkin, M. B. H. Youdim, Neurochem. Res. 2010 ,35,2 1 1 7 - 2123. [18] J. R. Hoult, M. Paya, Gen. Pharmacol. 1996 ,27, 713 -722. [19] W. B. Liu, J. Zhou, Y. Qu, X. Li, C. T. Lu, K. L. Xie, X. L. Xun, Z. Fei, Neuro- chem. Int. 2010 ,57, 206 -215. [20] R. D. H. Murray, J. Mendez, S. A. Brown, The Natural Org. Nat. Prod. 2002 ,83, 1 -673. [22] F. Borges, F. Roleira, N. Milhazes, L. Santana, E. Uriarte, Curr. Med. Chem. 2005 ,12, 887 - 916. [23] F. Borges, F. Roleira, N. Milhazes, L. Santana, E. Uriarte, Front. Med. Chem. 2009 ,4, 23 - 85. [24] Coumarins: Biology, Applications, and Mode of Action (Eds.: R. nedy, R. D. Thornes), Wiley, New [25] Secci, ,52, 6685 -6706.[27] Gnerre, Catto, P. Weber, P.-A. Carrupt, C. Altomare, A. Carotti, B. Testa, ,43, -4758. [28] B. Rendenbach, M. Catto, C. Gnerre, L. Summo, A. De Marco, S. Rose, P. Jenner, B. Testa, Chem. Biodiversity 2006 ,3, 134 -149. [30] M. J. Matos, Vi\u00c7a, E. Quezada, C. Picciau, G. Delogu, F. Lett. ,19, -3270. Matos, D. Vi\u00c7a, C. Picciau, Orallo, L. Santana, E. Chem. Lett. 2009 ,19, 5053 -5055. [32] M. J. Matos, D. Vi\u00c7a, P. Janeiro, F. Borges, L. Santana, E. Uriarte, Bioorg. Med. Chem. Lett. 2010 Podda, E. Uriarte, D. Vi\u00c7a, Eur. J. Med. Chem. 2011 ,46, 1147 - 1152. [34] M. J. Matos, S. V/C181zquez-Rodriguez, E. Uriarte, L. Santana, D. Vi\u00c7a, Bioorg. Med. Chem. Lett. 2011 ,21, J. Matos, C. Ter/C181n, Y. P/C216rez-Castillo, E. Uriarte, L. Santana, D. Vi\u00c7a, J. Med. Chem. 2011 ,54, 7127 -7137. [36] D. Vi\u00c7a, M. J. Matos, M. E. Uriarte, MedChemComm 2011 , DOI: 10.1039/C1MD00221J. [37] L. Santana, Zagotto, R. Soto-Otero, E. M/C216ndez-/C141lvarez, J. Med. -1156. [38] L. Santana, H. Gonz/C181lez-D/C237az, Quezada, E. M. Y/C181\u00c7ez, D. Vi\u00c7a, Chem. 2006 ,49, 4912 - 4925. [40] A. Gaspar, T. Silva, M. Y/C181\u00c7ez, D. Vi\u00c7a, F. Orallo, T. Ortuso, E. Uriarte, S. Alcaro, F. Borges, J. Med. Chem. 2011 ,54, 5165 -5173. [41] C. Binda, P. Newton-Vinson, F. Hubalek, D. E. Edmondson, A. Mattevi, Nat. Struct. Mol. Biol. 2002 ,9, 22 -26. [42] C. Binda, M. Li, F. Hub/C181lek, N. Restelli, D. E. Edmondson, A. Mattevi, Proc. Sci. 2003 ,100, 9750 - 9755. [43] L. De Colibus, M. Li, C. A. Lustig, D. E. Edmondson, A. Mattevi, Proc. Natl. Acad. Sci. 2005 ,102, 12684 -12689. [44] C. Binda, F. Hubalek, M. Li, Y. Herzig, J. Sterling, D. E. Edmondson, A. Mattevi, J. Med. Chem. 2004 ,47, 1767 - 1774. [45] E. M. Milczek, D. Bonivento, C. Binda, A. Mattevi, I. A. McDonald, D. E. Edmondson, J. Med. Chem. 2008 ,51, 8019 - 8026. [46] F. Hub/C181lek, C. Binda, A. Khalil, Li, N. Castaganoli, D. E. Ed- mondson, J. Biol. ,280, 15 761 -15 766. [47] S-Y . Son, J. Ma, Yamashita, T. Tsukihara, Proc. USA 2008 ,105, 5739 - 5744. [48] C. Binda, J. Wang, L. Pisani, C. Caccia, A. Carotti, P. Salvati, D. E. Edmond- J. Med. Chem. 2007 ,50, 5848 -5852. [49] M. J. Matos, G. Delogu, G. Podda, E. Uriarte, Synthesis 2763 2006 ,344, 688 -695. [51] D. E. Edmondson, C. Binda, J. Wang, A. K. Upadhyay, A. Mattevi, Bio- chemistry Jaguar version 7.8, QSite version 5.7, Schr\u00e7dinger LLC, New York, NY (USA), 2011 . [53] Prime version 3.0, Schr\u00e7dinger LLC, New York, NY (USA), 2011 . [54] Glide version 5.7, Schr\u00e7dinger LLC, New York, NY 2011 . [55] F. R. Fioravanti, A. Orallo, Ortuso, S. version 5.7, Prime version 3.0, Schr\u00e7dinger LLC, New York, NY (USA), 2011 . [57] LigPrep version 2.5, Schr\u00e7dinger LLC, New York, NY (USA), 2011 . [58] Jaguar version 7.8, Schr\u00e7dinger LLC, New York, NY (USA), 2011 . Received: November 18, 2011 Revised: January 13, 2012 Published January 27, 2012 470 www.chemmedchem.org /C23 2012 Wiley-VCH Verlag GmbH Co. KGaA, Weinheim ChemMedChem 2012, 7, 464 - 470MED M. J. Matos, G. Ferino, et al. 165Send Orders Reprints Eugenio Uriarte1 and Lourdes Santana1,* 1Departamento de Qu\u00edmica Org\u00e1nica, Facultad de Farmacia, Universidad de Santiago de Compostela, Spain; 2Departamento de Farmacolog\u00eda, Facultad de Farmacia, Universidad de Santiago de Compostela, Spain Abstract: It is commonly a ccepted t hat monoamine ox idase (MAO) may play a critical role in th e reg ulation of t he cen- tral nervo us system a ctivity and contrib ute to t he pat hogenesis of human ne urodegenerative and depressive disorders . This en couraged an ac tive resear ch in th e development of new dr ugs, M AO in hibitors, sin ce they may represent an impor- tant advanc e in t he treatment of comple x diseases s uch as A lzheimer and Parkinson, w hich are be coming prevalent pa - thol ogies du e to t are - sively wor king in t his area wit h the aim of finding new inhibitors . The p urpose of t his review to s ummari ze the find - ings reported in t his area, parti cularly he idase (MAO) is a FA D-depending enz yme found in t he outer mito chondrial membrane of ne cellular lev - els of biogenic amines in t he brain and t he tiss ues [2, 3]. AO lays a c role in t he regulation of c entral nervou s system a ctivity and contribu tes to th e pat hogenesis sive disorders [4] . Fifty years MAO in hibitors (MAOIs ) was AOIs were c onsidered useless in t herapy d ue to t he serio us side effe cts ind uced by t hese dr on t he basis and tyramine ommon s ub- strates for bot h isoforms . As a res ult of t hese p hysiologic al properties, M AOIs becam e ologic (P D), Alzheimer\u00b4s disease (AD ) and vario of depression [13 ]. Additionally, th e *Address correspondenc e to t his author at t he Departamento de Q u\u00edmica Org\u00e1nica, Facultad de F arma cia, Universidad de Santiago de Compostela, Spain ; Tel: 00 34 88181100014 936; E-mail: lo Orallo in memoriam, who had introduced and incentivated us in the study of the MAOIs. description of t he crystal str ucture of t he two M AO isoforms by C . Binda et al. abou e by t he aggressive ph enotype seen in male mi ce deficient in M AO-A and in males in a Du tch ki ndred bearing a spontaneou s mutation (resulting in antisoc and adult violent crime t han children wit h a high-activity M AO- A genotype as demonstrated by he fac t that [11C]-harmine - labeled is elevated by only 3 4% throughout brain of u n- treated depressed patients c ompared to c ontrols, yet it ap - pears to be t he major c ontribu tor to th e monoamine metabo - lism in only may promote cognitive impairment, bu t also may be a ris k factor for AD [22]. Not s urprisingly, M AO-A w hich is often a tar - get for t he treatment of depression, is also a potential ris k factor for late -onset AD [2 3-26]. In contrast to irreversible in hibitors are better toler ated ave been cularly effi against stri - atal damage produc by t he mito chondrial poison malonate and appears to Inhibitors Current Topics Chemistry, 2012 , Vol. 12, No. 20 2211 On the other hand, it h as been demonstrated t hat sele ctive and irreversible and RO S [35] have been fo und in t he vicinity of (A/g1) at lower c oncentrations t han those re quired for in hibition of t he enzym e [ 36]. It has been associated wit protein cleavage [ 37]. sig nificant in crease of life e xpectancy. Co umarins are a wide family of c ompo unds present in remark able amo unts ure [3 8, 39]. Representative compou nds occu r in th e vegetable k ingdom, either in privileged s only in organic chem- b t [42] . In the literatu re, coumarin ave 3, [52 -54]. In 19 81, it was fou nd for t he first time an interesting MAOI activity of th e coumarin moiety, w hen organo - phosph ate gro up was atta ched to t he umbelliferone ring [55] . But it was only in th 1990\u00b4s wh en the coumarin n ucleus M corylifolia L., Peucedanum j aponicum L. as M AOIs [57- 59]. Although natural poten cy, properly modi a nat ural 7- substitued t he t he impor - tance of t he number and position of different s ubstituents on the coumarin n ucleus, coumarin and sele ctivity Fig. (2). Although pos itions 3 and 7 of the coumarin ring were t he most st udied, all t he substitu- tion possibilities were ta ken into a ccount and a big nu mber of coumarin derivatives h been synt hesized and eval uated as M AOIs, being most given in he following tables xperimental set - . 2. COUMAR IN DERIVATIV ES AND MAO ACTIVITY The first str ucture-activity relations hip stu dies (SAR) about coumarin t hat selec tivity was mainly determined by t he natu re of t he linkage between t he coumarin and t he substituent grou p at position 7. A series of 7-hydrox ycoumarin derivatives I bearing at position 7 et her, ester or c arbamate f unctions of varying si ze and mod ulate favou s ub- stituent for t he whereas a nd M AO-B inhibitiory described a large family of c ompo unds related to these str uctures. On the other hand, it h as been proved t hat an al kylsulfonylox y grou p at position 7 provided M AOIs -A like . This effe pronou he ulfonates udied t he potential of et her derivatives and s ulfonic acid esters F ig. (3), checking t hat introd uction of a s ulfonic ester lin kage, instead of t he ether bridge, dramati cally changed t he activity profile of t c ompou nds [63] . S ubs titutions at position 3 t he coumarin n u- ribed can site s hould ze sele cted polar s ubstituents at position led to new M AOIs-B with an improved ph arma cokinetic he impor - tance of t he presen ce of a h eteroarylal koxy grou p at position 7 of t he coumarin s caffold to modu late t he activity against MAO i soforms [56 ]. In this small or halogen grou ps were introduc ed positions 3 and 4 of t he skeleton . grou ps, were introd uced at positions 3 and 4 of t his coumarin n ucleus. Based on previo usly des AR introduc tion of cycloalip hatic or al. described Medicinal Chemistry , 2012, Vo l. 12, No. 20 Matos et al. Fig. (2). Chemical str uctures of known coumarins as M AOIs. y coumarin derivatives . 66]. annelation wit h 5- and -acetonylox y-substitutents, higher a ctivity against bot h isoforms t the 7-hydrox y pre s hown in t he (Table 2). In order to c omplete t he study of 7- substitu ted coumarin Carotti et vitro biologic al M AO a ctivity of novel series of c oumarins bearing different s ubstituents at position 7. Such s ubstituents consisted of a ph enyl ring link ed to a coumarin core by bridges of different si ze, lengt h and lipoph ilic and ele ctronic nature. for 7- substituted coumarins contain- ing a benz ene ring fu sed at 3 ,4 positions en couraged M . J. Matos et al. to analy ze the importanc e of t he aryl s ubstituent on the ring, synt 3-aryl en couraged t he authors to synt hesize and st udy the MAO in hibitory a ctivity of new analogu es. A variety of grou ps wit h different si ze, electronic and lipoph properties were introduc ed in both aromati in order to clarify t he infl uence of t he substi- tuti on pattern in he MAO in 3-phenyl ring. /g1The best c ompou nd of t he methyl-3-(4'- methylphenyl)coumarin (compou nd wit 1 nM . This compo und proved to be not only 6 4 times more a ctive in vitro than more sele ctive t han it (com- pound 245 is > of t he cou- marin s keleton was introduc the obtained res ults, it c ould be estab - 169Focusing on New Monoamine Oxidase Inhibitors Current Topics in 2012 No. 20 2213 Table 1. Ch emical Structures and MAO C H3 H H OCH 3 80.3 0 > 100 66 2 H H C H3 H H C H3 > 100 71.3 2 66 3 H H C H3 H H H > 100 80. 41 66 4 H N H2 H H H OCH 3 > 100 > 100 66 5 OCH3 H3C CH 3 C H3 H H H 11. 0 0. 004 61 6 H3CO O CH 3 C H3 H H H 9.20 0.9 4 61 7 OO H3C CH 3 C H3 H H H 5 .90 0. 11 61 8 O OCH3 H3C CH 3 C H3 H H H 7 .70 0. 014 61 9 O OCH3 H3CCH3 CH 3 C H3 H H H 4 .10 0. 004 61 10 O O CH 3 C H3 H H H 20 (15%) 0 .028 61 11 O O CH 3 C H3 H H H 10 (0%) 10 (27%) 61 12 N O CH 3 C H3 H H H 34.0 0. 89 61 13 N HO H3C CH 3 C H3 H H H 0 .70 0. 84 61 14 NHCH3 H3CO CH 3 C H3 H H H 1 .13 0 .14 61 15 H3CO H H H H H > 100 0. 044 66 16 O H C H3 H H H 0 .041 0. 006 66 17 O H C H3 H H OCH 3 2 .66 0 .86 66 18 O H C H3 H H C H3 0 .007 0. 011 66 19 O H C H3 H H H 4 3.0 > 100 66 20 O H C H3 H H OCH 3 15. 45 > 100 66 21 O H C H3 H H C H3 0 .40 0. 004 66 22 CH 3 C H3 C H3 H H H 0 .071 0. 0005 63 1702214 Current Topics in Medicinal Chemistry , 2012, Vo l. 12, No. 20 Matos et H H H 31.60 3.24 67 24 CH3H3C Cl CH 3 H H H > 10 0. 004 56 25 H H H H H 6.76 0 .055 62 26 CH 3 H H H H 5 .50 0. 007 67 27 H C H3 H H H 1 .95 0. 018 62 28 CH 3 C H3 H H H 0 .69 0 .004 62 29 H OH H H H 15 (26%) 1 .58 62 30 H C F3 H H H > 5 1 .38 62 31 CH 3 H H H 3 (4%) 3 (8%) 62 32 H H H H > 4 > 4 62 33 CH 3 C H3 H H C H3 0 .56 3.31 62 34 CH 3 C H3 H O H > 0.4 > 0.4 62 35 CH 3 C H3 H OH H 112. 20 3.09 62 36 CH3 CH 3 C H3 H H H 3.55 0.3 2 62 37 CH3 CH 3 C H3 H H H > 0.54 0. 001 56 38 H3C CH 3 C H3 H H H 0 .39 0 .001 56 39 H3C CH 3 C H3 H H H 0 .56 0 .001 56 40 CH3 H3C CH 3 C H3 H H H > 10 0. 004 56 41 H3CH3C H H H H H > 10 0. 002 56 42 H3CH3C H C H3 H H H > 10 0. 005 56 43 H3CH3C CH 3 H H H H > 10 0. 003 5 6 44 H3CH3C CH 3 C H3 H H H > 10 0. 007 56 45 H3CH3C CH 3 C H3 H Cl H > 10 0. 031 56 46 H3CH3C CH 3 C H3 H H C H3 > 100 > 100 63 47 H3C H3CCH3 CH 3 C H3 H H H > 10 10. 0 63 48 H3CH3C H3C CH 3 C H3 H H H > 10 0. 032 56 49 F F F CH 3 C H3 H H H 0 .30 0. 001 56 50 F F F CH 3 C H3 H H H > 10 0. 002 56 171Focusing on New Monoamine Oxidase Inhibitors Current Topics in 3 C H3 H H H 1 .51 0. 004 62 52 H3CO CH 3 C H3 H H H 2 .10 0. 0006 5 6 53 OF F F CH 3 C H3 H H H 5 .89 0 .011 62 54 F CH 3 C H3 H H H 0 .58 0. 003 62 55 F CH 3 C H3 H H H 0 .12 0. 003 62 56 F F CH 3 C H3 H H H 0 .12 0. 001 62 57 F F CH 3 C H3 H H H 0 .68 0. 003 62 58 HO F CH 3 C H3 H H H 0 .11 0. 007 62 59 F F F F F CH 3 C H3 H H H 0 .69 0 .006 62 60 Cl CH 3 H H H H 12. 59 0 .005 67 61 Cl CH 3 C H3 H H H 1 .12 0. 003 62 62 Cl CH 3 C H3 H H H 0 .12 0. 003 62 63 O2N H C H3 H H H 0 .13 0 .013 62 64 O2N CH 3 C H3 H H H 0 .076 0 .003 62 65 O2N CH 3 C H3 H H H 0 .83 0 .009 62 66 O2N O2N CH 3 C H3 H H H 0 .18 0. 006 62 67 H2N CH 3 C H3 H H H 1 .0 0. 035 62 68 H N OH3C CH 3 C H3 H H H 7 .08 0. 25 62 69 HO CH 3 C H3 H H H 0 .42 0. 010 62 70 CN CH 3 C H3 H H H 0 .42 0. 023 62 71 NC CH 3 C H3 H H H 0 .22 0. 011 62 72 NC CH 3 C H3 H H H 0 .10 0. 004 62 73 (CH2)2 CH 3 C H3 H H H 1 .0 0. 006 62 74 (CH2)2 CH 3 C H3 H C H2CH 3 H > 10 0. 010 56 75 OH CH 3 C H3 H H H 10. 0 0. 071 67 1722216 Current Topics in Medicinal Chemistry , 2012, Vo l. 12, No. 20 Matos et 3 C H3 H H H 9.77 0. 018 67 77 (CH 2)3 H H H H H 1 .50 0. 004 56 78 (CH 2)3 CH 3 C H3 H H H 1 .20 0. 004 56 79 (CH2)2 O CH 3 C H3 H H H 10. 23 0 .027 67 80 H H CH 3 C H3 H H H 31.62 0. 11 67 81 H H H H H H H 100. 0 0. 058 67 82 N CH 3 C H3 H H H 1 .80 0. 009 63 83 N CH 3 C H3 H Cl H > 10 0. 0007 65 84 CH 3 C H3 H H H > 10 0. 011 65 85 O O CH 3 C H3 H H H 10. 0 0. 008 65 86 O CH 3 C H3 H H H > 10 0. 002 65 87 SO2 H3C CH 3 C H3 H H H 110. 0 > 100 63 88 SO2 H3C CH 3 C H3 H H H 0 .008 5. 0 63 89 S O2(CH2)4 H3C CH 3 C H3 H H H 0 .016 2 .20 63 90 SO2(CH 2)7 H3C CH 3 C H3 H H H 0 .034 > 10 63 91 SO2 H H H H H 0 .45 54.9 5 67 92 SO2 CH 3 C H3 H H H 0 .024 1. 10 63 93 SO2 H3C CH 3 C H3 H H H 0 .047 15 (17%) 62 94 SO2 H3CO CH 3 C H3 H H H 0 .071 16.98 62 95 SO2 Cl CH 3 C H3 H H H 0 .005 0. 004 63 96 SO2 NC CH 3 C H3 H H H 0 .008 > 100 63 97 SO2 Br CH 3 C H3 H H H 0 .006 > 100 63 98 SO2 O2N CH 3 C H3 H H H 0 .013 2 (20%) 62 99 SO2 CH 3 C H3 H H H 2 .0 100. 0 67 100 SO2 CH 3 C H3 H H H 2 .82 0. 87 67 101 O Cl CH 3 C H3 H H H > 10 0. 017 65 102 SH3C CH 3 C H3 H H H 0 .35 0. 0005 65 103 S CH3 CH 3 C H3 H H H 0 .23 0 .0005 65 104 SH3C H3CH3C CH 3 C H3 H H H > 10 0. 001 65 173Focusing on New Monoamine Oxidase Inhibitors Current Topics in CH 3 C H3 H H H 10. 0 0. 003 65 106 S N CH 3 C H3 H H H 3.20 0. 006 65 107 NN OH3C CH 3 C H3 H H H 10. 0 0. 001 68 108 S NH3C CH3 CH 3 C H3 H H H > 10 0. 003 65 109 S NH3C H3C Cl CH 3 H Cl H > 10 0. 002 65 110 S N CH 3 C H3 H H H 10. 0 0. 001 65 111 S N Cl CH 3 H Cl H > 10 0. 002 65 112 N OH3C CH 3 C H3 H H H 1 .50 0. 002 65 113 NOH3C CH 3 C H3 H H H 10. 0 0. 002 65 114 NOOH3C CH 3 C H3 H H H 10. 0 0. 005 65 115 NOH3CCH3 CH 3 C H3 H H H 6.0 0. 0007 65 116 NOH3COCH3 CH 3 C H3 H H H 2 .90 0. 001 65 117 NOH3C CH3 CH 3 C H3 H H H 10. 0 0. 002 65 118 NOCH3 H3C H3C CH 3 C H3 H H H > 10 0. 001 65 119 N O CH 3 C H3 H H H > 10 0. 001 65 120 O N CH 3 C H3 H H H 7 .0 0. 001 65 121 N O CH 3 C H3 H H H > 10 0. 001 65 122 NO CH 3 C H3 H H H > 10 0. 001 65 123 NO CH 3 C H3 H H H > 10 0. 014 65 124 N OCH3 CH 3 C H3 H H H 20. 0 0. 0006 65 125 NOO CH 3 C H3 H H H 5 .0 0. 004 65 126 NNH3CCH3 CH3 CH 3 C H3 H H H 10. 0 0. 005 65 127 N NH3CCH3 H3C CH 3 C H3 H H H > 10 0. 002 65 1742218 Current Topics in Medicinal Chemistry , 2012, Vo l. 12, No. 20 Matos et Cl CH 3 H H H > 10 0. 002 65 129 NNCH3 H3C H3C CH 3 C H3 H C H2CH 3 H > 10 0. 009 65 130 NNH3C H3C CH 3 C H3 H H H > 10 0. 010 65 131 N N OH3C CH 3 C H3 H H H 5 .60 0. 015 65 132 N N O CH 3 C H3 H H H 10. 0 0. 001 65 133 NN O O H3C CH 3 C H3 H H H > 10 0. 008 65 134 N NOH3C CH 3 C H3 H H H 4 .0 0. 004 65 135 N N OCH3 H3C CH 3 C H3 H H H > 10 0. 001 65 136 N N O CH 3 C H3 H H H 7 .0 0. 001 65 137 N NN H3CCH3 CH 3 C H3 H H H > 10 0. 013 65 138 NN SH3C CH3 CH 3 C H3 H H H > 10 0. 001 68 139 NN SH3C CH3 CH 3 C H3 H Cl H > 10 0. 003 68 140 NN SH3C CH 3 C H3 H H H 3.60 0. 003 65 141 NN SH3C CH 3 C H3 H C H2CH 3 H > 10 0. 007 65 142 NN SH3C CH 3 H H H H > 10 0. 015 65 143 NN SH3C Cl CH 3 H H H > 10 0. 006 65 144 NN SH3C CH 3 C H3 H Br H > 10 0. 001 65 145 NN SCH3 CH 3 C H3 H H H > 10 0. 002 68 146 H NHNH2O H H H 1 .44 0. 040 64 147 Cl H NHNH2O H H H 2 .50 0. 090 64 148 Cl H NHO NH2 H H H > 100 > 10 64 175Focusing on New Monoamine Oxidase Inhibitors Current Topics in Medicinal Chemistry, 2012 , Vol. 12, No. 20 NH2O H H H 8 .0 0. 20 64 150 Cl H NH2O H H H 2 6.0 0. 030 64 151 F H NH2O H H H 70. 0 0. 050 64 152 HO H NH2O H H H 4 .27 1. 0 64 153 H NH2CH3O H H H 2 .80 0. 015 64 154 Cl H NH2CH3O H H H 0 .50 0. 024 64 155 Cl H NHO CH3 H H H > 100 > 10 64 156 Cl H NHO H H H > 100 5. 0 64 157 H NO CH3CH3 H H H 2 3.10 0. 40 64 158 Cl H NO CH3CH3 H H H > 100 0. 040 64 159 Cl H NO CH3 CH3 H H H > 100 > 10 64 160 N H NH2O H H H 21. 0 1.3 0 64 161 N H NH2O H H H 2 6.50 2. 0 64 162 H NH2O H3C H H H 6.26 0 .10 64 163 F H NH2O H3C H H H 2 .0 0. 10 64 164 H H N CH3 H H H 15. 40 0. 028 64 165 Cl H H N CH3 H H H 5 .94 0. 013 64 166 F H HN CH3 H H H 1 3.50 0. 018 64 1762220 Current Topics in Medicinal Chemistry , 2012, Vo l. 12, No. 20 Matos et O H H N CH3 H H H 5 .40 0. 020 64 168 F H H N CH3 H H H 22.6 0 0. 10 64 169 F H H N CH3 CH3 H H H 91.0 3.80 64 170 Cl H HN H H H > 100 3.60 64 171 H N CH3CH3 H H H 100. 0 1. 80 64 172 Cl H N CH3CH3 H H H 50. 80 1. 12 64 173 F H N CH3CH3 H H H > 100 0. 51 64 174 Cl H NH3C H H H > 100 8. 0 64 175 H NH2 H H H 4 .40 0. 021 64 176 Cl H NH2 H H H 2 .0 0. 015 64 177 H CN H H H 0 .20 0. 23 64 178 Cl H CN H H H 0 .47 0. 016 64 179 H HNNH2 O H H H 100. 0 0.6 8 64 180 Cl H HNNH2 O H H H 10 (35%) 0 .21 64 181 H NNH2 O H H H 99.80 16. 10 64 182 Cl H NNH2 O H H H 10 (5%) 9.60 64 183 Cl H HNNH2 OCH2OH H H H > 100 2. 40 64 184 H H NO NH2 H H H 22. 70 1. 80 64 185 H NO NH2 H H H 35.0 0.3 8 64 186 F H NO NH2 H H H > 100 0. 85 64 177Focusing on New Monoamine Oxidase Inhibitors Current Topics in NH2 H H H 31.80 0. 25 64 188 Cl H NH CH3 H H H 74. 0 0.3 0 64 189 H N CH3CH3 H H H 25.9 0 0. 46 64 190 H H H H O H 2 3.44 2. 04 62 191 H C H3 C H3 H O H 112. 20 3.09 62 192 H C H3 C H3 O H H 30 (35%) 30 (18%) 62 Table 2. Chemi cal Structures and MAO I nhibition or II H 1 .58 0. 003 62 194 H 1 .58 0. 003 62 195 H 1 (7%) 0 .050 62 196 NNSH3C H > 10 0. 007 65 197 NNH3C H3CH3C H > 10 0. 10 65 198 H H 48. 20 > 100 66 199 H OCH3 63.53 > 100 66 200 H CH 3 > 100 > 100 66 201 H OCH3 > 100 50. 20 66 202 H CH 3 60.11 > 100 66 203 H3C O OCH3 0 .12 12.9 8 66 1782222 Current Topics in Medicinal Chemistry , 2012, Vo l. 12, No. 20 Matos et CH 3 0 .24 0. 17 66 205 H3C O OCH3 0 .37 12. 12 66 206 H3C O CH 3 0 .004 17.3 0 66 207 H3C O OCH3 11.93 9.36 66 208 H3C O CH 3 2 .56 28. 13 66 209 Br O CH 3 0 .13 1 .18 66 210 Br O CH 3 0 .70 0. 24 66 211 Br O CH 3 2 .38 0. 001 66 Table 3. Ch emical Structures and MAO I nhibition Data of Coumarin s Bearin g a Carbo, Thio or Aza Spacer at Position 7 III H CH 3 C H3 0 .41 0. 028 62 213 S CH 3 C H3 10. 0 0. 040 67 214 S O O CH 3 C H3 18.6 2 2. 75 67 215 SO2 NH3C H3C CH 3 C H3 4 .57 31.62 67 216 SO2 HNH3C CH 3 C H3 67.61 40 (29%) 62 217 HNO CH 3 C H3 1 .38 0. 19 62 218 HN CH 3 C H3 1 .58 0. 16 62 219 CH 3 C H3 7 .08 0. 46 67 179Focusing on New Monoamine Oxidase Inhibitors Current Topics in Medicinal Chemistry, 2012 , H H 0 .39 0 .085 62 221 NH H H 41.69 2 .14 62 222 S H H 3.80 1. 29 67 223 SO H H 6.17 0. 58 67 224 SO O H H 21. 88 25. 70 67 225 OO H H 9.55 2. 40 67 Table 4. Ch emical Structures and MAO I nhibition Data of Differently Substituted H H H H H H H H > 100 11. 81 74 227 OH H H H H Cl H H > 100 0. 44 69 228 H OH H H H Cl H H > 100 0. 21 69 229 H H OH H H Cl H H > 100 0. 13 69 230 OCH 3 H H H H Cl H H > 100 > 100 69 231 H OCH 3 H H H Cl H H > 100 0. 001 69 232 H H OCH 3 H H H H H > 100 0. 004 69 233 OH H H H H Br H H > 100 0. 48 69 234 H OH H H H Br H H > 100 0. 29 69 235 H H OH H H Br H H > 100 0.6 4 69 236 OCH 3 H H H H Br H H > 100 > 100 69 237 H OCH 3 H H H Br H H > 100 0. 002 69 238 H H OCH 3 H H Br H H > 100 0. 006 69 239 H H H H H Br H OCH 3 > 100 0. 083 7 3 240 H H H H H Br H OH > 100 30.91 73 241 H H OCH 3 H H Br H OCH 3 > 100 1.3 5 73 1802224 Current Topics in Medicinal Chemistry , 2012, Vo l. 12, No. 20 Matos H OH H H Br H OH 20. 74 16. 87 73 243 H H H H H C H2Br H H > 100 0. 043 69 244 H H H H H C H3 H H > 100 0. 28 72 245 H H C H3 H H C H3 H H > 100 0.3 1x 10-3 72 246 H C H3 H H H C H3 H H > 100 0. 015 72 247 H OCH 3 H H H C H3 H H > 100 0. 80x 10-3 72 248 H OH H H H C H3 H H 35.04 0.6 5 72 249 H H OCH 3 H H C H3 H H > 100 0. 013 72 250 H H OH H H C H3 H H > 100 0. 16 72 251 H OCH 3 OCH 3 H H C H3 H H 25. 14 0. 003 72 252 H OCH 3 H OCH 3 H C H3 H H > 100 0. 009 72 253 H OCH 3 OCH 3 OCH 3 H C H3 H H > 100 0. 16 72 254 H Br OCH 3 H H C H3 H H > 100 0. 74x 10-3 72 255 H OCH 3 Br H H C H3 H H > 100 0. 003 72 256 H O H3CO H H H C H3 H H > 100 0. 18 72 257 OCH 3 H H H H C H3 H H > 100 > 100 72 258 OH H H H H C H3 H H 21. 58 0. 12 72 259 Br H H H H C H3 H H > 100 4.3 4 75 260 Br OCH 3 H OCH 3 H C H3 H H > 100 54. 03 72 261 Br OCH 3 OCH 3 OCH 3 H C H3 H H > 100 > 100 72 262 H H H H H C H3 H Br > 100 0. 011 75 263 H H OCH 3 H H C H3 H Br > 100 0. 003 75 264 H OCH 3 H OCH 3 H C H3 H Br > 100 0. 007 75 265 H OCH 3 OCH 3 OCH 3 H C H3 H Br 31.20 4. 89 75 266 H C H3 H H H OCH 3 H H > 100 0. 018 72 267 H H C H3 H H OCH 3 H H > 100 0. 002 72 268 H H C H3 H H OH H H 24.9 0 0. 067 72 269 H H C H3 H H O H3CO H H > 100 5. 52 72 270 H H C H3 H H O H H > 100 14. 47 72 271 H H H H H H H C H3 6.26 0 .078 76 272 H H OCH 3 H H H H C H3 21.6 0 0. 003 7 6 273 H H C H3 H H H H C H3 > 100 0. 005 76 274 H H Br H H H H C H3 > 100 0. 020 76 275 H H H H H H H OCH 3 > 100 0. 15 76 276 H H Br H H H H OCH 3 > 100 0. 003 7 6 277 H H H H H H H OCH2CH3 > 100 1. 06 76 181Focusing on New Inhibitors Current Topics H OCH 3 H H H H OCH2CH3 > 100 0. 21 76 279 H H C H3 H H H H OCH2CH3 > 100 0. 15 76 280 H H H H OH H H H > 100 > 100 77 281 H H OCH 3 H OH H H H > 100 69.59 77 282 H H OCH 3 H OH C H3 H H > 100 32.04 77 283 H H OCH 3 H OH Cl H H > 100 > 100 77 284 H Cl OCH3 H OH H H H > 100 9.26 77 285 H Cl OCH3 H OH C H3 H H > 100 42.6 8 77 286 H Cl OCH3 H OH Cl H H > 100 2. 79 77 Table 5. Chemi cal Structures and MAO I S H H H > 100 6.37 79 288 S H OCH 3 H > 100 0.63 7 9 289 S H H OCH 3 > 100 0. 26 7 9 290 S OCH3 H OCH 3 > 100 > 100 79 291 S H H H > 100 13.30 79 292 S H OCH 3 H > 100 0. 23 7 9 293 S H H OCH 3 4 .16 0 .056 7 9 294 S OCH3 H OCH 3 > 100 > 100 79 295 H N H H H > 100 1.9 2 79 1822226 Current Topics in Medicinal Chemistry , 2012, Vo l. 12, No. 20 Matos H N H OCH 3 H > 100 > 100 79 297 H N H H OCH 3 9.67 0. 046 7 9 298 HN OCH3 H OCH 3 > 100 > 100 79 Table 6. Ch emical Structures and MAO I CH 3 H H H > 100 14. 45 78 300 CH 3 H H OH 39.36 42. 13 78 301 CH 3 H OH H > 100 > 100 78 302 CH 3 OH H H 100 (45%) 64.17 78 303 CH 3 H OCH 3 H 100 (45%) 15. 40 78 304 CH 3 H N (CH2CH 3)2 H > 100 18. 07 78 305 CH 3 C H3 H H > 100 100 (45%) 78 306 CH 3 Cl H H > 100 17. 72 78 307 CH 3 Br H H 51.63 100 (45%) 78 308 CH 3 H 100 (45%) 2 .01 78 309 CH 3 Cl H Br 55 .16 0 .14 78 310 CH 3 Br H Br > 100 0.20 78 311 CH 3 I H I > 100 >100 78 312 Cl H H H 0 .060 0. 12 80 313 Cl CH 3 H H 0 .029 0 .10 80 314 Cl Br H H 0 .020 0. 11 80 315 Cl Cl H H 0 .030 0. 010 80 316 Cl NO 2 H H 0 .029 0 .10 80 183Focusing on New Monoamine Oxidase Inhibitors Current Topics in 2012 No. 20 2227 Table 7. Ch emical Structures and MAO I of 3-benzoylcoumarin H H H H > 100 > 100 78 318 H Br H H > 100 > 100 78 319 H Br H OCH 3 > 100 > 100 73 320 H Br H OH 4 6.81 73.92 73 321 OH Br H OH 1 9.17 > 100 73 322 OCH3 Br H OCH3 > 100 > 100 73 323 H H H OH 40. 47 27. 11 78 324 H OH H H 51.66 17.9 7 78 325 H H OH H > 100 > 100 78 326 H H OCH 3 H > 100 100 (45%) 78 327 H H N (CH 2CH 3)2 H > 100 23. 84 78 328 H C H3 H H > 100 100 (45%) 78 329 H Cl H H > 100 > 100 78 330 H Cl H Br > 100 100 (45%) 78 331 H Br H Br > 100 100 (45%) 78 332 H I H I > 100 > 100 78 Table 8. Ch emical Structures and MAO I 2CH 3 H H H 0 .23 5 .01 80 334 CH 2CH 3 H H OH 40. 55 14. 81 78 335 CH 2CH 3 H OH H > 100 > 100 78 336 CH 2CH 3 OH H H 4 9.07 10. 06 78 337 CH 2CH 3 H OCH 3 H 100 (45%) 2 3.46 78 1842228 Current Topics in Medicinal Chemistry , 2012, Vo l. 12, No. 20 Matos et H H > 100 21.63 78 339 CH 2CH 3 H N (CH2CH 3)2 H > 100 45. 52 78 340 CH 2CH 3 Cl H Br > 100 17. 51 78 341 CH 2CH 3 Br H Br > 100 100 (45%) 78 342 CH 2CH 3 I H I > 100 > 100 78 343 CH 2CH 3 H O H 4 6.35 0. 021 78 344 CH 2CH 3 C H3 H H 0 .19 1 .0 80 345 CH 2CH 3 Br H H 0 .21 1. 0 80 346 CH 2CH 3 Cl H H 0 .50 1. 0 80 347 CH 2CH 3 N O2 H H 0 .26 1 .0 80 348 CH 2CH 3 H O H > 100 0. 007 78 349 CH 2CH 3 H OCl H > 100 0. 061 78 350 CH 2CH 3 H O H3C H3C H3C H > 100 3.75 78 351 CH 2CH 3 H OCl Cl H > 100 0. 009 78 352 H H H H 15. 14 0. 017 80 353 H C H3 H H 12. 02 0. 019 80 354 H Br H H 1 .0 0. 033 80 355 H Cl H H 0 .50 0. 023 80 356 H N O2 H H 0 .068 0. 019 80 357 H H H OH 5 9.61 100 (45%) 78 358 H OH H H 40. 20 100 (45%) 78 359 H H OCH 3 H > 100 100 (45%) 78 360 H OCH 3 H H > 100 > 100 78 361 H H N (CH 2CH 3)2 H > 100 > 100 78 362 H Cl H Br > 100 > 100 78 363 H Br H Br > 100 > 100 78 364 H I H I > 100 17. 78 78 365 H H O H > 100 8.6 2 78 366 H H OCl H > 100 1. 80 78 /g1 185Focusing on New Monoamine Oxidase Inhibitors Current Topics H3C H3C H3C H > 100 > 100 78 368 H H OCl Cl H > 100 0. 41 78 Table 9. Ch emical Structures and MAO I H > 100 0. 003 78 370 HN H H 41. 40 4. 52 78 371 HNO2N H H 39.56 > 100 78 372 HN CH3 H H 58. 43 > 100 78 373 HN Cl H H 48. 02 1. 19 78 374 HN NO2O2N H H 60.49 5 6.12 78 375 H H > 100 0. 50 81 376 CH3CH3 H H > 100 25.36 81 377 CH3CH3 H H > 100 3.27 81 378 H H > 100 > 100 81 379 NH2 H H > 100 7.6 8 81 380 H H 1 3.12 0. 76 81 381 H H > 100 0.9 1 81 1862230 Current Topics in Medicinal Chemistry , 2012, Vo l. 12, No. 20 Matos H 14. 50 0.6 0 81 383 OCH3 H H > 100 0.6 4 81 384 F H H > 100 0. 25 81 385 CF3 H H > 100 0. 25 81 386 CH3 H H 1 9.45 0. 71 81 387 CH3 H H 15.6 7 0. 89 81 388 CH3CH3 H H 15. 14 0.6 5 81 389 OOCH2CH3 H H 15.9 8 > 100 81 390 OCH3 H H > 100 0. 82 81 391 SCH3 H H 14. 76 2 .84 81 392 F H H 1 3.06 0 .067 81 393 CO2H H H 9.97 1. 14 81 394 COCl H H 9.67 > 100 81 395 SO2CH3 H H 9.33 0 .001 81 396 OH H H > 100 0. 80 81 397 Cl H3C H H > 100 19. 07 81 398 H3CCH3 H H 15.9 5 22. 45 81 399 H3CCH3 H H 12.3 2 13. 74 81 400 H3C CH3 H H 20.63 18. 27 81 401 H3CH3C H H 9.79 1 .29 81 /g1 187Focusing Current Topics in Chemistry, 2012 , 12. 76 9.23 81 403 CH3CH3 H H 18. 77 0.3 8 81 404 OCH3OCH3 H H 9.45 0. 86 81 405 CH3CH3 H H 17. 56 0 .70 81 406 OCH3OCH 3 H H 61.46 4 .18 81 407 FF F F F H H > 100 0. 46 81 408 FF F CN F H H 1 6.04 0. 86 81 409 N FF F F H H 11. 43 0 .58 81 410 H H > 100 1.96 81 411 H H > 100 > 100 81 412 CH 3 H > 100 8. 89 81 413 CH 3 H > 100 > 100 81 414 H > 100 > 100 81 415 H O > 100 64.45 81 416 CH3CH3 H O 63.52 > 100 81 417 CH3CH3 H O 58.64 9.59 81 418 CH3 CH3 H O 60.93 3.69 81 419 FF F CN F H O 61.38 16. 54 81 1882232 Current Topics in Medicinal Chemistry , 2012, Vo l. 12, No. 20 Matos H3CCl H O 49.75 61.49 81 422 OCH3OCH3 H O > 100 4.39 81 423 OCH3OCH 3 H O 52.89 3.36 81 424 H O > 100 0.99 81 425 HN H O 41.40 4. 52 81 426 FF F CN F H OF 58.49 3.45 81 427 H OF 55.83 > 100 81 428 H3CCl H OF 59.56 41.6 4 81 429 OCH3OCH3 H OF 49.20 2. 87 81 430 OCH3OCH 3 H OF 52.62 21. 56 81 431 CH3 CH3 H OF > 100 > 100 81 432 OCH3OCH3 CH 3 O > 100 2.3 7 81 lished a potential th ues as a new interesting caffold with interest against age -related ne urodegenerative diseases s uch as PD or A D [77]. Delogu et al. synt hesized new c oumarin derivatives V in w hich the 3-aryl ring is ch anged for a h eteroaryl gro up and e xplored t he importan ce of t he number and position of methoxy grou ps on derivatives were fo und ubstitution of t he coumarin n ucleus at position 3 has been widely c arried o ut with phenyl and met hyl grou ps, bu t less data h ave been wit h polar or ethyl esth (Table 8). D. al. have dedi cated par - ticular attention to t he study of t he infl uence of t hese grou ps on M hibitory a ctivity and on A/B selectivity . For these derivatives, t he steri c hindran ce of t he substituent at position 6 is parti culary important, in w hich only 189Focusing 2012 , Vol. 12, No. 20 2233 By analyz ing the data reported in t he previou s (Table 6), it can be seen t hat hylketone was wh en the 3-ben [73 ]. Therefore, t he simple introd uction of a ca rbonyl bridge between t he coumarin and t he position, im - proved ac tivity t acids in (Table 8). D . Secci al. derivatives (T able 9) [81]. It can be seen t hat the majority of t he compou nds s how at position 7 on t he coumarin ring by a benz yloxy grou p leads to a dec rease in t he activity against bot h MAO iso - forms . Inhibitory a ctivity in analogs X and st udied t he possibility of link ing the amidi c grou p to t he coumarin by t he nitrogen atom [74] . cules IX. In spite of th ese considerations, the new c ompo unds res ulted to be poor M AOIs . Howe ver, some of t hem s howed AChE inhibitory a ctivity, being c on- sidered as d ual M AO/A ChE inhibitors [74]. Com - pounds wit h ual hibitory a ctivities are e xpected to have potential for t he treatment of AD cause to t he interest of coumarins in ind ustry c chemistry Different met hodologies can be u sed to obtain t he des cribed compou nds, depending on t he starting materials and on t he desired final s ubstituents. enols wit h /g1-ketoesters, in t he presen ce of a cid catalysts (usually s ulphuric acid) (Scheme 1). Although this is were performed, de - pending on t he stability and rea ctivity of t he used p henols /g1-dicarbonyls [6 2, 64, 66, are still being devoted to improve its performan ce by t he use of spe - cific catalysts and /or mi condensing agent allows, rea ction is condensation of an or- tho-hydrox ybenz aldehyde and t he conveniently s ubstituted acid an hydrides, in t he presen ce of an al kali salt of th e acid (Scheme 2). This meth odology is perh aps the most dire ct and simple met hod known for t he preparation of 3-aryl cou mar - ins. However, t he overall yields of t he final produc ts in th ese re actions are invariably low and t he variety of s ubstrates is, in most cases, limited [47]. Thus, a lig htly modified version of this c t s ubstituted 69-73, 75, 76, In rea ction, t he coumarin n obtained starting rea a c rea ction t hat affords Scheme 2). The reac tion is usually catalysed by wea k bases or by s uitable combinations of amines (usually piperidine ) and c a ac ids under homogeneou s conditions [78, 81]. The use presen ce ionic liquids, res simple hod to obtain 3-c arboxycoumarins [ 92]. hesis and easy purification, F. Chimenti et al. described t he preparation of 3-carboxycoumarin c hydrolysis of t he carbox termediate and t subsequent hod 5]. via Wittig rea ction, under classical conditions or im - proved protoc ols 9 8, Chemistry , 2012, Vo l. 12, No. 20 Matos et al. Scheme 1. Pechmann reac tion. Scheme 2. Perkin rea ction. Spe cial mention m ust be t he aryl marin derivatives by ommon . Therefore, libraries of 3-arylcoumarins were pre - starting from t he 3-bromoc oumarin by P d-cataly zed o ur resear ch grou p has used for the first time th e 3-chlorocoumarin as starting material and has prepared different 3-aryl coumarins by a P d- cataly x [105] . Other starting materials for t he arylation of t he coumarin ring are t he 4-hydrox ycoum arin derivatives . Due to t rea ctivity of th e 4-hydrox ycoumarin ring, t he coupling arylation can ta ke pla ce in eit her 3 or 4 positions, depending on the rea ction conditions . protoc -ar yl coumarins can be pre - pared in h igh yields [9 8, 106 , 107]. However, ta gies, wh en t he starting c ompou nds are 4 -hydrox y-3- to cou- marin moiety [6 1, 64]. For this reason, du ring t he last years new synt hetic strategies h ave been des cribed using as start - ing materials t he previo usly synt hesized coumarin ring . n in Current Topics 2012 No. 20 2235 Table 10. Ch emical and MAO (C (/g46M) MAO-B IC50 (/g46M) Ref 433 H > 100 0. 76 74 434 CH 3 CH3 45.97 0. 17 74 435 H CH3 > 100 7.96 74 436 H OCH3 > 100 30.50 74 437 H Cl > 100 1.9 5 74 438 H NO2 > 100 > 100 74 439 H OCH3 OCH 3 > 100 58.3 8 74 440 H OCH3 OCH3OCH 3 > 100 72. 58 74 441 H Cl Cl > 100 5.95 74 442 H > 100 49.96 74 443 H C H3 38.93 > 100 74 444 H C H2Br > 100 > 100 74 445 H C H2Cl > 100 > 100 74 Scheme 5. Synthetic strategies u sing as starting materials t he synt hesized , 2012, Vo l. 12, No. 20 Matos et al. Scheme 6. Functionali zation of coumarins ubstituted bromides were fu rnished target c oumarins in t he presen ce of um carbonate et hanol, under ux The rs adding s uitable ction was also possible starting from t he formation of and t e [62]. In general, t hese et herifications were t he most c ommon s ub- stitutions under t he coumarin n desired of al kylsulfonylox y derivatives was from t in potassi he subsequent f unctionali zation afford- an array (Scheme 6). Finally it m ust be mentioned t hat 3-aryl and 3- benz oylcoumarins can be f urther s ubstituted in different po- sitions of bot h aromati c rings u sing t he same aforementioned methodologies [69-7 3, 75, 76 ]. Bromination of t - tives was 70]. The met hoxy/ ethoxy derivatives c an be h ydrolyz ed eit her wit h hydriodic acid, in t he presen ce of a cetic acid and a cetic BBr3 in 72, differently he et hers [72]. 3. CONCLUSION Sin ce the pioneering work of H. A. Kadir et al. [55], and the disc overy of t he potential of th e coumarin s caffold against bot isoforms, Some of t he are a ctive and sele These and safe t t he rational g design of new mole cules. CONFLICT OF INT ERE ST The author(s) confirm t hat this arti cle content Elsevier: Amsterdan, 1 982, pp. 197. [3] Singer, T. P. In Chemistry and Biochemistry of Flavoenzymes ; Muller, F., Ed.; CRC Pre ss: Raton of o xidase Topics in Medicinal Chemistry, 2012 , Vol. 12, No. 20 2237 differen ces in en zymati c properties . Proc. Natl. Acad. Sci. Neve, hen, K.; Shih, J. C. sue distrib ution of hu man monoamine o xidase A and B m RNA. J. Neu- cata- lytic site and me chanism . Med. Res. Rev., 1995 , 15, 3 25-388. Geha, R. C. Substrate and tor spe cificities for human monoamine o xidase A and B are infl u- enced a amino R. G. The agi ng pro cess: wh ere are xidase B, a dr ug tar- get for t he treatment of neu rologi cal disorders . Nat. hts into th e mode of inh ibition of human mito - chondrial monoamine o xidase uc- tures. Proc. Natl. Acad. A, 9750-9 755. [16] De Colib us, L.; Li, (MAO-A) : Relation to t he structures of rat M AO-A and human M AO B. Proc. Natl. Acad. Sci. U S A, 2005 102, comple x with four inhibitors of t he N-propargylaminoindane class. Med. Edmondson, of re com human o ciated with a gene for monoamine .; Moffitt, T. E.; Mill, J .; Martin, J .; Craig, I. W.; Taylor, A.; Poulton, R. Role of t he an e x- planation for t he monoamine imbalanc e of major depression onset Alzheimer\u00b4s J. Mol. Neurosci. , . Age-related with dementia and depression. Adv. Sarro, G. Conventional and new Strial damage ans o xidative stress ind uced by t he mito - chondrial malonate Monoamine idase c signaling pat Sci. , 1 0 3, idase in J . vivo imaging A. occurren ce. In Chemistry and Biochemistry ; John Wiley and Sons: Chichester, 1 982. [39] Murray, R. D. o ccurring Uriarte, E. Sim - ple coumarins and analogu medi Thornes R.D. (Ed), John Wiley and Sons: New Y [43] A.; Le, N.; T. C. Di scovery of novel DN A gyrase in hibitors Medicinal Chemistry , 2012, Vo l. 12, No. 20 Matos et al. and cytotox C to el ucidate t he putative binding motif and ex plain str ucture-activity relations hips. J. Me d. Chem. , 2008 9. [53] Zhou, hesis, and zine nervo us system agents . Of- fen. (1990), DE 3834861 A1 199 00419. [57] Kong, L. D.; Tan, Woo, A. Cheng, C . Inhibition by psoralen and Choi, H. C.; Rho, T. C.; Lee, H. S.; Lee, M . K., Kim, Y. H. Inhibitory a ctivity of monoamine o xidase by c oumar ins from Peucedan um japoni cum. Arch. Pharm. Res., 1999 h aving monoamine o thetic Geiparavins De Marco, enner, P.; Testa, B. Lipoph ilicity plays a ma e inh ibition of ctive o xidase A B - hibitors . J. Med. , 2008 Appl. A1 40 427. [69] S as cou- of as and St udy of a Series of [73] M. J.; V\u00e1zquez-Rodrig coumarins as d ual inhibitors of A ChE and M AO for th e treatment of A D.; Janeiro, P.; F.; L.; in hibitory activity Coumarins A QSAR model . J. Med. Chem. , 2006 , 49, 1149- Binda, C J 20 [85] Campos C; Wang, Y; Ma, Jing -J; Wang, C ; Zhang, by u sing biodegradable cellulose s acid solid Synth. hesis and anti -inflammatory effects of a series of 7 -hydroxycoumarin derivatives Eur. J. V.; T. Sing P. , 70, Fernandes, T. A.; Carvalho, R. C. C.; Gonc al ves, T. M. Costa, P.R. and cient for Revised: June 15, 2012 Accepted: June 18, 2012 196Original (coumarin-3-yl)carbamates as docking Vilara,b, M a Gonzalez-Francoc, Eugenio Uriartea, Lourdes Santanaa, Carol Nicholas Organic of Pharmacy, University of Santiago de Compostela, 15782 Santiago de Compostela, Spain bDepartment of Biomedical Informatics, Columbia University Medical Center, New York, NY 10032, USA cDepartment of Pharmacology, Faculty of Pharmacy, University of Santiago de Compostela, 15782 Santiago de Compostela, Spain dDepartment of Pharmacology, CIMUS, University of Santiago de Compostela, 15782 Santiago de Compostela, Spain article info Article history: these compounds achieve inhibitory comparable compound (IC 50against SAS. All rights reserved. 1. Introduction of life of the aging population in the today' s society is, to a great extent, determined by the normal aging process of neurons in nervous in around the world. Alz- is by Parkin- son 's disease (PD). most common cause of senile dementia, affecting approximately 3% of the population between the ages of 65e74 and nearly 50% of those 85 years pathway. was described as a neurotransmitter, which showed low levels in the basal ganglia in animal models of parkin- sonism. After the success a placebo-controlled trial, levo-dopa an essential drug for the treatment of PD [9]. Even today the standard treatment of PD rights reserved. http://dx.doi.org/10.1016/j.ejmech.2013.02.009European Journal This recent discovery an increase in MAO-B activity is associated with which of hydrogen activity of MAO-B in the increases, but not so for MAO-A. The largest increases are in the basal ganglia and thalamus, followed by the frontal cortex and, to a lesser cerebellum and parietal cortices [14]. of different suchas neuronal, glial and mammalian cells [17]. MAO-A two isoforms of MAO suggest that both derived from a common ancestral gene. Overall MAO-A and MAO-B 70% amino that allows the covalent attachment of FAD through cysteine. DA and tyramine are common substrates for enzymes are involved pathologiessuch as Coumarins are large family of compounds from both natural and synthetic origin and display a variety of pharmacological properties. Due their for treating AD [29e 31]. importance to the MAO on phenyl ring the coumarin or spaced with a carbonyl or amide group) at the coumarin moiety ( Fig 1)[32e 37]. Also, MAO-B inhibitory activity and group was for the 3-benzoyl one. Therefore, the presence or absence of a carbonyl group between the coumarin and the 3-substituted is focused the molecular structure of our very potent MAO-B inhibitors by introducing new functional groups at position to improve their at po-sition 7, inhibitory activity of new (coumarin-3-yl)carbamate derivatives, in which a variety of groups with different size, electronic properties and lipophilicity were MAO-B an improved The analogue in vitro was studied in silico and in vivo , in order to gain a better understanding of its activity and to new SAFIRs, SSRs,and docking studies that potency corroborate and clarify to inhibit A and B isoforms of hMAO. and 1e8, with general structure outlined in direct acylation . Fig. 1. 3-Substituted coumarins with MAO activity which have been previously re- ported by our research group.M.J. Matos et al. / European Journal of Medicinal Chemistry 63 (2013) 151 e161 152 1982.2. Pharmacology evaluated for their was measuring the of hydrogen peroxide (H 2O2)f r m using Alcobendas, Spain) [42]. The production of H 2O2catalyzed by the two MAO with H 2O2in the presence of horseradish peroxidase to produce a which that these drugs do not interfere with the measurements. On the other hand, in our experiments and underspeci c conditions, hMAO-A maximum against which is inactive. Isopropyl (coumarin-3-yl)carbamate (compound 3)p r o v e d to be more active than the ethyl derivative (compound 2). In the same way, isobutyl (coumarin-3-yl)carbamate (compound 4)p r o v e dt ob 36 times more potent the activity 's modulation is the importance of the volume that these additional atoms occupy atom on the methyl group of compound 1(compound 5) does not seem to improve the activity. Compound inactive (100 mM). However, the introduction of a bromine on the ethyl of compound 2(compound 6) improved activity over six 3and6, a bromoethyl attached to the carbamate, presented a similar pro le MAO-B, with IC50values of 6.63 and 5.08 activity modulation was methylene bridge, respectively, were prepared. Compound 8proved to be 540 times more active than compound 7. Compounds 2and 7, presenting an ethyl compound 8as an interesting candidate for in vivo assays. In are not activity of derivative 8, which resulted the most active compound of the series in the in vitro as- says, was evaluated on unpretreated mice. This test was performed to observe the results of the administration of selegiline and compound 8in normal mice. Doses of 10 mg/kg of compound 8did not present signi cant effect on the motor time moving and straightening of the animals caused a decrease of mg/kg) was used ( chloride, pyridine, 3h Matos et al. / European Journal of Medicinal Chemistry 63 (2013) 151 e161 153 199expected an activity. In the literature found regarding its effects on dose, by inhibiting the metabolism of DA, an increase in the residence time of the DA in nigrostriatal to hypokinesia in experimental animals. It is important to notice that reserpine is not very selective and also affects the vesicular storage of NA selegiline (10 mg/kg) signi cantly increased motor activity regarding the group as well as the others analyzed parameters. Increasing the average speed of ani- mals, ). In order to check the tendency of the compound 8, the assays were repeated at a higher dose (100 mg/kg) ( 4 Increasing the it can be appreciated an increase in motor activity of animals treated tistically treated with compound 8, followed the same pattern as in the case of motor activity. By analyzing how motor activity, velocity and movement have evolved over time, it was possible to notice that the start of activityin mice selegiline treatedwith compound 8. Nevertheless, in the last minute, all the pa- rameters evaluated for animals treated with compound 8were ). During the performance of all assays, mortality in experimental animals was monitored for 24 h and 48 h, after the execution thereof. In that in activity, even at high concentrations, con rmed the interest of its in vitro activity. these it possible pound 8not only achieved also to simulations were performed for the most active coumarin 8, in order to understand the enzyme-inhibitor key interactions that contribute to the most stable complex confor- mation. A similar docking protocol was recently used by our group [35] where the crystal structure of the hMAO-B in complex with 7- (3-chlorobenzyloxy)-4-carboxaldehyde-coumarin 2V60 with Prime help of Maestro software [45e 47]. The validation of the docking protocol was the calculation of the RMSD (root mean square deviation) of the heavy atoms coordinates between the theoretical and experimental Fig. 2. Results obtained in unpretreated D) Straightening. **p<0.01.M.J. Matos et al. / European Journal of Medicinal Chemistry 63 (2013) 151 e161 and or 8(100 mg/kg). Motor activity; B) Velocity; C) Movement; D) Straightening. *p<0.05.M.J. Matos et al. / European Journal of Medicinal Chemistry 63 (2013) 151 e161 155 201conformations of and most favourable docking conformation was retrieved the calculation. crystallized van der Waals interactions ( Fig. 7 The results extracted from docking simulations for the compound 8 are agreement with recently [36,39] . In this article, to study the of compound 8to- wards the hMAO-B we the hMAO-A cavity with did not have enough space to appropriately accommo-date compound 8. However, we also carried out molecular with no water molecules. The RMSD between the calculated and thecrystal was for compound 8placed deeply in (see Fig. 7 c). This conformation would have to displace three water molecules preserved crystal structure that can energetic role in the stabilization. the coumarin ring wasshifted towards a deeper region in the case of hMAO-A [36]. On the other hand, both isoenzymes present some different residues in the pocket, such as the Phe208 residue in the hMAO-A instead of the Ile199 in the hMAO-B that affect the shape and the an important role and in stabilization of a particular ligand inside the protein Through molecular docking simulations we the possible binding mode for the compound 8and proposed, as said before, that the coumarin ring is directed towards the FAD cofactor in the hMAO-B and is positioned inside the hy- drophobic entrance 2V60 8causes the coumarin ring 's position to shift towards the FAD compared to the coumarin c17in 2V60. On the other previously published binding modes for this type of compounds [35,36] .On the other hand, the selec- region were found with the MAO-A, which can exert different in fluence in the 2.4. of In properties the described Molinspiration property calculation program [48]. or European Journal of Medicinal Chemistry 63 (2013) 151 e161 156 202Fig. 7. a) Comparison of the co-crystallized ligand c17(purple color) and the calculated pose for the compound 8(colored by element, green carbons) by the docking simulation in thehMAO-B . b) Analysis of the binding proposed for the compound 8in the hMAO-B. FAD cofactor and residues in purple establish van der Waals interactions with the ligand. Residues in yellow establish both van der Waals and forces. Arene-H interactions with Tyr326 and Ile316 are represented in white. The FAD cofactor and the water molecule are represented in CPK. c) Comparison of the grey ribbons) hMAO-A (pink blue ribbons). The compound is placed in a deeper region in the hMAO-A. However, for this buried conformation to happen in thehMAO-A structure that an the fluence binding to hMAO-B. (For interpretation of the references to colour in this gure legend, the reader is referred to the web version of this article.)M.J. Matos et al. / European Journal of Medicinal Chemistry 63 (2013) 151 e161 157 prediction . From the data presented in Table derivatives also found to be In addition, can be observed that no violations Lip- donors and acceptors) were found. As MAOIs have to pass different membranes and reach the CNS, supports derivatives as drug candidates. 3. In this study, a general and ef cient synthesis of a new series of (coumarin-3-yl)carbamates nanoMolar In addition, it can be observed that no violations of Lipinski rule active compound in vitro against MAO-B, was evaluated in vivo . In mice pretreated with reserpine, the administration of compound 8 (100 mg/kg) resulted in an increase of the motor activity, velocity and movement comparable with selegiline, in the last minute of the experiment. Molecular docking simulations were also performed to study the type of derivatives. 4. Experimental protocols 4.1. General Starting materials and reagents were obtained from commercial suppliers and were used without further puri cation (Sigma e Aldrich). Melting points (mp) are uncorrected and were deter- mined with a Reichert Ko s doublets), and m and are within 0.4% of calculatedvalues in all cases. Flash chromatography (FC) was performed on silica gel (Merck 60, after pyridine (1.1 mmol) was added. The mixture was cooled to The corresponding acid chloride (1.1 was dropwise at this temperature, and the mixture was stirred, at room temperature, for 3 h. The solvent was evaporated under vacuum and the dry residue was puri ed by FC 219 (M\u00fe, 100), 188 (22), 187 (96), 147 (22), 132 (82), 104 (25), 77 (28), 59 (11). Anal. Calcd. for C 11H9NO4: C, (M\u00fe, 100), 161 (12), 134 (27), 98 (50), 84 (30), 69 (41), 56 (66). Anal. Calcd. for C 12H11NO4: C, 61.80; H, 219 (100), 188 (22), 187 (96),147 (22),132 (82),104 (25), 77 (28), 59 (11). Anal. Calcd. for C13H13NO4: C, 63.15; (100), 174 (58),160 (22),132 (88), 104 (35), 77 (35), 51 (30). Anal. Calcd. for C11H8ClNO 4: C, 218.91 4 68.54 Molinspiration calculation software [48].M.J. Matos et al. / European Journal of Medicinal Chemistry 63 (2013) 29), 312 (4), 311 (28), 187 (24), 174 (27), 161 (23), 132 (100), 109 (38), 107 (40), 103 (20), 77 (60), 51 (48). Anal. Calcd. for C 12H10BrNO 91 (58). Anal. Calcd. for C 17H13NO4: C, 68.42; H, 4.42. previously Brie fly, 0.1 mL of sodium phosphate buffer (0.05 M, pH 7.4) transformed/min/ incubation period, the reaction was started by adding ( 1 U/mL horseradish peroxidase 1 The of H 2O2and, consequently, of resoru n quanti 545 nm, emission, 590 nm) over a 15 min period, in which the fluorescence increased linearly. Control experiments were carried only the the activity, which vials all components phosphate buffer \"CD1 \"mice weighing 30 /C65 g were housed in groups of 4 or 8 animals under regulated conditions(light/dark cycle between 8.00 and 20.00 h at /C14C) in standard Makrolon cages (215 /C2465/C2145 mm3). The standard laboratory chow and tap water ad libitum until the beginning of the experiments. 4.3.2.2. Reserpine, LD (200 mg/kg) (10 mg/kg) were supplied by Sigma eAldrich (St. Louis, MO, USA) and CD (50 mg/kg) was kindly provided by DupontPharma.Sodium carboxymethyl cellulose (CMCNa) used chemicals were of analytical baseline. Compound 8was tested at doses of 10 and 100 mg/kg, in a sus- pension of 1% CMCNa. 4.3.2.3. Locomotor activity. of animals in (50 /C250/C230 cm3) under a video camera sus- pended from the ceiling was recorded over a 1 h period between 10.00 and 14.00 h and analyzed using a computerized animal observation Wageningen, Netherlands), separated room. The variables considered were (in cm), velocity (cm/s), during the test run and straightening. 4.3.2.4. Protocol. Animal models for study were twofold: mice: Compound 8was tested by ip adminis- tration at doses of 10 mg/kg or 100 mg/kg in untreated mice, comparing with the vehicle (1% CMCNa) The involves the administration of reserpine (2.5 mg/kg, ip) to the animals 22 h before the completion of each trial. After this time, the vehicle (1% CMCNa) or new molecules under test were administered. min later. evaluated 1 h after the last administration during a period of 1 h. 4.3.2.5. Expression of and statistical analysis. ANOVA(treatment-time) followed by Boferroni test. 4.4. Molecular docking in Schr\u00f6dinger 2011 package [45] was to [45] used to pre-process the crystal structure of in complex with the coumarin c17(PDB code: 2V60) and with the co-crystallized coumarin was retained in the calculations for the hMAO-B. Two different protocols were followed in the hMAO-A: 1) no water molecules were retained in the cavity protein and 2) only waters within 5/C23A from the ligand were retained. Hydrogen were added and energy minimized with the OPLS_2005 force eld. Optimizations of the hydrogen bonding network and the protonation states of some residues were also carried out through procedure. belonging to force Matos et al. / European Journal of Medicinal Chemistry 63 (2013) 151 e161 ligand hMAO-B in harmine hMAO-A with an outer box length of 20/C23A. The receptor van der Waals scaling factor was 1.0 with a partial charge cut-off New partial charges of the ligands inside the protein pocket were calculated with the help of Jaguar module The the improved charges were mode and poses perligand were retained. Finally, the best pose according to the energy score was taking protein region de ned by 5/C23A from the ligand. Average MMGBSA free energy of brated in Table 4 ). Acknowledgments to the Xunta de Galicia (09CSA030203PR, PGI- DIT07PXIB, 10PXIB203303PR) and Spanish Ministerio de PS09/00501). MJM thanks Funda\u00e7\u00e3o SV thanks the Angeles Alvari\u00f1o program from Xunta de Galicia (Spain). References [1] Y. Zhu, K. Xiao, L. Ma, B. Xiong, Y. Fu, H. Yu, W. Wang, X. Wang, D. Hu, H. Peng, J. Li, Q. Gong, Q. Chai, X. Tang, H. Zang, J. Li, J. Shen, Bioorg. Med. Chem. 17 (2009) 1600 e1613. [2] E. Scarpini, e344. [4] J. Saura, J.M. Luque, A.M. Cesure, M. Da V. Chan-Palay, G. Huber, J. J. Neural 109 (2002) 777 [11] E. Abel, (1995) in: F. Muller (Ed.), Chemistry and Biochemistry of Flavoenzymes, vol. 2, CRC Press, 4934e4938. [19] J. Wouters, Curr. Lan, R. Neve, K. Chen, J.C. Shih, J. Neurochem. 55 (1990) 1166 e 1169. [21] A.S. Kalgutkar, N. Castagnoli Jr., Med. Res. [22] Geha, I. Yoshimura, E. Yamashita, A. Nakagawa, A. Ito, T. Tsukihara, e114. Amit, J. Neurosci. Res. 79 (2005) 172 e179. [28] F. Borges, F. Roleira, N. Milhazes, E. Uriarte, L. Santana, Front. Med. Chem. 4 (2009) 23 e85. [29] R. Hoerr, e158. [30] D. Vi\u00f1a, M.J. Matos, M. Y\u00e1\u00f1ez, L. Santana, E. Uriarte, MedChemComm 3 (2011) 213e218. [31] C. Br\u00fchlmann, F. Ooms, F. Leonetti, C. Quezada, C. G. Delogu, F. Orallo, L. Santana, 19 3268 D. C. Picciau, L. Santana, E. Uriarte, 19 (2009) 5053 e5055. [34] M.J. Matos, D. Vi\u00f1a, P. Janeiro, F. Borges, L. Santana, E. Uriarte, Bioorg. Med. Chem. Lett. 20 (2010) 5157 M.J. Matos, G. Ferino, E. Cadoni, R. Laguna, F. Borges, E. Uriarte, L. Santana, Chem. Med. Chem. 7 (2012) 464 e470. [36] M.J. Matos, C. Ter\u00e1n, Y. P\u00e9rez-Castillo, E. Uriarte, L. Santana, D. Vi\u00f1a, J. Med. Chem. 54 (2011) 7127 e7137. [37] S. Serra, G. Ferino, Matos, S. V\u00e1zquez-Rodr\u00edguez, G. Delogu, D. Vi\u00f1a, E. Cadoni, L. Santana, E. Uriarte, Bioorg. Med. Chem. Lett. 22 (2012) 258 e261. [38] M.J. Matos, S. V\u00e1zquez-Rodr\u00edguez, E. Uriarte, L. Santana, Bioorg. Med. Chem. 21 Castagnoli, Altomare, M. Catto, C. Gnerre, L. Summo, A. De Marco, S. Rose, P. Jenner, B. Testa, Chem. Biodiversity 3 (2006) 134 e149. [42] Cano, Biophys. Res. 688 e695.Table 4 Experimental p KibCalculated no in the harmine in provided the r\u00bc0.42 and r\u00bc0.41 for hMAO-B and hMAO-A respectively.M.J. Matos et al. / European Journal of Medicinal Chemistry 63 (2013) 151 e161 160 206[43] C. Binda, J. Wang, L. Pisani, A. P. Salvati, NY, 2011. [46] QM-polarized Ligand Docking Protocol; Glide Version 5.7, Jaguar Version 7.8, QSite Version 5.7, Schr\u00f6dinger, LLC, New York, NY, 2011. [47] Prime, Version 3.0, Schr\u00f6dinger, LLC, New York, NY, 2011. Rev. 23 (1997) 3 e26. [50] P. Ertl, B. Rohde, P. 43 (2000) A. Gaspar, S. Kachler, K.-N. F. Borges, L. Santana, E. Uriarte, J. Pharm. Pharmacol. 65 (2013) 30 e34. [52] H. Takahashi, H. Kubo, T. 72 (2007) 123e126. [53] LigPrep, Version 2.5, Schr\u00f6dinger, LLC, New York, NY, 2011. [54] Jaguar, Version 7.8, Schr\u00f6dinger, LLC, New York, NY, 2011.M.J. Matos et al. / European Journal of Medicinal Chemistry 63 (2013) 151 e161 161 2073-Substituted coumarins as dual inhibitors of AChE and MAO for the treatment of Alzheimer's disease Dolores Vi ~na,aMaria Joa etiology of Alzheimer's disease (AD) has encouraged active research in the development of multi-target drugs with two or more complementary biological activities, since they may represent animportant advance in the treatment of this disease. A of 3-substituted coumarins might direction developing today. Among them, Alzheimer's dementia, affecting approxi-mately 3% of the population between the ages of 65-74 and nearly 50% of those 85 years and levels of H 2O2and in and cognitive function but do not appear to prevent or slow the progressive neurodegeneration.5 On the hand, a a single target may beinadequate for the treatment of AD. It has encouraged activeresearch in the development of multifunctional drugs biological activities, since they may represent an important advance in the treatment of the disease. a 9 Coumarins are a large family of compounds, of natural and synthetic origin, that display a variety of pharmacologicalproperties. Due to their structural variability they occupy animportant of them have been proposedfor treating AD. 11,12Substitution in position 3 resulted in potent MAO research group has reported, studies, importance of the MAO inhibitory activity of different substituents on the phenyl ring in position 3 of the coumarin (Fig. 1\u2014 I).15-18Our work is now focused on modifying molecular of these potent MAO-B inhibitors, an (amidic the coumarin and the 3-phenyl ring) (Fig. 1\u2014 II) or an alkylamide group in that position (Fig. 1\u2014 III) in order to provide them de Farmacia, Universidad de Santiago de Compostela, 15782 Santiago de Facultad de Farmacia, Universidad de Santiago de Compostela, 15782 Santiago de Compostela, Chemistry 2012 Med. Chem. Commun. were synthesized according to the protocol outlined in Scheme 1, under Perkin condensation conditions, starting the presence of sodium hydride, at room temperature, for three hours. are described in Experimentalsection. Fig. 1 General structures of the coumarin derivatives. 110/C14C, 24 h; (ii) NaH, Ac 2O, r. t., 3 h; (iii) H 2, EtOH, Pd/C, t., 3 h; substituted studied compounds 1-16 Compounds RR 1 1 H 2 CH 3 3 CH 3 4 CH 3 5 H 6 H 7 H 8 H 9 H 10 H 11 H 12 H 13 H 214 | Med. Chem. Commun. , 2012, 3, 213-218 This journal is Society of Chemistry 2012 2103. Pharmacology 3.1. assay kit (Molecular Probes, Eugene, Oregon, USA) and did not interference with the used theMAO-B selectivity Enzymatic revealed was measured by the increase in absorbance at 412 nm due to the yellow color of 5-mercapto-2-nitrobenzoic acid produced by the 293 (Sigma-Aldrich Qu /C19mica S.A., Alcobendas, Spain). The control activity from using due to the presence of test compounds was calculatedand the IC 50values are reported in Table RR 14 H 16 H Table 2 IC50values and hMAO-B selectivity index for index compounds and enzymatic Chemistry 2012 Med. Chem. Commun. in HEK 293 cells. substitutions in 3 of the coumarin moiety important for the selectivity. 15-18Also, the presence of an amidic group in the same position was an important structural change to improve andpicomolar range. The introduction of a methyl group in the position of methyl group in position para of the 3-aryl ring of the same scaffold inhibitory activity range. Despite these results, the presence of both methyl groups in the six position and the amidic group between the coumarin and MAO-/AChE inhibitory activities, modica-tions under ination of the methyl group in the six position (compound 5) leads to a selective MAO-B inhibitor, with an increase activity. these experimental data, the importance of the substitutions under the aryl ring of be inactive against AChE, showing the of this ring. A methoxy group incorporated in the para position of the ring (compound 7) seems to be less favorable for the AChE and MAO-B inhibition than a methyl group (compound 5). A chloro group in the same position allows a new compound ( 8) with similar AChE inhibitory MAO-B activity. Introduction of a nitro group at the same position (compound 9) leads to a slightly more active compound against AChE, but inactive against MAO-B. Another strategy than under the aryl ring. Introduction of additional the meta position of the arylring resulted in a compound ( 12) with MAO-B inhibitory activities to the mono-substituted derivative (compound 8). From the experimental results it can be observed that the nature, number and position of the substituents in thearyl ring to modulate the AChE MAO-Binhibitory activities. Finally, in order to determine the importance of the aryl ring, it was replaced with an alkyl or with a linked to the amidic group, instead less bulky group leads to a compound ( 14) activity MAO-A, in the micromolar range. Introduction of group in the same leads to inactive both MAO iso- (compounds 5. Experimental 5.1. General Starting materials and reagents were obtained from commercial suppliers and were used without purication. Melting are uncorrected d doublets) and m spectrometry small portions, and the reaction mixture was stirredfor 3 hours, crude was ltered and washed with diethyl ether. The was then puri- ed by flash chromatography (hexane/ethyl acetate 9 amount of Pd/C added to the 216 | Med. Chem. Commun. , 2012, 3, 213-218 This journal is \u00aaThe Royal Society of Chemistry 2012 212mixture. The solution was stirred, at room temperature, under H2atmosphere, for 5 hours. After the completion of the reaction, the mixture was ltered by flash chromatography acetate : 1) the desired coumarins. General methodology to prepare 3-amidocoumarins: To (1 mmol) and pyridine (1.1 mmol) in dichloromethane (9 the corresponding acid (1.1 mmol) was added dropwise and the reaction wasstirred, at room temperature, for 3 hours. The solvent wasevaporated under vacuum and the dry residue of sodium M, in a flat-black bottom 96-well microtest plate, placed in the dark fluorimeter chamber. After this incubation period, the reaction was started by adding (nal concentrations)200 mM Amplex Red reagent, 1 U mL /C01horseradish peroxidase and 1 mM p-tyramine. The production of conse- quently, 545 nm, emission, 590 nm) over a 15 min period, inwhich the fluorescence increased linearly. Control experiments were Red by drugs to containingonly the Amplex phosphate pH \u00bc7.4, with the addition of 0.25 acid), 0.165 unit per mL recombinant acetylcholinesterase expressed in HEK 293 (Sigma-Aldrich Qu /C19mica S.A., Spain), and 5 mM of substrate (acetylthiocholine iodide). Testcompounds were added to the buffer and preincubated at 37 /C14C with the enzyme for 5 min followed by the by measuring in absorbance at 412 nm at 1 min intervals for 10 min at 37 /C14C. Control experiments were carried out simultaneously by replacing vehicles. specic This journal is Royal Society of Chemistry 2012 Med. Chem. Commun. 3, the nal results) was calculated activity, determinedfrom containing all components by a sodium phosphate buffer solution. Conclusions In the current study, a of 3-substituted coumarin deriva- tives were synthesized and evaluated as AChE. In general, and in accordance with previous results, an aryl ring in that position, additionally to the substitution in thesix position of the coumarin, led to interesting MAO inhibitors which lack the activity on AChE. an and AChE in the micromolar ring for alkylamidic exploring. Acknowledgements Thanks to the Spanish Ministry (PS09/00501) and to da Galicia (PGIDIT09CSA030203PR and 10PXIB203303PR). M.J. M. thanks FCT for a PhD (SFRH/BD/61262/2009). Notes and references 1 Y. Zhu, K. Xiao, L. Ma, B. Xiong, Y. Fu, H. Yu, W. Wang, X. Wang, D. Hu, H. Peng, J. Li, Q. Gong, Q. Chai, X. Tang, H. Zang, J. Li and J. Shen, Bioorg. Med. Chem. , 2009, 17, 1600. 2 E. Scarpini, P. Scheltens and H. Feldman, Lancet Neurol. , 2003, 2, 539. 3 H. W. Querfurth and F. M. LaFerla, N. Engl. J. Med. , 2010, 362, 329. 4 J. Saura, J. M. Luque, A. M. Cesure, M. Da Prada, V. Chan-Palay, G. Huber, J. Loffler and J. G. Richard, Neuroscience 1994, 62, 15. 5 M. Weinstock, CNS Drugs , 1999, 12, 307. 6 M. Amit, M. Falach-Yogev, O. Bar-Am, W. Amit, J. Neurosci. Res. , 2005, 79, 172.7 A. Cavalli, M. L. Bolognesi, A. Minarini, M. Rosini, V. Tumiatti, M. Recanatini and C. Melchiorre, J. Med. Chem. , 2008, 51, 347. 8 M. I. Fern /C19andez-Bachiller, C. P /C19erez, G. C. Gonz /C19alez-Mu ~noz, S. Conde, M. G. L /C19opez, M. A. G. Garc /C19a and M. /C19guez-Franco, Med. 53, Yogev-Falach, O. O. Weinreb M. B. Youdim, FASEB J. , 2006, 20, 2177. 10 F. Borges, F. Roleira, N. Milhazes, E. Uriarte and L. Santana, Front. Med. Chem. Online , 2009, 4, 23. 11 R. Hoerr and M. Noeldner, CNS Drug Rev. , Ooms, Carrupt, B. A. Carotti, J. Med. Chem. , 2001, 44, 3195. 13 X. Zhou, X.-B. Wang, T. Wang and L.-Y. Kong, Bioorg. Med. Chem. , 2008, 16, Med. Chem. Lett., 2004, 14, 3697. 15 J. F. Archer and J. Grimshaw, J. Chem. Soc. B , 1969, 3, 266. 16 M. Natarajan, T. Manimaran and V. T. Ramakrishnan, Chem. Incl. Med. Chem. , 1984, 23, 529. 17 M. J. Matos, D. Vi ~na, E. Quezada, C. Picciau, G. Delogu, F. Orallo, and Uriarte, Bioorg. Med. Chem. Lett. , 2009, 19, 3268. 18 M. J. Matos, D. Vi ~na, C. Picciau, F. Orallo, L. Santana and E. Uriarte, Bioorg. Med. Chem. Lett. , 2009, 19, 5053. 19 M. J. Matos, D. Vi ~na, P. Janeiro, F. Borges, L. Santana and E. Uriarte, Bioorg. Med. Chem. Lett. , 2010, 20, 5157. 20 M. J. Matos, S. V /C19azquez-Rodr /C19guez, E. Uriarte, L. Santana and D. Vi ~na,Bioorg. Med. Chem. Lett. , 2011, 21, 4224. 21 C. S. Barnes, M. I. Strong and J. L. Occolowitz, Tetrahedron , 1963, 19, 839. 22 D. S. Pat. Appl. Publ. , US 20090163545 A1 Merchant and G. Martyres, Curr. Sci. , 1981, 50, 410. 24 J. B. Lambooy, J. Am. Chem. Soc. , 1956, 78, 771. 25 G. Rodighiero and C. Antonello, Boll. Chim. Farm. , 1958, 97, 592. 26 and A. K. Mukerjee, J. Prakt. Chem. , 1989, 331, 493. 27 V. Maddi, S. N. Mamledesai, D. Satyanarayana and S. Swamy, Indian J. Pharm. Sci. , 2007, 69, 847. 28 Lacova, J. Chovancova and V. Konecny, Chem. Pap. , L. Santana, H. Gonz /C19alez-D /C19az, E. Quezada, E. Uriarte, M. Y /C19a~nez, Vi ~na and F. Orallo, J. Med. Chem. , 2008, 51, 6740. 30 G. L. Ellman, K. D. Counrtney, V. Andres and R. M. A. Featherstone, Biochem. Pharmacol. , 1961, 7, 88. 218 | Med. Commun. , 2012, 3, 213-218 This journal aDepartamento de Qu\u00edmica Org\u00e1nica, Facultad de Farmacia, Universidad de Santiago de Compostela, 15782 Santiago de Compostela, Spain bDipartimento Farmaco Chimico Tecnologico, Facolt\u00e0 tyrosinase inhibitory we report the synthesis and pharmacological evaluation of a new series of phenylcoumarin derivatives with different number of hydroxyl or ether groups bromo substituent in 50than Compound 12(IC50= 215 lM) is the best tyrosinase inhibitor this /C2112011 Elsevier Ltd. the presence of cop-per at its active site. 1In fungi and vertebrates, tyrosinase catalyzes the responsible have been with the mam- malian one. So, it is suited melanogenesis and tyros- inase bio-pathways studies. Coumarins are of compounds, of natural and syn- thetic origin, which presents different pharmacological activities.6 Structurally they are lactones of the cinnamic to their structural variability, they occupy an important place synthetic a lic compound in grapes and red wine.15It is a phytoalexin produced by some species in response damage (such as a fungal infection).15,16In in vitro, ex the last et al. of those con- different positions particularly suitable these modications.20,21Recently, it whether a pol- yphenol may act as an inhibitor.26So, was proved ideal drug candidate has not been attained, an intensive search for and innovative tyrosinase This ef- increased in recent years. In this and in the templates were present. 21 Resveratrol ( Fig. 1 , A) and umbelliferone (B) are very good tyrosinase inhibitors.2,20Umbelliferone-resveratrol hybrid (C) and 3-phenylumbelliferone (D) are less by us 6,8,30,40,50-pentahydroxy proved to be the most active compound of the evaluated 3-arylcoumarin series, with an IC 50of 0.27 mM.21This molecule have two hydroxyl groups under the coumarin ring, being like the coumarin-resveratrol hybrid (E). Based on these results,21in the present work we proposed to continue the bromo 1 ). We decided to explore the impor- tance of the number and position of ether and hydroxyl groups lo-cated in the 3-phenyl ring or in the aromatic ring of the coumarin and, at the same time, the bromination . The 3- the were 1 In the present effect the introduction of a halogen obtained from compound 9to compound 10 and from 11to12, with the bromo atom in the coumarin nucleus, leads in the Table 1 , compound 12is the most active compound of this series. This compound, with a bromo atom and two hydroxyl groups in the 3-phenylcoumarin moiety, has an in the coumarin moiety, the better activity the compounds have. When compared with compound 10, the introduction of one hydroxyl group more in compound 12in- R=O ;R1=O 9 >5.0 10 0.302 \u00b1 12 \u00b1 0.085 Umbelliferone 0.42a aObtained from data in Matos Bioorg. Med. Chem. Lett. 21 (2011) 3342-3345 3343 216positions, at the same of a bromo and a hydroxyl substituent, respectively, contributed to an increase of show that the methoxyl and derivatives (compounds 5-8) do not present tested enzyme. in of the bromination of methoxycoumarins, could be an important step in the synthesis of novel tyrosinase plot as a plot of 1/V versus 1/[S], gave three straight lines with different slopes and a horizontal line that intersected at the same point. With an increase in compound a non-competitive tyrosinase inhibitor. The inhibition constant of this was Figure 2 . In conclusion, in the present study it was shown the activity in the micromolar range. The presence of a bromo atom in position 6 of the hydroxycoumarins improves the inhibitory activity respect to the other synthesized derivatives. So, the introduction of a bromo atom improves the pharmacologi- cal potential of these 3-phenylcoumarins, conrming lead could be effectively optimized in a candidate for the treatment of some hyperpigmentation skin diseases. These nds have encour- aged us the efforts towards pharmacological prole these 3-phenylcoumarins. Acknowledgement Thanks to the Spanish Ministry (PS0900501) and to Xunta da Galicia (INCITE09E2R203035ES and PGIDIT09CSA030203PR) for nancial support. We are also grateful to the RAS-LR7/2007 (CRP2_133). This work was also authors are grateful to Professor Gianni Podda, of Cagliari University, for insightful suggestions. References and notes 1. Lerch, K. Life Chem. Rep. 1987 ,5, 221. 2. Kim, Y. M.; Yun, J.; Lee, C.; Lee, H.; Min, ,19, 550. 4. He, Q.; Luo, Y.; Chen, P. Food Chem. 2008 ,110, 847. Chen, J.; Guo, Y. J.; Chen, Q. X. Food Chem. 2009 ,112, 609. 6. Borges, F.; Roleira, F.; Milhazes, N.; Uriarte, E.; Santana, L. Front. 2009 ,4, 23. 7. Hoult, J. R. S.; Pay\u00e1, M. Gen. Pharmacol. 8. D. J. J. J. Enzyme Testa, B. Chem. Biod. 2006 2009 ,19, 3268. 15. Fr\u00e9mont, L. Life Sci. 2000 ,66, 663. 16. 2006 ,16, 257. 17. Orallo, F., Jr. In Resveratrol in Health and Disease ; Aggarwal, B. B., Shishodia, S., Eds.; CRC Press: ,75, 1156. 19. Orallo, F. Curr. 461. 24. Likhitwitayawuid, K. ,94, 44. 25. Likhitwitayawuid, K.; Sritularak, B.; De-Eknamkul, W. Planta Med. 2000 ,66, 275. 26. Chang, Te.-S. Int. J. Mol. Sci. 2009 ,10, 2440. 27. 8-Ethoxy-3-phenylcoumarin (5). It was obtained with a 266 (M+, 83), 239 (16), 238 (20), 212 (14) 211 (20), 181 (15), 153 (25). Anal. Calcd for C 17H14O3: C, 76.68; H 5.30. Found: C, 76.66; H, 5.35. 6-Bromo-8-methoxy-3-phenylcoumarin (6). It was 331 (30), 330 (M+, 100), 304 (40), 302 (40), 261 (25), 259 (26), 194 (16), 165 (12), 153 (14), 151 (23), 102 (19), 76 (34). Anal. Calcd for C 16H11BrO 3: C, 58.03; H, 3.35. 58.01; (7). 296 (M+, 100), 268 (54), 240 (47) 225 (45), 197 (13), 152 (11), 139 (15). Anal. Calcd for C 18H16O4:C 362 (M+, 100), 361 (19), 334 (24), 332 (23), 319 (33), 317 (34), 291 (11), 289 (11), 182 (18), 167 (17), 139 (21), 91 (11). Anal. Calcd for C 17H13BrO 4: (9). 238 (M+, 100), 210 (80), 181 (13), 153 (22) 152 (20), 105 (9), 76 (15), 51 (6). Anal. Calcd for C 15H10O3: C, 75.62; H, 4.23. (10). plot of 1/ Vmax versus concentration compound 12, to determine the inhibition constant ( Ki).3344 M. J. Matos et al. / Bioorg. Med. Chem. Lett. 21 (2011) 3342-3345 217318 (99), 317 (17), 316 (M+, 100), 291 (12), 289 (13), 153 (22), 152 (51), 151 (12), 76 (25). Anal. Calcd for C 15H9BrO 3: 254 (M+, 100), 227 (16), 226 (98), 197 (15), 169 (12), 115 (12). Anal. Calcd for C 15H10O4: C, 70.83; H, 3.87. (12). 333 (45), 332 (M+, 100), 307 (31), 305 (35), 225 (26), 197 (29), 169 (35), 168 (46), 153 (24), 141 (21), 140 (16), 118 (17), 115 (28), 98 (13), 89 (14), 84 (18), 75 (11), 63 (13). Anal. Calcd for C 15H9BrO 4: C, 54.08; Indian J. 1996 ,35B, 1159. 29. Perkin, W. H. J. Chem. Soc. 1868 ,21, 53.30. Matos, M. J.; Vi\u00f1a, D.; Janeiro, P.; Bioorg. 5053. 33. Pre-incubation with the enzyme: 1/15 M phosphoric acid buffer solution (pH 6.8, 1.8 mL), an aqueous solution of mushroom tyrosinase (1000 U/mL, Sigma Chemical Co., 0.1 mL) and DMSO (0.1 mL) with or without the sample. The mixture was incubated at 25 /C176C for 10 min. Then, a 1.05 mM of L-3,4- dihydroxyphenylalanine (DOPA) solution (1 mL) was added and the reaction was monitored at 475 nm, for 5 min. of tyrosinase activity inhibition was represents the difference in the absorbance of control sample between 0.5 and 1.0 min, and B represents the difference in absorbance of the test sample between 0.5 and 1.0 min. The IC 50value, a concentration giving 50% as reference J. Matos Faisc aDepartamento de Qu\u00edmica Org\u00e1nica, Facultad de Farmacia, Universidad de Santiago de Compostela, Santiago de Compostela, Spain and bDipartimento Farmaco Chimico T ecnologico, Facolt\u00e0 e OrganicChemistry , University of Santiago de Compostela, Fac Farmacia, Campus Vida, Santiago de Compostela, 15782, Spain. E-mail: mariajoao.correiapinto@rai.usc.es W e report evaluation new series of 3-aminocoumarins differently substituted hydroxyl groups, which have structures the mimick-ing the its active site.[1,2]This enzyme is responsible for unwanted browning of fruits and vegetables.[4]Therefore, it is Coumarins are a large family of compounds, of natural and synthetic origin, which present different pharmacological actions.[13]Chemically they are lactones of cinnamic acid. Their structural variety is responsible for the importantplace that they occupy of tested series, with esculetin proving tobe the strongest inhibitor of the series. [22]Recently, and in contrast to ndings, The Authors. JPP \u00a9 2012 Royal Pharmaceutical Society 2012 Journal of and Pharmacology, 64, pp. 742-746 groups in could have broad applications. As the ideal drug candidate has not been attained, an intensivesearch for is effort considerably increased in the recent years. In this coumarin and the resveratroltemplates were present. [23,27]Based on this work, and with the aim of nding new structure-activity features, we proposethe study of a series tyrosine-like condensed molecules(Figure 1). The similarity of these compounds to the tyrosi-nase substrate is the are to Methods W e synthesized (Figure 2) and evaluated a small of3-aminocoumarins. W e decided to explore the importance ofthe position of a hydroxyl group under the 3-aminocoumarinmoiety, based on the idea of mimicking the dry Schlenk tube, anhydride as sodium hydride, room tem- perature, for 3 was puried chromatography, using give acid, in the presence of acetic acid and aceticanhydride, at 110\u00b0C, for 5 h. The residue was puried crystallization of acetonitrile, and the hydroxy derivatives were in 60%. Compound reduction carried out: 1/15mphosphoric acid buffer solution (pH 6.8, ml), an aqueous solution of mushroom tyrosinase (1000 U/ml; Sigma Chemical Co., Milan, Italy, 0.1 ml) and dimethylsulfoxide (DMSO) (0.1 ml) with or without the sample.The mixture was incubated at 25\u00b0C for 10 min. Then, 1.5 m m L-DOPA solution (1 ml) was added and the reaction wasmonitored at 475 nm for 5 min. The percent inhibition was difference in the absorbance of control sample between 0.5 and 1.0 min, andB represents the difference in absorbance of the test samplebetween and 1.0 The tyrosinase acti-vity reference tyrosinaseinhibitor. Statistical methods All experiments were out Authors. JPP \u00a9 Pharmaceutical Society 2012 Journal Pharmacology, 64, the new compounds were calculated (T able 1). In the presence of compound 7, kinetic studies on mush- room Increasing the concentration of 7resulted in a family of lines with different slope and intercept, which inter-sected in the second quadrant. This showed 7can bind not only with free enzyme enzyme-substrate complex, with different equilib-rium The constants for the inhibitorbinding I(2.14 mm), and with enzyme- substrate complex, different positions of the 3-aminocoumarinmoiety was studied. In this way a small series of compounds that both position 3. The 3-aminocoumarin(compound 4) was synthesized and evaluated and did 8, which have the hydroxyl group in positions 7 and 8, respectively, of the coumarin nucleus(benzene ring) and compound 9, with the hydroxyl group in position 4 of the coumarin (pyrone ring). As shown in T able 1, compound 7was the most active compound of this series, with an IC50 value in the micromolar range (53 mm). This compound was more than 10 times more active than umbelliferone, the reference compound. 7had the groups that precisely mimicked the positions O O OO Oa 1 R1 = R2 = H 2 R1 = OMe, R 2 = H 3 R1 = H, R 2 = OMe 7 R1 = OH, R 2 = H 8 R1 = H, R 2 = OH4 R1 = R2 = H 5 R1 = OMe, R 2 = H 6 R1 = H, R 2 = OMeb c b 9 Figure 2 Protocols 3 h; (b) H 2, EtOH, Pd/C, r .t., 5 The Authors. JPP \u00a9 2012 Royal Pharmaceutical Society 2012 Journal of Pharmacy and Pharmacology, 64, pp. 742-746 221compound 9was activity depends on the the hydroxyl group in the coumarin moiety. Also, the presence of the hydroxyl group at the same position that of tyrosine and umbelliferone isimportant to the inhibitory activity. hydroxyl group in the seven position of the3-aminocoumarin, the same position as in tyrosine and umbelliferone, inhibitory be effectively optimized in a can-didate for the treatment of some These encouraged Conflict interest declare(s) conflicts of est to disclose. Funding This work was supported -2 024 6 8 1 0 1 21/V (ODnm)[I] (m M) 0 0.02 2012 The Authors. JPP \u00a9 Pharmaceutical Society 2012 Journal of Pharmacy and Pharmacology, 64, pp. 742-746 222References 1. Lerch K. Molecular and Life Chem Rep of extracts containing carotenoids Ohguchi K et al .G n e t o la sap o t e n t as dual inhibitors synthesis of Matos MJ et . series 3-arylcoumarins as I n Authors. JPP \u00a9 2012 Royal Pharmaceutical Society 2012 Journal 64, Bioqu\u00edmica, Faculdade de Ci\u00eancias, Universidade do Porto, Porto, Portugal,bDepartamento de Qu\u00edmica Org\u00e1nica, Facultad de Farmacia, Universidad de Santiago de Compostela, Santiago de Compostela, Spain andcInstitut f\u00fcr Pharmakologie und de Qu\u00edmicaOrg\u00e1nica, Facultad de Farmacia, Universidad de Santiago de Compostela, Spain. E-mail: mariajoao.correiapinto@rai.usc.es Received April 19, 2012 Accepted June and selectivity, a introduced at position 4 of the coumarin moiety.Methods A new series of coumarins the ARs. None of the compounds interacted with the hA The most remarkable derivative is compound 7, which presents the best afnity and selectivity for the A 3adenosine receptor (K i=5500 towards been intensied as the role of these receptors in many areas is continuously expanding.[24,25]In A 3AR has beenthe subject of intensive research during the last decade as it is recognized as being a potential therapeutic target due to to has and anti-glaucoma treatment.[29] Since AR ligands have broad applications, and an ideal drug candidate has not yet been attained, intensive research still needed. This considerably increased in recent years. In this context, and with the aim of nding new structure-activity features, this work based on coumarinderivatives was carried out. T o our knowledge, no infor-mation has been published so far concerning the coumarin scaffold as a putative ligand of the ARs. Therefore, this is an innovative study, performed for the rst time, on this interest-ing and versatile moiety. Our groups have recently coumarins, to novel AR ligands. [30,31]These recent ndings, and the lack of data coumarin scaffold,bs_bs_banner And PharmacologyJournal of PharmacyResearch Paper \u00a9 2012 The Authors. JPP \u00a9 2012 Royal Pharmaceutical Society 2013 Journal of Pharmacy and Pharmacology, 65, pp. 30-34 225encouraged were prepared starting from commercially available 3-aminocoumarin (compound 1) or 85%. The reaction conditions and chemical characterization of the new compounds are experimental altham, MA, USA). 1H and13CN M Rs p e c t r aw e r er e c o r d e do naB r u k e r AMX spectrometer at 300 and 75.47 MHz, respectively, Silica gel (Merck used (Merck 60 F254, Scientic, UV-Vis software was used for data acquisition. Different analytical columns and mobile phases solvents tested. The mobile phasewas H 2O:C H 3CN (70 : 30) and an xdb C18 column particle Agilent Santa Clara, CA, USA) was used. The purity of the compounds was found to be (2) The MO, in ethanol and a catalytic amount of Pd/C was added to the mixture (Sigma-Aldrich). The solution was stirred, at room temperature, under H 2atmosphere, for 5 h. After the completion of the reaction, the mixture was ltered to catalyst. The was then puri- ed by FC (hexane-ethyl acetate, 9 : 1) to give the desired coumarin 2, in a yield of 90%. [32] dichlo-romethane (9 ml), then pyridine (Sigma-Aldrich) (1.1 mmol) was added and the mixture sub-stituted puried by column chromatography(hexane-ethyl acetate, to give the desired compound.OH NO 2NH2 1: R = H 2: R = OH 3: R = H ; R1 = COCH 3 4: R = OH ; R1 = COCH 3 5: R = H ; R1 = COCH 2Br 6: R = H ; R1 = COCH 2Cl = H ; R1 COOCH (b)O O O synthesis of (a) h; to r AR with coumarins \u00a9 2012 The Authors. JPP \u00a9 2012 Royal Pharmaceutical Society 2013 Journal of and Pharmacology, 65, pp. 30-34 226Biological assays The afnity for 2A,hA 3, was hamster ovary transfected with the [36,37]The n m (2R, hA 1, 10 nm (1-(6-amino-9H-purin-9-yl)-1-deoxy-N-ethyl- for K is (dissociation were calculated with the program SCT-FIT . [38]Due to the lack a hA 2Brecep- tors, the potency of antagonists the hA 2Breceptor Hz, (7), 261 (M +, 42), 188 (23), 161 (70), 133 (28), 57 (41). Anal. Calcd for C CH), 4.00 277 (M+, 40), 203 (27), 177 (100), 148 (15), 121 (65), 88 (18), 57 (50).Anal. Calcd for C 14H 15NO (M +, 43), 203 (59), 177 (30), 148 (41), 121 (61), 65 (13). Anal. Calcd for C 12H 11NO 5: summarized in T able Details for pharmacological experiments are in Materials and previous work. [36-38] framework, represented by an amidic or a carbam- ate group at position 3, were studied for their ability to bind toARs. In addition, the presence or the absence of a hydroxylgroup at position 4 was also explored in these preliminarystudies. The experimental results binding subtype. The presence of a hydroxyl func-tion at position 4 of the coumarin scaffold is not tolerated,T able 1 Afnity (K 1,A 2Aand A 3adenosine receptors assays CompoundKi(nM) Selectivity hA 2A hA 3 hA 1/hA 3 hA 2A/hA 3 3 53 900 (35 900-81 100) >30 000 7 160 (5 700-9 000) 7.5 >4.2 4 >100 000 >100 000 >100 000 - - 5 25 000 (21 600-29 000) >30 000 27 800 (22 600-34 300) >0.9 >1.1 6 7 760 (4 070-14 800) 36 600 (20 500-65 500) 13 700 (12 000-15 600) 0.57 2.7 7 >100 000 >100 000 5 (3 670) >18.2 >18.2 8 >100 000 >100 000 - - 9 >100 000 >30 000 >100 000 - - These results are the average of three experiments.Targeting AR with coumarins Maria Jo\u00e3o Matos et al. \u00a9 2012 The Authors. JPP \u00a9 2012 Royal Pharmaceutical Society 2013 Journal of Pharmacy and Pharmacology, 65, pp. 30-34 227notwithstanding the presence of acetamide (compound 4), isobutylcarbamate (compound 8) or ethylcarbamate (compound 9) at position 3. On the other hand, 3ARs were observed. Compound 3, with an aceta- mide group at position 3 of the coumarin moiety, has a higher afnity to hA 3AR (K i=7160 nm) than to hA 1 (K i=53 900 nm) and no afnity for hA 1Ki=25 000 nm and hA 3Ki=27 800 nm). Nevertheless it is interesting to note that the afnity for hA 1AR is enhanced by this substitution. The substitution of a bromine for a chlo-rine atom leads to compound 6, which is almost twice as selective for hA 1than hA 3AR and about ve times more selec- tive for hA 1than hA 2AAR. The substitution of the acetamide group (compound 3) for an isobutylcarbamate function (compound 7) allows one to obtain a very active and selective compound for hA 3ARs (K i=5500 hA of the amide-like (carbamate) a for the ligand-receptorinteraction. interesting result found for 7 provides a and the design of novel AR ligands. A detailed analysis of the experimental results obtained so allow thenature of their substituents. Compound 7exhibits the best performance and can be considered as the starting point forthe design and synthesis of nancial support Consumo Xunta de Galicia (PGIDIT09CSA030203PR) and Funda\u00e7\u00e3o para a Ci\u00eancia e T ecnologia (projects PTDC/QUI/70359/2006 and PTDC/QUI-QUI/113687/2009) are acknowledged. Gaspar thank FCT grants (SFRH/BD/61262/2009; SFRH/BD/43531/2008). References 1. Borges F DA et al .D i s c o v e r yo fn o v e l DNA gyrase inhibitors by Pisani L et a novel class of potent coumarin MJ 2012 The Authors. JPP \u00a9 2012 Royal Pharmaceutical Society 2013 Journal of Pharmacy and Pharmacology, 65, pp. 30-34 22814. Matos MJ et al . Synthesis and study series 3-arylcoumarins as coumarins as dual inhibitors of AChE of Alzheimer's disease. MedChemComm 2011; 3: 213- 4-substituted 1H-imidazo[4,5-c]quinolin-4-aminederivatives as allosteric 2098-2108. 25. Bansal R et thio-Cl-IB-MECA, induces CJ et al .I nv i v or o l eo ft h e adenosine A3 receptor: N6-2-(4-aminophenyl)ethyladenosine induces 1148-1156. 30. Gaspar A et al .D i s c o v e r yo fn o v e lA 3 adenosine A et al .R e c e p t o r e sA 3da adeno- sina: uma 1417- agonist selective Eur J Pharmacol 2007; 556: 14-18. 38. De Lean A et al . V alidation and statisti- cal analysis of a computer modelingmethod for quantitative analysis of radioligand binding \u00a9 2012 The Authors. JPP \u00a9 2012 Royal Pharmaceutical Society 2013 Journal of Pharmacy and Pharmacology, 65, J. Matos 1,*, Saleta V azquez-Rodrigue z 1, Lourdes S antana 1, Eugenio Uriarte 1, Cristina Fu entes-Edfuf 2, Ysabel Santos 2 and Angeles Mu\u00f1oz-C rego 2 1 Departamento de Qu \u00edmica Org\u00e1nica, Facultad de Farmacia, Universidad de Santiago de Compostela, 15782 Santiago de Microbiolog\u00eda y Parasitolog\u00eda, Facultad de Biolog\u00eda, Universidad de Santiago de Compostela, 15782 Santiago de Compostela, Spain ; 2 17 January 2013 / Published: 24 January 2013 exhibited S. comparable acid and ampicillin). preliminary str antibacterial activity against S. position of substitu th e different positions of nitro, met hyl, methoxy, amino E. coli OPE ACCE 237Molecules 2013, 18 1395 1. Introduction Drug disc overy is c onsidered a c omplex slow ac tivity. However, with the intention of discovering new chemi cal chemistry researchers have the new products are based on found and extracted from sources . Coumarins are a large family of compou nds of natural or synthetic origin, associated species The fused heterocyclic coumarins as a prototype scaffold for the synthesis of a wide variety of analog ues in order to study and improve their biological properties. Its structural variety is responsible for t he important pla ce they occupy in time in 1945 when he studied the dicoumarol (Figure 1) [18]. s in wh ich 1. Chemical structures of active of them is novobiocin, isolated from Streptomyces niveus and wh G bac teria. Although they antagoniz e the B DNA th ey are not u sed in th e clinic due to their relatively weak activity against Gram -negative bacteria, side effe cts and poor water solubility [4,26]. On the other han d, these three examples are antibioti cs, is increasing and the Gram-positive MR SA are of particular importance. The ability of 238Molecules 2013, 18 1396 S. aureus to develop resistan ce to virtu ally all antibiotic s is a major c oncern and th e disc overy of new is to therefore, search of mole cules and new chemical entities an important topi c chemistry [28,29] the candidate has not been attain ed, an intensive sear new and innovative Unfortunately, ave considerably de creased this effort in re cent years Results an d Discussion Based on previous findings in the area [24,25], and in o ur experience with s ubstituted 3-arylcoumarins [15,31,32], in the present synthesis and antibacterial eval uation f different substitu ted amino/nitro 3-arylc oumarins (Scheme 1). With the aim res for dec ided to ex plore the importance of the nature and position of small gro ups (meth oxy, bromo, nitro, amino and meth yl substituents) into bot h coumarin nuc leus and 3-aryl ring (Scheme 1). Scheme of 3-arylcou marins h. New derivatives and 9-11, as well as the in presenc of sodium hydride and with acetic anhydride as solvent, at room temperat ure for three hours. The reaction xture by as from different commercially derivative 11 was obtained 239Molecules 2013, 18 1397 from 4, in eth anol, with palladiu m/carbon as c atalyst and under hydrogen atmosp here for three hours. The by obtained the desired derivate in good yield (80%). Then, methodologies employed for th e antibacterial used as The inh ibition zones for growth inhibitory effects of the new compounds and controls were measu red in millimetres A). The hibitory concentrations of the new c ompou nds and c ontrols were measu red in mic B (g/mL) S. aureus E. coli S. aureus E. coli 1 19 N A 128 - 2 25 NA 64 - 3 22 N A 32 - 4 22 NA 32 - 5 25 NA 64 - 6 32 N A 8 - 7 14 NA 256 - 8 NA N A >512 - 9 N A N A >512 - 10 N A N A >512 - 11 18 N A 128 - Oxolinic acid 26 31 2 <1 Ampicillin 32 23 2 8 a These results are average res ults of three experiments; b The compounds were used at the concentration of 100 g/disk and the inhibition zones are stated in mm ; NA = not active; diameter of in hibition zone /g148 5 mm. amino derivative 11 presented ac 8-10) were inactive against S. test assays, independently of th e relative position of this nitro gro up (para or meta positions). From the data, it is shown that compound 6 and ampic illin presented th e same inhibition zone against mm) and a higher inhibition zone th an th e oxolinic Hence, the preliminary ex perimental data revealed t hat some of the tested c ompou nds sh owed a very interesting activity against ampicillin and ox olinic acid. In addition, the different nature and position of the substituent in the coum arin previously resu lts by method A, could be by differences in the diff usion of the compounds. This study was performed 240Molecules 2013, 18 1398 against the same bacteria strain, by a mi crodilu tion assay with serial dilutions (from 512 to 1 /mL) of the synthesized and the reference compounds. MICs compounds coli evaluated, taking into account the lack of inhibition zones in the previous disk diffusion test (inhibition zones MICs for S. aureus , it is c lear th at the presence of a nitro substituent at the six position of coum arin moiety (compou nds 1-7) is more benefic ial th an its presence only at meta or para positions of the 3-aryl ring (compounds 8-10). Compou nds with e aryl grou p (compou 1 and 4) are not better than compounds wh ere th e nitro in th e aryl ring is substituted for a m ethyl or a methoxy group (compounds 2 and 3 compared to c ompou nd 1, and compounds 5 and 6 compared to compound 4). However, compound 4 (MIC = 32 g/mL), with the nitro substitu ent in meta position of the 3-aryl ring, is better than compound 1 (MIC = 128 g/ mL), with the same su bstitu ent in para position. The presence of a m ethyl grou p in th e meta position is the best substitution when one nitro substituent is present at six position of th e coumarin moiety (compou nd 6, MIC are more favourable th bstitu by meta-nitro and finally meta -methoxy. There is one exception to t his conclusion. The introduction of a brom o atom at th e same position was th e worst substitution of the studied 3-aryl-6-nitrocoumarins (compound = g/mL). A para- methyl su bstitu ent in th e 3-aryl ring (compound 3, MIC = 32 g/ mL) is the best substitution in this para position. Therefore, th e para- substitu compou nds 4 and 11). In order to evalu ate if there was a correlation between th e activity and th e li pophilicity, and to better understand the overall 4,120 3,607 9 h calculation [ 37]. 241Molecules 2013, Analysing the obtained data, it can be concluded th at there are no linear c orrelations between e lipophilicity and the activity of th e compou nds. Compou nds 5 and 6 are two of the best compounds against S. aureus nd 1. 841) and th e pou nd 7, 4. 457) logP presented activity. Compound 9, with the same logP lted to be a ctivity and logP values. It is important to high light that the calculated logP val ues for all the described compounds are lower than 5. 3. Experimental using a Reichert Kofler thermopan or capillary tu bes on a B \u00fcchi 510 apparatu s and are uncorrected. 1H-NMR (300 MHz) internal Spin of and m (multiplet). Mass spe ctrometry was c arried ou t with a Kratos MS or MAT- were within \u00b10.4% of calculated valu es in all cases. Flash Chromatography (FC) was performed on silica gel (Merck th e preparation of 3-arylcoumarins 1-10. In a 20 mL dry Schlenk t ube, to a solution of the conveniently su bstitu t ed salic in small portions, and the reaction mixture was stirred for 3 hours, at room temperatu The obtained crude was filtered and washed with diethyl ether. The t pu rified by flash chrom atography 2.60. 242Molecules 2013, 3.73. Found: Found: C, 3.73. Found: C, 64.63; and a c atalytic amount of Pd/C was added to the mi xture. The solution was stirred, at room temperature, under a H 2 atmosph ere, for 3 h. After completion of th 9:1) th e desired coumarin 11 as a wh ite solid = 2.4 Hz), method, following the procedures of th e Clinic al and L aboratory Standards Institute (CLSI, 2006). The inoculum was prepared as a saline suspension of colonies 24 h M ueller Hinton Agar (MHA) (Cultim ed, Barcelona, of the strea with the swab c ontaining the bruzz i, Italy) embedded i n the drug at a final concentration of 100 g /disk were on Sterile disks c ontrol. The plates were incubated at 37 \u00b0C for 24 h. Zones of inhibition were measured in millimeter. into ea ch well. The inoculum was prepared by ma king a MHB s uspension of colonies from a 24 h plates and counting the bacterial colonies M HB with and without inocul um was used as growth-control and negative c ontrol, respec tively. The plates were in cubated at 37 \u00b0C for 24 h. The MIC was established comparing the amo unt of growth in the wells containing th e antim icrobial agents with t he amount of growth in the growth-control wells both with t he unaided eye and by using a photometric devic e (OD620). 4. Conclusions In conclusion, in th e present study it was shown that eight out of the eleven substituents, being 3-(3 /g397-methylphenyl)-6-nitroc oumarin (6) the best on e. A nitro su bstitu ent at th e 6-position of of th is kind of compou nds. The introduction of an amino su bstitu tively optimiz ed into a candidate the treatment of some ba cterial infectious diseases. 244Molecules 2013, 18 1402 Acknowledgments Thanks are due to the Ministerio Espa \u00f1ol (PS09/00501), Xunta da G alicia (PGIDIT09CSA030203PR and PGIDT08MMA011200PR) and IN845B-2010/089 for the financial support. M.J.M. thanks to Funda\u00e7\u00e3o para Ci\u00eancia grant (SFRH/BD/6 1262/2009). S .V.R. thanks the Ministerio de Educaci\u00f3n y Ciencia for a PhD grant (AP2008-04263). Referenc Uriarte, medi antiba cterial D.; Borges, Santana, L.; and study of a series of 3-arylcoumarins as potent and selective monoamine oxidase B inhibitors. A. The antibac terial properties of Shi, Y.; Zhou, C. Synthesis and evaluation of stu dies and Cu(II) complex es with ONOO donor coumarin Schiff bases. J. Mol. Struct. 2011, their robial and ac tivities. Eur. 2079-2084. 246Molecules 2013, 18 1404 27. Nathan, C. Antibiotics at the crossroads. Nature 2004, 431, 899-902. 28. Cartee, Antibiotics, Actions, Origins, Resistance ; ASM: revival? F.; 35. Kremky, E. Chromatograph ic method the compounds are available he authors. 2013 by the authors; licensee MD PI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of Eugenio Ana Tecnologia, Universidade de Coimbra, 3004-535 Coimbra, Portugal bDepartamento de Qu\u00edmica Org\u00e1nica, Facultad de Farmacia, Universidad de Santiago de Compostela, 15782 Santiago de Compostela, Spain article info Article history: 3-arylcoumarins influence of bromine, methyl scaffold, by differential at different compounds have presence in bioactive dairy products. Fruits, vegetables, oil and wine have been as health protectors be- cause the protective effects in vivo. These compounds are known to be the most common plants, and their help in the identication of the active constituents in beverages, vegetables and fruit that may help sustain antioxidant status and protect against free radical damage [1]. Phenolic compounds are a very wide group of in hormones, vitamins, and food in which phenol is converted into a to the aromatic rings. It is known that pH one in a large group of in vitro , ex vivo and/or in vivo experiments [14,15] . The fusion of a pyrone with a benzene gives rise to as or coumarins[16]. Coumarins group of compounds present in remarkable amounts in the nature [17]. Representatives of this group occur in the vegetable kingdom, either in free or combined state [18]. Due to their structural variability, they are an elite class of compounds which occupy an important role toxicity, biological properties have a special ability to interact with more than one target [29]. In medicinal chemistry, this represents a signicant source and of functionalized analogues with the aim of improving the pharmacological Limited data are antioxidant conditions, using cyclic, differential and square wave voltammetry. The information on these mechanisms was obtained at different pH and is shown to play a crucial role in understanding its antioxidant activity. 2. Experimental 2.1. 1-10[33,36-38] were efciently outlined conditions cases. Silica gel (Merck 230-00 mesh) was used for flash chromatography (FC). (TLC) was performed on plates precoated with silica gel (Merck 60 F254, were prepared out at room temperature (25 \u00b1 1 /C176C) and in the presence of dissolved oxygen. The pH were carried with an Ingold combined glass electrode. All experiments were done at room temperature (25 \u00b1 1 /C176C) and preparation of 3-phenylcoumarins mmol) heated in an oil-bath at 110 /C176C for 24 h. Triturate ice (100 mL) and acetic acid (10 mL) were added to the reaction mix- ture. After keeping it at room temperature for 2 h, the mixture was extracted with ether (3 /C225 mL). The organic layer was extracted with sodium bicarbonate solution (50 mL, 5%) and then water(20 mL). The solvent was dried with 266 (M+, 83), 239 (16), 238 (20), 212 (14) 211 (20), 181 (15), 153 (25). Anal. Calcd for C 17H14O3: C, 76.68; 296 (M+, 100), 268 (54), 240 (47) 225 (45), 197 (13), 152 (11), 139 (15). Anal.Calcd for C 18H16O4: C, (s, 3H, -CH 3), 4.20 (dd, 2H, -CH 2,J= 7.0, 280 (M+, 80), 252 (78), 225 (16), 224 (56), 223 (20), 165 (30), 142 (45), 115 (17). Anal. Calcd for C 18H16O3: C, 362 (M+, 100), 361 (19), 360 (59), 334 (24), 332 (23), 319 (33), 317 (34), 291 (11),289 (11), 182 (18), 167 (17), 139 (21). Anal. Calcd for C 17H13BrO 4: (98), 345 ([M+1]+, 26), 344 (M+, 100), 318 (47), 316 (46), 275244 P. Janeiro et al. / Journal of Electroanalytical Chemistry 689 (2013) 243-251 250(18), 273 (18), 208 (11), 166 (52), 165 (43), 115 (15), 83 (14). Anal. Calcd for C 17H13BrO 3: C, 59.15; for the preparation of a solution (0.50 mmol) substituted methoxy/ethoxy-3- phenylcoumarin in (5 mL) acetic acid acetic anhydride at 0/C176C, (10 hydriodic The mix- ture was for 3 The was evaporatedunder vacuum and the dry residue 252 (M+, 100), 225 (26), 223 (23), 165 (15), 153 (12), 152 (25), 115 (11). Anal. Calcd for C 16H12O3: C, (99), 333 ([M+1]+, 45), 332 (M+, 100), 307 (31), 305 (35), 225 (26), 197 (29), 169 (35), 168 (46), 153 (24), 141 (21), 140 (16), 139 (51), 118 (17), 115 (28), 84 (18), 84 (46). Anal. Calcd for C 15H9BrO 4: (98), 331 ([M+1]+, 18), 330 (M+, 100), 305 (13), 304 (77), 303 (22), 302 (79), 223 (12), 166 (14), 165 (30),Scheme 1. Synthesis experimental conditions: (i) DCC, + 2HPO 4 8.5 NaH 2PO4+N a 2HPO 4P. Janeiro et al. / Journal of Electroanalytical Chemistry 689 (2013) 243-251 245 251152 (30), 115 (14). for 10 running with GPES 4.9 software, Eco-Chemie, Utrecht, Netherlands. Measurements were carried out using a Inc., USA). Glassy mV s/C01. For square wave (SW) pulse of frequency of and a potential increment of 2 mV, corresponding to effective rinsed thoroughly with water. Following this mechanical treatment, the GCE was placed in buffer supporting electrolyte oxidation potential caused halogen on structure was investigated. pull the electron the the lone elec- tron pairs this para positions. The effect of an alkyl group, in this specic case a methyl group, in the oxidation potential of a compound was studied. The in pH Fig. 1 , showing on the rst peak P +0.65 = +50 mV indicates oxidation formed during the oxidation at peak P 1. In the second scan at lower potentials a new oxidation peak P 2a, atEp2a= +0.08 V, conrmed the reversibility of peak P 2, that occurs with the transfer of two electrons [40]. The same behavior was found for compounds 8and10, both with only one oxidizable hy- droxyl group their structure. CVs of compound 8showed an identical behavior to compound 6. That means presence of a weak electron donating sub- stituent, in a different ring where hydroxyl group is, does not influence the always decreased in the second scan.In the case of compound 10,Fig. 2 , the oxidation peak P slightly higher potential, at Ep1= +0.71 V. This can be due to the presence of bromine, an electron withdrawing substitu- irreversible for compounds 6,8and10and occurs with the transfer of one elec- tron. It has been proved in this work that the oxidation of the hy- droxyl group at the position C8 occurs irreversibly and it is formed an oxidation product which is oxidized at a peak 2a-P2cwith the transfer of two electrons. The compound 10peak P 1oxidation product, occurs P V and Ep2c= +0.05 V, and pre- sented very similar behavior to compound 6,Fig. 1 , showing that bromine does not interfere on the redox reaction of compound 10 oxidation product, with the oxidisable hydroxyl group and the-0,2 0,0 0,2 0,4 0,6 0,8 1,0 1,20.2 A P2cP2aP1 E / V (vs. Ag/AgCl) Fig. 1. CVs in 0.5 mM compound 6, in 0.2 M phosphate buffer pH = 7.0: (\u2014) rst, (- - -) second and /C15/C15/C15) third scans. Scan rate 50 mV s/C01. -0,2 0,0 0,2 0,4 0,6 0,8 1,0 1,2P2cP2aP1 0.2 A E / V (vs. Ag/AgCl) Fig. 2. CVs in 0.5 mM compound 10, in 0.2 M phosphate buffer pH = 7.0: (\u2014) rst, (- - -) second and ( /C15/C15/C15) third scans. Scan rate 50 mV s/C01.246 P. Janeiro et al. / Journal of Electroanalytical Chemistry 689 (2013) 243-251 252halogen in the meta position in the same ring. It can be remarked that compound 10peak P 2current was lower than compound 6 peak P 2current, which could indicate that the different substitu- ents do not affect the peak P 1current, but affect the peak P 2 current. The presence of electron withdrawing substituents, that deacti- vate and para- positions, in respect to the hydroxyl group, due to conju- gation of these positions with the group. This explains the oxi- dation potential of potential than P 1that presents a not so acidic hydroxyl group. The CV study was done in the pH range between 4.5 and 8.5. The oxidation process is complex and pH-dependent, indicating that the oxidation of all compounds To clarify acetate buffer showed the occur- peak P l,a t Ep1= +0.80 V, and after the second scan peak P 2,a t Ep2= +0.20 V, which corresponds to the oxidation of the peak P loxidation product, Fig. 3 . The peak P lwidth at half height was W1/2= oxidation 8on 4 , but the peak was for a higher potential than at compounds compound peak as in compounds 6and8, but compound 10peak P 2current was lower. The DP voltammogram in compound 7, that has two hydroxyl groups, presented two oxidation peaks due to two oxidizable hy- droxyl groups, Fig. 5 . In the rst voltammogram the oxidation peak P lwidth at half W1/2/C24200 mV corresponding to two oxidation peaks overlapped, that was after the baseline was subtracted in the DP voltammogram. The peaks over- lap is due to the two similar hydroxyl groups in the compound 7, the hydroxyl groups in positions C40and C8 of the 3-arylcoumarin, and the oxidation occurs at similar potentials, as they are both phe- nol groups. The rst scan DP voltammogram in a poten- of a catechol peak P 2appears already on the rst scan, peak P 2is due to the oxi- dation product of peak P 1. This denotes that oxi- dized during 2width at half height was W1/2/C2460 mV indicating On scan, the oxidation +0.05 V, occurs, as observed by CV, and is due to the oxidation of the hydroxyl group at position C8 in theP 1oxidation product. This is conrmed by the appearance of peak P3only in the second scan and also at lower oxidation potential. The peak P 3width at half height was W1/2/C2460 mV indicates that two electrons are involved on the oxidation of the hydroxyl group at position C8 oxidation product of compound 7. The strong adsorption of the oxidation products, which blocked the electrode0,0 0,2 0,4 0,6 0,8 1,0 1,2P2 P1 0.5 A E / V (vs. Ag/AgCl) Fig. 3. Successive DP voltammograms (1 ?5) in 0.5 mM compound 8, in 0.2 M acetate buffer pH = 4.5. Scan rate 5 mV s/C01.0,0 0,2 0,4 0,6 0,8 1,0 1,250 nAP2 P1 E / V (vs. Ag/AgCl) Fig. 4. DP voltammograms in 0.5 mM compound 10, in 0.2 M acetate buffer pH = 4.5: (\u2014) rst, ( /C15/C15/C15) second and (- -) third scans. Scan rate 5 mV s/C01. -0,2 0,0 0,2 0,4 0,6 0,8 1,0 1,2P3 P2P1 0.2 A E / V (vs. Ag/AgCl) Fig. 5. DP voltammograms in 0.5 mM compound 7, in 0.2 M phosphate buffer pH = 7.0: (\u2014) rst scans. Scan rate 5 mV s/C01.P. Janeiro al. / of Electroanalytical Chemistry 689 (2013) 243-251 247 253surface, enabled to observe easily on the second scan the overlap that occurs in P 1corresponding to a transfer of one elec- tron in each peak. The DP voltammetric study was for compounds and10, for a wide pH the potentials of peaks P the electron electrons and From Table 2 , the transfer of one electron and one proton occurs for peak P 1, attributed to the hydroxyl group correspondent to a phenol group, whereas, oxidation product peaks P 2and P 3, both oc- cur with the transfer of two electrons and two protons. Compound 9shows a DP voltammogram very similar to that of compound 7,Fig. 6 . The oxidation peak P 1observed is broad, indi- cating the presence of two hydroxyl groups that oxidize at similar potential. It also appears in the rst scan a peak P 2at lower poten- tial. The peak P 3, a product of oxidation of P 1, appears in the second scan. A great decrease in peak P 1current on hydroxyl group, has an electron effect and a decreasing in the reactivity of the ring. 3.3. Square wave voltammetry The advantages of SW voltammetry are greater speed sibility if the electron transfer reaction is reversible or not. Since the current is sampled in both the positive and the negative-going pulses, peaks at the electrode sur- face i.e. peaks and peaks, a strong adsorption on their oxidation product P 2, in compounds 6,8and their structure, irreversible peak P 1with overlapping, at Ep1= +0.85 V, and two reversible peaks, peak P 2, atEp2= +0.39 V, due to oxidation during synthesis, and 3, atEp3= +0.21 V, 8 , conrmed in the second scan after reversing the potential just before obtained. It foundthat only a slightly effect upon Table 2 DP voltammetric data for compounds 6-10. Peak P 1 Peak 0.43-0.057 pH 2 2 -0,0 0,2 0,4 0,6 0,8 1,0 1,20.1 AP3 P2P1 E / V (vs. Ag/AgCl) Fig. 6. DP voltammograms in 0.5 mM compound 9, in 0.1 M phosphate buffer pH = 7.0: (\u2014) rst, (- - -) second and /C15/C15/C15) third scans. Scan rate 5 mV 0.2 0.4 0.6 0.8 1.0 1.2P1P2 IbIfIt 1 A E / V (vs. Ag/AgCl) Fig. 7. Second SW voltammogram in 0.5 mM of compound 6, in pH = 8.5, third scan. It- total current, Janeiro et / Journal of (2013) 243-251 a hydroxyl group on position C8 and differ by the presence or absence of bro- mine, an electron withdrawing atom, in the benzene ring and the presence or absence of a in the benzene ring position C3 of the coumarin structure. Electrochemi- cal studies of this consecutive steps in for 4.5 < pH < 8.5. The irreversibility of all these steps was established by CV and SW voltammetry. The involvement one and one proton in the oxidation steps was evaluated from the peak width at half height of the DP voltam- mograms and the slope of pvs. oxidation peaks two protons. Compounds bromine at position have the highest oxidation potentials on the series studied. This is due to the presence of an electron withdrawing substituent which the reactivity of these compounds is different from the others. An oxidation mechanism for identical behavior to compound 6. That means that presence of a methyl group weak electron donating substituent, in a different ring from the hydroxyl group, does not influence the reactivity on the position C8 have another hydroxyl group in position C40, and this two oxi- dations potentials are very near and their peaks oxida-tion mechanism occurs in two consecutive irreversible reactions with the transfer of an electron and a proton for the overlapped peaks in P 1. The oxidation products formed after peak P 1,identied as peak P3, corresponds to the oxidation of the hydroxyl group on present in compounds 6,8and 10. The oxidation products formed after peak P peak P 2, had a reversible oxida- tion process with transfer oxidation potential values with to group, corresponding to the oxidation of the hydroxyl group for compounds .0.0 0.2 0.4 0.6 0.8 1.0 1.2IbIfItP2 P1'P1P3 1 A Fig. 8. Second SW voltammogram in 0.5 mM compound 9, in 0.1 M acetate pH = 4.5 buffer, fourth scan. It- al. Chemistry 689 (2013) 243-251 249 2555. Conclusions The synthesis ten new 3-arylcoumarins was carried out in an efcient, direct and versatile way using a Perkin reaction as key step. The ether derivatives had been hydroxylated, with good yields, giving the oxi- dized. The electrochemical data showed that these cou- marins can be oxidized at relatively of 3-arylcoumarins can be claried. In compounds 6,8and10, with only electro-chemical easier to C8 of the coumarin structure than the hydroxyl group at position C4 0. As expected, the radical phenoxyl in C40is more stable. The C8 and good (Research Unit 285), Xunta de Galicia (PGIDIT09CSA030203PR) and Ministerio de Sanidad y Consumo of Spain are [2] M. Naczk, F. Shahidi, J. Pharm. Biomed. Anal. 41 (2006) 1523. [3] D. Ryan, M. Antolovich, P. Prenzler, K. Robards, S. Lavee, Scientia Horticulturae 92 (2002) 147.[4] Bast, Free Radical Biol. Med. 20 (1996) 331. [5] P. Janeiro, A.M. Oliveira-Brett, Anal. Chim. Acta 518 (2004) 109. [6] P. Janeiro, A.M. Oliveira-Brett, Electroanalysis 17 (2005) 733. [7] P. Janeiro, A.M. Oliveira-Brett, Electroanalysis 19 (2007) 1779. [8] P. Janeiro, (2005) Janeiro, I. Novak, M. Seruga, A.M. Oliveira-Brett, (2003) S. Nagano, T. Osakai, Y. Tsujino, Biochim. Biophys. Acta 1526 (2001) 159. [13] L. Fr\u00e9mont, 66 (2000) 663. in: Aggarwal, S. Shishodia (Eds.), Press, USA, 2005. [15] F. Orallo, Curr. Med. Chem. 15 (2008) 1887. [16] F. Borges, F. Roleira, N. Milhazes, E. Uriarte, L. Santana, Front. Med. Chem. 4 (2009) 23. [17] J.R.S. Hoult, Matos, C. Ter\u00e1n, Y. P\u00e9rez-Castillo, E. Uriarte, L. Santana, D. Vi\u00f1a, J. Med. Chem. 54 (2011) 7127. [20] L. Kabeya, A. Marchi, A. M. Pupo, Y. Lucisano- Valim, Bioorg. Med. Chem. E. Uriarte, A. Guiotto, L. Pinna, F. Meggio, S. Moro, J. Med. Chem. 51 (2008) 752. [22] F. Belluti, G. Fontana, L. Bo, N. Carenini, C. Celis, [28] Vilar, Quezada, L. Santana, E. Uriarte, M. Yanez, N. Fraiz, C. Alcaide, E. Cano, F. Orallo, E. Quezada, C. Picciau, G. Delogu, F. Orallo, L. Santana, Bioorg. Chem. Lett. 19 (2009) 3268. [31] D. Vi\u00f1a, M.J. Matos, G. Ferino, E. Cadoni, R. Laguna, F. Borges, E. Uriarte, L. Santana, Chem. Med. Chem. 7 (2012) 464. [32] D. Vi\u00f1a, M.J. Matos, M. Y\u00e1\u00f1ez, L. Santana, E. Uriarte, Med. Chem. Comm. 3 (2012) 213. [33] M.J. Matos, L. Santana, E. Uriarte, G. Delogu, M. Fadda, B. (2011) 3342. [34] B. Barroso, I. Iglesias, J. Benedi, A. Villar, Biol. Pharm. Bull. oxidation mechanism for compounds 7and9.250 P. Janeiro 472. [36] M.J. Matos, D. Vi\u00f1a, P. Janeiro, F. Borges, L. Santana, E. Uriarte, Bioorg. Med. Chem. Lett. 20 (2010) 5157. [37] M.J. Delogu, L. Santana, Uriarte, Synthesis 16 (2010) 2763.[38] M.J. Matos, S. Vazquez-Rodriguez, F. Borges, L. Santana, E. Uriarte, Tetrahedron Lett. [40] T.A. Enache, A.M. Oliveira-Brett, J. Electroanal. Chem. Janeiro et al. / Journal Electroanalytical Chemistry 689 (2013) 243-251 251 257Remarkable Pharmacy, University of Santiago de Compostela, 15782 Santiago de Compostela, Spain bCIQUP/Department of Chemistry and Biochemistry, Faculty of Sciences, University of Porto, Porto, Portugal cDepartment of Inorganic and Analytical Chemistry, Laboratory of Free Radicals and Antioxidants, Faculty of Chemical and Pharmaceutical Sciences, University of Chile, Santiago de Chile, Chile article info Article history: Received 13 December 2012 Revised 26 synthesized a series of hydroxy-3-arylcoumarins (compounds carried out. From the ORAC-FL, ESR and CV data it was concluded that these derivatives are very good antioxidants, most effective antioxidant of kingdom. Generally, group of compounds has one or more aromatic rings in their structure and one or more hydroxyl groups. They have been described to act as natural anti- oxidants and their presence contributes to prevent or benets tive phenolic substances from diet has been intensied in the last years, either for the development of nutraceutics or medicines.1 Due to their antioxidant properties they can protect cells from the oxidative damage the reactive oxygen species (ROS). In fact, have been related to cellular membrane to neuronal damage and cell death.3,4 Suggestion has been made that the etiology Alzheimer's in oxidative stress through altering the redox state of neuronal and glial cells, leading to neuronal death. 9Consequences are an over-production of MAO matter /C2112013 The Authors. Published by Elsevier Ltd. All rights reserved. http://dx.doi.org/10.1016/j.bmc.2013.04.015qThis is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, degradation products, that increased activity on D2receptors mechanism of neuroprotection of to MAO-B inhibition also to with Organic Chemistry and Medicinal Chemistry.16-23 Recently, was pharmaco- and the low cost of the commercial reagents to begin with. Also, the influence of the substituents in the desired activity taken into account. 2. and cases. Silica gel was used for flash matography was plates precoated with silica gel (Merck 60 F254, 0.25 mm). 2.1.1. General procedure for the preparation of methoxy-3- arylcoumarins mixture was heated at110/C176C for 24 h. Then, ice (100 mL) and acetic acid (10 mL) were added to the reaction mixture. After keeping it at room tempera- ture for 2 h, the mixture was extracted with ether (3 /C225 mL). The organic layers were combined and washed with sodium bicar-bonate solution (50 mL, 5%) and water (20 mL). Subsequently, the solvent was evaporated under vacuum and a solution of a methoxy-3-arylcoumarin (0.50 mmol) in ace- tic acid (5 mL) and acetic anhydride (5 mL), at 0 /C176C, hydriodic acid 57% (10 mL) was added dropwise. The mixture was stirred under reflux, for 3 h. The solvent was evaporated under vacuum and the (13), 268 (M +, 100), 241 (31), 240 (70), 239 (22), 165 (30), 125 (12), 111 (10); Anal. Calcd for C16H12O4: 269 (76), 268 (M+, 82), 241 (47), 240 (100) 239 (57), 211 (23), 166 (19), 165 (58), 152 (18), 139 (14),125 (30), 111 (28), 82 (19); Anal. Calcd 100), 241 (12), 240 (63), 239 (26); Anal. Calcd for C 16H12O4: 2H, 10.60 (s, 1H, -OH);13CN M R( 7 5 M H z ,D M S O 284 (M+, 100), 283 (84), 256 (32), 181 (10) 141 (10); Anal. Calcd for C16H12O5: C, 67.60; top, with an excitation wavelength of 485/20 nm and an emission lter of 528/20 nm. The plate reader was controlled by Gen 5 soft- ware. The reaction was carried out in 75 mM sodium phosphate buffer (pH 7.4), and 200 lL nal volume. FL (70 nM, nal concen- tration) and hydroxy-3-arylcoumarin solutions in methanol withM. J. Matos (2013) 3900-3906 3901 260a each well of 96-well plate. The mixture was pre-incubated for 15 min at 37 /C176C, before rapidly adding the AAPH solution (18 mM, nal concentration). The microplate was immediatelyplaced in the reader and automatically prior to each read- ing. The fluorescence was recorded every 1 min for 120 min. A with FL and 2,2 0-azobis(2-methylpropionamidine)dihydro- chloride ORAC values and is quantied by integrationof the area under the curve (AUC NET). All reaction mixtures were prepared in integrating where F 0is the initial fluorescence read at 0 min and Fis the fluorescence read at time. The net AUC corresponding to the sample was calculated by subtracting the AUC corresponding to the blank. Data processing was performed using Origin Pro 8 SR2 (Origin Lab Corporation, (9.7 GHz) using a Bruker ECS 106 spectrometer with a rectangular and 50 kHz eld modulation, gain ms. and the control reaction at the same time, and is expressed as scavenging percent of To prepare the 150 lLo fN,N-dimethylformamide (DMF) and 50 lL of NaOH (3 mM) were mixed, followed by the addition of 50lL of 5,5-dimethyl-1-pyrroline- trap 50 lL of hydrogen peroxide 30%. The mixture was put in an ESR cell and the spectrum was recorded after ve minutes of reaction. All the compounds were studied to 4 mM nal concentration (300 antioxidant-radical reaction. All the reaction mixtures contained 1.0 mM of DPPH and 1.0 mM of the studied compound. The control solution was prepared in absence of the studied com- 0.95 G, receiver gain 59 db, time constant ms and conversion time 40.96 ms. The and the control reaction at the same the working electrode. The electrode a mirror nish with alumina tip was used as a ref- erence electrode. of (10 nal volume). Finally, the antioxidant activity was as- sessed from the change in the cathodic current of the voltammograms in absence and present of the derivatives, using pertinent using GraphPad Prism 5 software (GraphPad Software, Inc., San Diego, CA). The data are ex- pressed as means \u00b1 SD. The experimental data were analyzed by one-way analysis of level of signi- cance was set at p<0.05, and all experiments were replicated 3 times. . The general reaction con- ditions and the characterization data of the new compounds were described in section. E fluorophore, this case fluorescein peroxyl of fluorescence of FL generally corresponds to an induction time and is reliant on antioxidant capacity of a compound. In fact, it refers to the time in which the FL is protected against the oxidative damage of peroxyl radicals and this behavior is associated to a competitive reaction between the radical and the antioxidant. 46,47ORAC data take into account the induction time,3902 M. J. Matos et al. / Bioorg. Med. Chem. 21 (2013) 3900-3906 261initial rate The ORAC-FL prole, intensity of fluorescence at 528 nm versus the incubation time was obtained for all derivatives. shows against in presence increasing concentrations of com- 9. It was obtained a prole of fluorescence measure at 528 nm versus the incubation time at different concentration, for all derivatives.In order to study the NaOH + H lines, due to the DMPO-OH adduct formation, as it is shown depicted 2 (black line). spectra decreases when the hydroxy-3-aryl- coumarin derivatives were added into the system. For compound 9, 100% of scavenging of hydroxyl radicals was obtained (Fig. 3 \u2014black line). type of response was observed for all derivatives, reflect- radical 1 or is the DPPH and peroxyl radicals (the - O H 2:R=6 - C H 3;R1=3 ' - O H 3:R=6 - C H 3;R1=2 ' - O H 4:R=6 - C H 3;R1=3 ' , 4 ' - O H 5:R=8 - C H 3;R1=3 ' , 4 ' - O H 6:R=8 - C H 3;R1=3 ' , 5 ' - O H 7:R=8 - C H 3;R1=3 ' , 4 ' , 5 ' - O H 8:R=8 - O H;R 1=4 ' - C H 3 9:R=8 - O H;R 1=4 ' - O HR or R 1=O C H 3i ii Scheme 1. and conditions: 27.7 17.4 2 6.7 5.2 3.4 17.5 3 8.4 100 10.6 25 4 5.3 6.05 28.3 28.9 5 5.7 100 66.7 77.3 6 5.5 75 11.2 22.6 7 5.3 100 100 76.5 8 6.3 16 28.6 17.4 9 13.5 double-integral ESR for the rst line of samples in the and absence of the absence of the studied compounds and Ipc aox is the cathodic current in the presence of the studied compounds. cData collected from Ref. 45. 1. ORAC-FL protection FL probe against peroxyl radicals) for compound 9.M. J. Matos et al. / Med. Chem. 21 (2013) 3900-3906 3903 room temperature (25 /C176C). Then, the voltammetric performance of the nine compounds was studied, one by one, in DMSO and TBAP0.1 M. The resultant CV responses In of the application for ND 120 and nM.28On the other hand the recent medicinal chemistry paradigms drugs, to combat this type of multifactorial diseases prompted us to look for other properties for this type of coumarins. Based on this data, a new family of derivatives sharing the same scaffold and type of substituents and synthesized. the goals. From concluded that the antioxidant scavenging activity is related in the 3-arylcoumarin skeleton. Compound 9was found to be the most interesting coumarin of the series. This compound has two hydroxyl groups in its structure, one at position 8 and another at position 40of the 3-arylcoumarin scaffold. The line) and for adduct DMPO-OH compound 2(black line). 9(black line). signal from at room temperature, with scan rate of 30 mV/s.3904 M. J. Matos et al. / Bioorg. Med. Chem. 21 (2013) 3900-3906 their structure a methyl group position 6 of the coumarin moiety and a hydroxyl group in the 3-aryl ring. The ORAC-FL indexes are 6.1 and 8.4, respectively, but the position of the hydroxyl group in the exocyclic aromatic ring seems to influence on the hy- droxyl radical scavenging capacity (100%, in cases). these Compounds 5and7have at position 8 of the coumarin moiety, and two or three hydroxyl groups, respectively,in the ring. Both respectively) proving that the presence of the extra hydroxyl group does not seem is 66.7% for compound 5and 7. Compounds 2,4and 8, with for compound 1(40-hydroxy substituted), it can be concluded that the presence of two hydroxyl groups led to the decline in the ORAC-FL in the ORAC-FL index (from 6.7 to 5.3), caused by the presence of two hy- droxyl groups pattern, changing only the methyl to8. This modication 28.9% to 77.3%). Compound 6, with a methyl group at position 8 of the coumarin moiety and two hydroxyl groups at positions spite 5,7and9presented good trends against all the studied radicals. From the obtained data, it is also all the couma- rin derivatives possess with those to be can be observed that no violations number donors and acceptors) were found. This is important information the promising potentialof these derivatives. All as novel antioxidants. 5. remarks antioxidant proles were to be the most interesting molecule of the whole series, with an ORAC-FL of 100% of very interesting notice that compound 7also presented good trends all the Molinspiration calculation software.50M. J. Matos et 21 (2013) 3900-3906 3905 264Fulbright doctoral stay fellowships and Vazquez-Rodriguez de Educaci\u00f3n y notes 1.Guardado-Yordi, J.; E. and Health ; ,40, 413. 3.Hamdi, N.; Puerta, C.; Valerga, 10. Shoham, S.; Youdim, M. B. Cell M. B.; Fridkin, M.; Zheng, H. M.; Atia, A. S.; Abdelsalam, R. M. Sherer, T. B.; Greenamyre, J. Roleira, N.; Uriarte, E.; 2006 ,16, 257. 19. Kostova, I. Curr. HIV Res. 2006 ,4, 347. 20. De J. J. Med. 1486. 21. Vi\u00f1a, D.; Matos, M. J.; Y\u00e1\u00f1ez, M.; Santana, L.; Uriarte, Janeiro, Santana, ,54, Chem. Lett. 33. Kostova, I. Med. Chem. 34. Buu-Hoi, N. P.; Eckert, B.; Royer, R. J. Org. M.; Acta - Gen. Subjects 1999 ,1427,1 3. 37. Jin, Z.-Q.; Chen, X. J. Pharmacol. Toxicol. Methods 1998 ,39,6 3. Suvarna, S. Phys. C: Supercond. 1997 ,276,6 5. 39. S\u00e1nchez-Moreno, C. Food Sci. Technol. Int. 2002 ,8, 121. 40. Brand-Williams, W.; Cuvelier, M. E.; Berset, C. Food Sci. L.; Banks, J. T.; Ingold, K. U.; J.; J. Chem. 2002 ,50, 1619 . 44. Ahmed, S.; Shakeel, F. Pak. J. Pharm. Sci. 2012 ,25, 501 . 45. Ou, B.; Hampsch-Woodill, M.; Prior, R. L. Food 4619 . 46. Niki, E. Radic. Med. . Bisby, R. H.; Brooke, R.; Navaratnam, Spectrosc. 2007 ,67, 230 . 50. M cheminformatics, Bratislava, Slovak Republic, http://www.molinspiration. com/services/properties.html Lipinski, C. A.; Lombardo, F.; Dominy, B. W.; Feeney, P. J. Adv. Drug Delivery Rev. 1997 ,23,3. 52. Ertl, P.; Rohde, B.; Selzer, P. J. Med. Chem. 2000 ,43, 3714 .3906 M. J. Matos et al. / Bioorg. Med. of Pharmacy, University of Santiago de Compostela, 15782 Santiago de Compostela, Spain 2Department of Biomedical Informatics, Columbia University Medi cal Center, New York, NY 10032, USA 3Department of Pharmacology, Center for Research in Molecular Medicine and Chronic Disease, University of Santiago de Compostela, 15782 Columbia University Medi cal Center, New York, NY halogenated 3-arylcoumarins were performed with the aim of selectivity to with IC 50 values on the low-nanoMolar (compounds 6, 7, 10, 16, 17, 20 and 23) and picoMolar range (compounds 5, 8, 9, 11, 12, 14 and of the active compound, being several times more active than selegiline and of the PD is the second most common neurodegenerative disease in the western countries and up to now it cannot be cured. The disease is characterized by dopaminergic in the substancia nigra pars loss of (DA) of PD exists, in treatment, the missing DA is still replaced, without targeting the progress of neurodegeneration and is still widely used, but recently approaches have been done to combine pharmacophoric features addressing several peripheral tissues.10 In humans, two subtypes of to phenylethylamine and benzylamine.11,12 On the other hand, DA and tyramine are common substrates for both isoforms. The enzymatic isoforms have been they an important role in the inactivation of ne urotransmitters and if a (clorgyline and moclobemide) are used in the treatment of depression and an xiety,18 while M AOI-B (selegiline and and (selegiline in selective hMAO-B discovery levels of this isoenzyme in neuronal tissue increase 4-fold with age, resulting in an increment of DA as well as production of hydrogen peroxide (H2O2), cause oxidative stress, and role in the etiology of neurodegenerative diseases.21 with different structural Additionally, the des cription of the crystal str ucture of the two MAO isoforms by Binda et al. has provided relevant information abo ut the selective interactions and potent and sele ctive inhibitors.30-34 Due to the presence of MAO in the brain cells, MAOIs must be able to achieve and cross the blood- brain barrier (BBB), which prevents the access of polar molecules to the brain. The distribution of the compounds between blood and brain is a very important consideration tool.35 Due to the above described, in the last few years, a broad consensus has been reached concerning the necessity for the research and less toxic MAO-B selective inhibitors. 270Coumarin is can be found in several plants like tonka bean, vanilla grass and sweet woodruff.36 Derivatives of this benzopyrone are of pharmaceutical interest because they have been showing different biological activities.36 Works have been done mainly determined by the nature of the linkage and as - present 3- arylcoumarins (coumarin -stilbene derivatives to AO-B isoenzyme. 54-63 These synthesize and study the MAO inhibitory activity of new analog ues, in which a variety of gro ups wit h different si ze, electronic and lipophilic properties were introduced in the pattern in 3- MAO a ctivity, do interesting results, our research group is still looking for more active and selective M outlined in Scheme 1. The detailed chemical structures of t he compounds are organized in Table 1. The general reaction conditions and t he compounds characterization are described experimental section. 5-8 and treatment of 7 and acidic 272hydrolysis of the respective methoxy and 15, using hydriodic a cid 57% in the presence of acetic acid and acetic anhydride .56 Finally, the Williamson OR O OOR4' O OOR4' OR2'R3' R4' 1 R = R 2' = R 3' = R 4' = H 2 R = CH 3 , R2' = R 3' = R 4' = H 3 R = OCH 3 , R2' = R 3' = R 4' = H 5 R = CH 3 , R2' = R 3' = H , R 4' = CH 3 6 R = CH 3 ,R2' = R 4' = H , R 3' = CH 3 7 R = CH 3 , R2' = R 3' = H, R 4' = OCH 3 8 R = CH 3 , R2' = R 4' = H, R 3' = OCH 3 11 R = CH 3 , R2' = R 3' = H, R 4' = Br 12 R = CH 3 , R2' = R 4' = H, R 3' = Br 13 R = CH 3 , R2' = Br , R 3' = R 4' = H 14 R = OCH 3 , R2' = R 3' = H, R 4' = Br 15 R = OCH 3 , R2' = R 4' = R 2' = R 3' = R 4' = Hii Scheme 1. Reagents and conditions: (i) ctivity was investigated by the Red MAO kit Oregon, Spain).69 The production of H 2O2 catalyzed by the two isoforms can (Amplex Red reagent), sensitive probe t hat reacts with H2O2 in the presence of horseradis h peroxidase to prod a indicates these drugs do not interfere with t he measurements. On the other hand, in our experiments and under our experimental conditions, hMAO-A displayed a Michaelis constant (Km) equal \u00b5M and a maximum reaction velocity (Vmax) 220.33 \u00b1 32.80 \u00b5M and V max of 24.32 \u00b1 H H H H * 11. 81\u00b10. 80 M > 8.5c 2 CH3 H H H * 283. 75\u00b119.9 0 nM > 352c 3 OCH3 H H H * 413. 25 \u00b1 6 0.50 nM > 242c 4 OH H H H 2 9.89 \u00b1 2.02 \u00b5M 3.39 \u00b1 0 .23 \u00b5M 8 .8 5 CH3 H H C H3 * 310.0\u00b120. 0 pM > 333,333c 6 CH3 H C H3 H ** 15. 01\u00b10. 83 nM > 6,667c 7 CH3 H H OCH3 * 1 3.05\u00b10.90 nM > 7,663c 8 CH3 H OCH3 H * 800. 0\u00b150. 0 pM > 125,000c 9 CH3 H Br OCH3 * 740. 10 H OCH3 Br * 3.25\u00b10. 387.04\u00b125.96 pM 12 H 1 34.04\u00b18.99 pM > 746,045c 13 CH3 Br H H * 4 .34\u00b10.29 M > 23c 14 OCH3 H H Br * 320.0\u00b10.17 pM > 312,500c 15 OCH3 H Br H * 650.0\u00b10.35 pM > 153,846c 16 OH H H Br 12 .83\u00b10.66 M 32.0\u00b11.7 nM 387 17 OH H Br H * 8 .0\u00b10.43 nM > 12,500c 18 C3H5O2 H H Br * ** - 19 C5H9O H H Br * 7 .02\u00b10.3 8 M > 14c 20 C2H2O2Cl H H Br 12.66 \u00b10.84 M 47 nM 1,80 9 27521 C3H5O2 H Br H * 1 .48\u00b10. 079 M > 68c 22 C5H9O H Br H 44.29\u00b12.40 M 1 .79\u00b10.096 M 25 23 C2H2O2Cl H Br H * 2 .4\u00b10.14 nM > 37,037c Selegiline - - - - 67.25\u00b11. 02 \u00b5M 1 9.60\u00b10.86 nM 3,431 Ipronia zide - - - - 6.56\u00b10.76 7 .54\u00b10.36 \u00b5M 0 .87 a Each IC50 value is the mean \u00b1 S.E.M. from five e xperiments (n = 5). * Inactive at 100 \u00b5M reference c Values obtained under the assumption that the 50 against M AO-A is nervous system (CNS) should be able to cross the BBB to reach the therapeutic target. It has been shown that compounds with logBB (logarithm of the ratio of the concentration of the compound in the brain and in the blood) <-1 are poorly distributed in the brain while molecules with logBB>0.3 can cross readily the BBB.70,71 The distribution of the compounds 1-23 between the blood and the brain was calculated through a discriminant equation extracted section). the equation (1). If the result in the equation is >0 the compounds are 276predicted to have a logBB 0.3 which means that the compounds readily cross the BBB.70 If the result is <0 the compounds could still cross the BBB but with logBB<0.3. Although two different models with cut-off of 0.3 and -1 were recently published,35 only the equation using the threshold of 0.3 was used since all the compounds were predicted to cross readily the BBB (see Table 2). In order to better understand t he overall properties of t he described out 2. Molecular Descriptors Equation (1) and logBB Prediction for the 27 + 1 0 1 0 -4.55 6.63 222. 24 2 4.216 26.300 1. 100 + 1 0 1 0 -5.02 7. 08 236. 27 3 3.874 35.530 0.66 8 + 2 0 1 0 -4.60 7. 27 252. 27 4 3.61 46. 530 0. 227 + 2 1 1 0 -4.19 6.76 238.24 5 4.514 26.3 00 1. 254 + 1 0 1 0 -5.50 7. 52 250.3 0 6 4.551 26.3 00 1. 273 + 1 0 1 0 -5.50 7. 52 250.3 0 7 4.172 35.530 0. 822 + 2 0 1 0 -5.07 7. 72 266.3 0 8 4.209 35.530 0. 841 + 2 0 1 0 -5.07 7. 72 266.3 0 9 5.005 35.530 1. 252 + 2 0 1 0 -6.16 8.47 345.19 10 5.005 35.530 1. 252 + 1 0 -6.16 8.47 345.19 11 5.014 26.3 00 1. 512 + 1 0 1 0 -6.11 7. 82 315.17 12 5.051 26.3 00 1. 531 + 1 0 1 0 -6.11 7. 82 315.17 277 logP(o/w) = log of violations = log sol published,57 complex 7-(3-chlorobenzyloxy)-4-carboxaldehyde-coumarin (PDB: 2V60)67 was used to dock the compounds under study. Water molecules were deleted with the exception of the water molecule establishing a hydrogen bond with for a detailed description). To validate the docking protocol we used the co-13 5.012 26.3 00 1. 511 + 1 0 1 0 -6.11 7. 82 315.17 14 4.672 35.530 1. 080 + 2 0 1 0 -5.69 8.01 331.16 15 4.709 35.530 1. 099 + 2 0 1 0 -5.69 8.01 331.16 16 4.408 46. 530 0.639 + 2 1 1 0 -5.28 7. 50 317.14 17 4.445 46. 530 0.6 58 + 2 1 1 0 -5.28 7. 50 317.14 18 4.353 52.6 00 0. 442 + 3 0 1 0 -6.03 9.02 373.20 19 6.209 35.530 1. 873 1 -6.65 9.67 385.26 20 5.077 52.6 00 0. 816 + 1 0 -6.84 9.06 393.6 2 21 4.39 52.6 00 0. 462 0 1 0 -6.03 9.02 373.20 22 6.246 35.530 1. 892 1 -6.65 9.67 385.26 23 5.114 52.6 00 0. 835 393.6 coordinates the calculated and crystallized poses was evaluated 4a). Between the Most carried out also for of the synthesized series in the hMAO-B, although two of the most active compounds with substitutions at 6 position of the coumarin ring and meta or para positions in the 3-aryl ring were 279considered representative of the study (compounds 12 and 14, see Figure 4b-4d). The most favourable poses according to score Emodel were for all the compounds. As it reported previously this type docking that the oriented toward the bottom of the binding pocket in 15 out of the 23 docked coumarin derivatives. This fact showed the described binding conformation (see phenyl the FAD cofactor, Tyr60, Tyr398, 3-aryl the entrance cavity, establishing for compound 12 (the best compound of the presented series) hydrophobic and van mode for the compounds 12 and 14 also showed that the ligand conformations are stabilized by a hydrogen bond between the Cys172 and the oxygen in the carbonyl group of the coumarin ring. However, the hydrogen bond is not optimum to the Cys172 also interacts through an intramolecular hydrogen bond with the Leu171 Ile199 establish arene-H ligands also the described protocol to analyze the binding mode of this type of coumarin derivatives. the most stable ligand conformation could be highly dependent on the nature of the substituents in the 3-aryl ring as well as the coumarin in the hMAO-B (PDB: 2V60) and the most stable pose retrieved by the docking calculation (red color). The FAD cofactor is colored in yellow and the water molecule in blue. b) Comparison of the most stable binding modes for the compounds 12 and 14 (colored by element, grey carbons) against the co- crystallized compound c17 in the crystal hMAO-B (colored by element, green carbons). c) Analysis of the most stable pose of the compound 12 into the hMAO-B pocket. The hydrogen bond between Cys172 and the oxygen in the carbonyl group along with the arene-H interactions with Leu171 ligand. Leu328 and Pro104 (red color) interact with the compound 12 through hydrophobic forces. Residues that establish both hydrophobic and van der Waals interactions with the ligand are colored in orange. d) Most stable binding mode for the compound 14 in the hMAO-B. The hydrogen bond between Cys172 281and the coumarin along the arene-H interactions in white. binding residue property: red and the hydrophilic residues are colored in green. In this str ucture 2Z5X to dock t he compound 11 that showed low hMAO-A a ctivity. Water molecules within 5 \u00c5 t co-crystallized ligand were retained in the The RMSD the harmine was 0.49 \u00c5. The compound 11 was placed in a similar area as the co-crystallized ligand (see Figure 5a). However, unlike the harmine ligand, he pose for compound 11 determined by do cking did not s how any hydrogen bond contacts wit h any water molecules. This could the difference of hMAO-A a ctivity between compounds. To further st udy the hMAO-A a ctivity, compound 20 was also investigated by do cking. No water molecules were retained in the cavity due to the larger size of the compound. The docking pose is in agreement with t he previous calculation (see Figure 5b). However, oxyacetyl chloride 6 in cavity. Although t his conformation should have to displace some water molecules present in the crystal str ucture that establish an important H- bond network with t protein be establis hed a t he Tyr197 that could stabilize the ligand conformation (see Figure co-crystallized and the pose retrieved by the interactions yield H-bond interactions. b) Comparison of the binding modes compounds 11 (pink carbons) and 20 (aquamarine carbons) in the hMAO-A. The carbonyl group in the oxyacetyl chloride chain at position 6 of t he compound 20 establishes an H-bond with t he residue Tyr197. Discussion All des well as the help us physicochemical des criptors, of the BBB cross was carried out and the res ults also encouraged us to e xplore the potential of chemical family as drug candidates. All the compounds 1-23 were predicted to readily cross the BBB a ccording to t he theoretical model. The model is very simple and explains t he BBB crossing through passive diff usion without into account other phenomena, transport mechanisms of p umps. partition coefficient and polar surfa ce area as good des criptors to e xplain this property.70,73,74 In addition, other have been calculated. Although many drugs in the market have a logS greater than -4 our compounds still present acceptable ranges of sol ubility with an average logS=- 5.7. In addition, it can be observed found for almost all t he compounds (21 from 23). As MAOIs have to pass different membranes and reach the CNS, this supports the potential of derivatives as dr ug candidates. From the experimental results it can be observed t hat most range In fact, only IC50 against hMAO-B selegiline (IC 50 = 19.60 nM, . Thus, compounds 5, 8, 9, 11, 12, 14 and 15 proved to in hibit selectively the B isoform of hMAO xtremely good a hMAO-B a ctivity (IC 50 \u00b5M) in the same range of ipronia zide (IC = 284times more selective than this reference compound. This was t he inspiration to continue with t he synthesis of new derivatives presenting t his scaffold. The presence of one methyl group at position 6 (compound 2) increased the hMAO-B a ctivity forty times, maintaining t he excellent selectivity (IC50 hMAO-B = 284 nM). The presence of a methoxyl group at the same position afforded compound 3, which s howed similar M AOI-B a ctivity to compound 2 (IC 50 hMAO-B = 413 nM). The hydrolysis of that methoxyl group into a hydroxyl one (compound 4) resulted in a signifi cant loss activity against hMAO-B (IC 50 = 3.39 M). Nevertheless, compound 4 was still better M AOI-B t han the non- substituted 3-phenylcoumarin (compound 1). According to t his data, derivatives s ubstituted at position 6 were explored in the current work. According to previo us work,54-61 it was the very interesting profile of compound 9, with a methoxy group at position 4 and a bromine atom at position 3 of the 3-aryl group, which made us have a special interest for t he bromine derivatives . Also us t para positions favourable points to s ubstitute. Therefore, further experimental work was developed ta king this information into a ccount. Four of the most active compounds are the new coumarin derivatives 11, 12, 14 and 15, with IC50 against hMAO-B between 134 and 650 pM. Compounds 11 and 12 present a methyl group at position 6 of the scaffold, changing only the position of bromine atom lin ked in the 3-aryl ring, w hereas compounds 14 and 15 have the same substitution pattern. In this case position 6 is substituted wit h a methoxy group, and presented respe 3- aryl ring. Comparing the presence of a methyl group (compounds 5 and 6) or a methoxy group (compounds 7 and 8) in the 3-aryl ring, keeping the same scaffold, wit h the compound 11 and 12, presenting a bromine atom at t he same positions, it can be observed a general improvement of t he activity. So, we can infer that the presence of an electron withdrawing atom (bromine atom) instead of an electron donating gro up (methyl methoxyl) decided to deeply explore the importance of the nature of the substitution at position 6. Eight new derivatives (compounds 16-23) have been synthesized wit h the ucing gro ups wit h different physicochemical properties at position 6 of the coumarin moiety. Compounds and 17, obtained by hydrolysis of derivatives 14 and 15, only a slight loss of a ctivity. These still good candidates, with IC50 values against hMAO-B 32 and 8 nM, respectively. Having these hydroxyl derivatives as starting materials, to obtain ults did not significantly but it was fo und some interesting data. Either the 6-(2-oxopropoxy) derivatives 18 and 21, or the 6-(cyclopentyloxy) derivatives 19 22, lost sele ctivity against hMAO-B. Compounds only one chlorine atom more, respe cting to compounds 18 profile, wit hMAO-B nM . Nevertheless, compound 20 presenting the bromine atom in para position, lost both potency and selectivity against this isoform. To better understand t he experimental results, and to s upport general binding conformation for the coumarins under study in the hMAO-B pocket that orientates the coumarin ring towards the FAD This fact is in accordance with t he observation that small s ubstituents at position 6 are better than bulky An increase of the position 6 in the showed a loss of hMAO-B a ctivity probably due to the lack of spa ce in the binding cavity with a possible disruption of t he proposed mode and hift of n ucleus towards t he hydrophobic cavity. On the to establish hydrogen bonds, s hift of the coumarin ring towards t he cofactor with the consequent disruption of some hydrophobic interactions the cavity. In fact, docking analysis of the compounds 16 and 17 with a hydroxyl substituent at position 6 s howed the possibility of establis hing a hydrogen bond with t he FAD cofactor favourable for the compound binding but causing at the same time a de crease in the hydrophobic interaction contribution by t shown by compounds 1 and 2 against the hMAO-B (IC 50 values are 11.81 and 0.284 M respectively). The docking retrieved a pose for compound 1 slightly shifted towards the FAD that could diminish t he contribution of the hidrophobic interactions to the binding with t he entran ce cavity. However, the coumarin ring for compound 2 is placed in a very similar manner as the compounds 12 and 14, shown in Figure 4, that allows a better fit for t he 3- aryl that ortho position the 3-aryl ring, such s howed an IC50 = 4.34 compound was recently reported Contrarily, polar s at meta and para positions are not as appropriate for t he activity as hydrophobic s ubstitutions. This fa ct corroborates t he information that was also recently reported by o ur research group.57 Selectivity of to recognize the pocket in hMAO-B w hereas a more limited binding has been fo und against the hMAO-A. On one hand, compound 11 did not s how H-bond interactions with hMAO-A. On the other hand, and alt hough compound 20 showed the capability of s hifting some water mole cules placed deeply in the cavity through t he establishment of an H-bond with Tyr197, this overall pro binding of the studied study, a general and effi cient synthesis of a new series of 3-arylcoumarins was developed using the Perkin, hydrolysis hMAO isoform selectivity the hMAO-B isoenzyme range of nano and picoMolar concentrations . Compound 12 is more than 6000 times more active and more than 200 times sele to establis interaction between the studied compounds and the great potential of this type of compounds to cross the BBB and acting in the CNS. The res ults encourage to f urther explore the potential of this chemical family as dr ug candidates for the treatment of Parkinson's disease. chromatography was on plates precoated with silica gel (Merck 60 F254, 0.25 mm). The purity of the compounds ) on an Agilent Technologies 1200 a G1311A quaternary pump. Instrument software Agilent ChemStation LC systems was used for data acquisition. Different analyti cal columns and mobile phases (all solvents were HPLC grade) were tested. The mobile H 2O:CH 3CN=70:30 and Eclipse used. The purity of the compounds was fo und to be 95%. General P rocedure for the Preparation of 3-Phenylcoumarins 1-3, 5-8 and 11-15. and heated in an oil-bath at 110 \u00baC for 24 h. Ice (100 mL) and acetic acid (10 mL) were added to the reaction mixture. After keeping it at room temperature for 2 h, the mixture was extracted with ether (3 x 25 mL). The organic layer was extracted with sodium bicarbonate solution (50 mL, 5%) and then water (20 mL). The solvent was evaporated under vacuum and the dry residue (99), 315 ([M + 1]+, 19), 314 (M+, 100), 288 (34), 287 (22), 286 (34), 285 (17), 179 (17), 178 (36), 152 (9), 118 (14), 89 (11), 76 (12). Anal. Calcd for C 16H11BrO 2: C, 60.98; 315 ([M + 1]+, 19), 314 (M+, 100), 286 (34), 285 (17), 179 (17), 178 (36), 152 (9), 118 (14), 89 (11), 76 (12). Anal. Calcd for C 16H11BrO 2: (99), 331 ([M + 1]+, 17), 330 (M+, 100), 304 (14), 302 (14), 261 (11) 259 (11), 180 (12), 152 (55), 126 (20), 76 (11). Anal. Calcd for C 16H11BrO3: C, 58.03; H, (99), 331 ([M + 1]+, 18), 330 (M+, 100), 304 (14), 302 (14), 180 (14), 152 (44), 126 (16). Anal. Calcd for C 16H11BrO3: C, 58.03; H, 3.35. Found: C, 58.07; H, 3.40. General P rocedure for the Preparation of 3-(Bromomethoxyphenyl)coumarins 9 and 10. A solution of 3-(methoxyphenyl)coumarins or 8, 3.76 mmol), NBS (4.51 mmol) mL) was stirred under refl ux for 18 h. The res ulting solution was filtered to remove the succinimide. The 41% General P rocedure for the Preparation of Hydroxy -3-phenylcoumarins 4, 16 and 17. A solution of substituted 6-methoxy-3-phenylcoumarin (3, 14 or 15, 0.50 mmol) in acetic a cid (5 mL) and acetic anhydride (5 mL), at 0 \u00baC, was prepared. Hydriodic a cid 57% (10 mL) mixture was stirred, under refl ux h. solvent was evaporated under vacuum and the dry resid ue was purified by CH 3CN crystallization 317 ([M + 1]+, 19), 316 (M+, 100), 290 (58), 288 (60), 181 (19), 153 (12), 152 (44), 126 (15), 118 (11), 76 (14). Anal. Calcd for C15H9BrO3: C, 317 ([M + 1]+, 18), 316 (M+, 100), 290 (55), 288 (57), 181 (27) 153 (17), 152 (50), 151 (13), 126 (16), 119 (17), 76 (14), 71 (15), 69 (12), 57 (24), 55 (16). Anal. Calcd for C 15H9BrO3: C, 56.81; H, 2.86. Found: P rocedure for the Preparation of 6-(2-Oxopropoxy)-3-phenylcoumarins 18 and 21. To a suspension of anhydrous K2CO3 (16 or 17, suspension was stirred, at ux temperature, for 16 cooled and the precipitate was recovered by filtration and was hed with anhydrous acetone (3 x 40 mL). The solvent was evaporated under vacuum and the dry resid purified by FC 374 (100), 373 ([M + 1]+, 73), 372 (M+, 99), 332 (28), 331 (87), 330 (30), 329 (88), 302 (28), 301 (54), 245 (31), 164 (48), 163 (78), 152 (84), 151 (19), 126 (48). Anal. Calcd for C18H13BrO 4: C, 57.93; H, 373 ([M + 1]+, 21), 372 (M+, 100), 331 (43), 329 (43), 301 (15) 273 (10), 164 (17), 163 (31), 152 (30), 126 (13). Anal. Calcd for C 18H13BrO 4: C, 57.93; H, 3.51. Found: C, 57.88; H, 3.47. Preparation of 6-(2-Cyclopentyloxy)-3-phenylcoumarins 19 and 22. To a suspension of anhydrous K2CO3 (0.25 mmol) and the The suspension was stirred, reflux temperature, for 24 h. The was and was recovered by filtration and washed with anhydrous acetone x 40 mL). The solvent was evaporated under vacuum and the dry residue was purified by FC (hexane/ethyl acetate 9:1) 385 ([M + 1]+, 6), 384 (M+, 25), 319 (22), 318 (100), 317 (24), 316 (99), 290 (41) 288 (42), 181 (11), 152 (38). Anal. Calcd for C 20H17BrO3: C, 62.35; H, 385 (M 292+ 1]+, 12), 384 (M+, 45), 319 (19), 318 (100), 317 (22), 316 (100), 290 (27) 288 (27), 152 (11). Anal. Calcd for C 20H17BrO3: C, 62.35; H, H, 4.39. of anhydrous K2CO3 (0.25 mmol) and the suspension was ux temperature, for 24 h. mixture cooled and t he precipitate was recovered by filtration and was hed with anhydrous acetone (3 x 40 mL). The solvent was evaporated under vacuum and the dry by 10), 392 (M+, 50), 319 (14), 318 (82), 317 (15), 316 (82), 297 (11) 295 (11), 290 (42), 288 (43), 216 (13), 214 (13), 181 (16), 172 (48), 171 (26), 170 (50), 169 (24), 152 (30), 126 (24), 118 (11), 90 (20), 89 (13). Anal. Calcd for C 17H10BrClO 4: 10), 392 (M+, 50), 391 (17), 390 (86), 389 (17), 388 (86), 319 (16), 318 (99), 317 (29) 316 (100), 315 (13), 290 (53), 289 (19), 288 (54), 181 (21), 153 (17), 152 (60), 126 (23), 119 (16). Anal. Calcd for C 17H10BrClO 4: M, 2937.4) containing different experimental conditions t he same reaction velocity, i .e., to oxidize (in the control group) t he same concentration of substrate: 165 pmol of incubated in a flat -black-bottom 96-well microtest plate, placed in the dark fluorimeter chamber. After this incubation period, the reaction was started by adding (final concentrations) M Amplex Red reagent, 1 U/mL horseradis h peroxidase and 1 mM p-tyramine. The production of H 2O2 and, consequently, of resorufin was quantified at fluorescence generated (excitation, 545 nm, emission, 5 90 nm) over a 15 min period, in w hich the fluorescence increased linearly. Control experiments by drugs to solutions only the Amplex Red reagent a sodium phosphate To determine the kinetic parameters of hMAO-A and hMAO-B (Km and V max), corresponding enzymatic a ctivity of both isoforms was evaluated (under the experimental conditions des cribed above) in the presence of a number was after subtraction of the background activity, replaced by a sodium phosphate buffer solution. In our experimental conditions, t his background activity was pra the theoretical logBB (the logarithm of the ratio of the concentration of the compound in brain and in blood) was described with more detail in a previous publication.41 protonation was established with Ionizer at pH 7. After calculating the of compounds used in the training set of t he model developed to extract the discriminant equation, U is the Wilks\u00b4statistic, F is the Fisher ratio and p is the significance level. If the result in the equation is >0 the compounds are predicted have a that compounds cross If the result the compounds cross the blood-brain but logBB<0.3. Calculation of other pharmacophore atom counts were with the ligand Hydrogens were added through this procedure and minimized with the OPLS_2005 force field were constrained. Hydrogen bonding was carried out of hydroxyl groups, the water molecule and amide groups of Asn and Gln residues. Protonation of Receptor grid generation: A calculated using a van der Waals scaling factor of 1.0 with a partial charge cut-off of the ligands were docked poses retained. Next, polarization of the ligand the receptor calculated. Ultrafine SC level are carried out to determine the partial charges on the ligands atoms inside t he protein pocket. In the third step, t he ligands were redo cked with t he new charges using Extra Precision (XP) mode and t hree poses were retained for ea ch ligand . Ligands van der Waals s caling was 0.8. The selection of the final pose was made taking into account the energy score E model hMAO-A: Similar treatment was carried out for de Galicia (09CSA030203PR, PGIDIT07PXIB, 10PXIB203303PR) and Ministerio de Sanidad y Cons umo (FIS PS09/00501) for financial support. Maria Jo\u00e3o Matos t hanks Funda\u00e7\u00e3o para a Ci\u00eancia e Tecnologia for the fellowship (SFRH/BD/61262/2009). Santiago Vilar thanks the Angeles Alvari\u00f1o program from Xu nta de Galicia (Spain). REFERENCES (1) study. mechanism of (5) Bilen, J.; Bonini, N Drosophila as a model for human neurodegenerative disease. Annu. Rev. Genet. 2005, lore. Clevel. Clin. J. Med. 2012, 77, 859-882. Enzymology Amsterdan, 1982, pp. 97. (c) Singer, T. P. In Chemistry and Biochemistry of Flavoenzymes ; Muller, F., Ed.; CR C Press: Boca Raton FL, 1991; specifi c recognitions for substrates and in hibitors. 1990, 47, 391-417. (13) Bach, A. W. J.; Lan, N. C .; Johnson, D. L.; Abell, C. W .; Bembenek, M. E.; Kwan, Seeburg, 1998, 5, 137-162. (15) N. C .; Neve, R.; Chen, K.; Shih, J. C . Tissue distribution of human monoamine oxidase A and B mRNA. J. Neurochem. of its catalytic site and mechanism. Med. Res. Rev. 1995, 15, 325 (17) Geha, human monoamine oxidase A and B are influenced by a single amino acid. J. Biol. Chem. 2001, 276, 9877- V. Z. comparative review of t he clinical pharmacology therapeutic use of the \"newer\" vers J . Monamine oxidase Selegiline a long randomized placebo-controlled trial. C zech and slovak senile dementia of Alzheimer type study group. J. Psychiatr. Neurosci. 1999, 24, 234-243. (23) Annan, N.; Silverman, R. B. New analogs of N-(2-aminoethyl)-4-chlorobenzamide (Ro inhibitors based on t he 5H- indeno[1,2-c]pyridazin-5-one core. J. Med. of B monoamine target for the treatment of neurological disorders . Nat. Struct. Mol. Biol. str uctures. Natl. Acad. Sci. U. S. A. 2003, 100, Colibus, to of rat and human MAO B. Proc. Natl. Acad. Sci. U.S.A. Crystal structures of monoamine o xidase B in complex with fo ur inhibitors of the N -propargylaminoindane class. J. Med. Chem. 2004, 47, 1767-1774. (34) J. cinal E.; Finton, K. A.; Le, N.; Rowe, C. Discovery of novel DNA gyrase inhibitors by high-throughput virtual as inhibitors of HIV reverse trans criptase. Current HIV 2008, 51, 752-759. (45) Timonen, a series of novel 7 -hydroxycoumarin derivatives. Eur. J. Med. nervous system agents . Patent D E plays mod ulating the inhibition oxidase B plays mod ulating the inhibition Spain. (2010), ES 2343347 A1 20100728. (55) Matos, Picciau, P\u00e9rez-Castillo, Y.; Uriarte, E.; Santana, L.; Vi\u00f1a, D. and Study of a Series of as Potent Selective Monoamine Med. (58) Matos, M. J .; V\u00e1zquez-Rodriguez, S.; Uriarte, Matos, .; Y\u00e1\u00f1ez, Santana, L.; Uriarte, E. 3-Substituted coumarins as dual 303inhibitors of AChE and MAO for the treatment of Alzheimer\u00b4s disease. Med. Chem. Commun. 2012, 3, 213-218. (60) Matos, M. J .; Vi\u00f1a, D.; Janeiro, P.; Borges, F.; Santana, L.; E.; Laguna, Borges, 1147-1152. as at 2.2 \u00c5 resolution: he entry for substrates/in hibitors. Proc. Natl. Acad. Sci. U. S. 344, 688-695. D. E. Rapid calculation of polar mole cular surfa ce area and its application to the prediction transport phenomena. 2 . Prediction J. 821. (71) Abraham, M. H.; Tak\u00e1cs-Nov\u00e1k, K.; Mitchell, R. C. On the partition of amp holytes: application to blood-brain distribution. J. Pharm. (72) J permeability: A analysis LigPrep, version 2.5, Schr\u00f6dinger, LLC, New York, NY, 2011. (76) Maestro, version 9.2, Schr\u00f6dinger, LLC, New York, NY, 2011. (77) M OE software, version 2011.10; C hemical Computing protocol; version 7.8, QSite version 5.7, Schr\u00f6dinger, LLC, New York, NY, 2011. 305 (79) Glide, version 5 .7, Schr\u00f6dinger, LLC, New York, NY, 2011. 306Table of Contents Graphic 307Synthesis and adenosine receptor of a series 1 of 3-aryl coumarin s Maria Jo\u00e3o de Universidade do Porto, 4169- 6 007Porto, Portugal 7 bDepartamento de Qu\u00edmica Org\u00e1nica, Facultad de Farmacia, Universidad de Santiago de Compostela, 8 15782, Santiago de Compostela, Spain 18 Abstract 19 20 Objectives In the present communication we report evaluation, theoretical ADME properties, compounds were evaluated stu introd in both of at 25 positions 6 and 3' or 4' of t he moiety. The lack of data on the 3-arylcoumarin scaffold 26 encouraged us to explore series he experimental data it can be observed t hat neit her the simple 30 4'-nitro derivatives binding affinity profiles, especially against the hA1/hA3 or only hA 3 AR. 33 Conclusions The most remarkable derivative is compound 2, presenting t he best 34 affinity for hA 3 AR (K i = 2,680 nM) and signifi cant selectivity a Adenosine receptors a of four different receptor subtypes: A1, A2A, 42 309A2B and A 3.[1] ARs are distrib uted throughout a wide variety of ues cked by natural 45 antagonists .[2,3] During the last years, the search for agonist and antagonist ligands 46 binding to individual AR subtypes has been intensified, as t he role of t hese receptors in 47 drug discovery is continuously expanding.[4-6] Most the AR antagonists are promising 48 candidates processes AR, the recently 51 identified s ubtype, has been the subject of intensive resear ch during the last decade as a 52 potential therapeutic target in preventing ischemic damage in the brain and heart.[11] In 53 addition, as the A3 AR is expressed in relatively high densities in the lung, liver, 54 neutrophils, macrophages and glial cells, it can the mixed A3-mediated has to be Therefore, 60 additional studies must be performed to verify t he modulating effect of the A3 61 agonists and ne urodegenerative diseases . have and investigated for t heir potential 63 therapeutic applications in diseases w here the A 3 AR seems to have a positive role. 64 Of the of compounds have to develop the so-called classical AR 66 antagonists . In the search for nonclassical AR ligands, novel str uctures have recently Examples the quinolinone derivatives (F igure 1 - I), recogni zed as putative A1, A2A and A 2B AR ligands.[15] Based on taken into 69 consideration coumarin be a non -nitrogen aromatic bioisoster 70 scaffold, it was fo und to be relevant to explore it in the design of novel AR antagonists. 71 Our interest in this new scaffold was also motivated by t - II), previously described as 73 AR antagonists t hat present a particular selectivity for t he A3 and A 2A AR subtypes.[16-74 18] Among them, our attention was fo cused on the 3-arylcoumarin ring system (Figure 1 75 - III), which has never been proposed as a s caffold for AR ligands. The recent findings, 76 and the lack of data on the 3-arylcoumarin scaffold encouraged us to e xplore the a selected series derivatives 78 (Figure 1) 80 derivatives (III). 83 84 are an important class of ben zopyrone heterocyclic compounds, of nat ural structure. [19-33] The fused heterocyclic framework of coumarins has 89 used as a archetype for the synthesis of a wide variety of analog ues suitable to perform 90 structure-activity their biological 91 properties.[19,20] In the last few years our research group has been engaged in the 92 synthesis of new biologically active coumarins. In particular, the 3-arylcoumarin 93 scaffold has been a focal point of o ur recent studies demonstrating t heir to 95 obtain the arylcoumarin scaffold. The principal one is the nucleus Perkin condensation 97 perhaps t he most direct and simple method known for the preparation of t hese 98 molecules.[23] Some variations of t his methodology are des cribed in the chemistry 99 section below. 100 In the evaluation, 101 theoretical evaluation ADME properties synthesized compounds 1-9 were evaluated in this study. 104 105 Material s and M ethods 106 107 Chemistry 108 109 Compounds Perkin condensation ortho- reaction conditions have been also fo und to be 114 appropriate when t he reagents en compass in t ethoxyl or 115 halogen However, in t he case of the hydroxyl substituents, these groups must be 116 previously protected by acetylation . Therefore, compound 4 was obtained starting from 117 the 2,5-dihydroxybenzaldehyde and the 4 -methylphenylacetic a cid, hours. pyrone using a substituted ortho-hydroxybenzaldehyde and 4 -nitrophenylacetic a cid, in presen ce of 122 NaH in acetic anhydride, for 20 hours.[43] Compounds 7 and 8[32] 3 and 4, using hydriodic 124 acid 57% in the presence of acetic a cid and acetic anhydride.[29] Finally, the Williamson 125 of the with chloroacetone, under refl ux of a cetone for 16 126 hours, gave the corresponding et her 9.[32] 127 128 (Scheme 1) 129 130 311Scheme 1 . and acetone, refl 16 a Reichert Kofler thermopan internal in Hz). of calculated all 140 cases. gel 60, 230-00 mesh) was used for flas h chromatography (FC). layer chromatography (TLC) was performed on plates pre coated with 142 silica gel (Merck 60 F254, 0.25 mm). The purity of compounds was ( HPLC) coupled Quest Spectrasystem (Thermo Fisher Scientific, Waltham, P4000 pump, an UV6000 UV-Vis diode array detector, and an SN4000 interface 146 to be operated via a personal computer. Instrument software ChromQuest 5.0 (Thermo 147 Fisher Scientific, Waltham, MA) was used for data acquisition. Different analytical 148 columns and mobile phases (all solvents were HPLC grade) were tested. The phase was H2O:CH3CN=70:30 Eclipse xdb C18 column (5 0.46 cm was used. The purity of the compounds 151 was found to be higher than 95%. 152 153 Synthetic methodologies 154 155 General procedure for t he 1-3. added, and t he mixture was heated in an 159 oil bath at 110 \u00baC for 24 h. After reaction, ice (100 mL) and acetic a cid (10 mL) were 160 added to the mixture. The reaction was kept at room temperature for 2 h, and then 161 extracted with ether (3 x 25 mL). The organic layer was washed with sodium 162 bicarbonate solution (50 mL, 5%) and then water (20 mL). The solvent was evaporated 163 under vacuum, and the dry residue was purified by FC (hexane/ethyl acetate 9:1) to give 164 the products 1 (mp 131-132 \u00baC)[37], 2 (mp 139-140 as 165 beige powders, in yields of 70 %, 65% and 75%, respectively. 166 167 Synthesis of 6-acetoxy-3-(4'-methylphenyl)coumarin (4). Compound 4 60 \u00baC for least 12 h 169 and at 300 \u00baC during few minutes immediately before use. A solution containing 170 anhydrous CH 3CO 2K (2.94 mmol), the 4-methylphenylacetic a cid derivative (1.67 171 mmol) and the 2,5-dihydroxybenzaldehyde (1.67 mmol), in Ac 2O (1.2 mL) was 172 prepared and refl uxed (138 \u00baC) for 16 h. The reaction mixture cooled, ne utralized 173 with 10% a queous NaHCO 3, and extracted (3 x 30 mL) with EtOAc. The organic layers 174 312were combined, was hed water, (anhydrous Na 2SO 4), and evaporated 175 under reduced pressure. The product was purified by recrystallization in EtOH and 176 dried, to beige powder . 177 178 Synthesis of 3-(4'-nitrophenyl)coumarins 5 and 6. To a dry 100-mL (60% dispersion in mineral oil ) (42.5 mmol) was added in 182 small aliquots. After the dissolution of the reagents, an instantaneous (after 2 -5 minutes) precipitation process was observed. The reaction mixture was stirred for 20 h and then 7 184 mL of water were added . After the addition of 4 3 mL acetic a cid, the mixture was 185 cooled to 4 \u00baC for 4 h. The res ulting precipitate was filtered and was hed with cold 186 glacial acetic a cid. The acetic a cid was then removed as an azeotrope upon addition of 187 250 . The times. final resid ue was dried under vacuum and purified by FC (hexane/ethyl 189 acetate to give the products 5 64%, respectively. 191 192 Synthesis of 6-hydroxy-3-phenylcoumarins 7 and 8. A solution of the 6- 193 methoxy/acetoxy substituted 3-phenylcoumarin (3 or 4, 0.50 mmol) in acetic a cid (5 194 mL) and acetic anhydride (5 mL) at 0 \u00baC, was obtained . Hydriodic a cid 57% (10 mL) was then added dropwise . The mixture was stirred at 110 \u00baC for 5 h. The solvent was 196 evaporated under vacuum and the dry residue was purified by CH 3CN crystallization to 197 give 7 or 8 (mp 214-215 \u00baC)[32] as beige powders, in yields of 198 respectively. 199 200 Synthesis of 3-(4'-methylphenyl)-6-(2-oxopropoxy)coumarin (9). To a suspension of 201 anhydrous (0.25 anhydrous acetone (3 mL), (0.25 suspension was stirred, at refl ux temperature, for 16 h. mixture cooled, and the 204 precipitate was recovered by filtration and was hed with anhydrous acetone (3 x 40 mL). 205 The solvent was evaporated under vacuum, and the dry resid ue was purified by FC 206 (hexane/ethyl acetate 85:15) to give (mp 128-129 as a beige powder, 207 in a yield of 74 %. 208 209 Biological assays 210 211 The adenosine binding and hA 3, expressed in cells, was spe cific specifi c binding of 216 [3H]HEMADO at hA 3 ARs. The res ults were expressed as K i (dissociation constants ), 217 which were calculated with t he program SC TFIT, and given as geometric means of at 218 313least three experiments, including 95 % confidence intervals.[46] Due to the lack of a 219 suitable radioligand for hA2B receptor in binding assay, t of antagonists at 220 hA2B determined was inhibited in a concentration- 223 dependent fashion, and IC 50 and K i values, respectively, were determined. 224 225 ADME properties 226 227 data for an 228 Molinspiration property values (Table 1) are reported experiments tested of compounds measured in 234 duplicates. Ki were calculated with t he program SC TFIT. As an interval estimate for t he .7, 2.7 Hz, H-7), 7.63 (2H, d, J = 8 Anal. Calcd for 18H14O4: 73.46; H, Calcd for C 16H12O3: C, 76.18; H, 4.79. Found: C, 255 76.15; H, 4.76. 256 257 Biological results 258 259 The data from radioligand binding compounds for pharmacological experiments were previo usly described in 261 materials and methods and in references 44-47. 262 314 263 Table 1 . Affinity (Ki) to bind human A1 and A 3 ARs expressed in CHO cells of 264 coumarins 1-9, in radioligand binding assays . 265 267 268 One of the important requirements for a mole cule to be a good dr ug candidate is the 269 ability to cross membranes. Also, associated with t his characteristic, molecule must possess t he appropriate ADME properties. To properties synthesized coumarins, preliminary data for an profile analysis compounds was and described by (Table 2).[49,50] derivatives 1-9.a 280 Compounds 1-9 hA2A, hA2B and hA 3, expressed in CHO cells. In the present 285 communication, st udies of t he effe ct on the binding affinity by the presence of substituents in the 3-arylcoumarin scaffold, at positions 3', the 3-arylcoumarin scaffold never been described as AR ligand, to explore ARs' binding activity of a selected series of derivatives. The 289 experimental data s how that all th e 3-arylcoumarin derivatives have no detectable 290 binding affinity to hA 2A and hA2B ARs (Ki > 30,000 - 100,000 nM). Compound 1, the 291 non-substituted 3-arylcoumarin, presents no binding affinity for any of the evaluated 292 receptors (Ki > 30,000 nM). The introduction of electron donating gro ups in both 293 (methyl groups at positions 6 and 4') afforded compound 2, the most 294 interesting compound of this series with a K i at the hA3 AR of 2,680 nM. The structural 295 significant affinity for hA 3 ARs. 296 The interesting result found for compound 2 was inspiring for the development of new 297 hA3 AR selective ligands. The changing of the methyl substituent 298 for a strong electron withdrawing nitro gro up led to compound 5, which displays no 299 binding affinity for any of AR subtypes. The presence of a nitro group at that position 300 doesn' t seem to be compatible with receptor binding, as confirmed by the data obtained 301 with compound 6. As the presence of a methyl group at position 4' seems to be 302 important for t he binding affinity, compou nds 4, 8 and 9 were synthesized and studied. 303 For compound 8, with a hydroxyl group at position 6, a decrease in the selectivity was 304 observed, although t he affinity data for both hA1 and hA3 ARs were interesting (Ki = 305 3157,900 and K i = 4,910 nM, respectively). Compound 4, with an acetoxy group in the 306 same position of t he coumarin skeleton, is a selective compound, with good binding 307 affinity for t he hA3 AR (Ki = 7,280 nM). Finally, the presence of a 2 -oxopropoxy group 308 (compound 9) in the previously mentioned position of t he coumarin moiety led also to a 309 noteworthy hA 3 AR ligand (K i = 4,680 nM). 310 To complete the present st udy, the methyl group at 4' position (present in the best 311 compound of the series -compound 2) was transposed to position 3' (compounds 3 and 312 7). In the case of compound 7, as previously described for compound 8, the presence of 313 a hydroxyl group at position 6 has a strong influence on the selectivity and affinity 314 towards hA1 and hA 3 ARs (Ki = 9,250 nM and K i = 14,600 nM, respectively). 315 Compound 3 with a methyl group at position 3' of the 3-aryl ring is a selective hA3 AR 316 ligand (Ki = 5,050 nM), similar to the other non-hydroxylated 4'-methyl derivatives. In 317 fact, the protection of the hydroxyl groups forming ether (compound 3) or ester 318 (compounds 4 and 9) derivatives results in an increase in selectivity. 319 From these preliminary results one can conclude that t he presence of the methyl group 320 in the aryl substituent will provide an strategy ligands . In addition, chemical at 6 322 important for mod ulating the selectivity of compounds against hA 1/hA3 or hA 3 ARs. 323 Moreover, due to the demonstrated importance of the 3-arylcoumarins as MAO 324 inhibitors, t hese AR ligands can be f urther developed to give improvements in bot h ARs 325 activity and ARs vs MAO selectivity. Also, since A3 AR ligands are involved in 326 neurodegenerative diseases, t his study can be an encouragement for the development of 327 multitarget drugs as AR ligands and M AO inhibitors. Compound 2, presenting t he 328 better hA3 affinity/selectivity of t his series, was previously described as M AO-B 329 selective inhibitor, with an IC 50 of 308 pM. This compound is one of the best MAO-B 330 inhibitors des cribed by our research group. This is an additional data to consider this 331 compound an excellent candidate for f uture st udies in donors the cribed coumarins. Also, TPSA, penetration, is also fo be for t hese drug 337 candidates. 338 339 Conclusions 340 341 In the current study, a series of 3-arylcoumarin derivatives were synt hesized and adenosine receptor ligands. A detailed analysis of t he experimental 343 results allows us to conclude that the affinity t he synthesized 344 coumarins is influenced by the presence and the nature of t he substituents at positions 345 3', 4' and 6 of t he 3-arylcoumarin scaffold . The experimental data s how that neither 346 simple 3-arylcoumarin nor the 4' binding affinity profiles, especially against the hA1/hA3 or only hA 3 AR. In 349 316general, one can conclude t hat the presence of a met hyl gro up at positions 3' or 4' of t he 350 3-aryl ring important for t he binding affinity. Fulfilling condition, of 351 a methyl, methoxy, acetoxy or 2-oxopropoxy groups at position 6 of the scaffold, res ults 352 in a noticeable affinity and sele ctivity for hA3 AR. The presence of a hydroxyl group at 353 position 6 gives rise to non-selective ligands binding to bot h hA1 and hA 3 ARs. This 354 study demonstrates t hat 3-arylcoumarin is an interesting s caffold for the design of novel 355 ARs ligands. Accordingly, compound 2 (Ki hA3 AR = 2,680 nM), is also a very 356 interesting MAO-B selective inhibitor, can be t he 357 synthesis of new hA3 AR coumarin-based selective ligands. This compound, as all 358 compounds in this series, is in a ccordance wit h the Lipinski's rule. Therefore, the substitution variability privileged multitarget scaffolds in the diseases . 362 363 Acknow ledgement 364 365 Partial financial support from Ministerio de Sanidad y Cons umo (PS09/00501), Xunta 366 de Galicia (PGIDIT09CSA030203PR) and Funda\u00e7\u00e3o para a Ci\u00eancia e Tecnologia 368 . M .J. Matos (SFRH/BD/61262/2009), A. 369 (SFRH/BD/43531/2008) and F. Borges (SFRH/BSAB/1090/2010) thank FCT grants. 370 371 Referen ces and notes 372 373 1. Fredholm et al. International Union of Pharmacology. XXV. Nomenclature and Med. 378 Res. Rev. 2000; 20: 103-128. 379 4. Kim Y et al. Novel and 4-substituted 1H-imidazo[4,5-c]quinolin-4-amine 380 derivatives as allosteri c modulators receptor. J. Med. Chem. 381 2009; 52: 2098-2108. 382 5. Lopes LV et al. Adenosine and related dr ugs in brain diseases: present and f uture 1087-1101. et al. Shah RH re ceptor antagonism: a new t herapeutic approach for 388 the of decompensated heart Rev. 2009; 17: optimized adenosine A 2A/A1 390 receptor antagonists for t he treatment of Parkinson' s disease. Chem. 2012; 391 55: 1402-1417. 392 3179. Armentero T Past, present and f uture of A(2A) adenosine receptor 393 antagonists adenosine Pharmacological and therapeutic effe cts of New 2 -arylpyrazolo[3,4-c]quinoline derivatives as potent Mosti L al. Q uinolinedione nucleus as a novel s caffold for A1 and A2 A 408 adenosine receptor antagonists novel adenosine A(2A) receptor 410 by virtual screening. J. Med. Chem. 2012; 55: 1904-1909. 411 17. Gaspar A et al. Discovery of novel A 3 adenosine receptor 413 18. Gaspar A et al. In search for new chemical entities as adenosine receptor ligands: 414 development of agents based J. Med. Chem. 415 2012; 54: 914-918. 19. Borges F Simple Coumarins: Privileged Scaffolds in Medi 2009; 4: 2 3-85. 418 20. Borges F et al. Simple coumarins and analogues in medicinal chemistry: 18: 3 424 M A novel synthesis of 3-aryl coumarins 4: 347-363. 431 25. Pisani L et al. Discovery of a novel class of potent coumarin monoamine o xidase 432 3-Substituted Coumarins as Dual Inhibitors of AChE and MAO MedChemComm 2011; 3: 213-218. 440 series of 3-ph enylcoumarins as and 1147-1152. 450 32. Matos MJ et al. Synthesis and Study of a Series of 3-Arylcoumarins as Potent and 451 14: 3697-3703. 463 37. Singer LA et al. Stereoselectivity in hydrogen atom transfer to equilibrated al. AR and computational studies of 3-{4- derivatives. Ulrich H a cids. J. Org. Chem. 476 KN 319subtypes 1-9. 482 novel tritiated agonist selective for the human Pharmacol. 2007; 556: 14-18. 484 Cheng t he inhibition constant (K1) and the 485 concentration of in hibitor which causes 50 per 487 47. De Lean A et al. Validation and statistical analysis of a computer modeling 488 method for quantitative analysis of radioligand binding data Pharmacol. 1982; 21: 490 48. M cheminformatics, Bratislava, Slovak Republic, 491 http://www.molinspiration.com/services/properties.html (2009). 492 49. Lipinski CA et al. Experimental and computational approa ches to estimate 493 494 Deliv. Rev. 1997; 23 : 3-25. 495 50. Ertl P al. Fast calculation of molecular polar surfa ce area as a sum of fragment 496 based contributions and its appli cation to Chem. 3714-3717. 498 499 320Table 1 500 501 Compounds hA 1 hA 3 S electivity R R1 K i (nM) K i (nM) hA 1/hA 3 1 H H > 30,000 > 30,000 - 2 CH3 4'-CH 3 > 30,000 2,680 (1,440-5,010) > 11.2 3 OCH 3 3'-CH 3 > 30,000 5,050 (3,670-7,000) > 5.9 4 OCOCH 3 4'-CH 3 > 30,000 7,280 (4,130-12,800) > 4.1 5 CH3 4'-NO 2 > 30,000 > 30,000 - 6 OCH 3 4'-NO 2 > 100,000 > 100,000 - 7 OH 3'-CH 3 9,250 (8,270-10,300) > 30,000 4,680 (3,870-5,660) > 6.4 These results are average results of three experiments. 502 503 504 321Table 2 66.30 2 97.27 area; n bond - 507 OHNH, hydrogen 508 Molinspiration calculation software .[45] 509 510 511 322Graphical Abstract 512 513 In the present communication we report t he synt properties and S AR study of a selected series 3- 516 arylcoumarins (compou compou nds 1-9 were eval uated in t his study. Most of t he 519 substitu ted derivatives have good 521 remarkable derivative is compou nd 2, presenting t he best affinity for AR (Ki = 2,680 nM selectivity for th is subtype. 524 525 323Cumarinas: Versatilidad estructural y aplicaciones en Qu\u00edmica Farmac\u00e9utica 2013 89 6. ConclusionesCumarinas: Versatilidad estructural y aplicaciones en Qu\u00edmica Farmac\u00e9utica 2013 91 \u00fc Effective and versatile synthetic methodologies for the preparation of of compounds were developed. The new compounds incorporate and stilbene , or the coumarin core and different groups such as ester s, amides or carbamates. The methodologies in good yields, with the desired degree in sufficient quantity for the and/or physicochemical tests. \u00fc All mass spectra, characterized some of of tested compounds without modifying the against MAO -A. particular the 3-(3'- bromophenyl)-6-methylcoumarin proved to be more than 6000 times more active (IC 50 = 134.04 pM) and over 200 times more selective than selegiline. \u00fc Some of activity against AChE. Others proved to be ligands of one or more of the four adenosine a MIC against S. particular, 3-(4'- 327Cumarinas: Versatilidad estructural y aplicaciones en Qu\u00edmica Farmac\u00e9utica 2013 hydroxyphenyl)-8-hydroxycoumarin presented an ORAC -FL of hydroxyl radicals trapping. studies are the result of interesting collaborations with different groups in different national and foreign uni versities. Without the joint effort these projects would not be possible and the results presented in this report have not been achieved. The work is necessarily interdisciplinary. 328Cumarinas: Versatilidad estructural y aplicaciones en Qu\u00edmica Farmac\u00e9utica 2013 93 7. Bibliograf\u00edaCumarinas: Versatilidad estructural y aplicaciones en Qu\u00edmica Farmac\u00e9utica 2013 95 1 Somberg, J.C. The York, 2 Pizzi, R. Salving with Science. The Pharmaceutical Century: Ten Decades of Drug Discovery Supplement to American Chemical Society, 2000. 3 Tsinopoulos, C.; McCarthy, I. An Evolutionary Classification of the Strategies for Drug Discovery. Manufacturing C omplexity Network Conference; Cambridge, 2002. 4 Rotella, D.P. ACS Med. Chem. Lett. 2012, 3, 172. 5 Lowe, D.B. ACS Med. Chem. Lett. 2012, 3, 3. 6 Reitz, A.B. ACS Lett. 2012, Hadjipavlou-Litina, D. J. Enzyme Inhib. Med. Chem. 2003, 18, 63. 8 Ribeiro, C.; Kaplan, M. Quim. Nova 2002, 25, 533. 9 Murray, R.D.H. Nat. Prod. Rep. 1995, 12, 477. 10 Proen\u00e7a A. Farmacognosia e Chem. 2009, 4, 23-85. 12 Accame, M. Panorama Actual Med. 2000, 24, 432. 13 De Surya, K.; Richard, A. Synthesis 2005, 8, 1231. 14 Hoult, J.R.S.; Pay\u00e1, M. Gen. Pharmacol. 1996, 48, 7592. 331Cumarinas: Versatilidad estructural y aplicaciones en Qu\u00edmica Farmac\u00e9utica 2013 96 20 Manolov, I.; Dankev, N.D. Eur. J. T.; Baba, N.; 1682. 25 Xiao, C.; Luo, X. -Y.; D.-J.; Lu, H.; Song, Z.-G.; Jin, Y.-H. Eur. L.M.; Lee, 1999, 42, 2662. 30 De Clercq, E. Med. Res. Rev. 2000, 20, 323. 31 Bedoya, L.; Beltran, M.; Sancho, R.; Olmedo, D.A.; del J.L.; Feliciano, Chem. 1999, 42, 2662. 332Cumarinas: Versatilidad estructural y aplicaciones en Qu\u00edmica Farmac\u00e9utica 44 Rachakonda, S.; Cartee, L. Curr. Med. Chem. 2004, 11, 775. Periers, A.M. Tetrahedron Lett. 2000, 41, 867. 46 Sardari, S. Bioorg. Med. Chem. 1999, 7, 1933. 47 9, 2079. (b) Nathan, C. Nature 2004, (c) Y.; Zhou, C. Bioorg. Med. Chem. Patel, D.; Kumari, P.; Patel, N. D.; Kumari, P.; Patel, N. Arch. Appl. Daly, J.W.; Spande, T.F.; Garrafo, H.M. Chem. Res. 2012, 21, 1780. 333Cumarinas: Versatilidad estructural y aplicaciones en Qu\u00edmica Farmac\u00e9utica 2013 Xiang, Singh, De V.U.; Rao, A.V. Syn. Commun. 1987, 17, 341. 334Cumarinas: Versatilidad estructural y aplicaciones en Qu\u00edmica Farmac\u00e9utica 2013 99 70 Roman, J.; Kozhkov, V.; Larock, Eicher, T.; Schneider, 78 Bogdal, D. J. Chem. Research (S) 1998, 468. 79 Hoz, A.; Moreno, A.; V\u00e1zquez, E. Synlett 1999, 5, 608. 80 Kidwai, M.; Kumar, P. J. Chem. Research (S) 1997, 178. 81 Bose, P.; Banerji, J. Indian J. Chem., Sect. B 1990, 29B, 422. 82 Chandrasekhar, S.; Catal. Lett. 77, 3. 84 (a) Rosen, T. The Perkin Reaction. In Comprehensive Organic Synthesis, Volume 2 Disease , CRC Press, Boca Raton, USA, 2005. Langcake, P.; Pryce, R.J. Plant Pathol. 1976, 9, Siemann, E.H.; Creasy, L.L. Am. J. Enol. Vitic. 1992, 43, 49. 335Cumarinas: Versatilidad estructural y aplicaciones en Qu\u00edmica Farmac\u00e9utica 2013 100 91 Renaud, S.; De Lorgeril, M. Lancet 1992, 339, 1523. 92 Leger, A.S.; Cochrane, A.L.; Moore, F. Lancet E.; Soldo, T.; Erbersdobler, H.; Somoza, V. , 482. 94 Andrus, M.; Jirillo, Cao, K.J.; Xu, Y.N.; Wu, J.M. Int. Mol. Med. 2002, 9, 77. 99 Kovacic, P.; Somanathan, R. Oxid. D.S.; Kang, B.S.; Ryu, S.Y.; Chang, I.M.; Min, K.R.; Y. Biochem. Pharmacol. 1999, 57, 705. 105 Qian, Y.-P.; Cai, Y.-J.; Fan, G.-J.; Wei, Q.-Y.; Yang, J.; Zheng, L.-F.; Li, X.- Z.; Fang, J.-G.; Zhou, B. J. Med. Chem. 2009, 52, 1963. 106 Fan, G. -J.; Liu, X.-D.; Qian, Y.-P.; Shang, Y.-J.; Li, X.-Z.; Jin, L.; 2009, 17, 2360. 107 Rastija, V.; Medi-ari, M. Eur. J. Med. 2011, 46, 2586. 336Cumarinas: Versatilidad estructural y aplicaciones en Qu\u00edmica Farmac\u00e9utica 2013 101 110 Zhang, W.; Sviripa, 111 Lu, J.; Li, Li, Z.; Tang, R.; Jia, H.; Liu, B. Eur. J. Med. Chem. 2011, 46, 2908. 116 Kung, H.F. ACS Med. Chem. Lett. 2012, 3, E.; Scheltens, Lancet Van der Schyf, C.J. Curr. Med. Chem. 2013, 20, 1662. 120 Factor, S. Neurotherapeutics 2008, 5, 164. 121 Li, X.; Sundquist, J.; Hwang, H.; Sundquist. Chen, J.; Ravina, B. Neurosci. 129 Guay, D. Am. J. Geriatr. Pharmacother. 2006, 4, 330. 337Cumarinas: Versatilidad estructural y aplicaciones en Qu\u00edmica Farmac\u00e9utica 2013 102 130 Piazzi, L.; M.B.H.; Fridkin, M.; 1455. 132 Weinstock, M. CNS Drugs 1999, 12, 307. 133 Orhan, G.; Gurkas, E. Mini -Rev . Med. 134 Cesura, A.M.; Pletscher, A. Prog. Danielczyk, E. R.; Marco-Contelles, J. Curr. Med. Chem. 2011, Fern\u00e1ndez-Bachiller, M.I.; - Franco, M.I. J. Med. Chem. 2012, 55, 1303. 139 Huang, L.; Lu, C.; Sun, Mao, F.; Luo,Z.; Su, H.; W.; Li, X. 140 H.; Fridkin, M.; Youdim, M.B. Mini Rev. Med. Chem. 142 Nagatsu, T. Neurotoxicology 2004, F., Ed.; Neurotherapeutics 2009, 6, 141. 149 Ramsay, R. Curr. Top. Med. Chem. 2012, 12, 2189. 338Cumarinas: Versatilidad estructural y aplicaciones en Qu\u00edmica Farmac\u00e9utica 2013 103 150 Geha, R. 103. 155 Rudorfer, M.V.; Potter, V.Z. Drugs Bevan, A.B.; 166 Kadir, H.A.; Knowles, C.O. Toxicol. 2001, 88, 75. 339Cumarinas: Versatilidad estructural y aplicaciones en Qu\u00edmica Farmac\u00e9utica 2013 Beauchamp, (S) 2002, 242. 181 Perkin, W.H. J. Chem. Soc. 1868, 21, 53. 182 Matos, M.J.; Vazquez-Rodriguez, S.; Borges, F.; Santana, L.; Uriarte, 2011, 52, 1225. 185 Hansen, J.B.; Bjerring, P. Med. Chem. 1985, 28, 1001. 186 Tominaga, H. J. Med. Chem. 1991, 34, 2169. 340Cumarinas: Versatilidad estructural y aplicaciones en Qu\u00edmica Farmac\u00e9utica 2013 105 187 Fraginals, R.; Schaeffer, M. J. Med. Chem., 1991, 34, 1024. 188 Wang, L.; Jing, H.; Bu, X.; Chang, T.; Jin, L.; Liang, Y. Cat. 2007, 8, 80. 189 Larock, R.C. Comprehensive Organic Transformations: A guide to Functional Group New 1997. 190 Butler, A; Walker, J.V. 4187. 192 Bisarya, S.C.; Rao, Soc., Trans. 2000, 1119. 196 Xiao, T.; Matos, M.J.; Santana, L; Uriarte, G.; Netherton, M.R.; Fu, G.C. Org. Lett. 2001, 3, Barry, M.; F.; Uriarte, E.; Santana, L. Org. Prep. Proc. Inter. 2012, 44, 522. 204 Dalla Via, L.; Uriarte, E.; Santana, L.; Magno, S.M.; Gia, C.; P\u00e9rez-Castillo, Uriarte, E.; Med. Chem. 2011, 54, 7127. 341Cumarinas: Versatilidad estructural y aplicaciones en Qu\u00edmica Farmac\u00e9utica 2013 106 206 Matos, ChemMedChem 2012, 7, 464. 209 Janeiro, P.; Matos, M.J.; Santana, L.; Uriarte, E.; Oliveira-Brett, A.M. Bioorg. Med. Vi\u00f1a, D.; Matos, Y\u00e1\u00f1ez, M.; Santana, L.; Uriarte, E. Med. 212 M.J.; 65, 3342. 218 Schr\u00f6dinger Suite, in, Schr\u00f6dinger, LLC, New York, NY, USA. 219 Matos, M.J.; Uriarte, E.; Santana, L.; Vilar, S. J. Mol. Struct. 2013, 1041, 144. 342 "}